metformin has been researched along with Pregnancy in 891 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 9.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children." | 9.69 | Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. ( Armson, A; Asztalos, E; Barrett, J; Donovan, L; Fantus, IG; Feig, DS; Hamilton, J; Haqq, AM; Jiang, Y; Karanicolas, P; Klein, G; Lipscombe, L; Mangoff, K; Murphy, KE; Sanchez, JJ; Simmons, D; Tobin, S; Tomlinson, G; Zinman, B, 2023) |
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 9.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "Our study assesses perinatal outcomes among women with type 2 diabetes, with gestational weight gain (GWG) within and outside of US Institute of Medicine (IOM) guidelines, by conducting a secondary analysis of the Metformin in Type 2 Diabetes in Pregnancy (MiTy) trial." | 9.51 | Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial. ( Feig, DS; Fu, J; Tomlinson, G, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 9.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "The Pregnancy Outcomes: Effects of Metformin study is a multicentre, open-label, randomised, controlled trial." | 9.51 | Pregnancy Outcomes: Effects of Metformin (POEM) study: a protocol for a long-term, multicentre, open-label, randomised controlled trial in gestational diabetes mellitus. ( Erwich, JJHM; Hoogenberg, K; Kooy, A; Lutgers, HL; Prins, JR; van Dijk, PR; van Hoorn, EGM, 2022) |
| "In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin." | 9.51 | Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 9.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 9.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 9.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| "Metformin is widely used in pregnancy, despite lack of long-term safety for children." | 9.51 | Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood. ( Denison, FC; Dhaun, N; Drake, AJ; Lacey, L; Norman, JE; Quenby, S; Reynolds, RM; Whyte, S; Yang, L, 2022) |
| " Metformin, which ameliorate hormonal disturbances in non-pregnant women with PCOS is increasingly used in pregnancy." | 9.41 | Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Madsen, A; Mellgren, G; Sagen, JV; Salvesen, Ø; Vanky, E; Ødegård, R, 2021) |
| "To evaluate whether extended release metformin could be used to prolong gestation in women being expectantly managed for preterm pre-eclampsia." | 9.41 | Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. ( Brownfoot, F; Cluver, CA; Decloedt, EH; Hall, DR; Hiscock, R; Kaitu'u-Lino, TJ; Mol, BW; Schell, S; Tong, S; Walker, SP, 2021) |
| "Metformin is considered as first-line treatment for type 2 diabetes and an effective treatment for polycystic ovary syndrome (PCOS)." | 9.41 | Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. ( Abolhassani, N; Del Giovane, C; Jaques, C; Kaplan, YC; Minder Wyssmann, B; Panchaud, A; Winterfeld, U, 2023) |
| "Metformin is used worldwide in the treatment of type 2 diabetes and has been used in the treatment of diabetes in pregnancy since the 1970s." | 9.41 | Focus on Metformin: Its Role and Safety in Pregnancy and Beyond. ( Dunne, FP; Ero, A; Newman, C; Rabbitt, L, 2023) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 9.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy." | 9.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 9.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 9.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "To compare the effects of metformin and insulin treatment on maternal serum lipids in patients with gestational diabetes (GDM), and to analyse the associations between individual lipids and birth weight (BW)." | 9.34 | Serum lipids and their association with birth weight in metformin and insulin treated patients with gestational diabetes. ( Huhtala, MS; Rönnemaa, T; Tertti, K, 2020) |
| "This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic parameters in overweight women with a recent history of gestational diabetes mellitus." | 9.34 | A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. ( Elkind-Hirsch, KE; Harris, R; Seidemann, E, 2020) |
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 9.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| " Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group." | 9.30 | Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. ( Andræ, F; Berg, AH; Bixo, M; Carlsen, SM; Gómez-Real, F; Hestvold, KV; Hirschberg, AL; Hjelle, S; Lønnebotn, M; Løvvik, TS; Mohlin, J; Poromaa, IS; Salvesen, Ø; Steffensen, B; Thorarinsdottir, S; Trouva, A; Underdal, M; Vanky, E; Zabielska, R, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 9.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| "A total of 202 patients with clomiphene citrate (CC) -resistant polycystic ovary syndrome (PCOS) were randomly allocated into two arms of induction of ovulation; the first group (n = 102) received CC 100 mg and metformin 500 mg while the second group (n = 100) received letrozole 2." | 9.27 | Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. ( Rezk, M; Saif El-Nasr, I; Shaheen, AE, 2018) |
| "We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR)." | 9.27 | Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study. ( Abusada, N; Candia, P; Cuellar, E; Manukian, B; Orellana, R; Sepúlveda-Martínez, A; Valdés, E, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 9.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 9.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 9.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "Metformin has been used in pregnancy since the 1970s." | 9.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial." | 9.22 | Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome. ( Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022) |
| "The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate the role of metformin in improving the reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome." | 9.22 | Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. ( Kheirelseid, EAH; Lewis, S; Magzoub, R; Perks, C, 2022) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 9.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "To evaluate the efficacy and safety of using metformin in pregnant women with polycystic ovarian syndrome (PCOS) and to explore the most effective and safe protocol by using a meta-analysis method." | 9.22 | Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials. ( He, J; Zhao, Q, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 9.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "gov for randomized controlled trials (RCTs) that compared metformin to insulin in pregnancy." | 9.22 | The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials. ( Ge, J; Guo, Q; He, K; Jing, Z; Li, C; Li, J, 2022) |
| "Metformin in pregnancy did not affect cervical length in women with PCOS." | 9.22 | Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect? ( Carlsen, SM; Salvesen, Ø; Shetelig Løvvik, T; Stridsklev, S; Vanky, E, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 9.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to insulin in this high risk population." | 9.22 | Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. ( Armson, AB; Asztalos, E; Barrett, JF; Fantus, IG; Feig, DS; Lipscombe, LL; Murphy, K; Ohlsson, A; Ryan, EA; Sanchez, J; Tomlinson, G; Zinman, B, 2016) |
| "A pilot randomized, controlled trial was conducted of metformin versus insulin for the treatment of T2DM during pregnancy." | 9.20 | A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. ( Blackwell, SC; Gowen, R; Hutchinson, M; Pedroza, C; Ramin, S; Refuerzo, JS, 2015) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 9.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 9.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| "We sought to compare weight loss in the first 6 weeks postpartum among women with gestational diabetes mellitus (GDM) treated with metformin or placebo, a promising therapy to reduce later risk of progression to diabetes mellitus." | 9.20 | The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial. ( Blackwell, SC; Hutchinson, M; Pedroza, C; Ramin, SM; Refuerzo, JS; Tyson, JE; Viteri, OA, 2015) |
| "To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability." | 9.20 | Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015) |
| "To determine if metformin monotherapy or metformin in combination with insulin is equally effective as insulin monotherapy at glycemic control in diabetes mellitus in pregnancy among Ghanaians." | 9.20 | Metformin versus Insulin in the Management of Pre-Gestational Diabetes Mellitus in Pregnancy and Gestational Diabetes Mellitus at the Korle Bu Teaching Hospital: A Randomized Clinical Trial. ( Adjepong-Yamoah, KK; Beyuo, T; Bugyei, KA; Marfoh, K; Obed, SA; Oppong, SA, 2015) |
| "To assess the adjuvant effect of metformin and N-acetylcysteine (NAC) to clomiphene citrate (CC) in induction of ovulation in Polycystic Ovary Syndrome (PCOS) patients." | 9.20 | The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome. ( Abdelhafez, A; Bakry, A; Elsawah, H; Maged, AM; Mostafa, WA, 2015) |
| "Berberine and metformin treatments prior to IVF improved the pregnancy outcome by normalizing the clinical, endocrine and metabolic parameters in PCOS women." | 9.19 | The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. ( An, Y; Guan, Y; Liu, B; Lu, M; Sun, Z; Zhang, Y, 2014) |
| "Metformin is used to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS), although it is not approved for this indication and solid evidence is lacking." | 9.19 | Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. ( Carlsen, SM; Clemens, I; Salvesen, Ø; Stridsklev, S; Vanky, E, 2014) |
| "Metformin is suggested to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS)." | 9.19 | Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin. ( Carlsen, SM; Helseth, R; Stridsklev, S; Vanky, E; Vogt, C, 2014) |
| "Training during pregnancy was not associated with altered levels of cffDNA cfmDNA or cftDNA, but metformin treatment may reduce cfmDNA and cftDNA in pregnant PCOS women." | 9.19 | The effect of exercise and metformin treatment on circulating free DNA in pregnancy. ( Carlsen, SM; Christiansen, SC; Klungland, H; Mørkved, S; Salvesen, KÅ; Stafne, SN; Sæther, M; Vanky, E, 2014) |
| "Total, but not bioavailable, vitamin B12 stores were depleted during pregnancy to a greater extent in metformin-treated than in insulin-treated women with GDM, but neither analyte differed between groups at any stage." | 9.17 | Vitamin B12 and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment. ( Baghurst, PA; Coat, S; Gatford, KL; Hague, WM; Houda, CM; Lu, ZX; Owens, JA; Rowan, JA; Sikaris, K, 2013) |
| "The aim of this study was to evaluate the effectiveness of Metformin on ovulation and eventual clinical pregnancy in different phenotypes of polycystic ovary syndrome (PCOS)." | 9.17 | Metformin treatment in different phenotypes of polycystic ovary syndrome. ( Alleyassin, A; Fanisalek, M; Hosseini, MA; Kokab, A; Safdarian, L; Sarvi, F, 2013) |
| "To compare the efficacy of metformin with insulin in the management of pregnancy with diabetes." | 9.17 | Efficacy of metformin versus insulin in the management of pregnancy with diabetes. ( Malik, FP; Mazhar, SB; Waheed, S, 2013) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 9.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes between women receiving metformin plus letrozole and women undergoing bilateral ovarian drilling in clomiphene citrate (CC)-resistant women with polycystic ovary syndrome (PCOS)." | 9.17 | Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. ( Abd Elgafor, I, 2013) |
| "The role of metformin in the treatment of infertility in women with polycystic ovary syndrome (PCOS) is still controversial." | 9.16 | Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. ( Bloigu, R; Hippeläinen, M; Morin-Papunen, L; Perheentupa, A; Puukka, K; Rantala, AS; Ruokonen, A; Tapanainen, JS; Tiitinen, A; Tinkanen, H; Unkila-Kallio, L, 2012) |
| "To study the significance of breast size increment in pregnancy, and the impact of metformin during pregnancy on breastfeeding in women with polycystic ovary syndrome (PCOS)." | 9.16 | Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. ( Carlsen, SM; Hjorth-Hansen, AK; Leithe, H; Martinussen, M; Nordskar, JJ; Vanky, E, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 9.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "To compare the effect of combined metformin and clomiphene citrate (CC) with laparoscopic ovarian diathermy (LOD) meant for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 9.15 | Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; El Lakany, N; Sherief, L, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 9.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome." | 9.15 | The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Piomboni, P, 2011) |
| "To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS)." | 9.15 | Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. ( Carlsen, SM; Haapaniemikouru, K; Holst-Larsen, T; Humaidan, P; Kjøtrød, SB; Mellembakken, J; Morin-Papunen, L; Rasmussen, PE; Sunde, A; Thurin-Kjellberg, A; von Düring, V, 2011) |
| "To evaluate the effects of metformin on the ovarian response to gonadotropins given for in vitro fertilization (IVF) programs in patients with polycystic ovary syndrome (PCOS) and reduced ovarian reserve." | 9.15 | Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. ( Cappiello, F; Di Cello, A; Falbo, A; Palomba, S; Tolino, A; Zullo, F, 2011) |
| "To test whether metformin administration reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovary syndrome (PCOS) who have been treated with gonadotropins for IVF." | 9.15 | Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. ( Capasso, S; Cappiello, F; Carrillo, L; Cittadini, E; Colao, A; Di Cello, A; Falbo, A; La Sala, GB; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tolino, A; Villani, MT; Zullo, F, 2011) |
| "To compare the effect of clomiphene citrate, metformin, and lifestyle modification on treatment of patients with polycystic ovary syndrome (PCOS)." | 9.14 | An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. ( Javedani, M; Karimzadeh, MA, 2010) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "The aim of this study was to evaluate the effects of calcium-vitamin D and metformin on the menstrual cycle and ovulation in patients with polycystic ovary syndrome (PCOS)." | 9.14 | The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. ( Haghollahi, F; Rashidi, B; Shariat, M; Zayerii, F, 2009) |
| "This study was conducted to determine the efficacy of metformin vs placebo in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment." | 9.14 | Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. ( Abu-Salem, AN; Al-Ahmad, N; Al-Ibrahim, N; Al-Khaderei, S; Al-Khateeb, M; Al-Zpoon, A; Megdadi, M; Qublan, HS, 2009) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 9.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 9.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "The purpose of this study was to compare the effectiveness of laparoscopic ovarian diathermy (LOD) vs clomiphene citrate (CC) plus metformin in infertile patients with CC-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. ( Battista, L; Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Venturella, R; Zullo, F, 2010) |
| "For women with BMI > 32 kg/m(2), clinical pregnancy and live birth rates were 22% (7/32) and 16% (5/32) with metformin, 15% (5/33) and 6% (2/33) with placebo." | 9.14 | PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. ( Buckingham, KL; Falkiner, J; Farquhar, CM; Johnson, NP; Milsom, S; Okonkwo, QL; Singh, VP; Stewart, AW, 2010) |
| "This study was performed with the aim of evaluating the effect of metformin in reducing miscarriage when continued until the end of the first trimester of pregnancy in patients with polycystic ovary syndrome (PCOS) and infertility." | 9.14 | Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome. ( Bagheri, B; Haghollahi, F; Shariat, M; Sohrabvand, F, 2009) |
| "To compare the efficacy of metformin and clomiphene citrate (CC) therapies for ovulation induction in anovulatory infertile women with polycystic ovary syndrome (PCOS)." | 9.14 | Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. ( Api, M; Baran, S; Cetin, A; Goksedef, BP, 2010) |
| "Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications." | 9.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "To compare the effects of combined N-acetyl cysteine (NAC) and clomiphene citrate (CC) and of combined metformin and CC on ovulation induction in anovulatory CC-resistant women with polycystic ovary syndrome (PCOS)." | 9.14 | N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; Anwar, K; El-Fatah, RA, 2010) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 9.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 9.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "To determine the effect of metformin pretreatment on in vitro maturation (IVM) in the patients with clomiphene citrate-resistant polycystic ovary syndrome." | 9.13 | Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome. ( Cao, Y; Cong, L; Li, J; Wei, Z; Zhang, Z; Zhou, P, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 9.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "To review the current evidence for the use of metformin in pregnancy for women with type 2 diabetes." | 9.12 | Metformin in Pregnancy for Women with Type 2 Diabetes: a Review. ( Benham, JL; Donovan, LE; Yamamoto, JM, 2021) |
| " Metformin is known to decrease insulin resistance and is also associated with weight loss." | 9.12 | Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence. ( Ayala, NK; Werner, EF; Whelan, AR, 2021) |
| "To evaluate metformin's effects on pregnancy outcomes in women with polycystic ovary syndrome." | 9.12 | Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies. ( Cao, Q; Fu, J; Hu, Y; Huang, W; Huang, X; Wu, L; Zhang, J, 2021) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 9.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "To assess the impact of bariatric surgery on pregnancy outcomes in women with PCOS compared to metformin therapy in a systematic review and meta-analysis." | 9.12 | The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis. ( Chang, C; Chang, S; Poles, J; Popov, V, 2021) |
| "The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine reducing insulin resistance appears to be promising." | 9.12 | Metformin administration during pregnancy - current insight. ( Cypryk, K; Krekora, M; Skibinska, M; Zurawska-Klis, M, 2021) |
| "This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome. ( Chronopoulou, E; Homburg, R; Raperport, C, 2021) |
| "We systematically assessed the impact of metformin treatment on maternal pregnancy outcomes." | 9.12 | Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. ( Aiken, CE; Ozanne, SE; Tarry-Adkins, JL, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy." | 9.12 | Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. ( Bjerve, K; Carlsen, SM; Hjorth-Hansen, H; Salvesen, KA; Vanky, E, 2006) |
| "To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS)." | 9.12 | A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. ( Ardawi, MS; Rouzi, AA, 2006) |
| "Current data supporting the effectiveness of metformin as a fertility treatment for women with polycystic ovary syndrome have been misinterpreted." | 9.12 | No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. ( Johnson, NP, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "Metformin is better for ovulation induction than CC alone and equivalent for pregnancy achievement." | 9.12 | Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. ( Granger, L; Lavoie, HB; Neveu, N; St-Michel, P, 2007) |
| "A prospective cohort study was set up to determine the beneficial effects of metformin on PCOS patients during pregnancy." | 9.12 | Metformin reduces abortion in pregnant women with polycystic ovary syndrome. ( Al-Inany, H; Foutouh, IA; Khattab, S; Moaz, M; Mohsen, IA; Ramadan, A, 2006) |
| "Metformin appears to be an effective medicine to induce ovulation in women with polycystic ovary syndrome and insulin resistance." | 9.12 | Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome. ( Hirano, Y; Kikuchi, K; Shibahara, H; Suzuki, M; Suzuki, T; Takamizawa, S, 2007) |
| "We randomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene for up to 6 months." | 9.12 | Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, GG; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2007) |
| "Forty pregnant women with polycystic ovary syndrome (PCOS) were enrolled in a randomized, double-blind, placebo-controlled trial of metformin (1700 mg/day) during pregnancy." | 9.12 | Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation? ( Carlsen, SM; Salvesen, KA; Vanky, E, 2007) |
| "Serum homocysteine levels were unaffected by metformin treatment both in nonpregnant and pregnant women with polycystic ovary syndrome." | 9.12 | Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, S; Romundstad, P; Vanky, E, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 9.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "The aim of the study was to compare in a clinical setting the efficacy of CC and metformin as first-line approaches for treating anovulation in infertile PCOS patients." | 9.12 | Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 9.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 9.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 9.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 9.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "Investigation of a possible effect of metformin on androgen levels in pregnant women with polycystic ovary syndrome (PCOS)." | 9.11 | Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. ( Carlsen, SM; Fougner, KJ; Heimstad, R; Romundstad, P; Salvesen, KA; Vanky, E, 2004) |
| "At present, it is unclear what the role is of laparoscopic ovarian diathermy (LOD) and of metformin administration as second-line treatments for ovulation induction in women with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate (CC) treatment." | 9.11 | Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. ( Colao, A; Corea, D; Doldo, P; Falbo, A; Lombardi, G; Nardo, LG; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2004) |
| "To determine the clinical, biochemical, hormonal, and ultrasonographic effects of 6 months of metformin therapy in women with polycystic ovary syndrome (PCOS) and compare with pretherapy parameters." | 9.11 | Metformin therapy in women with polycystic ovary syndrome. ( Aruna, J; Dadhwal, V; Kumar, S; Misra, R; Mittal, S; Vimala, N, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients." | 9.11 | Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "To evaluate the effect of ultra-short (12 days) metformin pretreatment in clomiphene-citrate (CC) resistant polycystic ovary syndrome (PCOS)." | 9.11 | Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. ( Huang, WY; Hwu, YM; Lee, RK; Lin, MH; Lin, SY, 2005) |
| "In the present study, we investigated the impact of metformin therapy on in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes in patients with polycystic ovary syndrome (PCOS)." | 9.11 | Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. ( Bagis, T; Ceyhan, T; Cincik, M; Goktolga, U; Onalan, G; Pabuçcu, R, 2005) |
| "To compare the efficacy of clomiphene citrate (CC) administration for ovulation induction in CC-resistant oligo-ovulatory women with polycystic ovary syndrome (PCOS) after metformin treatment or laparoscopic ovarian drilling (LOD)." | 9.11 | Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. ( Caterina, G; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "To evaluate the effect of metformin therapy on hyperandrogenism, insulin resistance, cervical scores, ovulation, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS)." | 9.10 | Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. ( Caliskan, E; Haberal, A; Kocak, M; Simsir, C, 2002) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 9.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| "To determine whether metformin pretreatment has beneficial effects in clomiphene resistant infertile women with polycystic ovary syndrome (PCOS) in an infertility clinic." | 9.10 | Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. ( Fay, TN; Lannon, B; Sturrock, ND, 2002) |
| "To study the effect of metformin in combination with clomiphene citrate, as compared with placebo plus clomiphene citrate, on the ovulation and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome." | 9.10 | The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. ( Malkawi, HY; Qublan, HS, 2002) |
| "To evaluate whether pretreatment with metformin improves FSH-induced ovulation in women with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 9.09 | Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. ( Cianci, A; De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 9.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To determine whether metformin treatment increases the ovulation and pregnancy rates in response to clomiphene citrate (CC) in women who are resistant to CC alone." | 9.09 | Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. ( Evans, WS; Kauma, SW; Nestler, JE; Ratts, VS; Stovall, DW; Vandermolen, DT, 2001) |
| "Previous randomized and observational studies on the efficacy of metformin in pregnancy to reduce incident gestational diabetes mellitus (GDM) in women at high risk (obesity, polycystic ovary syndrome [PCOS], or pregestational insulin resistance) have been conflicting and several groups are planning further randomized controlled trials (RCTs) to answer this question conclusively." | 9.05 | Metformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials. ( Clark, J; Doi, SAR; Furuya-Kanamori, L; Islam, N; Musa, OAH; Thalib, L; Toft, E, 2020) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 9.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| "Metformin is widely used among women with polycystic ovary syndrome (PCOS)." | 9.05 | Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. ( Huang, Y; Liu, Y; Tu, M; Wu, Y; Zhang, D, 2020) |
| "A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed." | 9.05 | The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis. ( Liu, X; Zhang, W; Zhao, J, 2020) |
| "It seems to have no sense to prolong the use of metformin after a pregnancy diagnosis in women with PCOS." | 9.01 | Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions. ( Alvariñas, J; Bagnes, MFG; Di Girolamo, G; Gonzalez, CD, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 8.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 8.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 8.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "Metformin has been prescribed in pregnancy for over 40 years; for much of this time, use has been limited both in numbers and geographically, and the evidence base has been confined to observational studies." | 8.95 | Metformin use in pregnancy: promises and uncertainties. ( Lindsay, RS; Loeken, MR, 2017) |
| "Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS." | 8.95 | Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. ( , 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "To assess the short- and long-term maternal and fetal impact of metformin in pregnancy compared with insulin." | 8.95 | Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. ( Aitken, E; Butalia, S; Donovan, L; Gutierrez, L; Lodha, A; Zakariasen, A, 2017) |
| " Metformin may increase the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy." | 8.95 | Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. ( Bordewijk, EM; Costello, MF; Mol, BW; Nahuis, M; Tso, LO; Van der Veen, F; van Wely, M, 2017) |
| "The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 8.93 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. ( An, RF; Tian, Q; Xue, Y; Zeng, XL; Zhang, YF, 2016) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 8.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "PubMed, SCOPUS and CENTRAL databases were searched until April 2014 with the key words: PCOS, polycystic ovary syndrome, metformin, clomiphene citrate, ovulation induction and pregnancy." | 8.91 | Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Abu Hashim, H; Foda, O; Ghayaty, E, 2015) |
| "In women with polycystic ovary syndrome, metformin treatment before or during assisted reproductive technology cycles increases clinical pregnancy rates and decreases the risk of ovarian hyperstimulation syndrome." | 8.91 | Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Marjoribanks, J; Tso, LO, 2015) |
| "Metformin is used among patients with polycystic ovary syndrome (PCOS), but findings for its effects on outcomes of assisted reproductive technology (ART) have been conflicting." | 8.91 | A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. ( Huang, X; Li, Y; Lv, F; Tal, R; Wang, P; Zhang, X, 2015) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 8.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| "The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction." | 8.90 | Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2014) |
| "Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women." | 8.90 | The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). ( Nathan, N; Sullivan, SD, 2014) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial." | 8.89 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. ( Gu, W; Shan, PF; Zheng, J, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 8.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| "Metformin is widely used for treating women with polycystic ovary syndrome (PCOS), and many patients with PCOS who are infertile receive gonadotrophins while being treated with metformin." | 8.89 | Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 8.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 8.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS)." | 8.88 | On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. ( Carlsen, SM; DE Zegher, F; Díaz, M; Ibáñez, L; Vanky, E, 2012) |
| "To evaluate the efficacy of metformin (MTF) in treatment of clomiphene (CC)-resistant patients with polycystic ovary syndrome (PCOS)." | 8.88 | [Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis]. ( Cheng, QF; Fan, XD; Ren, W; Wang, LL, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 8.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 8.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| "To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients." | 8.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| "Metformin improves the endocrinopathy of polycystic ovary syndrome (PCOS), facilitates conception, appears to reduce first trimester miscarriage and gestational diabetes and does not appear to be teratogenic." | 8.84 | Metformin before and during pregnancy and lactation in polycystic ovary syndrome. ( Glueck, CJ; Wang, P, 2007) |
| "To report a case of triplet pregnancy after metformin treatment only, in a woman with polycystic ovary syndrome (PCOS) and a family history of twin pregnancies." | 8.84 | Triplet pregnancy after metformin in a woman with polycystic ovary syndrome. ( Clapauch, R; Mattos, TM, 2008) |
| "Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS)." | 8.84 | Role of metformin in patients with polycystic ovary syndrome: the state of the art. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tollino, A; Zullo, F, 2008) |
| "To update the state of evidence on the efficacy of metformin, used either alone or in combination with clomiphene citrate in women with polycystic ovary syndrome, by examining three outcomes: ovulation, pregnancy, and live birth." | 8.84 | Use of metformin in polycystic ovary syndrome: a meta-analysis. ( Bradley, HM; Creanga, AA; McCormick, C; Witkop, CT, 2008) |
| "To describe the first reported cases of two women with polycystic ovary syndrome (PCOS) desirous of pregnancy who conceived trichorionic pregnancies following ovulation induction with metformin alone and metformin plus clomiphene." | 8.83 | Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. ( Boothroyd, C; Yazdani, A, 2006) |
| "A systematic review of randomized controlled trials (RCTs) comparing whether metformin co-administration with gonadotrophins for ovulation induction (OI) with timed intercourse or IVF improves outcome in women with polycystic ovary syndrome (PCOS)." | 8.83 | A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. ( Chapman, M; Conway, U; Costello, MF, 2006) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 8.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "The aim of this literature search is to establish if metformin is efficacious when given to clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS) patients." | 8.83 | Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. ( Kruger, TF; Nosarka, S; Siebert, TI; Steyn, DW, 2006) |
| "To review the effectiveness of metformin in restoring regular menstrual cycles and ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS)." | 8.82 | A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. ( Costello, MF; Eden, JA, 2003) |
| "To familiarize obstetrician-gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS)." | 8.82 | Metformin for the treatment of polycystic ovary syndrome. ( Barbieri, RL, 2003) |
| "To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome." | 8.82 | Metformin in polycystic ovary syndrome: systematic review and meta-analysis. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "No adverse pregnancy outcomes with metformin use have been reported, except in one unmatched study." | 8.82 | Metformin therapy and diabetes in pregnancy. ( McIntyre, HD; Rowan, JA; Simmons, D; Walters, BN, 2004) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 8.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 8.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| "Metformin counteracts excessive weight gain and leptin resistance in pregnant women with polycystic ovary syndrome." | 8.12 | Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. ( Bixo, M; Dehlin, E; Løvvik, TS; Molin, J; Vanky, E, 2022) |
| "The mean steady-state serum concentration of metformin during pregnancy was 9." | 8.12 | Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome. ( Espnes, KA; Gundersen, POM; Hønnås, A; Løvvik, TS; Naavik, A; Skogvoll, E; Spigset, O; Vanky, E; Westin, AA, 2022) |
| "This study aimed to investigate if maternal pregnancy exposure to metformin is associated with increased risk of long-term and short-term adverse outcomes in the child." | 8.12 | Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. ( Boutmy, E; Brand, KMG; Foch, C; Hakkarainen, KM; Korhonen, P; Morin-Papunen, L; Saarelainen, L; Schlachter, J; Sonajalg, J; Vääräsmäki, M, 2022) |
| "We used the detailed maternal-placental-fetal PBPK model within the Simcyp Simulator V20 to predict the maternal and fetal drug exposure of acyclovir, emtricitabine, lamivudine, and metformin during pregnancy and at delivery." | 8.12 | Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. ( Abduljalil, K; Jamei, M; Ning, J; Pansari, A, 2022) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 8.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 8.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "To use the framework of the Health Belief Model (HBM) to explore factors associated with metformin use among adults with prediabetes." | 8.12 | Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2022) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 8.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| "To investigate effects of maternal diabetes and metformin treatment on metabolic newborn screening (NBS) results of infants born to mothers with hyperglycemia during pregnancy." | 8.02 | Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening. ( Estrella, J; Hng, TM; McLean, M; Simmons, D; Wiley, V, 2021) |
| " We compared patients who received metformin throughout pregnancy to those with no metformin exposure." | 8.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Recent research has demonstrated the benefits of metformin treatment in gestational diabetes (GDM) on short-term pregnancy outcomes (including excessive fetal growth and pre-eclampsia), but its effects on fetal metabolism remain mostly unknown." | 8.02 | Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone. ( Huhtala, MS; Pellonperä, O; Rönnemaa, T; Tertti, K, 2021) |
| "Gestational metformin attenuated the adiposity in obese dams and increased the gestation length without correcting the offspring in utero growth restriction and catch-up growth caused by maternal obesity." | 8.02 | Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Ozanne, SE; Schoonejans, JM, 2021) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 7.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| " This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality." | 7.96 | Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis. ( Burden, C; Carlsen, SM; Dodd, JM; Hague, W; Hilkka, I; Løvvik, T; Morin-Papunen, L; Mousa, A; Nicolaides, K; Norman, JE; Rönnemaa, T; Rowan, J; Shehata, H; Syngelaki, A; Teede, HJ; Tertti, K; Vanky, E, 2020) |
| " In our study, we explored the changes in metabolic health and cognitive function in mice of middle- and old- age after exposure to GDM, and whether metformin therapy during pregnancy provided long-term benefits." | 7.96 | Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes. ( Baker, PN; Chen, X; Han, TL; Qi, H; Wang, A; Yu, X; Zhang, H; Zhao, X; Zhao, Y; Zhou, X, 2020) |
| "Metformin use in pregnancy is controversial because metformin crosses the placenta and the safety on the fetus has not been well-established." | 7.96 | Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant. ( Chang, SH; Chiou, MJ; Huang, YT; Kuo, CF; Lin, SF; Lin, WT, 2020) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 7.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "Metformin has been reported to be involved in the pathogenesis of PE (pre-eclampsia)." | 7.91 | Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9. ( Ding, Y; Gu, W; Lu, L; Yuan, X, 2019) |
| "Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia." | 7.91 | Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet. ( Cao, G; Cao, X; Li, L; Wang, F; Yi, W, 2019) |
| "We found no clear evidence of any adverse outcomes related to the use of metformin for the treatment of hyperglycemia in pregnancy." | 7.91 | Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register. ( Barzi, F; Boyle, J; Brown, A; Chitturi, S; Connors, C; Corpus, S; Cotter, M; Dowden, M; Inglis, C; Kirkham, R; Kirkwood, M; Lee, IL; Lindenmayer, G; Longmore, D; Maple-Brown, LJ; McIntyre, HD; Moore, E; O'Dea, K; Oats, J; Shaw, JE; Thomas, S; van Dokkum, P; Whitbread, C; Wicks, M; Zimmet, P, 2019) |
| "We evaluated the risk of major birth defects and pregnancy losses in a cohort of pregnant women exposed to metformin during the first trimester for different indications relative to a matched unexposed reference group." | 7.88 | Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. ( Amar, E; Baud, D; Beau-Salinas, F; Bernard, N; Buclin, T; Cassina, M; Csajka, C; Dautriche, A; De Santis, M; Duman, MK; Dunstan, H; Eleftheriou, G; Hernandez-Diaz, S; Kaplan, YC; Klinger, G; Maňáková, E; Panchaud, A; Passier, A; Pistelli, A; Rothuizen, LE; Rousson, V; Vial, T; Winterfeld, U, 2018) |
| "The initiation of metformin in early pregnancy in Gestational Diabetes mellitus (GDM) remains controversial." | 7.88 | How safe is metformin when initiated in early pregnancy? A retrospective 5-year study of pregnant women with gestational diabetes mellitus from India. ( Asha, HS; Dasgupta, R; Gupta, V; Mathews, JE; Paul, T; Ramachandran, R; Regi, A; Thomas, N; Visalakshi, P, 2018) |
| "To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies." | 7.88 | Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. ( Addor, MC; Bakker, M; Bertaut-Nativel, B; Dolk, H; Garne, E; Gatt, M; Given, JE; Klungsoyr, K; Lelong, N; Loane, M; Morgan, M; Neville, AJ; Pierini, A; Rissmann, A, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 7.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| "To evaluate the norepinephrine (NE) and placental NE transporter (NET) in women with polycystic ovary syndrome (PCOS) non-treated and treated with metformin during pregnancy." | 7.85 | Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome. ( Crisosto, N; Echiburú, B; Lara, HE; Maliqueo, M; Medina, G; Sir-Petermann, T, 2017) |
| " Clinical pregnancy rates and implantation rates were similar in all groups, although the numbers of oocytes, mature oocytes, fertilized oocytes, and transferred embryos were lower in the treatment groups received metformin compared to the OC group and control group." | 7.85 | Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. ( Gurgan, T; Kalem, MN; Kalem, Z, 2017) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 7.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 7.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| "To assess the effect of metformin in controlling Gestational Diabetes Mellitus (GDM) in women with Polycystic Ovarian Syndrome (PCOS)." | 7.81 | Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome. ( Aftab, S; Ainuddin, JA; Kamran, A; Kazi, S, 2015) |
| "To evaluate the effectiveness of metformin therapy in reducing early pregnancy loss in pregnant women with polycystic ovary syndrome (PCOS)." | 7.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "Pregnant nondiabetic mice were administered metformin beginning on the first day of pregnancy." | 7.80 | Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy. ( Lee, HY; Loeken, MR; Wei, D, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 7.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 7.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 7.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes." | 7.77 | Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ( Cavalli, RC; Dantas Moisés, EC; Dantes Moisés, EC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL, 2011) |
| "Our objective was to evaluate the pharmacokinetics of metformin during pregnancy." | 7.76 | Pharmacokinetics of metformin during pregnancy. ( Carr, D; Clark, SM; Easterling, TR; Eyal, S; Hankins, GD; Hebert, MF; Kelly, EJ; Miodovnik, M; Risler, L; Shen, DD; Umans, JG; Wang, J, 2010) |
| " Women who had elective cryopreservation due to ovarian hyperstimulation syndrome risk were found to have significantly higher LBRs if metformin was taken in the fresh IVF/ICSI cycle (A = 44." | 7.76 | Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. ( Acharya, S; Balen, A; Brewer, C; Tang, T; Thake, F, 2010) |
| "The aim of the present study was to assess whether continuation of metformin therapy throughout pregnancy can reduce the development of gestational diabetes in women with polycystic ovarian syndrome (PCOS)." | 7.75 | Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. ( Begum, A; Begum, MR; Begum, MS; Ferdous, J; Khan, F; Khanam, NN; Quadir, E, 2009) |
| "Women with GDM treated with metformin and with similar baseline risk factors for adverse pregnancy outcomes had less weight gain and improved neonatal outcomes compared with those treated with insulin." | 7.75 | Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. ( Balani, J; Hyer, SL; Rodin, DA; Shehata, H, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 7.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 7.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "In women with PCOS, continuous use of metformin during pregnancy significantly reduced the rate of miscarriage, gestational diabetes requiring insulin treatment and fetal growth restriction." | 7.74 | Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? ( Khalid, R; Naru, T; Nawaz, FH; Rizvi, J, 2008) |
| "Metformin-associated lactic acidosis is a rare but serious condition and potentially even more hazardous during pregnancy." | 7.74 | Metformin-associated lactic acidosis in a pregnant patient. ( Chen, IC; Hong, YC; Hsiao, CT; Kuan, JT; O'Boyle, CP, 2008) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 7.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "In women with polycystic ovary syndrome, metformin administration, not laparoscopic ovarian drilling, reduces plasminogen activator inhibitor 1 (PAI-1) activity." | 7.73 | Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "The pharmacokinetic disposition of metformin in late pregnancy was studied together with the level of fetal exposure at birth." | 7.73 | Population pharmacokinetics of metformin in late pregnancy. ( Charles, B; Hague, W; Norris, R; Xiao, X, 2006) |
| "To review pregnancy outcomes in women with Type 2 diabetes (Type 2 DM), comparing women treated with those not treated with metformin." | 7.73 | Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006) |
| "To determine the effects of pregnancy on metformin pharmacokinetics." | 7.73 | Effect of pregnancy on the pharmacokinetics of metformin. ( Begg, EJ; Gardiner, SJ; Hughes, RC; Zhang, M, 2006) |
| "A pregnant patient with polycystic ovary syndrome asked me whether continuing metformin, which she was taking to treat infertility before her pregnancy, is safe for her fetus." | 7.73 | Metformin use during the first trimester of pregnancy. Is it safe? ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To analyze pregnancy complications and outcome in patients with polycystic ovary syndrome (PCOS) treated with metformin." | 7.73 | Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. ( Jackson, EM; Thatcher, SS, 2006) |
| "To report the effect of metformin treatment on a patient with recurrent miscarriage (RM) and polycystic ovary syndrome (PCOS)." | 7.73 | Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "55 g metformin per day throughout pregnancy and lactation." | 7.73 | Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. ( Glueck, CJ; Salehi, M; Sieve, L; Wang, P, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 7.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| "The mean birth weight percentile of neonates exposed to metformin in utero during the first trimester was significantly lower than that of neonates delivered to normal healthy matched controls." | 7.73 | Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. ( Glezerman, M; Gur, D; Kovo, M; Levran, D; Rotmensch, S; Weissman, A, 2006) |
| "To evaluate the effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome (PCOS)." | 7.72 | [Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome]. ( Chi, HH; Lin, JJ; Lin, WQ; Ye, BL; Zhao, JZ, 2003) |
| "The aim of this study was to assess the efficacy of metformin on induction of ovulation in Asian women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 7.72 | Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome. ( Choktanasiri, W; Rojanasakul, A; Sophonsritsuk, A; Tingthanatikul, Y; Wansumrith, S; Weerakiet, S, 2004) |
| "We sought to determine whether metformin, which had facilitated conception in 72 oligoamenorrhoeic women with polycystic ovary syndrome (PCOS), would safely reduce the rate of first trimester spontaneous abortion (SAB) and increase the number of live births without teratogenicity." | 7.71 | Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. ( Glueck, CJ; Goldenberg, N; Sieve-Smith, L; Wang, P, 2002) |
| "To determine if metformin therapy improves in vitro fertilization (IVF) outcomes in patients with clomiphene-resistant polycystic ovarian syndrome (PCOS)." | 7.71 | Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. ( Riehl, RM; Stadtmauer, LA; Talbert, LM; Toma, SK, 2001) |
| "We evaluated the fertility promoting effect of metformin in infertile patients with polycystic ovary syndrome." | 7.71 | Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. ( Batukan, C; Baysal, B, 2001) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 7.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| "To assess pregnancy outcome in anovulatory infertility patients diagnosed with polycystic ovary syndrome (PCOS) who were treated with metformin." | 7.71 | Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. ( Buster, JE; Carson, SA; Heard, MJ; Pierce, A, 2002) |
| "To assess the therapeutic effects of metformin in patients with polycystic ovary syndrome (PCOS) and clomiphene (CC) resistant cases." | 7.71 | [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. ( Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 7.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 7.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Treatment with metformin and NAC significantly increased ovulation and pregnancy rates in CC-resistant PCOS patients." | 6.84 | Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. ( Heidari, B; Nemati, M; Nemati, S; Taheri, AM, 2017) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 6.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "Metformin is a safe, cheap drug that can help in prevention of OHSS." | 6.72 | Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. ( Fotouh, IA; Khattab, S; Metwally, M; Moaz, M; Mohesn, IA, 2006) |
| "When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence." | 6.61 | Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. ( Balen, AH; Morley, LC; Norman, RJ; Sharpe, A; Tang, T, 2019) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 6.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| "Metformin is an effective insulin sensitizer treating type 2 diabetes mellitus." | 6.50 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. ( Wang, A; Yu, H; Zhuo, Z, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 6.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 6.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 6.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 6.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 6.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 6.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "Primary articles were identified by a MEDLINE search (1966-March 2007) using the MeSH headings: pregnancy in diabetics, pregnancy, polycystic ovary syndrome, hypoglycemic agents, glipizide, glyburide, metformin, rosiglitazone, pioglitazone, clinical trial, controlled clinical trial, multicenter study, randomized controlled trial, case-control studies, and cohort studies." | 6.22 | Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? ( Briggs, GG; Feig, DS; Koren, G, 2007) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 5.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| "Metformin treatment reduced weight gain and visceral fat accumulation." | 5.72 | Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice. ( Appel, S; Bae-Gartz, I; Dötsch, J; Gellhaus, A; Gründemann, D; Handwerk, M; Hucklenbruch-Rother, E; Janoschek, R; Kammerer, MD; Köninger, A; Kretschmer, T; Schmitz, K; Turnwald, EM; Voßbrecher, K; Wohlfarth, M, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 5.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "Metformin for women with overweight or obesity during pregnancy has been evaluated in randomized trials to reduce adverse pregnancy and birth outcomes." | 5.69 | Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity. ( Deussen, AR; Dodd, JM; Louise, J, 2023) |
| "Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children." | 5.69 | Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. ( Armson, A; Asztalos, E; Barrett, J; Donovan, L; Fantus, IG; Feig, DS; Hamilton, J; Haqq, AM; Jiang, Y; Karanicolas, P; Klein, G; Lipscombe, L; Mangoff, K; Murphy, KE; Sanchez, JJ; Simmons, D; Tobin, S; Tomlinson, G; Zinman, B, 2023) |
| "To compare body composition, visceral adiposity, adipocytokines, and low-grade inflammation markers in prepubertal offspring of mothers who were treated with metformin or insulin for gestational diabetes mellitus (GDM)." | 5.69 | Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years. ( Koskensalo, K; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Parkkola, R; Rönnemaa, T; Tertti, K; Tossavainen, P; Vääräsmäki, M; Veijola, R, 2023) |
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 5.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "<6." | 5.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "Metformin is prescribed to women with polycystic ovary syndrome (PCOS) to prevent pregnancy complications." | 5.51 | Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study. ( Ebbing, C; Grindheim, S; Karlsen, HO; Kessler, J; Lønnebotn, M; Løvvik, T; Real, FG; Skulstad, SM; Vanky, E, 2022) |
| "Our study assesses perinatal outcomes among women with type 2 diabetes, with gestational weight gain (GWG) within and outside of US Institute of Medicine (IOM) guidelines, by conducting a secondary analysis of the Metformin in Type 2 Diabetes in Pregnancy (MiTy) trial." | 5.51 | Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial. ( Feig, DS; Fu, J; Tomlinson, G, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 5.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "The Pregnancy Outcomes: Effects of Metformin study is a multicentre, open-label, randomised, controlled trial." | 5.51 | Pregnancy Outcomes: Effects of Metformin (POEM) study: a protocol for a long-term, multicentre, open-label, randomised controlled trial in gestational diabetes mellitus. ( Erwich, JJHM; Hoogenberg, K; Kooy, A; Lutgers, HL; Prins, JR; van Dijk, PR; van Hoorn, EGM, 2022) |
| "In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin." | 5.51 | Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 5.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 5.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 5.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| "To evaluate the impact of preemptive metformin on the level of glycosylated hemoglobin (HbA1c) at 36 weeks of pregnancy in women with gestational diabetes mellitus controlled by diet change (GDMA1)." | 5.51 | Metformin in gestational diabetes mellitus: A double-blind placebo-controlled randomized trial. ( Hong, JGS; Omar, SZ; Saaid, R; Tan, PC; Tew, MP, 2022) |
| "Metformin is widely used in pregnancy, despite lack of long-term safety for children." | 5.51 | Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood. ( Denison, FC; Dhaun, N; Drake, AJ; Lacey, L; Norman, JE; Quenby, S; Reynolds, RM; Whyte, S; Yang, L, 2022) |
| "Metformin (Met) has been found to modify the methylation of H19 and to alter its expression." | 5.51 | Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. ( Chen, C; Dong, S; Gu, J; He, J; Mo, Y; Shah, NK; Shu, C; Wu, L; Yan, D, 2019) |
| "Metformin is a hydrophilic cation and relies on organic cation transporters to move across cell membranes." | 5.48 | Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy. ( Easterling, TR; Hebert, MF; Lee, N; Liang, CJ; Rice, K; Wagner, DJ; Wang, J, 2018) |
| "Letrozole-treated patients required a significantly lower amount of gonadotropins units (p < 0." | 5.48 | Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study. ( Cantatore, C; Caringella, AM; Caroppo, E; D'Amato, G; Palini, S; Stanziano, A, 2018) |
| "Metformin has been used for the treatment of some metabolic diseases during gestation and the beneficial effects of metformin to the vascular system have been described in diabetic and obese animal models." | 5.46 | Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings. ( Ceravolo, GS; Forcato, S; Gerardin, DCC; Loiola, GH; Novi, DRBS; Vidigal, CB, 2017) |
| "Metformin has potential to prevent or treat preeclampsia." | 5.43 | Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Illanes, SE; Kaitu'u-Lino, TJ; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2016) |
| "The use of metformin in gestational diabetes is safe and effective, yet some women require additional insulin therapy to achieve glycaemic targets." | 5.43 | Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. ( Fulcher, GR; Glastras, SJ; Hocking, S; McGrath, RT, 2016) |
| " Metformin, which ameliorate hormonal disturbances in non-pregnant women with PCOS is increasingly used in pregnancy." | 5.41 | Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Madsen, A; Mellgren, G; Sagen, JV; Salvesen, Ø; Vanky, E; Ødegård, R, 2021) |
| "To evaluate whether extended release metformin could be used to prolong gestation in women being expectantly managed for preterm pre-eclampsia." | 5.41 | Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. ( Brownfoot, F; Cluver, CA; Decloedt, EH; Hall, DR; Hiscock, R; Kaitu'u-Lino, TJ; Mol, BW; Schell, S; Tong, S; Walker, SP, 2021) |
| "Unlike insulin, metformin lowered neonatal birth weights (mean difference - 122." | 5.41 | Short-term neonatal outcomes in women with gestational diabetes treated using metformin versus insulin: a systematic review and meta-analysis of randomized controlled trials. ( Jiang, G; Li, H; Lin, X; Lv, B; Ni, J; Sheng, B, 2023) |
| "Metformin is considered as first-line treatment for type 2 diabetes and an effective treatment for polycystic ovary syndrome (PCOS)." | 5.41 | Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. ( Abolhassani, N; Del Giovane, C; Jaques, C; Kaplan, YC; Minder Wyssmann, B; Panchaud, A; Winterfeld, U, 2023) |
| "A total of 27 RCTs with 12 interventions were included, and all therapies tended to increase clinical pregnancy, especially pioglitazone (PIO) (log OR 3." | 5.41 | The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. ( Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z, 2023) |
| "Metformin is used worldwide in the treatment of type 2 diabetes and has been used in the treatment of diabetes in pregnancy since the 1970s." | 5.41 | Focus on Metformin: Its Role and Safety in Pregnancy and Beyond. ( Dunne, FP; Ero, A; Newman, C; Rabbitt, L, 2023) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 5.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy." | 5.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| " Included were 3 case reports detailing pregnancy outcomes in individual patients that conceived while on a GLP-1 RA and 2 randomized controlled trials (RCTs) and a follow-up study to one of the RCTs that reported on patients randomized to GLP-1 RA or metformin prior to conception." | 5.41 | Glucagon-like peptide-1 receptor agonists and safety in the preconception period. ( Mahalingaiah, S; Minis, E; Stanford, FC, 2023) |
| "To evaluate the benefits of myoinositol plus metformin versus myoinositol alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction cycles." | 5.41 | Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. ( Bhatla, N; Gupta, M; Kachhawa, G; Khadgawat, R; Kumari, R; Mahey, R; Prabhakar, P; Sharma, JB; Vanamail, P, 2021) |
| " Except one woman in the myoinositol group, all women provided glycaemia data throughout their pregnancy." | 5.41 | Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial. ( Balani, S; Bhatla, N; Kachhawa, G; Kulshrestha, V; Kumari, R; Sharma, JB; Vanamail, P, 2021) |
| "We conclude that addition of ALC therapy is superior to metformin plus pioglitazone in ameliorating insulin resistance, polycystic ovaries, menstrual irregularities, and hypoadiponectinemia in women with PCOS." | 5.41 | Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial. ( Badshah, H; Ehtesham, E; Habib, SH; Israr, M; Malik, MO; Rauf, B; Raza, MA; Shah, FA; Shah, I; Shah, M; Tauqir, S; Usman, M, 2021) |
| "Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant." | 5.36 | Metformin treatment for Type 2 diabetes in pregnancy? ( Simmons, D, 2010) |
| "GVHD had little effect." | 5.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "Sixty women with gestational and type 2 diabetes were enrolled, 30 each for metformin and insulin." | 5.35 | Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy. ( Kamath, A; Meenakshi, D; Rai, L, 2009) |
| "An 8-year clinical follow-up study including self-reported asthma diagnoses and spirometry of women with PCOS randomized to metformin or placebo during pregnancy in the original studies (the Pilot and the PregMet-study), compared with matched controls from a population-based cohort study (The HUNT Study)." | 5.34 | Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study. ( Andersen, M; Henriksen, AH; Salvesen, Ø; Underdal, MO; Vanky, E, 2020) |
| "Gestational diabetes mellitus is a condition similar to type 2 diabetes mellitus (T2DM) in that patients are unable to compensate for the degree of insulin resistance, and both conditions are often treated with metformin." | 5.34 | Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. ( Ahmed, MS; Brown, Z; Caritis, S; Clark, S; Easterling, TR; Flood Nichols, SK; Haas, DM; Haneline, LS; Hebert, MF; Ma, X; Manuck, TA; Morris Brown, L; Quinney, SK; Ren, Z; Shen, DD; Shireman, LM; Shuster, DL; Thummel, KE; Tita, AT; Venkataramanan, R, 2020) |
| "Metformin is widely used in pregnancy to treat gestational diabetes mellitus and polycystic ovary syndrome (PCOS)." | 5.34 | Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT. ( Greger, HK; Hanem, LGE; Vanky, E; Østgård, HF, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 5.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| "Optimising health outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA) is a multicentre placebo-controlled double-blind randomised feasibility trial, where we will randomly allocate 160 postnatal women with gestational diabetes treated with medication to either metformin (intervention) or placebo (control) tablets to be taken until 1 year after delivery." | 5.34 | Effectiveness and acceptability of metformin in preventing the onset of type 2 diabetes after gestational diabetes in postnatal women: a protocol for a randomised, placebo-controlled, double-blind feasibility trial—Optimising health outcomes with Metformi ( Amaefule, CE; Bolou, A; D'Amico, M; Daru, J; Dodds, J; Drymoussi, Z; Gonzalez Carreras, FJ; Harden, A; Heighway, J; Hitman, G; Huda, MS; Khan, K; Lanz, D; Pardo Llorente, MDC; Pérez, T; Pizzo, E; Robson, J; Sanghi, A; Sobhy, S; Sweeney, L; Thangaratinam, S; Thomas, A; Zamora, J, 2020) |
| "Metformin had beneficial effects on maternal serum IGFBP-1 concentrations compared to insulin, as increased IGFBP-1 related to lower total and late pregnancy maternal weight gain." | 5.34 | Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial. ( Huhtala, MS; Juhila, J; Rönnemaa, T; Sorsa, T; Tertti, K, 2020) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 5.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity." | 5.34 | Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial. ( Deussen, AR; Dodd, JM; Louise, J; Poprzeczny, AJ, 2020) |
| "To compare the effects of metformin and insulin treatment on maternal serum lipids in patients with gestational diabetes (GDM), and to analyse the associations between individual lipids and birth weight (BW)." | 5.34 | Serum lipids and their association with birth weight in metformin and insulin treated patients with gestational diabetes. ( Huhtala, MS; Rönnemaa, T; Tertti, K, 2020) |
| "This study aimed to evaluate the treatment efficacy of dapagliflozin and metformin, alone and in combination, on body weight and anthropometric, cardiovascular, and metabolic parameters in overweight women with a recent history of gestational diabetes mellitus." | 5.34 | A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. ( Elkind-Hirsch, KE; Harris, R; Seidemann, E, 2020) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 5.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "Metformin was then administered." | 5.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "Polycystic ovary syndrome is the most common form of female infertility in the United States." | 5.31 | Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. ( Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE; Roberts, KA, 2002) |
| "For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10-20 weeks' gestation does not improve pregnancy and birth outcomes." | 5.30 | Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. ( Dekker, G; Deussen, AR; Dodd, JM; Grivell, RM; Hague, W; Louise, J; McPhee, AJ, 2019) |
| "The present study was planned to evaluate the benefit of synergetic effect of Metformin plus Myo-inositol versus Metformin alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction." | 5.30 | Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. ( Agrawal, A; Kachhawa, G; Khadgawat, R; Kriplani, A; Mahey, R; Vanamail, P, 2019) |
| "Metformin is increasingly used to treat gestational diabetes and type 2 diabetes in pregnancy, and in attempts to improve pregnancy outcomes in polycystic ovary syndrome and obesity." | 5.30 | Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Nossum, MCF; Salvesen, Ø; Vaage, MØ; Vanky, E; Ødegård, R, 2019) |
| " Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group." | 5.30 | Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. ( Andræ, F; Berg, AH; Bixo, M; Carlsen, SM; Gómez-Real, F; Hestvold, KV; Hirschberg, AL; Hjelle, S; Lønnebotn, M; Løvvik, TS; Mohlin, J; Poromaa, IS; Salvesen, Ø; Steffensen, B; Thorarinsdottir, S; Trouva, A; Underdal, M; Vanky, E; Zabielska, R, 2019) |
| "To evaluate the reproductive and metabolic effects of L-carnitine plus metformin in clomiphene citrate (CC) resistant obese polycystic ovary syndrome (PCOS) women." | 5.30 | l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. ( El Sharkwy, I; Sharaf El-Din, M, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 5.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| "A total of 202 patients with clomiphene citrate (CC) -resistant polycystic ovary syndrome (PCOS) were randomly allocated into two arms of induction of ovulation; the first group (n = 102) received CC 100 mg and metformin 500 mg while the second group (n = 100) received letrozole 2." | 5.27 | Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. ( Rezk, M; Saif El-Nasr, I; Shaheen, AE, 2018) |
| "We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR)." | 5.27 | Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study. ( Abusada, N; Candia, P; Cuellar, E; Manukian, B; Orellana, R; Sepúlveda-Martínez, A; Valdés, E, 2018) |
| "Metformin is used in an attempt to reduce pregnancy complications associated with polycystic ovary syndrome (PCOS)." | 5.27 | Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS. ( Eggebø, T; Engen Hanem, LG; Hjorth-Hansen, A; Salvesen, KÅ; Salvesen, Ø; Vanky, E; Ødegård, R, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 5.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 5.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 5.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "This is a randomized double-blind multi-center clinical trial of insulin plus metformin versus insulin plus placebo for the treatment of type 2 diabetes complicating pregnancy." | 5.27 | Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study. ( Berry, DC; Boggess, K; de Los Angeles Abreu, M; Dorman, KF; Ivins, AR; Thomas, SD; Young, L, 2018) |
| "Metformin has been used in pregnancy since the 1970s." | 5.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial." | 5.22 | Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome. ( Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022) |
| "The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate the role of metformin in improving the reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome." | 5.22 | Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. ( Kheirelseid, EAH; Lewis, S; Magzoub, R; Perks, C, 2022) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 5.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "To evaluate the efficacy and safety of using metformin in pregnant women with polycystic ovarian syndrome (PCOS) and to explore the most effective and safe protocol by using a meta-analysis method." | 5.22 | Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials. ( He, J; Zhao, Q, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 5.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "gov for randomized controlled trials (RCTs) that compared metformin to insulin in pregnancy." | 5.22 | The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials. ( Ge, J; Guo, Q; He, K; Jing, Z; Li, C; Li, J, 2022) |
| "Metformin in pregnancy did not affect cervical length in women with PCOS." | 5.22 | Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect? ( Carlsen, SM; Salvesen, Ø; Shetelig Løvvik, T; Stridsklev, S; Vanky, E, 2016) |
| "Among women without diabetes who had a BMI of more than 35, the antenatal administration of metformin reduced maternal weight gain but not neonatal birth weight." | 5.22 | Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. ( Akolekar, R; Balani, J; Hyer, S; Kotecha, R; Nicolaides, KH; Pastides, A; Shehata, H; Syngelaki, A, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 5.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to insulin in this high risk population." | 5.22 | Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. ( Armson, AB; Asztalos, E; Barrett, JF; Fantus, IG; Feig, DS; Lipscombe, LL; Murphy, K; Ohlsson, A; Ryan, EA; Sanchez, J; Tomlinson, G; Zinman, B, 2016) |
| "A pilot randomized, controlled trial was conducted of metformin versus insulin for the treatment of T2DM during pregnancy." | 5.20 | A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. ( Blackwell, SC; Gowen, R; Hutchinson, M; Pedroza, C; Ramin, S; Refuerzo, JS, 2015) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 5.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "Less maternal weight gain was found in the metformin treated groups (9." | 5.20 | Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. ( Ainuddin, J; Hasan, AA; Karim, N; Naqvi, SA, 2015) |
| "We sought to compare weight loss in the first 6 weeks postpartum among women with gestational diabetes mellitus (GDM) treated with metformin or placebo, a promising therapy to reduce later risk of progression to diabetes mellitus." | 5.20 | The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial. ( Blackwell, SC; Hutchinson, M; Pedroza, C; Ramin, SM; Refuerzo, JS; Tyson, JE; Viteri, OA, 2015) |
| " We present a protocol for a study to test the hypothesis that metformin will improve insulin sensitivity in obese pregnant women, thereby reducing the incidence of high birthweight babies and other pregnancy complications." | 5.20 | Efficacy of metformin in pregnant obese women: a randomised controlled trial. ( Chiswick, CA; Denison, FC; Drake, AJ; Forbes, S; Murray, GD; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Walker, BR; Whyte, SA; Wray, S, 2015) |
| "To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability." | 5.20 | Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015) |
| "To determine if metformin monotherapy or metformin in combination with insulin is equally effective as insulin monotherapy at glycemic control in diabetes mellitus in pregnancy among Ghanaians." | 5.20 | Metformin versus Insulin in the Management of Pre-Gestational Diabetes Mellitus in Pregnancy and Gestational Diabetes Mellitus at the Korle Bu Teaching Hospital: A Randomized Clinical Trial. ( Adjepong-Yamoah, KK; Beyuo, T; Bugyei, KA; Marfoh, K; Obed, SA; Oppong, SA, 2015) |
| "To assess the adjuvant effect of metformin and N-acetylcysteine (NAC) to clomiphene citrate (CC) in induction of ovulation in Polycystic Ovary Syndrome (PCOS) patients." | 5.20 | The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome. ( Abdelhafez, A; Bakry, A; Elsawah, H; Maged, AM; Mostafa, WA, 2015) |
| "Berberine and metformin treatments prior to IVF improved the pregnancy outcome by normalizing the clinical, endocrine and metabolic parameters in PCOS women." | 5.19 | The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. ( An, Y; Guan, Y; Liu, B; Lu, M; Sun, Z; Zhang, Y, 2014) |
| "Adding metformin to insulin therapy in women with insulin-resistant diabetes mellitus with pregnancy seems to be effective in proper glycemic control in a considerable proportion of women, along with benefits of reduced hospital stay, reduced frequency of maternal hypoglycemia as well as reduced frequency of neonatal hypoglycemia, NICU admission and neonatal respiratory distress syndrome." | 5.19 | The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial. ( Anwar, M; Faris, M; Hamdy, A; Ibrahim, MI; Shafik, A; Taha, S, 2014) |
| "Metformin is used to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS), although it is not approved for this indication and solid evidence is lacking." | 5.19 | Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. ( Carlsen, SM; Clemens, I; Salvesen, Ø; Stridsklev, S; Vanky, E, 2014) |
| "Metformin is suggested to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS)." | 5.19 | Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin. ( Carlsen, SM; Helseth, R; Stridsklev, S; Vanky, E; Vogt, C, 2014) |
| "Training during pregnancy was not associated with altered levels of cffDNA cfmDNA or cftDNA, but metformin treatment may reduce cfmDNA and cftDNA in pregnant PCOS women." | 5.19 | The effect of exercise and metformin treatment on circulating free DNA in pregnancy. ( Carlsen, SM; Christiansen, SC; Klungland, H; Mørkved, S; Salvesen, KÅ; Stafne, SN; Sæther, M; Vanky, E, 2014) |
| "Total, but not bioavailable, vitamin B12 stores were depleted during pregnancy to a greater extent in metformin-treated than in insulin-treated women with GDM, but neither analyte differed between groups at any stage." | 5.17 | Vitamin B12 and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment. ( Baghurst, PA; Coat, S; Gatford, KL; Hague, WM; Houda, CM; Lu, ZX; Owens, JA; Rowan, JA; Sikaris, K, 2013) |
| "Metformin was found to provide adequate glycemic control with lower mean glucose levels throughout the day, less weight gain and a lower frequency of neonatal hypoglycemia." | 5.17 | Randomized trial of metformin vs insulin in the management of gestational diabetes. ( Bernardes, LS; Francisco, RP; Spaulonci, CP; Trindade, TC; Zugaib, M, 2013) |
| "The aim of this study was to evaluate the effectiveness of Metformin on ovulation and eventual clinical pregnancy in different phenotypes of polycystic ovary syndrome (PCOS)." | 5.17 | Metformin treatment in different phenotypes of polycystic ovary syndrome. ( Alleyassin, A; Fanisalek, M; Hosseini, MA; Kokab, A; Safdarian, L; Sarvi, F, 2013) |
| "To compare the efficacy of metformin with insulin in the management of pregnancy with diabetes." | 5.17 | Efficacy of metformin versus insulin in the management of pregnancy with diabetes. ( Malik, FP; Mazhar, SB; Waheed, S, 2013) |
| "We conducted a single centre randomized controlled study with non-inferiority design comparing metformin and insulin in the treatment of 217 GDM patients having birth weight as primary outcome variable." | 5.17 | Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. ( Ekblad, U; Koskinen, P; Rönnemaa, T; Tertti, K; Vahlberg, T, 2013) |
| "Metformin should be considered for treatment of overt diabetes and early A2 gestational diabetes in pregnancy." | 5.17 | Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. ( Boggess, KA; Hickman, MA; McBride, R; Strauss, R, 2013) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 5.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes between women receiving metformin plus letrozole and women undergoing bilateral ovarian drilling in clomiphene citrate (CC)-resistant women with polycystic ovary syndrome (PCOS)." | 5.17 | Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. ( Abd Elgafor, I, 2013) |
| "The role of metformin in the treatment of infertility in women with polycystic ovary syndrome (PCOS) is still controversial." | 5.16 | Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. ( Bloigu, R; Hippeläinen, M; Morin-Papunen, L; Perheentupa, A; Puukka, K; Rantala, AS; Ruokonen, A; Tapanainen, JS; Tiitinen, A; Tinkanen, H; Unkila-Kallio, L, 2012) |
| "To estimate whether progestin-induced endometrial shedding, before ovulation induction with clomiphene citrate, metformin, or a combination of both, affects ovulation, conception, and live birth rates in women with polycystic ovary syndrome (PCOS)." | 5.16 | Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. ( Brzyski, R; Carr, BR; Carson, S; Casson, P; Cataldo, NA; Christman, G; Coutifaris, C; Diamond, MP; Eisenberg, E; Gosman, GG; Kruger, M; Legro, RS; McGovern, PG; Myers, EE; Nestler, JE; Santoro, N; Schlaff, W; Steinkampf, MP; Zhang, H, 2012) |
| "To study the significance of breast size increment in pregnancy, and the impact of metformin during pregnancy on breastfeeding in women with polycystic ovary syndrome (PCOS)." | 5.16 | Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. ( Carlsen, SM; Hjorth-Hansen, AK; Leithe, H; Martinussen, M; Nordskar, JJ; Vanky, E, 2012) |
| "This is a follow-up study of a randomized, controlled trial on PCOS women, randomized to metformin or placebo in pregnancy." | 5.16 | Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. ( Carlsen, SM; Ludvigsen, HV; Rø, TB; Vanky, E, 2012) |
| "The use of metformin throughout gestation by women with polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) significantly reduces the number of first-trimester spontaneous abortions and the rate of occurrence of gestational diabetes and hypertensive syndromes." | 5.16 | Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ( Cavalli, RC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL; Moisés, EC, 2012) |
| " The neonates of metformin group had less rate of birth weight centile >90 than insulin group (RR: 0." | 5.16 | Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. ( Akbari, S; Alavi, A; Amjadi, N; Moosavi, S; Niromanesh, S; Sharbaf, FR, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 5.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "To compare the effect of combined metformin-clomiphene citrate (CC) with highly purified urinary FSH (HP-uFSH) for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.15 | Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial. ( Abu Hashim, H; El Rakhawy, M; Wafa, A, 2011) |
| "To compare the effect of combined metformin and clomiphene citrate (CC) with laparoscopic ovarian diathermy (LOD) meant for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.15 | Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; El Lakany, N; Sherief, L, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 5.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome." | 5.15 | The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Piomboni, P, 2011) |
| " In women with PCOS, metformin co-treatment during IVF has been shown to increase pregnancy rates and reduce the risk of ovarian hyperstimulation syndrome (OHSS)." | 5.15 | Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. ( Child, T; Granne, I; Jayaprakasan, K; Lavery, S; Lighten, A; McVeigh, E; Raine-Fenning, N; Swanton, A; Talmor, A; Trew, G, 2011) |
| "To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS)." | 5.15 | Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. ( Carlsen, SM; Haapaniemikouru, K; Holst-Larsen, T; Humaidan, P; Kjøtrød, SB; Mellembakken, J; Morin-Papunen, L; Rasmussen, PE; Sunde, A; Thurin-Kjellberg, A; von Düring, V, 2011) |
| "Reduction of serum total testosterone (TT) is associated with pregnancy rate in polycystic ovary syndrome (PCOS) women receiving metformin, but most of the studies focus on the changes of basal levels of TT." | 5.15 | Prognostic value of total testosterone for pregnancy during treatment in patients with clomiphene-citrate-resistant polycystic ovary syndrome: a pilot study. ( Cheng, J; Huang, Z; Li, C; Lv, J; Wang, J; Xue, Y; Zhang, S, 2011) |
| "To evaluate the effects of metformin on the ovarian response to gonadotropins given for in vitro fertilization (IVF) programs in patients with polycystic ovary syndrome (PCOS) and reduced ovarian reserve." | 5.15 | Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. ( Cappiello, F; Di Cello, A; Falbo, A; Palomba, S; Tolino, A; Zullo, F, 2011) |
| "To test whether metformin administration reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovary syndrome (PCOS) who have been treated with gonadotropins for IVF." | 5.15 | Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. ( Capasso, S; Cappiello, F; Carrillo, L; Cittadini, E; Colao, A; Di Cello, A; Falbo, A; La Sala, GB; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tolino, A; Villani, MT; Zullo, F, 2011) |
| "To compare the effect of clomiphene citrate, metformin, and lifestyle modification on treatment of patients with polycystic ovary syndrome (PCOS)." | 5.14 | An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. ( Javedani, M; Karimzadeh, MA, 2010) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "The aim of this study was to evaluate the effects of calcium-vitamin D and metformin on the menstrual cycle and ovulation in patients with polycystic ovary syndrome (PCOS)." | 5.14 | The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. ( Haghollahi, F; Rashidi, B; Shariat, M; Zayerii, F, 2009) |
| "This study was conducted to determine the efficacy of metformin vs placebo in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment." | 5.14 | Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. ( Abu-Salem, AN; Al-Ahmad, N; Al-Ibrahim, N; Al-Khaderei, S; Al-Khateeb, M; Al-Zpoon, A; Megdadi, M; Qublan, HS, 2009) |
| "The aim of this study was to assess novel inflammatory markers [adipokines leptin, adiponectin, and leptinadiponectin ratio (L/A)] in overweight women with and without PCOS and to examine alterations in these markers [aldosterone, leptin, adiponectin, and L/A] with pharmacological interventions modulating insulin resistance (IR) in PCOS." | 5.14 | Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention. ( Hutchison, SK; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| "To determine how glucose control in women with GDM treated with metformin and/or insulin influenced pregnancy outcomes." | 5.14 | Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. ( Gao, W; Hague, WM; McIntyre, HD; Rowan, JA, 2010) |
| " The modest weight loss with metformin was maintained." | 5.14 | 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. ( Brenneman, AT; Brown-Friday, JO; Christophi, CA; Fowler, SE; Goldberg, R; Hamman, RF; Hoffman, HJ; Knowler, WC; Nathan, DM; Venditti, E, 2009) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 5.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 5.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "The purpose of this study was to compare the effectiveness of laparoscopic ovarian diathermy (LOD) vs clomiphene citrate (CC) plus metformin in infertile patients with CC-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. ( Battista, L; Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Venturella, R; Zullo, F, 2010) |
| "The aim of this study was to compare the effectiveness of myo-inositol (MYO) and metformin, in monotherapy or in association with recombinant follicle stimulating hormone (r-FSH), in the treatment of menstrual irregularities, chronic anovulation, and female infertility in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. ( Benedetto, V; Raffone, E; Rizzo, P, 2010) |
| "For women with BMI > 32 kg/m(2), clinical pregnancy and live birth rates were 22% (7/32) and 16% (5/32) with metformin, 15% (5/33) and 6% (2/33) with placebo." | 5.14 | PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. ( Buckingham, KL; Falkiner, J; Farquhar, CM; Johnson, NP; Milsom, S; Okonkwo, QL; Singh, VP; Stewart, AW, 2010) |
| "This study was performed with the aim of evaluating the effect of metformin in reducing miscarriage when continued until the end of the first trimester of pregnancy in patients with polycystic ovary syndrome (PCOS) and infertility." | 5.14 | Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome. ( Bagheri, B; Haghollahi, F; Shariat, M; Sohrabvand, F, 2009) |
| "To compare the efficacy of metformin and clomiphene citrate (CC) therapies for ovulation induction in anovulatory infertile women with polycystic ovary syndrome (PCOS)." | 5.14 | Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. ( Api, M; Baran, S; Cetin, A; Goksedef, BP, 2010) |
| "The only significant difference in outcome between the 2 treatment drugs was that maternal weight gain during pregnancy was less in the metformin (n=40) than in the glyburide group (n=32) (10." | 5.14 | Metformin compared with glyburide for the management of gestational diabetes. ( Bertini, AM; Bizato, J; de Souza, BV; Pacheco, C; Ribeiro, TE; Silva, JC, 2010) |
| "Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications." | 5.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "To compare the effects of combined N-acetyl cysteine (NAC) and clomiphene citrate (CC) and of combined metformin and CC on ovulation induction in anovulatory CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.14 | N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; Anwar, K; El-Fatah, RA, 2010) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 5.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "Previous non-randomized and uncontrolled studies indicate major metformin effects on glucose homeostasis in pregnant women with polycystic ovary syndrome (PCOS)." | 5.13 | Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study. ( Carlsen, SM; Fougner, KJ; Vanky, E, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 5.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "Continuation of pregnancy beyond the first trimester in all groups and presence or absence of teratogenicity in the delivered baby after metformin therapy." | 5.13 | Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. ( Kazerooni, T; Soveid, M; Taghieh, M; Tavana, Z; Zolghadri, J, 2008) |
| "To determine the effect of metformin pretreatment on in vitro maturation (IVM) in the patients with clomiphene citrate-resistant polycystic ovary syndrome." | 5.13 | Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome. ( Cao, Y; Cong, L; Li, J; Wei, Z; Zhang, Z; Zhou, P, 2008) |
| "We investigated whether poor adherence with metformin tablets may have contributed to the poor success rates seen in the metformin-containing arms of the Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial." | 5.13 | Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, G; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 5.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "To review the current evidence for the use of metformin in pregnancy for women with type 2 diabetes." | 5.12 | Metformin in Pregnancy for Women with Type 2 Diabetes: a Review. ( Benham, JL; Donovan, LE; Yamamoto, JM, 2021) |
| " Metformin is known to decrease insulin resistance and is also associated with weight loss." | 5.12 | Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence. ( Ayala, NK; Werner, EF; Whelan, AR, 2021) |
| "To evaluate metformin's effects on pregnancy outcomes in women with polycystic ovary syndrome." | 5.12 | Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies. ( Cao, Q; Fu, J; Hu, Y; Huang, W; Huang, X; Wu, L; Zhang, J, 2021) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 5.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "To assess the impact of bariatric surgery on pregnancy outcomes in women with PCOS compared to metformin therapy in a systematic review and meta-analysis." | 5.12 | The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis. ( Chang, C; Chang, S; Poles, J; Popov, V, 2021) |
| "The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine reducing insulin resistance appears to be promising." | 5.12 | Metformin administration during pregnancy - current insight. ( Cypryk, K; Krekora, M; Skibinska, M; Zurawska-Klis, M, 2021) |
| "This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome. ( Chronopoulou, E; Homburg, R; Raperport, C, 2021) |
| "We systematically assessed the impact of metformin treatment on maternal pregnancy outcomes." | 5.12 | Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. ( Aiken, CE; Ozanne, SE; Tarry-Adkins, JL, 2021) |
| "This review study of available literature shows that metformin can be a superior option in most neonatal and maternal adverse pregnancy outcomes in women with gestational diabetes mellitus; the results need to be further updated by including future more qualified studies." | 5.12 | Effectiveness of antidiabetic agents for treatment of gestational diabetes: A methodological quality assessment of meta-analyses and network meta-analysis. ( Amiri, M; Behboudi-Gandevani, S; Bidhendi Yarandi, R; Ramezani Tehrani, F, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "Adding metformin to clomiphene citrate in clomiphene-resistant polycystic ovary syndrome (PCOS) patients increases ovulatory response." | 5.12 | Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. ( Ansari, Sh; Bagheri, M; Sohrabvand, F, 2006) |
| "In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy." | 5.12 | Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. ( Bjerve, K; Carlsen, SM; Hjorth-Hansen, H; Salvesen, KA; Vanky, E, 2006) |
| "Metformin appears to improve reproductive function in some women with polycystic ovary syndrome (PCOS)." | 5.12 | The use of metformin for women with PCOS undergoing IVF treatment. ( Balen, AH; Barth, JH; Glanville, J; Orsi, N; Tang, T, 2006) |
| "To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS)." | 5.12 | A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. ( Ardawi, MS; Rouzi, AA, 2006) |
| "Current data supporting the effectiveness of metformin as a fertility treatment for women with polycystic ovary syndrome have been misinterpreted." | 5.12 | No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. ( Johnson, NP, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "Metformin is better for ovulation induction than CC alone and equivalent for pregnancy achievement." | 5.12 | Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. ( Granger, L; Lavoie, HB; Neveu, N; St-Michel, P, 2007) |
| "A prospective cohort study was set up to determine the beneficial effects of metformin on PCOS patients during pregnancy." | 5.12 | Metformin reduces abortion in pregnant women with polycystic ovary syndrome. ( Al-Inany, H; Foutouh, IA; Khattab, S; Moaz, M; Mohsen, IA; Ramadan, A, 2006) |
| "Metformin appears to be an effective medicine to induce ovulation in women with polycystic ovary syndrome and insulin resistance." | 5.12 | Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome. ( Hirano, Y; Kikuchi, K; Shibahara, H; Suzuki, M; Suzuki, T; Takamizawa, S, 2007) |
| "We randomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene for up to 6 months." | 5.12 | Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, GG; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2007) |
| "Forty pregnant women with polycystic ovary syndrome (PCOS) were enrolled in a randomized, double-blind, placebo-controlled trial of metformin (1700 mg/day) during pregnancy." | 5.12 | Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation? ( Carlsen, SM; Salvesen, KA; Vanky, E, 2007) |
| "Serum homocysteine levels were unaffected by metformin treatment both in nonpregnant and pregnant women with polycystic ovary syndrome." | 5.12 | Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, S; Romundstad, P; Vanky, E, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 5.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "The aim of the study was to compare in a clinical setting the efficacy of CC and metformin as first-line approaches for treating anovulation in infertile PCOS patients." | 5.12 | Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 5.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| "Metformin therapy has led to a higher pregnancy outcome, as well as to a decrease in hyperstimulation risk, cycle cancellations, and multiple pregnancy rates with a lower gonadotropin dosage." | 5.11 | The effect of metformin treatment to ovarian response in cases with PCOS. ( Basaran, T; Ficicioglu, C; Gurbuz, B; Tasdemir, S; Yalti, S; Yildirim, G, 2004) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 5.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 5.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 5.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "Investigation of a possible effect of metformin on androgen levels in pregnant women with polycystic ovary syndrome (PCOS)." | 5.11 | Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. ( Carlsen, SM; Fougner, KJ; Heimstad, R; Romundstad, P; Salvesen, KA; Vanky, E, 2004) |
| "At present, it is unclear what the role is of laparoscopic ovarian diathermy (LOD) and of metformin administration as second-line treatments for ovulation induction in women with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate (CC) treatment." | 5.11 | Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. ( Colao, A; Corea, D; Doldo, P; Falbo, A; Lombardi, G; Nardo, LG; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2004) |
| "To investigate the effects of metformin and clomiphene on infertility caused by polycystic ovary syndrome (PCOS) with insulin-resistance (IR) and to observe the effects of metformin on PCOS with pseudoacanthosis nigricans (AN) and IR." | 5.11 | [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome]. ( Cai, Q; Chen, H; Chen, LX; Cui, QH; Ge, J; Liu, ZA; Xue, YM; Yuan, T; Zhang, J, 2004) |
| "To determine the clinical, biochemical, hormonal, and ultrasonographic effects of 6 months of metformin therapy in women with polycystic ovary syndrome (PCOS) and compare with pretherapy parameters." | 5.11 | Metformin therapy in women with polycystic ovary syndrome. ( Aruna, J; Dadhwal, V; Kumar, S; Misra, R; Mittal, S; Vimala, N, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| "Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients." | 5.11 | Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| " Clomiphene citrate has been standard therapy for ovulation induction in patients seeking pregnancy, but recent evidence suggests that insulin sensitizing agents such as metformin may also be effective." | 5.11 | Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial. ( Hafley, G; Kunselman, AR; Legro, RS; Myers, ER; Nestler, JE; Silva, SG, 2005) |
| "To evaluate the effect of ultra-short (12 days) metformin pretreatment in clomiphene-citrate (CC) resistant polycystic ovary syndrome (PCOS)." | 5.11 | Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. ( Huang, WY; Hwu, YM; Lee, RK; Lin, MH; Lin, SY, 2005) |
| "In the present study, we investigated the impact of metformin therapy on in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes in patients with polycystic ovary syndrome (PCOS)." | 5.11 | Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. ( Bagis, T; Ceyhan, T; Cincik, M; Goktolga, U; Onalan, G; Pabuçcu, R, 2005) |
| "To compare the efficacy of clomiphene citrate (CC) administration for ovulation induction in CC-resistant oligo-ovulatory women with polycystic ovary syndrome (PCOS) after metformin treatment or laparoscopic ovarian drilling (LOD)." | 5.11 | Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. ( Caterina, G; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "This study was conducted to evaluate the efficacy of metformin compared with ovarian drilling in the treatment of clomiphene citrate (CC) resistant women with polycystic ovary syndrome." | 5.10 | Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Hamaideh, AH; Malkawi, HY; Qublan, HS, 2003) |
| " Further we tried to identify the preventive influence of metformin on development of ovarian hyperstimulation syndrome." | 5.10 | [Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome]. ( Crha, I; Ventruba, P; Visnová, H; Záková, J, 2003) |
| "To evaluate the effect of metformin therapy on hyperandrogenism, insulin resistance, cervical scores, ovulation, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS)." | 5.10 | Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. ( Caliskan, E; Haberal, A; Kocak, M; Simsir, C, 2002) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 5.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| "To determine whether metformin pretreatment has beneficial effects in clomiphene resistant infertile women with polycystic ovary syndrome (PCOS) in an infertility clinic." | 5.10 | Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. ( Fay, TN; Lannon, B; Sturrock, ND, 2002) |
| "To study the effect of metformin in combination with clomiphene citrate, as compared with placebo plus clomiphene citrate, on the ovulation and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome." | 5.10 | The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. ( Malkawi, HY; Qublan, HS, 2002) |
| "To evaluate whether pretreatment with metformin improves FSH-induced ovulation in women with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 5.09 | Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. ( Cianci, A; De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 5.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To determine whether metformin treatment increases the ovulation and pregnancy rates in response to clomiphene citrate (CC) in women who are resistant to CC alone." | 5.09 | Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. ( Evans, WS; Kauma, SW; Nestler, JE; Ratts, VS; Stovall, DW; Vandermolen, DT, 2001) |
| "Metformin, an insulin-sensitizing agent, has been used successfully as the first-line drug to induce ovulation in women with polycystic ovary syndrome." | 5.09 | Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. ( Ho, PC; Ng, EH; Wat, NM, 2001) |
| "Previous randomized and observational studies on the efficacy of metformin in pregnancy to reduce incident gestational diabetes mellitus (GDM) in women at high risk (obesity, polycystic ovary syndrome [PCOS], or pregestational insulin resistance) have been conflicting and several groups are planning further randomized controlled trials (RCTs) to answer this question conclusively." | 5.05 | Metformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials. ( Clark, J; Doi, SAR; Furuya-Kanamori, L; Islam, N; Musa, OAH; Thalib, L; Toft, E, 2020) |
| "Our aim is to evaluate the clinical effectiveness and safety by comparing N-acetyl-cysteine (NAC) with metformin administrated by polycystic ovary syndrome (PCOS) patients." | 5.05 | Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis. ( Huang, H; Song, Y; Wang, H; Zhu, Z, 2020) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 5.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| "Metformin is widely used among women with polycystic ovary syndrome (PCOS)." | 5.05 | Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. ( Huang, Y; Liu, Y; Tu, M; Wu, Y; Zhang, D, 2020) |
| "A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed." | 5.05 | The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis. ( Liu, X; Zhang, W; Zhao, J, 2020) |
| "In women with PCOS, letrozole improves live birth and clinical pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be recommended as the preferred first-line treatment for women with PCOS and infertility." | 5.01 | First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. ( Amer, SA; Bhattacharya, S; Bordewijk, EM; Falbo, A; Federica, G; Gao, J; Homburg, R; Huang, W; Johnson, NP; Kar, S; König, TE; Legro, RS; Li, W; Lord, J; Mol, BW; Moll, E; Morin-Papunen, L; Nazik, H; Norman, RJ; Özmen, Ü; Palomba, S; Sahin, Y; van Wely, M; Vegetti, W; Wang, R; Williams, CD; Wu, X; Zhang, H, 2019) |
| "It seems to have no sense to prolong the use of metformin after a pregnancy diagnosis in women with PCOS." | 5.01 | Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions. ( Alvariñas, J; Bagnes, MFG; Di Girolamo, G; Gonzalez, CD, 2019) |
| " Metformin is an effective oral antihyperglycaemic agent that is considered to be effective during pregnancy." | 5.01 | Metformin reduces maternal weight gain in obese pregnant women: A systematic review and meta-analysis of two randomized controlled trials. ( Benedetti Panici, P; Boccherini, C; Brunelli, R; D'Ambrosio, V; Di Mascio, D; Giancotti, A; Marchetti, C; Piccioni, MG; Vena, F, 2019) |
| "Oral antidiabetic medication of metformin is increasingly used in pregnant women with gestational diabetes mellitus (GDM), polycystic ovary syndrome (PCOS) and obesity." | 5.01 | Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis. ( Xie, Q; Xu, Q, 2019) |
| "Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are significantly smaller than neonates whose mothers were treated with insulin during pregnancy." | 5.01 | Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. ( Aiken, CE; Ozanne, SE; Tarry-Adkins, JL, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 4.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 4.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 4.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9)." | 4.98 | Review of Metformin Use for Type 2 Diabetes Prevention. ( Flory, JH; Herman, WH; Karter, AJ; Kruge, LE; Mangione, CM; Moin, T; Schillinger, D; Schmittdiel, JA; Walker, EA; Yeh, J, 2018) |
| "For more than 40 years, metformin has been used before and during pregnancy." | 4.98 | Metformin from mother to unborn child - Are there unwarranted effects? ( Chan, SY; Nguyen, L; Teo, AKK, 2018) |
| "The use of metformin and glyburide in pregnancy for treatment of GDM has dramatically increased since the early 2000s." | 4.98 | Oral Agents for the Treatment of Gestational Diabetes. ( Finneran, MM; Landon, MB, 2018) |
| "Metformin has been prescribed in pregnancy for over 40 years; for much of this time, use has been limited both in numbers and geographically, and the evidence base has been confined to observational studies." | 4.95 | Metformin use in pregnancy: promises and uncertainties. ( Lindsay, RS; Loeken, MR, 2017) |
| "Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS." | 4.95 | Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. ( , 2017) |
| "Our study concluded that metformin is fastest in glucose control, with a more favorable pregnancy outcomes-would be a better option, but its rate of glucose control is the lowest." | 4.95 | Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis. ( Liang, HL; Ma, SJ; Tan, HZ; Xiao, YN, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "To assess the short- and long-term maternal and fetal impact of metformin in pregnancy compared with insulin." | 4.95 | Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. ( Aitken, E; Butalia, S; Donovan, L; Gutierrez, L; Lodha, A; Zakariasen, A, 2017) |
| " Metformin may increase the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy." | 4.95 | Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. ( Bordewijk, EM; Costello, MF; Mol, BW; Nahuis, M; Tso, LO; Van der Veen, F; van Wely, M, 2017) |
| "Metformin use during pregnancy is controversial and there is disparity in the acceptance of metformin treatment in women with gestational diabetes mellitus (GDM) in Australia." | 4.95 | The emerging role of metformin in gestational diabetes mellitus. ( Cohen, N; Gray, SG; Little, PJ; McGuire, TM, 2017) |
| "Randomised controlled trials comparing eight ovulation induction treatments in women with WHO group II anovulation: clomiphene, letrozole, metformin, clomiphene and metformin combined, tamoxifen, gonadotropins, laparoscopic ovarian drilling, and placebo or no treatment." | 4.95 | Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis ( Bhattacharya, S; Costello, MF; Johnson, NP; Kim, BV; Legro, RS; Mol, BW; Ng, EH; Norman, RJ; van Wely, M; Wang, R; Zhang, H, 2017) |
| "The potential reproductive benefits of metformin, a drug endowed with the capacity to ameliorate insulin resistance in polycystic ovary syndrome (PCOS), has garnered much interest over the past 2 decades." | 4.93 | Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence? ( Abu Hashim, H, 2016) |
| "The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 4.93 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. ( An, RF; Tian, Q; Xue, Y; Zeng, XL; Zhang, YF, 2016) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 4.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "26); whereas, significantly reduced results were found in the metformin group in pregnancy-induced hypertension (PIH) rate (RR = 0." | 4.91 | Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. ( Cui, S; Li, G; Li, L; Li, Y; Xu, Y; Zhao, S, 2015) |
| "PubMed, SCOPUS and CENTRAL databases were searched until April 2014 with the key words: PCOS, polycystic ovary syndrome, metformin, clomiphene citrate, ovulation induction and pregnancy." | 4.91 | Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Abu Hashim, H; Foda, O; Ghayaty, E, 2015) |
| "In women with polycystic ovary syndrome, metformin treatment before or during assisted reproductive technology cycles increases clinical pregnancy rates and decreases the risk of ovarian hyperstimulation syndrome." | 4.91 | Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Marjoribanks, J; Tso, LO, 2015) |
| "In women with gestational diabetes, metformin use and insulin therapy have comparable glycemic control profile, but metformin use was associated with lower risk of neonatal hypoglycemia." | 4.91 | Metformin for the treatment of gestational diabetes: An updated meta-analysis. ( Kitwitee, P; Limwattananon, C; Limwattananon, S; Nguyen, TV; Phimphilai, M; Pongchaiyakul, C; Ratanachotpanich, T; Waleekachonlert, O, 2015) |
| "Metformin is used among patients with polycystic ovary syndrome (PCOS), but findings for its effects on outcomes of assisted reproductive technology (ART) have been conflicting." | 4.91 | A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. ( Huang, X; Li, Y; Lv, F; Tal, R; Wang, P; Zhang, X, 2015) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 4.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| " Metformin is widely used in fertility treatment of women with PCOS, due to a suggested positive effect of continued metformin treatment beyond the first trimester on pregnancy complications." | 4.91 | [Metformin and the obstetric patient]. ( Aaboe, K; Bülow, NS; Galsgaard, J; Lauenborg, J; Mathiesen, ER; Odgaard, HS; Pedersen, KD, 2015) |
| "The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction." | 4.90 | Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2014) |
| "Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women." | 4.90 | The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). ( Nathan, N; Sullivan, SD, 2014) |
| " Terms for Gestational diabetes/gestational diabetes mellitus/diabetes pregnancy AND/OR Metformin/hypoglycemic drugs/Hypoglycemic Agents/Antidiabetic Medications were used in the search." | 4.90 | Metformin vs insulin in the management of gestational diabetes: a systematic review and meta-analysis. ( Su, DF; Wang, XY, 2014) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial." | 4.89 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. ( Gu, W; Shan, PF; Zheng, J, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 4.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| " Research suggests that glyburide and metformin can each effectively manage hyperglycemia in pregnancy." | 4.89 | Oral agents for the management of gestational diabetes. ( Berggren, EK; Boggess, KA, 2013) |
| "Metformin is widely used for treating women with polycystic ovary syndrome (PCOS), and many patients with PCOS who are infertile receive gonadotrophins while being treated with metformin." | 4.89 | Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 4.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 4.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "To evaluate of metformin effectiveness of ovulation induction treatment in polycystic ovary syndrome (PCOS) women." | 4.88 | The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. ( Chang, S; Chen, S; Xiao, J; Zhang, C, 2012) |
| "Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS)." | 4.88 | On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. ( Carlsen, SM; DE Zegher, F; Díaz, M; Ibáñez, L; Vanky, E, 2012) |
| " The Pregnancy in PCOS trial II will determine the safety and efficacy of clomiphene citrate compared to letrozole, in achieving live birth in infertile women with PCOS." | 4.88 | Reproductive impact of polycystic ovary syndrome. ( Legro, RS; Usadi, RS, 2012) |
| "To evaluate the efficacy of metformin (MTF) in treatment of clomiphene (CC)-resistant patients with polycystic ovary syndrome (PCOS)." | 4.88 | [Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis]. ( Cheng, QF; Fan, XD; Ren, W; Wang, LL, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 4.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 4.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| "To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients." | 4.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| "Metformin improves the endocrinopathy of polycystic ovary syndrome (PCOS), facilitates conception, appears to reduce first trimester miscarriage and gestational diabetes and does not appear to be teratogenic." | 4.84 | Metformin before and during pregnancy and lactation in polycystic ovary syndrome. ( Glueck, CJ; Wang, P, 2007) |
| "Available evidence supports the use of glyburide during pregnancy." | 4.84 | Pharmacological management of gestational diabetes: an overview. ( Coustan, DR, 2007) |
| "To report a case of triplet pregnancy after metformin treatment only, in a woman with polycystic ovary syndrome (PCOS) and a family history of twin pregnancies." | 4.84 | Triplet pregnancy after metformin in a woman with polycystic ovary syndrome. ( Clapauch, R; Mattos, TM, 2008) |
| " Combined aspirin and heparin for antiphospholipid syndrome, and screening and treatment of bacterial vaginosis between ten and 22 weeks of pregnancy with clindamycin, are the only interventions proven to be useful in randomised controlled trials (RCTs)." | 4.84 | Non-surgical interventions for threatened and recurrent miscarriages. ( Tan, TY; Tien, JC, 2007) |
| "Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS)." | 4.84 | Role of metformin in patients with polycystic ovary syndrome: the state of the art. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tollino, A; Zullo, F, 2008) |
| "To update the state of evidence on the efficacy of metformin, used either alone or in combination with clomiphene citrate in women with polycystic ovary syndrome, by examining three outcomes: ovulation, pregnancy, and live birth." | 4.84 | Use of metformin in polycystic ovary syndrome: a meta-analysis. ( Bradley, HM; Creanga, AA; McCormick, C; Witkop, CT, 2008) |
| "To describe the first reported cases of two women with polycystic ovary syndrome (PCOS) desirous of pregnancy who conceived trichorionic pregnancies following ovulation induction with metformin alone and metformin plus clomiphene." | 4.83 | Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. ( Boothroyd, C; Yazdani, A, 2006) |
| "A systematic review of randomized controlled trials (RCTs) comparing whether metformin co-administration with gonadotrophins for ovulation induction (OI) with timed intercourse or IVF improves outcome in women with polycystic ovary syndrome (PCOS)." | 4.83 | A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. ( Chapman, M; Conway, U; Costello, MF, 2006) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 4.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "The aim of this literature search is to establish if metformin is efficacious when given to clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS) patients." | 4.83 | Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. ( Kruger, TF; Nosarka, S; Siebert, TI; Steyn, DW, 2006) |
| "To review the effectiveness of metformin in restoring regular menstrual cycles and ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS)." | 4.82 | A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. ( Costello, MF; Eden, JA, 2003) |
| "To familiarize obstetrician-gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS)." | 4.82 | Metformin for the treatment of polycystic ovary syndrome. ( Barbieri, RL, 2003) |
| "To evaluate the role of laparoscopic ovarian drilling and treatment with metformin in the management of the polycystic ovary syndrome (PCOS)." | 4.82 | Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? ( Pirwany, I; Tulandi, T, 2003) |
| "To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome." | 4.82 | Metformin in polycystic ovary syndrome: systematic review and meta-analysis. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "Metformin is a common treatment for women who have insulin resistance manifesting as type 2 diabetes or polycystic ovarian syndrome (PCOS)." | 4.82 | Metformin in obstetric and gynecologic practice: a review. ( Boyle, J; McCarthy, EA; McLachlan, K; Permezel, M; Walker, SP, 2004) |
| "No adverse pregnancy outcomes with metformin use have been reported, except in one unmatched study." | 4.82 | Metformin therapy and diabetes in pregnancy. ( McIntyre, HD; Rowan, JA; Simmons, D; Walters, BN, 2004) |
| "The use of insulin sensitizing drugs such as metformin in polycystic ovary syndrome has been increasingly popular and validated by systematic reviews." | 4.82 | Should we continue or stop insulin sensitizing drugs during pregnancy? ( Hague, W; Norman, RJ; Wang, JX, 2004) |
| "The purpose of this review is to provide a critical discussion on the place of laparoscopic ovarian drilling and medical treatment with metformin for polycystic ovary syndrome." | 4.82 | Laparoscopic treatment of polycystic ovaries: is its place diminishing? ( Al-Fadhli, R; Tulandi, T, 2004) |
| "This paper is a systematic review of metformin versus clomiphene citrate (CC) in women with polycystic ovary syndrome (PCOS)." | 4.82 | Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. ( Kashyap, S; Rosenwaks, Z; Wells, GA, 2004) |
| "Twenty female pregnant rats were used, and they were divided into four groups of control (normal pregnancy), disease (diabetic untreated), metformin (received 200 mg/kg metformin dissolved in distilled water) and tBHQ groups (received 25 mg/kg tBHQ in 1% corn oil), respectively, with five rats in each group." | 4.31 | Tert-butylhydroquinone Mitigates Renal Dysfunction in Pregnant Diabetic Rats ( Li, J; Liu, H; Shang, L, 2023) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 4.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| " Metformin treatment reduces the risk of late miscarriage and preterm birth in pregnant women with PCOS." | 4.31 | Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS. ( Giskeødegård, GF; Iversen, AC; Jarmund, AH; Løvvik, TS; Madssen, TS; Ryssdal, M; Steinkjer, B; Stokkeland, LMT; Vanky, E, 2023) |
| "Metformin is an antidiabetic drug, increasingly prescribed in pregnancy and has been shown to cross the human placenta." | 4.31 | Computational Modelling of Paracellular Diffusion and OCT3 Mediated Transport of Metformin in the Perfused Human Placenta. ( Cleal, J; Lewis, RM; Lofthouse, EM; Sengers, BG, 2023) |
| "Metformin is used by women during pregnancy to manage diabetes and crosses the placenta, yet its effects on the fetus are unclear." | 4.31 | Metformin Disrupts Signaling and Metabolism in Fetal Hepatocytes. ( Aagaard, KM; Brown, LD; Friedman, JE; Hennebold, JD; Jones, AK; Jones, KL; Kievit, P; Nash, MJ; O'Rourke, R; Rozance, PJ; Swenson, KS; Takahashi, DL; Wang, D; Wesolowski, SR, 2023) |
| "Metformin is increasingly used therapeutically during pregnancy worldwide, particularly in the treatment of gestational diabetes, which affects a substantial proportion of pregnant women globally." | 4.31 | The metabolic response of human trophoblasts derived from term placentas to metformin. ( Aiken, CE; Armstrong, JL; Holzner, LMW; Jenkins, B; Knapton, AE; Koulman, A; Murray, AJ; Ozanne, SE; Pantaleão, LC; Robinson, IG; Tarry-Adkins, JL; Thackray, BD; Virtue, S, 2023) |
| " Metformin (MET) is an oral hypoglycemic agent that activates AMPK-regulated signaling pathways and inhibits inflammation and oxidative stress responses." | 4.31 | Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK. ( He, L; Li, X; Wu, J; Wu, X; Zhan, F, 2023) |
| "Metformin counteracts excessive weight gain and leptin resistance in pregnant women with polycystic ovary syndrome." | 4.12 | Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. ( Bixo, M; Dehlin, E; Løvvik, TS; Molin, J; Vanky, E, 2022) |
| "Among 12,631 women with T2DM, insulin use in pregnancy was stable over the study years (55%-60% in the 2nd trimester), but 2nd trimester use of metformin increased from <5% to 20%." | 4.12 | The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States. ( Bateman, BT; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Patorno, E; Seely, EW; Vine, S; Wood, ME, 2022) |
| "The mean steady-state serum concentration of metformin during pregnancy was 9." | 4.12 | Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome. ( Espnes, KA; Gundersen, POM; Hønnås, A; Løvvik, TS; Naavik, A; Skogvoll, E; Spigset, O; Vanky, E; Westin, AA, 2022) |
| "This study aimed to investigate if maternal pregnancy exposure to metformin is associated with increased risk of long-term and short-term adverse outcomes in the child." | 4.12 | Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. ( Boutmy, E; Brand, KMG; Foch, C; Hakkarainen, KM; Korhonen, P; Morin-Papunen, L; Saarelainen, L; Schlachter, J; Sonajalg, J; Vääräsmäki, M, 2022) |
| "The nonsteroidal anti-inflammatory drug aspirin is an agent of interest for breast cancer prevention." | 4.12 | Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use. ( Acheampong, T; Agovino, M; Athilat, S; Lee Argov, EJ; Rodriguez, CB; Tehranifar, P; Terry, MB; Wei, Y, 2022) |
| "Elevated RIF1 in oocytes caused by maternal obesity may mediate abnormal embryonic epigenetic remodeling and increase metabolic risk in offspring by regulating histone modifications on MuERV-L, which can be partially rescued by metformin treatment." | 4.12 | Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice. ( Huang, J; Li, Z; Ru, G; Sun, J; Sun, L, 2022) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 4.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 4.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "The main aim was to study whether the long-term incidences of type 2 diabetes, pre-diabetes and metabolic syndrome differed between women who were treated with metformin or insulin for gestational diabetes." | 4.12 | Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials. ( Huhtala, M; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Rönnemaa, T; Tertti, K; Vääräsmäki, M, 2022) |
| "To use the framework of the Health Belief Model (HBM) to explore factors associated with metformin use among adults with prediabetes." | 4.12 | Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2022) |
| "Among individuals with prediabetes in Saudi Arabia, metformin use was very low despite the evidence supporting its safety, convenience, and efficacy." | 4.12 | The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia. ( Al Yami, MS; Al-Azzeh, O; Alfayez, OM; Aljabri, AF; Almalki, OS; Almohammed, OA; Almutairi, FS; Alsallum, AA, 2022) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 4.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| "Metformin is beneficial for GDM women to control total GWG compared with insulin, regulate fetal birth weight more than insulin and glyburide, and increase the risk of unmet treatment targets compared with insulin." | 4.12 | Efficacy and safety of hypoglycemic agents on gestational diabetes mellitus in women: A Bayesian network analysis of randomized controlled trials. ( Chen, H; Cui, W; Guo, H; Huang, L; Jing, Y; Liu, X; Song, L; Sun, B; Wang, M; Wang, N; Wang, T; Xu, J, 2022) |
| "To investigate effects of maternal diabetes and metformin treatment on metabolic newborn screening (NBS) results of infants born to mothers with hyperglycemia during pregnancy." | 4.02 | Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening. ( Estrella, J; Hng, TM; McLean, M; Simmons, D; Wiley, V, 2021) |
| " The effect of HFD on maternal rats was alleviated by prenatal metformin, which also ameliorated inflammation and apoptosis in the fetal liver and intestines." | 4.02 | Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. ( Hou, CY; Huang, LT; Huang, SW; Lin, IC; Ou, YC; Sheen, JM; Tain, YL; Tang, KS; Tiao, MM; Tsai, CC; Yu, HR, 2021) |
| "This study estimated the cost-effectiveness of metformin to reduce the risk of gestational diabetes mellitus (GDM) in pregnant women with polycystic ovary syndrome (PCOS) from the US health-care payer perspective." | 4.02 | Cost-effectiveness analysis of polycystic ovary syndrome management and the risk of gestational diabetes in pregnant women: a decision-tree model. ( Alenzi, EO, 2021) |
| "Women with GDM treated with insulin plus metformin had similar obstetric and neonatal complications, weight gained and insulin dose compared to those only treated with insulin." | 4.02 | Metformin combined with insulin in women with gestational diabetes mellitus: a propensity score-matched study. ( Almeida, M; Almeida, MC; Chaves, C; Cunha, F; Estevinho, C; Figueiredo, O; Garrido, S; Martinho, M; Melo, A; Morgado, A; Silva-Vieira, M, 2021) |
| " We compared patients who received metformin throughout pregnancy to those with no metformin exposure." | 4.02 | Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes. ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Racine, JL; Rhoades, JS; Stewart, KS, 2021) |
| "Recent research has demonstrated the benefits of metformin treatment in gestational diabetes (GDM) on short-term pregnancy outcomes (including excessive fetal growth and pre-eclampsia), but its effects on fetal metabolism remain mostly unknown." | 4.02 | Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone. ( Huhtala, MS; Pellonperä, O; Rönnemaa, T; Tertti, K, 2021) |
| "Gestational metformin attenuated the adiposity in obese dams and increased the gestation length without correcting the offspring in utero growth restriction and catch-up growth caused by maternal obesity." | 4.02 | Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Ozanne, SE; Schoonejans, JM, 2021) |
| " The mothers of the cases/controls and their diagnoses of diabetes (DM) before/during pregnancy as well as their insulin/metformin prescriptions during pregnancy were identified." | 3.96 | Maternal diabetes and risk of childhood cancer in the offspring. ( Hirvonen, E; Leinonen, MK; Madanat-Harjuoja, LM; Pitkäniemi, J; Seppälä, LK; Vettenranta, K, 2020) |
| "Metformin is the most commonly prescribed drug in the management of metabolic disorders such as polycystic ovarian syndrome (PCOS) and gestational diabetes in women of reproductive age." | 3.96 | Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. ( Adiga, SK; Agarwal, P; Kalthur, G; Kalthur, SG; Kumari, S; Mutalik, S; Nayak, G; Rao, A; Salian, SR; Shreya, AB; Suresh Poojary, P, 2020) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 3.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| " This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality." | 3.96 | Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis. ( Burden, C; Carlsen, SM; Dodd, JM; Hague, W; Hilkka, I; Løvvik, T; Morin-Papunen, L; Mousa, A; Nicolaides, K; Norman, JE; Rönnemaa, T; Rowan, J; Shehata, H; Syngelaki, A; Teede, HJ; Tertti, K; Vanky, E, 2020) |
| "Recent evidence suggests that metformin may prevent pre-eclampsia by reverting the angiogenic imbalance in maternal sera." | 3.96 | Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies. ( Heinonen, T; Huttala, O; Laivuori, H; Tihtonen, K; Toimela, T; Uotila, J; Virtanen, A, 2020) |
| " In our study, we explored the changes in metabolic health and cognitive function in mice of middle- and old- age after exposure to GDM, and whether metformin therapy during pregnancy provided long-term benefits." | 3.96 | Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes. ( Baker, PN; Chen, X; Han, TL; Qi, H; Wang, A; Yu, X; Zhang, H; Zhao, X; Zhao, Y; Zhou, X, 2020) |
| "Metformin use in pregnancy is controversial because metformin crosses the placenta and the safety on the fetus has not been well-established." | 3.96 | Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant. ( Chang, SH; Chiou, MJ; Huang, YT; Kuo, CF; Lin, SF; Lin, WT, 2020) |
| " The aims of this study were to evaluate the potential effect of metformin in GWG in overweight or obese women with GDM, to report our experience and to assess metformin's safety in this population." | 3.91 | Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. ( Belo, S; Bettencourt-Silva, R; Carvalho, D; Ferreira, MJ; Montenegro, N; Namora, G; Neves, JS; Oliveira, AI; Queirós, J; Souteiro, P, 2019) |
| "Although metformin has traditionally been avoided in pregnancy, evidence now supports its safety and efficacy for management of gestational diabetes mellitus (GDM)." | 3.91 | Implementation and Evaluation of the "Metformin First" Protocol for Management of Gestational Diabetes. ( Halperin, I; Kumar, R; Lipscombe, L; Lowe, J; Shah, B; Steinberg, D; Thompson-Hutchison, F, 2019) |
| "Metformin has been reported to be involved in the pathogenesis of PE (pre-eclampsia)." | 3.91 | Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9. ( Ding, Y; Gu, W; Lu, L; Yuan, X, 2019) |
| "Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia." | 3.91 | Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet. ( Cao, G; Cao, X; Li, L; Wang, F; Yi, W, 2019) |
| "We found no clear evidence of any adverse outcomes related to the use of metformin for the treatment of hyperglycemia in pregnancy." | 3.91 | Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register. ( Barzi, F; Boyle, J; Brown, A; Chitturi, S; Connors, C; Corpus, S; Cotter, M; Dowden, M; Inglis, C; Kirkham, R; Kirkwood, M; Lee, IL; Lindenmayer, G; Longmore, D; Maple-Brown, LJ; McIntyre, HD; Moore, E; O'Dea, K; Oats, J; Shaw, JE; Thomas, S; van Dokkum, P; Whitbread, C; Wicks, M; Zimmet, P, 2019) |
| "We evaluated the risk of major birth defects and pregnancy losses in a cohort of pregnant women exposed to metformin during the first trimester for different indications relative to a matched unexposed reference group." | 3.88 | Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. ( Amar, E; Baud, D; Beau-Salinas, F; Bernard, N; Buclin, T; Cassina, M; Csajka, C; Dautriche, A; De Santis, M; Duman, MK; Dunstan, H; Eleftheriou, G; Hernandez-Diaz, S; Kaplan, YC; Klinger, G; Maňáková, E; Panchaud, A; Passier, A; Pistelli, A; Rothuizen, LE; Rousson, V; Vial, T; Winterfeld, U, 2018) |
| "The initiation of metformin in early pregnancy in Gestational Diabetes mellitus (GDM) remains controversial." | 3.88 | How safe is metformin when initiated in early pregnancy? A retrospective 5-year study of pregnant women with gestational diabetes mellitus from India. ( Asha, HS; Dasgupta, R; Gupta, V; Mathews, JE; Paul, T; Ramachandran, R; Regi, A; Thomas, N; Visalakshi, P, 2018) |
| "As women with higher fasting glucose levels have higher chance of necessitating insulin in later pregnancies, appropriate addition of insulin at metformin initiation for these women could help better glycaemic control throughout pregnancy." | 3.88 | Predictors of metformin failure in gestational diabetes mellitus (GDM). ( Gates, S; Khin, MO; Saravanan, P, 2018) |
| "The biguanide metformin (MET) has been used during pregnancy for treatment of polycystic ovary syndrome and gestational diabetes." | 3.88 | Intrauterine exposure to metformin: Evaluation of endothelial and perivascular adipose tissue function in abdominal aorta of adult offspring. ( Akamine, EH; Ceravolo, GS; da Silva, MDV; de Andrade, FG; Gerardin, DCC; Montagnini, BG; Moura, KF; Novi, DRBS; Picinin, R; Silva, RNOD; Vidigal, CB, 2018) |
| "To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies." | 3.88 | Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. ( Addor, MC; Bakker, M; Bertaut-Nativel, B; Dolk, H; Garne, E; Gatt, M; Given, JE; Klungsoyr, K; Lelong, N; Loane, M; Morgan, M; Neville, AJ; Pierini, A; Rissmann, A, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 3.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| " Metformin, an insulin-sensitizing biguanide, is used in the therapy of diabetic pregnancy." | 3.88 | Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments. ( Alkhalayla, H; Bachanek, M; Pyzlak, M; Stangret, A; Szewczyk, G; Szukiewicz, D; Trojanowski, S; Wejman, J, 2018) |
| " Using metformin during pregnancy and nursing to improve the metabolic status of obese mothers could prevent the sequence of events that lead to an increase in postnatal serum estradiol levels in female offspring and, hence, reproductive dysfunction." | 3.88 | Prenatal metformin treatment improves ovarian function in offspring of obese rats. ( Álvarez, D; Ceballo, K; Cruz, G; Fernandois, D; Maliqueo, M; Martinez-Pinto, J; Olguín, S; Sotomayor-Zárate, R, 2018) |
| "To evaluate the norepinephrine (NE) and placental NE transporter (NET) in women with polycystic ovary syndrome (PCOS) non-treated and treated with metformin during pregnancy." | 3.85 | Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome. ( Crisosto, N; Echiburú, B; Lara, HE; Maliqueo, M; Medina, G; Sir-Petermann, T, 2017) |
| " Clinical pregnancy rates and implantation rates were similar in all groups, although the numbers of oocytes, mature oocytes, fertilized oocytes, and transferred embryos were lower in the treatment groups received metformin compared to the OC group and control group." | 3.85 | Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. ( Gurgan, T; Kalem, MN; Kalem, Z, 2017) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 3.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "Studies in rodents suggest that metformin treatment during pregnancy may have harmful effects on testicular development in offspring." | 3.83 | Metformin Treatment Does Not Affect Testicular Size in Offspring Born to Mothers with Gestational Diabetes. ( Rönnemaa, T; Sadov, S; Tertti, K; Toppari, J; Virtanen, HE, 2016) |
| "The children of mothers with GDM randomised to metformin (n = 47) or insulin (n = 50) treatment during pregnancy." | 3.81 | A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. ( Ijäs, H; Keravuo, R; Raudaskoski, T; Saarela, T; Vääräsmäki, M, 2015) |
| " Glucose-induced inflammation was partially reversed by metformin." | 3.81 | Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. ( Abrahams, VM; Flannery, CA; Han, CS; Herrin, MA; Mulla, MJ; Pettker, CM; Pitruzzello, MC; Werner, EF, 2015) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 3.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| "To assess the effect of metformin in controlling Gestational Diabetes Mellitus (GDM) in women with Polycystic Ovarian Syndrome (PCOS)." | 3.81 | Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome. ( Aftab, S; Ainuddin, JA; Kamran, A; Kazi, S, 2015) |
| "To evaluate the effectiveness of metformin therapy in reducing early pregnancy loss in pregnant women with polycystic ovary syndrome (PCOS)." | 3.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "Pregnant nondiabetic mice were administered metformin beginning on the first day of pregnancy." | 3.80 | Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy. ( Lee, HY; Loeken, MR; Wei, D, 2014) |
| "OBJECTIVE The Diabetes Prevention Program (DPP) trial investigated rates of progression to diabetes among adults with prediabetes randomized to treatment with placebo, metformin, or intensive lifestyle intervention." | 3.80 | Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. ( Christophi, CA; Dabelea, D; Dagogo-Jack, S; Florez, JC; Franks, PW; Jablonski, KA; Kim, C; Knowler, WC; Ratner, R; Sullivan, SD, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 3.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "The antidiabetic drug metformin is currently used prior and during pregnancy for polycystic ovary syndrome, as well as during gestational diabetes mellitus." | 3.79 | Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. ( Ailanen, L; Ilyasizadeh, J; Jäppinen, NT; Koulu, M; Laurila, K; Penttinen, AM; Pesonen, U; Salomäki, H; Vähätalo, LH, 2013) |
| "Diet induced-obesity/metabolic syndrome during pregnancy significantly enhanced fetal and placental cytokine production; maternal metformin reduced fetal cytokine levels." | 3.79 | Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. ( Chatterjee, PK; Desai, N; Gupta, M; Metz, CN; Rochelson, B; Roman, A; Tam Tam, H; Xue, X, 2013) |
| "The antidiabetic drug Metformin causes weight loss in both diabetic and non-diabetic individuals." | 3.79 | Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. ( Anini, Y; Gagnon, J; Sheppard, E, 2013) |
| "Metformin has been reported to reduce the risk of gestational diabetes (GD) in women with polycystic ovarian syndrome (PCOS)." | 3.79 | How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation. ( Busacca, M; Campagna, G; De Cicco, S; Gagliano, D; Guido, M; Lanzone, A; Romualdi, D, 2013) |
| "To evaluate the ovarian function during early infancy in daughters of women with polycystic ovary syndrome (PCOS) treated with metformin throughout pregnancy (PCOSd+M), as a means to reduce androgen and insulin levels, compared with daughters of nontreated PCOS women (PCOSd-M) and daughters of women who belong to a healthy comparison group (HCd)." | 3.78 | Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. ( Crisosto, N; Echiburú, B; Ladrón de Guevara, A; Maliqueo, M; Pérez, V; Preisler, J; Sánchez, F; Sir-Petermann, T, 2012) |
| "To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome." | 3.78 | Myo-inositol may prevent gestational diabetes in PCOS women. ( Corrado, F; D'Anna, R; Di Benedetto, A; Di Benedetto, V; Interdonato, ML; Raffone, E; Rizzo, P, 2012) |
| " Metformin was tolerated throughout the pregnancy by 90% of the women in the metformin+lifestyle advice group." | 3.78 | Introduction of metformin for gestational diabetes mellitus in clinical practice: Has it had an impact? ( Bustani, R; Farrell, T; Gandhi, P; Madhuvrata, P, 2012) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 3.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "A high rate of GD or IGT already was observed in the first weeks of pregnancy in our cohort under metformin treatment." | 3.77 | Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction. ( Bals-Pratsch, M; Grosser, B; Ortmann, O; Seifarth, C; Seifert, B, 2011) |
| "The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes." | 3.77 | Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ( Cavalli, RC; Dantas Moisés, EC; Dantes Moisés, EC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL, 2011) |
| "Metformin has failed to gain wide acceptance as a first-line treatment option for women with anovulatory infertility related to polycystic ovary syndrome." | 3.77 | Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. ( Bontekoe, S; Johnson, NP; Stewart, AW, 2011) |
| "In women with gestational diabetes mellitus, who were randomized to metformin or insulin treatment, pregnancy outcomes were similar (Metformin in Gestational diabetes [MiG] trial)." | 3.77 | Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. ( Battin, M; Hague, WM; Obolonkin, V; Rowan, JA; Rush, EC; Wouldes, T, 2011) |
| "The pregnancy in polycystic ovary syndrome (PPCOS) study was a prospective, multi-center, randomized clinical trial comparing three ovulation induction regimens: clomiphene citrate (CC), metformin and the combination of the two." | 3.76 | Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. ( Brzyski, RG; Casson, PR; Chen, X; Christman, GM; Coutifaris, C; Diamond, MP; Eisenberg, E; Huang, H; Krawetz, SA; Legro, RS; Santoro, N; Schlaff, WD; Zhang, H; Zhang, J; Zhang, L, 2010) |
| " Women who had elective cryopreservation due to ovarian hyperstimulation syndrome risk were found to have significantly higher LBRs if metformin was taken in the fresh IVF/ICSI cycle (A = 44." | 3.76 | Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. ( Acharya, S; Balen, A; Brewer, C; Tang, T; Thake, F, 2010) |
| "To evaluate the effect of metformin addition during ovarian hyperstimulation on cycle parameters and outcome of in vitro fertilization (IVF) treatment in polycystic ovary syndrome (PCOS) patients with a body mass index (BMI) <28 kg/m(2)." | 3.75 | Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. ( Kahraman, S; Kumbak, B, 2009) |
| "We evaluated the effect of hyperandrogenism in ovaries with functional and regressing corpora lutea (CL) and the action of metformin in preventing these possible alterations using a mouse model." | 3.75 | Effect of DHEA and metformin on corpus luteum in mice. ( Facorro, GB; Motta, AB; Piehl, L; Rubín de Celis, E; Sander, VA, 2009) |
| "The aim of the present study was to assess whether continuation of metformin therapy throughout pregnancy can reduce the development of gestational diabetes in women with polycystic ovarian syndrome (PCOS)." | 3.75 | Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. ( Begum, A; Begum, MR; Begum, MS; Ferdous, J; Khan, F; Khanam, NN; Quadir, E, 2009) |
| "Women with GDM treated with metformin and with similar baseline risk factors for adverse pregnancy outcomes had less weight gain and improved neonatal outcomes compared with those treated with insulin." | 3.75 | Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. ( Balani, J; Hyer, SL; Rodin, DA; Shehata, H, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 3.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 3.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "To date, among insulin-sensitizing drugs, only metformin should be used to improve reproductive function in well selected polycystic ovary syndrome patients." | 3.74 | Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2008) |
| "In women with PCOS, continuous use of metformin during pregnancy significantly reduced the rate of miscarriage, gestational diabetes requiring insulin treatment and fetal growth restriction." | 3.74 | Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? ( Khalid, R; Naru, T; Nawaz, FH; Rizvi, J, 2008) |
| " There is no evidence-based schema for achieving pregnancy in women with PCOS, though lifestyle modification, clomiphene citrate, and metformin are the current front line therapies." | 3.74 | Pregnancy considerations in women with polycystic ovary syndrome. ( Legro, RS, 2007) |
| " In a university teaching hospital, a total of 38 patients with polycystic ovarian syndrome were treated by metformin before undergoing an IVM cycle." | 3.74 | Controlled natural cycle IVF: a novel approach for a dominant follicle during an in-vitro maturation cycle. ( Fanchin, R; Frydman, N; Frydman, R; Kadoch, IJ; Le Du, A, 2007) |
| "To compare the incidence of multiple gestation following treatment with clomiphene citrate (CC), metformin (MET) or gonadotropins in polycystic ovary syndrome (PCOS) patients undergoing ovulation induction." | 3.74 | Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. ( Kraja, A; Odem, RR; Pauls, RN; Pinto, AB; Ratts, VS; Williams, DB, 2007) |
| " She would like to know whether she can continue using metformin during the pregnancy and also is concerned about the effect of the gastric bypass surgery." | 3.74 | A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery. ( Coustan, DR, 2008) |
| "Metformin-associated lactic acidosis is a rare but serious condition and potentially even more hazardous during pregnancy." | 3.74 | Metformin-associated lactic acidosis in a pregnant patient. ( Chen, IC; Hong, YC; Hsiao, CT; Kuan, JT; O'Boyle, CP, 2008) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 3.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "In women with polycystic ovary syndrome, metformin administration, not laparoscopic ovarian drilling, reduces plasminogen activator inhibitor 1 (PAI-1) activity." | 3.73 | Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "The pharmacokinetic disposition of metformin in late pregnancy was studied together with the level of fetal exposure at birth." | 3.73 | Population pharmacokinetics of metformin in late pregnancy. ( Charles, B; Hague, W; Norris, R; Xiao, X, 2006) |
| "To review pregnancy outcomes in women with Type 2 diabetes (Type 2 DM), comparing women treated with those not treated with metformin." | 3.73 | Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006) |
| "To determine the effects of pregnancy on metformin pharmacokinetics." | 3.73 | Effect of pregnancy on the pharmacokinetics of metformin. ( Begg, EJ; Gardiner, SJ; Hughes, RC; Zhang, M, 2006) |
| "A pregnant patient with polycystic ovary syndrome asked me whether continuing metformin, which she was taking to treat infertility before her pregnancy, is safe for her fetus." | 3.73 | Metformin use during the first trimester of pregnancy. Is it safe? ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To analyze pregnancy complications and outcome in patients with polycystic ovary syndrome (PCOS) treated with metformin." | 3.73 | Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. ( Jackson, EM; Thatcher, SS, 2006) |
| "To report the effect of metformin treatment on a patient with recurrent miscarriage (RM) and polycystic ovary syndrome (PCOS)." | 3.73 | Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "The objective of this study was to review the first 50 clinical pregnancies of women with polycystic ovarian syndrome (PCOS) who had ovulation induced either with metformin alone, or in combination with clomifene." | 3.73 | Outcome of clinical pregnancies after ovulation induction using metformin. ( Byrne, KM; Farah, N; Langan, H; Murphy, C; Turner, MJ; Walsh, J, 2006) |
| "55 g metformin per day throughout pregnancy and lactation." | 3.73 | Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. ( Glueck, CJ; Salehi, M; Sieve, L; Wang, P, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 3.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| "The mean birth weight percentile of neonates exposed to metformin in utero during the first trimester was significantly lower than that of neonates delivered to normal healthy matched controls." | 3.73 | Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. ( Glezerman, M; Gur, D; Kovo, M; Levran, D; Rotmensch, S; Weissman, A, 2006) |
| "To evaluate the effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome (PCOS)." | 3.72 | [Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome]. ( Chi, HH; Lin, JJ; Lin, WQ; Ye, BL; Zhao, JZ, 2003) |
| "The aim of this study was to assess the efficacy of metformin on induction of ovulation in Asian women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 3.72 | Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome. ( Choktanasiri, W; Rojanasakul, A; Sophonsritsuk, A; Tingthanatikul, Y; Wansumrith, S; Weerakiet, S, 2004) |
| "We sought to determine whether metformin, which had facilitated conception in 72 oligoamenorrhoeic women with polycystic ovary syndrome (PCOS), would safely reduce the rate of first trimester spontaneous abortion (SAB) and increase the number of live births without teratogenicity." | 3.71 | Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. ( Glueck, CJ; Goldenberg, N; Sieve-Smith, L; Wang, P, 2002) |
| "To determine if metformin therapy improves in vitro fertilization (IVF) outcomes in patients with clomiphene-resistant polycystic ovarian syndrome (PCOS)." | 3.71 | Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. ( Riehl, RM; Stadtmauer, LA; Talbert, LM; Toma, SK, 2001) |
| "We evaluated the fertility promoting effect of metformin in infertile patients with polycystic ovary syndrome." | 3.71 | Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. ( Batukan, C; Baysal, B, 2001) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 3.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| "To assess pregnancy outcome in anovulatory infertility patients diagnosed with polycystic ovary syndrome (PCOS) who were treated with metformin." | 3.71 | Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. ( Buster, JE; Carson, SA; Heard, MJ; Pierce, A, 2002) |
| "To assess the therapeutic effects of metformin in patients with polycystic ovary syndrome (PCOS) and clomiphene (CC) resistant cases." | 3.71 | [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. ( Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 3.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| "Measures of thrombophilia, hypofibrinolysis, reproductive hormones, and androgenic steroids before and after metformin therapy." | 3.70 | Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. ( Awadalla, SG; Cameron, D; Fontaine, RN; Glueck, CJ; Phillips, H; Wang, P, 2000) |
| "The prevalence of pre-eclampsia was significantly increased in the group of women treated with metformin compared to women treated with sulphonylurea or insulin (32 vs." | 3.70 | Oral hypoglycaemic agents in 118 diabetic pregnancies. ( Damm, P; Hellmuth, E; Mølsted-Pedersen, L, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 3.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Treatment with metformin is occasionally associated with the development of severe lactic acidosis." | 3.69 | Contraindications to metformin therapy in patients with NIDDM. ( Bosman, D; Krentz, AJ; Sulkin, TV, 1997) |
| "Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe." | 3.30 | Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. ( Anderson, BJ; Beckman, KB; Belani, HK; Bhat, NS; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Griffiths, G; Hartman, KM; Huling, JD; Karger, AB; Klatt, NR; Liebovitz, DM; Lindberg, SM; Mehta, T; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, M; Puskarich, MA; Rose, MR; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Wirtz, EL, 2023) |
| "Gestational diabetes is a common complication of pregnancy and the optimal management is uncertain." | 3.30 | Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. ( Alvarez-Iglesias, A; Bogdanet, D; Browne, M; Devane, D; Dunne, F; Egan, A; Ferguson, J; Finn, Y; Gaffney, G; Gillespie, P; Kgosidialwa, O; Khattak, A; Liew, A; Newman, C; O'Donnell, M; O'Keeffe, D; O'Shea, P; Smyth, A, 2023) |
| "Pregnant women with gestational diabetes treated with medication." | 3.30 | Metformin in the prevention of type 2 diabetes after gestational diabetes in postnatal women (OMAhA): a UK multicentre randomised, placebo-controlled, double-blind feasibility trial with nested qualitative study. ( Amaefule, CE; Bolou, A; Dodds, J; Drymoussi, Z; Gonzalez Carreras, FJ; Harden, A; Heighway, J; Hitman, G; Huda, MSB; Lanz, D; Pardo Llorente, MDC; Pérez, T; Pizzo, E; Sanghi, A; Thangaratinam, S; Thomas, A; Zamora, J, 2023) |
| "Metformin treatment for GDM is associated with similar offspring growth and glucose metabolism but a more favourable lipid profile at the age of 9 years as compared to insulin treatment." | 3.11 | Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow-up study of two open-label, randomized controlled trials. ( Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Rönnemaa, T; Tertti, K; Tossavainen, P; Vääräsmäki, M; Veijola, R, 2022) |
| "Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic." | 3.11 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. ( Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A, 2022) |
| "Pregnancies affected by gestational diabetes mellitus (GDM) are associated with an increased risk of adverse maternal and foetal outcomes." | 3.11 | A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol. ( Alvarez-Iglesias, A; Browne, M; Devane, D; Dunne, F; Gillespie, P; Newman, C; O'Donnell, M; Smyth, A, 2022) |
| " This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS." | 3.01 | Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. ( Cui, L; Qian, H; Tang, M; Wang, J; Wang, L; Wang, R; Wei, M; Xu, W, 2021) |
| "To evaluate the risk of miscarriage in IVF cycles in women with PCOS." | 3.01 | Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis. ( Díaz-Nuñez, M; Laínz, L; Matorras, R; Moreira, D; Pérez-Fernandez, S; Pijoan, JI; Sainz, H, 2023) |
| "Persons with gestational and pregestational diabetes during pregnancy may require pharmacologic agents to achieve pregnancy glycemic targets, and the available medications for use in pregnancy are limited." | 3.01 | Medications for Managing Preexisting and Gestational Diabetes in Pregnancy. ( Caughey, AB; Rickert, M; Valent, AM, 2023) |
| " In this meta-analysis, we aimed to compare the effectiveness and safety of exenatide alone or in combination with metformin versus metformin in patients suffering from PCOS." | 3.01 | Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. ( Guo, Y; Hamiti, S; Hu, Y; Ma, Y; Song, X; Wang, X; Yusufu, M; Zhang, K, 2023) |
| "Even normal pregnancy is characterized by relative insulin resistance and glucose intolerance." | 3.01 | Prophylactic metformin after antenatal corticosteroids (PROMAC): a double blind randomized controlled trial. ( Hong, JGS; Kamarudin, M; Omar, SZ; Tan, PC, 2021) |
| "Metformin treatment was associated with a better postprandial glycemic control than insulin for some meals, a lower risk of hypoglycemic episodes, less maternal weight gain, and a low rate of failure as an isolated treatment." | 3.01 | Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. ( González-Mesa, E; González-Romero, S; Molina-Vega, M; Olveira, G; Picón-César, MJ; Roldan-López, R; Romero-Narbona, F; Sola-Moyano, AP; Suárez-Arana, M; Tinahones, FJ, 2021) |
| " Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy." | 2.94 | Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. ( Ahmed, MS; Brown, LM; Brown, Z; Caritis, S; Clark, S; Easterling, TR; Flood Nichols, SK; Haas, DM; Haneline, LS; Hebert, MF; Ma, X; Manuck, TA; Quinney, SK; Ren, Z; Shen, DD; Shireman, LM; Shuster, DL; Thummel, KE; Tita, AT; Venkataramanan, R, 2020) |
| "In women with gestational diabetes mellitus (GDM) requiring pharmacotherapy, insulin was the established first-line treatment." | 2.90 | SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial. ( Akerboom, BMC; Assouiki, F; Bosmans, JE; Braams-Lisman, BAM; Brouwer, CB; Daemen-Gubbels, CRGM; de Boer, K; de Galan, BE; de Koning, EJP; de Valk, HW; de Wit, L; deVries, JH; Diekman, MJM; Dullemond, RC; Eskes, SA; Evers, IM; Franx, A; Galjaard, S; Gallas, PRJ; Groenendaal, F; Heijligenberg, R; Hermes, W; Hermsen, BB; Horree, N; Huisjes, AJM; IJzerman, RG; Jansen, HJ; Kiewiet-Kemper, RM; Klooker, TK; Kuppens, SMI; Laan, R; Mensing van Charante, NA; Mol, BW; Naaktgeboren, CA; Oosterwerff, MM; Painter, RC; Potter van Loon, BJ; Rademaker, D; Sanson-van Praag, ME; Schippers, DH; Soeters, MR; Sueters, M; van Bemmel, T; van Bon, AC; van den Akker, ES; van den Beld, AW; van der Heijden, OWH; van der Made, FW; van Houtum, WH; van Laar, JOEH; van Leeuwen, M; van Meir, CA; van Rijn, BB; Veldhuis-Vlug, AG; Vermeulen, MAR; Verwij-Didden, MAL; Vidarsdottir, S; Visser, W; Vogelvang, TE; Voormolen, DN; Wijbenga, JAM; Wouters, MGAJ; Wouters-van Poppel, P; Zandstra, M; Zwart, JJ; Zwertbroek, R, 2019) |
| " Metformin was not effective in reducing BMI and preventing GDM in obese pregnant women." | 2.87 | Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women. ( Dienstmann, G; Nascimento, IBD; Sales, WB; Silva, GDD; Silva, JC; Souza, MLR, 2018) |
| "Treatment with metformin and NAC significantly increased ovulation and pregnancy rates in CC-resistant PCOS patients." | 2.84 | Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. ( Heidari, B; Nemati, M; Nemati, S; Taheri, AM, 2017) |
| "Metformin is widely used to treat gestational diabetes (GDM), but many women remain hyperglycaemic and require additional therapy." | 2.84 | Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial. ( Alexander, CI; Bell, JL; Denison, FC; Juszczak, E; Lindsay, RS; Love, CDB; Mackenzie, F; Norman, JE; Penneycard, J; Reynolds, RM; Stenson, B; Strachan, MWJ; Whyte, S, 2017) |
| "Glyburide was started in 53 patients and metformin in 51." | 2.84 | Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. ( Gam Ze Letova, Y; Hasanein, J; Hissin, N; Nachum, Z; Salim, R; Suleiman, A; Yefet, E; Zafran, N, 2017) |
| "Oral hypoglycemic drugs for the treatment of gestational diabetes mellitus (GDM) are still controversial because they can pass through the placenta." | 2.82 | Comparison of the effectiveness and safety of insulin and oral hypoglycemic drugs in the treatment of gestational diabetes mellitus: a meta-analysis of 26 randomized controlled trials. ( Gao, C; Jia, X; Li, C; Shi, H; Zhang, L; Zhang, X, 2022) |
| "Metformin is considered to be a safe and effective alternative to insulin for the management of GDM if patients refuse insulin due to any reasons in China." | 2.82 | Efficacy and safety of metformin compared to insulin in gestational diabetes: a systemic review and meta-analysis of Chinese randomized controlled trials. ( Hu, Y; Li, F; Liu, L; Liu, W; Marx, CM, 2022) |
| "This review provides an update on gestational diabetes (GDM) and other adverse pregnancy outcomes in individuals with polycystic ovary syndrome (PCOS), one of the most common metabolic disorders and causes of infertility." | 2.82 | Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome. ( Powe, CE; Selen, DJ, 2022) |
| " Historically, oral progestins have been the mainstay of conservative management for atypical endometrial hyperplasia and stage IA endometrioid endometrial cancer with no myometrial invasion, although there is no consensus on dosage and treatment length." | 2.82 | Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. ( Bosco, M; Braga, A; Cianci, S; Dababou, S; Franchi, MP; Frigerio, M; Gardella, B; Garzon, S; Laganà, AS; Torella, M; Uccella, S; Zorzato, PC, 2022) |
| "Metformin is an effective and safe alternative to insulin in GDM." | 2.82 | Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus. ( Abdelnaby, M; Ashoush, S; El-Said, M; Fathi, H, 2016) |
| "In a south Indian population with gestational diabetes, metformin was associated with better neonatal outcomes than glibenclamide." | 2.80 | Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide--a randomised controlled trial. ( Abraham, A; Antonisamy, B; Beck, M; Benjamin, SJ; George, A; Jana, AK; Mathews, JE; Sam, D; Thomas, N, 2015) |
| "Offspring born following maternal gestational diabetes are at risk of excessive childhood weight gain and Type 2 diabetes in childhood, which in turn is associated with an increased rate of hypertension." | 2.80 | Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial. ( Battin, MR; Coat, S; Hague, W; Obolonkin, V; Rowan, J; Rush, E, 2015) |
| "Metformin has no significant effect on birthweight percentile in obese pregnant women." | 2.80 | Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. ( Chiswick, C; Denison, F; Drake, AJ; Forbes, S; Lashen, H; Murray, G; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Rodriguez, A; Walker, BR; Weeks, A; Whyte, S; Wray, S, 2015) |
| "Women with gestational diabetes mellitus were randomly assigned to metformin or insulin in the Metformin in Gestational Diabetes trial." | 2.78 | Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment. ( Barrett, HL; Callaway, LK; Coat, S; De Blasio, MJ; Dekker Nitert, M; Gatford, KL; Hague, WM; Houda, CM; McIntyre, HD; Owens, JA; Rowan, JA, 2013) |
| "Patients with gestational diabetes who did not achieve glycemic control on diet were randomly assigned to metformin (n=75) or glyburide (n=74) as single agents." | 2.75 | Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. ( Clokey, D; Curet, LB; Moore, LE; Rappaport, VJ, 2010) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 2.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "A past history of gestational diabetes mellitus (GDM) confers a very high risk of postpartum development of diabetes, particularly type 2 diabetes." | 2.73 | Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. ( Bennett, PH; Christophi, CA; Dabelea, D; Fowler, S; Kahn, SE; Metzger, BE; Pi-Sunyer, X; Ratner, RE, 2008) |
| " The majority (27/32) were easily controlled on the initial dosage (500 mg twice a day)." | 2.73 | Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. ( Bofill, JA; Briery, CM; Clokey, D; Martin, RW; Moore, LE; Morrison, JC; Williford, NJ, 2007) |
| "Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking." | 2.73 | Metformin versus insulin for the treatment of gestational diabetes. ( Battin, MR; Gao, W; Hague, WM; Moore, MP; Rowan, JA, 2008) |
| "Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS)." | 2.72 | Metformin - a new approach. ( Cwynar-Zając, Ł, 2021) |
| "The comparative efficacy of gestational diabetes (GDM) treatments lack conclusive evidence for choice of first-line treatment." | 2.72 | Metformin is comparable to insulin for pharmacotherapy in gestational diabetes mellitus: A network meta-analysis evaluating 6046 women. ( Abou-Samra, AB; Bashir, M; Chivese, T; Clark, J; Doi, SA; Furuya-Kanamori, L; Mohamed, AM; Musa, OAH; Syed, A; Thalib, L; Toft, E; Xu, C, 2021) |
| "Metformin exposure was also associated with decreased levels of the inflammatory cytokines TNFα, IL-1a, IL-1b and IL-6 in serum, placenta and omental tissue taken from pregnant women." | 2.72 | Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis. ( Anness, AR; Baldo, A; Khalil, A; Mousa, HA; Robinson, TG; Webb, DR, 2021) |
| "Maternal gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy, which can adversely affect the short- and long-term health of mothers and newborns." | 2.72 | Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options. ( Brunetti, A; Chiefari, E; Foti, D; Greco, E; Mirabelli, M; Tocci, V, 2021) |
| "Metformin is a safe, cheap drug that can help in prevention of OHSS." | 2.72 | Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. ( Fotouh, IA; Khattab, S; Metwally, M; Moaz, M; Mohesn, IA, 2006) |
| "Metformin was effective in DAP reduction and was well tolerated, but participants were on average 12 years beyond their GDM pregnancy." | 2.66 | Pharmacological intervention for diabetes after pregnancy prevention in women with prior gestational diabetes: A scoping review. ( Dasgupta, K; Mahmoud, I; Pancer, J; Wu, N, 2020) |
| "The prevalence of gestational diabetes mellitus (GDM) is increasing, with approximately 15% of pregnant women affected worldwide, varying by country, ethnicity and diagnostic thresholds." | 2.66 | Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. ( Alsweiler, J; Brown, S; Crowther, CA; Griffith, RJ; Middleton, P; Moore, AE; Shepherd, E, 2020) |
| "Metformin has been a longstanding and safe treatment for the control of blood glucose in people with T2DM." | 2.66 | Metformin for Preventing Type 2 Diabetes Mellitus in Women with a Previous Diagnosis of Gestational Diabetes: A Narrative Review. ( Anjana, RM; Beks, H; Dunbar, JA; Hague, W; Khunti, K; McNamara, K; Mohan, V; Versace, VL; Wesley, H, 2020) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Glyburide has been associated with increased neonatal hypoglycemia." | 2.61 | The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy. ( Blair, RA; Palermo, NE; Rosenberg, EA, 2019) |
| "When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence." | 2.61 | Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. ( Balen, AH; Morley, LC; Norman, RJ; Sharpe, A; Tang, T, 2019) |
| "Established risk factors for gestational diabetes mellitus (GDM) include ethnicity, obesity, and family history of diabetes." | 2.61 | Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. ( Farahvar, S; Sheiner, E; Walfisch, A, 2019) |
| "Pregestational and gestational diabetes are associated with significant maternal and fetal risks; therefore, screening and treatment during pregnancy are recommended." | 2.61 | Pharmacologic Treatment of Diabetes in Pregnancy. ( Bishop, KC; Boyd, BK; Brown, L; Harris, BS; Kuller, JA; Reiff, ES, 2019) |
| " The use of antenatal steroids in mothers at risk of preterm delivery complicates management of hyperglycaemia in the immediate antepartum period and requires appropriate dosing adjustments of insulin therapy." | 2.58 | Intra-partum management of women with diabetes. ( Jacob, JJ; Jewel, R, 2018) |
| "The diagnosis and treatment of gestational diabetes mellitus (GDM) have been in a state of flux since the World Health Organization accepted and endorsed the International Diabetes and Pregnancy Study Group's diagnostic pathway and criteria in 2013." | 2.58 | Changing environment of hyperglycemia in pregnancy: Gestational diabetes and diabetes mellitus in pregnancy. ( Cohen, N; Gray, SG; Little, PJ; Mcguire, TM; Ross, GP; Sweeting, AN, 2018) |
| "Metformin has well known anti-malarial properties." | 2.55 | Malaria and diabetes. ( Aggarwal, S; Dutta, D; Kalra, S; Khandelwal, D; Singla, R, 2017) |
| "Women with a history of gestational diabetes are at high risk for developing type 2 diabetes mellitus." | 2.55 | Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review. ( Grajower, MM; Kasher-Meron, M, 2017) |
| "Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta." | 2.55 | Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. ( Conde-Agudelo, A; Erez, O; Grossman, LI; Hüttemann, M; Maymon, E; Pacora, P; Panaitescu, B; Romero, R; Yoon, BH, 2017) |
| "Metformin has also proven to be safe and may be considered as an initial single agent for milder gestational diabetes." | 2.55 | The care of pregestational and gestational diabetes and drug metabolism considerations. ( Davis, SN; Hedrington, MS, 2017) |
| "Glyburide has good efficacy and short-term data but it also crosses the placenta and may be associated with increased rates of large-for-gestational-age (LGA) infants and neonatal hypoglycaemia when compared with insulin." | 2.55 | Pharmacological Management of Gestational Diabetes Mellitus. ( Feig, DS; Mukerji, G, 2017) |
| "Metformin is an effective alternative to insulin in glycemic control in pregnant women." | 2.55 | Gestational diabetes - is diet and insulin the only solution? ( Bieniek, E; Brzozowska, M; Lewinski, A; Szosland, K, 2017) |
| "Metformin has been gradually used in the management of gestational diabetes mellitus (GDM)." | 2.55 | Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis. ( Feng, Y; Yang, H, 2017) |
| "Hidradenitis suppurativa is a debilitating inflammatory skin disease with a chronic course and often disappointing response to treatment." | 2.55 | Management of hidradenitis suppurativa in pregnancy. ( Okoye, GA; Perng, P; Zampella, JG, 2017) |
| "Metformin may be beneficial in treating gestational diabetes." | 2.53 | Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. ( Cao, YS; Fan, YY; Li, XG; Liu, T; Wang, L; Zhang, L; Zhao, ZG; Zhu, B, 2016) |
| "The primary aims of the treatment of gestational diabetes (GDM) are to prevent macrosomia and pregnancy complications." | 2.53 | Is it worth treating gestational diabetes: if so, when and how? ( Vääräsmäki, M, 2016) |
| "It has also been widely used in the treatment of polycystic ovary syndrome (PCOS) and gestational diabetes mellitus." | 2.53 | Role of Metformin in Women's Health: Review of Its Current Place in Clinical Practice and Emerging Indications for Future. ( Sinai Talaulikar, V; Tang, T; Yasmin, E, 2016) |
| "A diagnosis of Gestational Diabetes (GDM) confers adverse risk to the health of the mother and fetus both in pregnancy and later life." | 2.53 | Prediction and prevention of Gestational Diabetes: an update of recent literature. ( Kennelly, MA; McAuliffe, FM, 2016) |
| "The overall incidence of gestational diabetes mellitus (GDM) is increasing worldwide." | 2.53 | Gestational diabetes mellitus: does an effective prevention strategy exist? ( Agha-Jaffar, R; Johnston, D; Oliver, N; Robinson, S, 2016) |
| "It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome." | 2.53 | Metformin: From Research to Clinical Practice. ( Alquraini, H; MacEachern, M; Mizokami-Stout, K; Tan, MH, 2016) |
| "Maternal obesity is associated with adverse perinatal outcome." | 2.52 | Placental dysfunction in obese women and antenatal surveillance strategies. ( Doshani, A; Jeve, YB; Konje, JC, 2015) |
| " Other oral medications have not been shown to be safe in pregnancy." | 2.52 | Safety considerations with pharmacological treatment of gestational diabetes mellitus. ( Simmons, D, 2015) |
| "At short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and metformin, while metformin (plus insulin when required) performs slightly better than insulin." | 2.52 | Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. ( Balsells, M; Corcoy, R; García-Patterson, A; Gich, I; Roqué, M; Solà, I, 2015) |
| "Obesity is a known risk factor for infertility in women." | 2.52 | Medical and surgical interventions to improve outcomes in obese women planning for pregnancy. ( Bahadursingh, S; Ramsewak, S; Sharma, A; Teelucksingh, S, 2015) |
| "Glycaemic control in women with gestational diabetes mellitus (GDM) has typically been achieved with diet, exercise and insulin therapy." | 2.52 | Metformin for the management of gestational diabetes mellitus. ( Barclay, M; Rahimpanah, F; Singh, KP, 2015) |
| "Metformin seems to be a superior choice to glyburide if oral antidiabetic drug therapy is to be initiated in GDM patients." | 2.52 | Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis. ( Amin, M; Malik, O; Poolsup, N; Suksomboon, N, 2015) |
| "Studies of the use of metformin in gestational diabetes show at least equivalent neonatal outcomes, while reporting reductions in neonatal hypoglycaemia, maternal hypoglycaemia and weight gain and improved treatment satisfaction." | 2.50 | The use of oral hypoglycaemic agents in pregnancy. ( Holt, RI; Lambert, KD, 2014) |
| "Metformin is an effective insulin sensitizer treating type 2 diabetes mellitus." | 2.50 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. ( Wang, A; Yu, H; Zhuo, Z, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 2.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Metformin seems to be an efficacious alternative to insulin and a better choice than glyburide especially those with mild form of disease." | 2.50 | Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis. ( Amin, M; Poolsup, N; Suksomboon, N, 2014) |
| " In this article, we review the efficacy, safety, and dosage of oral hypoglycemic agents for the treatment of gestational diabetes mellitus." | 2.50 | Gestational diabetes mellitus management with oral hypoglycemic agents. ( Hays, KE; Hebert, MF; Ryu, RJ, 2014) |
| "We used the key words "gestational diabetes" in combination with "metformin" and searched the databases including Pubmed, the Cochrane Library, Web of knowledge, and Clinical Trial Registries." | 2.49 | Metformin vs insulin in the management of gestational diabetes: a meta-analysis. ( Feng, L; Gui, J; Liu, Q, 2013) |
| "Pregnancy is an indication for intensive insulin therapy." | 2.48 | [Drug therapy for diabetes mellitus during pregnancy and breastfeeding in the beginning of 21 century: status quo and new challenges]. ( Zhelyazkova-Savova, M, 2012) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| " In this review, our objectives were to (1) summarise the available evidence on the efficacy these medications, (2) review available data on adverse effect, (3) discuss current gaps in research, outlining limitations in current study designs that deserve attention and (4) summarise key points for the practicing clinician." | 2.47 | Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety. ( Baptiste-Roberts, K; Nicholson, W, 2011) |
| "Insulin resistance is linked to polycystic ovary syndrome." | 2.47 | Current perspectives of insulin resistance and polycystic ovary syndrome. ( Legro, RS; Pauli, JM; Raja-Khan, N; Wu, X, 2011) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 2.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 2.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin has been found largely to be effective in the treatment of GDM." | 2.45 | Role of metformin in the treatment of gestational diabetes. ( Wensel, TM, 2009) |
| "The incidence of gestational diabetes is increasing." | 2.45 | The management of gestational diabetes. ( Cheung, NW, 2009) |
| "Polycystic ovarian syndrome is the commonest endocrine disorder of reproductive-age women." | 2.44 | Polycystic ovarian syndrome--prognosis and treatment outcomes. ( Hart, R, 2007) |
| "Polycystic ovary syndrome is a diagnosis of exclusion of other causes of hyperandrogenism." | 2.43 | Polycystic ovary syndrome--a management update. ( Costello, MF, 2005) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 2.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| "Hyperinsulinemia has been causally linked with all features of the syndrome, such as hyperandrogenism, reproductive disorders, and metabolic disturbances." | 2.43 | Metformin treatment of PCOS during adolescence and the reproductive period. ( Artensio, AC; La Marca, A; Stabile, G; Volpe, A, 2005) |
| " Evidence for the long-term use of metformin to protect against adverse cardiovascular outcomes and for the use of metformin throughout pregnancy to reduce the risk of miscarriage, gestational diabetes, pre-eclampsia and fetal macrosomia is still lacking." | 2.43 | Polycystic ovarian syndrome--prognosis and outcomes. ( Hart, R; Norman, R, 2006) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 2.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "The mechanism of anovulation is uncertain but there is evidence that arrested antral follicle development is associated with the abnormal endocrine profile, in particular the interaction of insulin and LH on granulosa cell differentiation." | 2.43 | Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. ( Franks, S; Gorry, A; White, DM, 2006) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 2.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "With the prevalence of type 2 diabetes mellitus having increased to approximately 8% during recent years and a further rise likely, type 2 diabetes will develop into a major health care problem in Europe." | 2.42 | [Optimized diabetes therapy in type 2 diabetics]. ( Clemens, A; Riemann, JF; Siegel, EG, 2003) |
| "Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder." | 2.42 | Insulin-lowering agents in the management of polycystic ovary syndrome. ( De Leo, V; la Marca, A; Petraglia, F, 2003) |
| "Insulin resistance is a central feature of polycystic ovary syndrome (PCOS)." | 2.42 | Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? ( Cheang, KI; Nestler, JE, 2004) |
| "Treatment with metformin, alone or in combination with clomiphene citrate, may also be beneficial." | 2.41 | Polycystic ovary syndrome and ovulation induction. ( Phipps, WR, 2001) |
| "The prevalence of gestational diabetes mellitus (GDM) has been increasing in Australia and worldwide." | 1.91 | Predictors for pharmacological therapy and perinatal outcomes with metformin treatment in women with gestational diabetes. ( Bliuc, D; Brzozowska, MM; O'Sullivan, A; Piotrowicz, AK; Puvanendran, A; Zuschmann, A, 2023) |
| "Metformin was the most prescribed medication for GDM, with large increases over the past 2 decades." | 1.91 | Use of metformin and insulin among pregnant women with gestation diabetes in the United Kingdom: A population-based cohort study. ( Filion, KB; Platt, RW; Reynier, P; Yu, OHY; Yu, YH, 2023) |
| "Metformin was offered to less than 2% of pregnancies to treat gestational diabetes (2017-2019)." | 1.91 | Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort. ( Baud, D; Ceulemans, M; Dao, K; Favre, G; Gerbier, E; Jenkinson, SP; Maisonneuve, E; Niznik, B; Panchaud, A; Schmid, CPR; Spoendlin, J; Winterfeld, U, 2023) |
| "To assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre-eclampsia undergoing expectant management." | 1.91 | Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia. ( Bergkvist, J; Bergman, L; Cluver, CA; Geerts, L; Hall, DR; Imberg, H; Mol, BW; Tong, S; Walker, SP, 2023) |
| "GDM metformin treatment was not associated with differences in offspring growth trajectories compared to insulin treatment." | 1.91 | Associations between maternal gestational diabetes metformin or insulin treatment and offspring growth trajectories from birth to 60 months of age: Findings from the Born in Bradford (BiB) study. ( Johnson, W; Martine-Edith, G; Petherick, ES, 2023) |
| "Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored." | 1.72 | Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Hargreaves, IP; Heaton, RA; Hufnagel, A; Jenkins, B; Koulman, A; Ozanne, SE, 2022) |
| "The increased prevalence of gestational diabetes mellitus (GDM) has caused a huge societal economic and healthy burden at both the population and individual levels." | 1.72 | Comparative efficacy and safety of glyburide, metformin, and insulin in treatment of gestational diabetes mellitus: A protocol for systematic review and meta-analysis. ( Hong, XY; Lin, J; Tu, RZ, 2022) |
| "The incidence of gestational diabetes mellitus (GDM) is increasing." | 1.72 | Metformin: A promising option for the management of gestational diabetes mellitus - Exploring the benefits, challenges and clinical needs in the current management of gestational diabetes mellitus. ( Bastian, B; Davis, W; Francois, ME; Pape, A; Smithers, LG, 2022) |
| "Metformin was more often used in patients with obesity who also required higher daily doses." | 1.72 | Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus. ( Eder, A; Eppel, D; Geissler, F; Göbl, CS; Hösli, I; Huhn, EA; Linder, T; Monod, C; Redling, K; Rosicky, I, 2022) |
| "Metformin treatment reduced weight gain and visceral fat accumulation." | 1.72 | Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice. ( Appel, S; Bae-Gartz, I; Dötsch, J; Gellhaus, A; Gründemann, D; Handwerk, M; Hucklenbruch-Rother, E; Janoschek, R; Kammerer, MD; Köninger, A; Kretschmer, T; Schmitz, K; Turnwald, EM; Voßbrecher, K; Wohlfarth, M, 2022) |
| "Cetirizine was measured to median milk concentrations of 13 ng/mL (range: 0." | 1.72 | Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS. ( Baranczewski, P; Lindqvist, A; Nordeng, H; Saleh, A; Smeraglia, J; Wegler, C, 2022) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 1.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "Metformin is a drug used for the treatment of type 2 diabetes and disorders associated with insulin resistance." | 1.62 | ( Acloque, H; Bertoldo, MJ; Chevaleyre, C; Dupont, J; Faure, MC; Fournier, I; Froment, P; Guerquin, MJ; Khoueiry, R; Quanico, J; Ramé, C; Salzet, M, 2021) |
| "Gestational Diabetes Mellitus (GDM) and Type 2 Diabetes Mellitus (DM2) are metabolic disorders characterized by increased insulin resistance." | 1.62 | The Use of Oral Hypoglycemic Agents during Pregnancy: An Alternative to Insulin? ( González-Rodríguez, LA; González-Sepúlveda, L; Mercado-Méndez, S; Romaguera, J, 2021) |
| "Once a woman is diagnosed with gestational diabetes mellitus (GDM), two strategies are considered for management; life-style modifications and pharmacological therapy." | 1.62 | Management of Gestational Diabetes Mellitus. ( Oskovi-Kaplan, ZA; Ozgu-Erdinc, AS, 2021) |
| "The aim of this study is to investigate the effects of metformin treatment at different dosage levels on the ovaries and uteruses of rat offspring in the course of the intrauterine period." | 1.62 | The effects of metformin treatment on the ovaries and uterus of offspring. ( Avcı, B; Ayas, B; Kırmızıkan, S; Kocaman, A, 2021) |
| "Metformin and insulin were used for therapy; the resulting changes to glycogen metabolism and embryo implantation were examined." | 1.62 | The Effects of Altered Endometrial Glucose Homeostasis on Embryo Implantation in Type 2 Diabetic Mice. ( Cui, ZH; Guo, WJ; Ma, YD; Nie, L; Wang, YC; Yuan, DZ; Yue, LM; Zhang, JH; Zhang, LX; Zhang, XQ; Zhao, D, 2021) |
| "Metformin has been used in the treatment of gestational diabetes, but the evaluation of its efficacy and safety is lack of reliable evidence-based medicine evidence." | 1.62 | Efficacy and safety of metformin in the treatment of gestational diabetes: A protocol for systematic review and meta-analysis. ( Mao, W; Shen, S; Wang, L; Zhang, S, 2021) |
| "Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy." | 1.62 | Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. ( Brownfoot, F; Cannon, P; Cruickshank, T; Garcha, D; Hannan, NJ; Hyett, J; Illanes, SE; Jellins, J; Kaitu'u-Lino, TJ; Kandel, M; Keenan, E; MacDonald, TM; Masci, J; Middleton, A; Murphy, C; Murray, E; Myers, J; Nguyen, TV; Nien, JK; Pell, G; Pritchard, N; Roddy Mitchell, A; Schepeler, M; Tong, S; Walker, SP; Whigham, CA; Wong, GP, 2021) |
| "Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM)." | 1.56 | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study. ( Begum, S; Lawlor, DL; Nelson, SM; Pasupathy, D; Poston, L; Sattar, N; Seed, P; Vieira, MC; Welsh, P; White, SL, 2020) |
| "Metformin treatment on male diabetic placental explant activated AMPK and stimulated PGC-1α expression, concomitant with increased H3K27 acetylation and decreased PGC-1α promoter methylation." | 1.56 | Role of metformin in epigenetic regulation of placental mitochondrial biogenesis in maternal diabetes. ( Chernausek, SD; Jensen, ME; Jiang, S; Teague, AM; Tryggestad, JB, 2020) |
| "<6." | 1.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "Pregnant women who develop gestational diabetes (GDM) are more likely to deliver by caesarean section (CS)." | 1.56 | Metformin versus insulin use for treatment of gestational diabetes and delivery by caesarean section: A nationwide Swedish cohort study. ( Abdi, L; Cesta, CE; Kieler, H; Pazzagli, L, 2020) |
| " In the present study, we aimed to develop a pharmacokinetic (PK) model of transplacental transfer of metformin to predict in vivo fetal exposure to metformin and to resolve the apparent inconsistency between open and closed ex vivo systems." | 1.56 | Development of a Pharmacokinetic Model of Transplacental Transfer of Metformin to Predict In Vivo Fetal Exposure. ( Chiba, K; Kurosawa, K; Nishimura, T; Noguchi, S; Tomi, M, 2020) |
| "Metformin appears to be an effective treatment for women with GDM and may reduce risk of some adverse neonatal outcomes when compared with insulin." | 1.51 | Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. ( Boggess, K; Engel, SM; Howe, AS; Jonsson Funk, M; Landi, SN; Radke, S; Stürmer, T, 2019) |
| "Metformin is an emerging option for treating gestational diabetes (GDM)." | 1.51 | Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. ( Boggess, K; Engel, SM; Funk, MJ; Howe, AS; Landi, SN; Radke, S; Stürmer, T, 2019) |
| "Metformin is an anti-hyperglycemic drug widely used for the treatment of insulin resistance and glucose intolerance and is currently considered for preventing large-for-gestational-age (LGA) offspring in pregnant women affected by obesity or diabetes." | 1.51 | Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses. ( Astiz, S; Encinas, T; Garcia-Contreras, C; Gonzalez-Bulnes, A; Heras-Molina, A; Pesantez-Pacheco, JL; Torres-Rovira, L; Vazquez-Gomez, M, 2019) |
| "Metformin (MET) is a widely-used drug for the treatment of type 2 diabetes mellitus and gestational diabetes." | 1.51 | Reproductive evaluations in female rat offspring exposed to metformin during intrauterine and intrauterine/lactational periods. ( Ceccatto Gerardin, DC; Ceravolo, GS; da Silva Novi, DRB; de Góes, MLM; Forcato, S; Inhasz Kiss, AC; Montagnini, BG, 2019) |
| "Metformin (Met) has been found to modify the methylation of H19 and to alter its expression." | 1.51 | Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. ( Chen, C; Dong, S; Gu, J; He, J; Mo, Y; Shah, NK; Shu, C; Wu, L; Yan, D, 2019) |
| "Hippocampus-based learning and memory deficits are key symptoms of FASD." | 1.48 | Hippocampus-dependent memory and allele-specific gene expression in adult offspring of alcohol-consuming dams after neonatal treatment with thyroxin or metformin. ( Ferreira, A; Lim, PH; Redei, EE; Tunc-Ozcan, E; Wert, SL, 2018) |
| "In addition, the steps in the gestational diabetes mellitus management decision path and the current cost of the use of insulin, glyburide, or metformin are addressed." | 1.48 | Pharmacological treatment of gestational diabetes mellitus: point/counterpoint. ( Langer, O, 2018) |
| " Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia." | 1.48 | A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. ( Aagaard, K; Barbour, LA; Buchanan, TA; Catalano, PM; Coustan, D; Frias, AE; Friedman, JE; Galan, HL; Hay, WW; Loeken, MR; Moses, RG; Sacks, DA; Scifres, C; Shankar, K; Simmons, RA; Thornburg, KL; Valent, AM, 2018) |
| "Metformin was thus found to be a safe, practical and cost effective medication to be offered to our population." | 1.48 | Metformin or insulin: logical treatment in women with gestational diabetes in the Middle East, our experience. ( Ashawesh, K; Beer, S; Boama, V; Christian, SJ; Dukhan, K; Elhadd, TA; Ramawat, J; Satti, H, 2018) |
| "Metformin has been increasingly popular in recent years." | 1.48 | Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin. ( Chen, C; Li, X; Zhen, XM, 2018) |
| "Metformin promotes AMPK-dependent telomerase activation (critical for telomere maintenance) and induces activation of the endonuclease RAG1 (promotes DNA cleavage and transposition) via AMPK." | 1.48 | Transposable elements, placental development, and oocyte activation: Cellular stress and AMPK links jumping genes with the creation of human life. ( Finley, J, 2018) |
| "Letrozole-treated patients required a significantly lower amount of gonadotropins units (p < 0." | 1.48 | Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study. ( Cantatore, C; Caringella, AM; Caroppo, E; D'Amato, G; Palini, S; Stanziano, A, 2018) |
| " In this investigation, PBPK modeling was used to assess the impact of pregnancy on the pharmacokinetic profiles of three medications (metformin, tacrolimus, oseltamivir) using the Simcyp® simulator." | 1.46 | Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. ( Avvari, S; Gollen, R; Jogiraju, VK; Taft, DR, 2017) |
| "Metformin has been used for the treatment of some metabolic diseases during gestation and the beneficial effects of metformin to the vascular system have been described in diabetic and obese animal models." | 1.46 | Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings. ( Ceravolo, GS; Forcato, S; Gerardin, DCC; Loiola, GH; Novi, DRBS; Vidigal, CB, 2017) |
| "We compared, in 733 women with gestational diabetes mellitus treated with metformin and/or insulin, rates of neonatal hypoglycaemia in those who had received a dextrose/insulin infusion during labour and prior to delivery (n = 132) with those who did not (n = 601)." | 1.46 | The use of dextrose/insulin infusions during labour and delivery in women with gestational diabetes mellitus: Is there any point? ( Battin, M; Farrant, MT; Hague, WM; Rowan, JA; Williamson, K, 2017) |
| "Metformin has potential to prevent or treat preeclampsia." | 1.43 | Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Illanes, SE; Kaitu'u-Lino, TJ; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2016) |
| "The use of metformin in gestational diabetes is safe and effective, yet some women require additional insulin therapy to achieve glycaemic targets." | 1.43 | Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. ( Fulcher, GR; Glastras, SJ; Hocking, S; McGrath, RT, 2016) |
| "In her fifth pregnancy, treatment for gestational diabetes mellitus with metformin was associated with a lowering effect on bile acids and liver enzymes, indicating a possible role for metformin in the management of obstetric cholestasis." | 1.43 | Managing Recurring Obstetric Cholestasis With Metformin. ( Ali, A; Elfituri, A; Shehata, H, 2016) |
| "Increasing prevalence of type 2 diabetes in women of childbearing age has led to a higher incidence of diabetes-associated birth defects." | 1.42 | Cellular Stress, Excessive Apoptosis, and the Effect of Metformin in a Mouse Model of Type 2 Diabetic Embryopathy. ( Fu, M; Quon, MJ; Wang, C; Wang, F; Wu, Y; Yang, P, 2015) |
| "Maternal obesity and gestational diabetes mellitus (GDM) are two increasingly common and important obstetric complications that are associated with severe long-term health risks to mothers and babies." | 1.42 | Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes. ( Lappas, M; Liong, S, 2015) |
| "Median maternal weight gain was 6 kg (gestational diabetes mellitus) and 10 kg (normal glucose tolerance); caesarean section rates were 25% and 11% respectively; baby birthweights were not significantly different." | 1.42 | Gestational diabetes mellitus screening, management and outcomes in the Cook Islands. ( Aung, YY; Ekeroma, A; Herman, J; Kenealy, T; Sowter, M, 2015) |
| "With the increasing prevalence of type 2 diabetes in young adulthood, treatment of diabetes in pregnancy faces new challenges." | 1.40 | Anti-diabetic drug utilization of pregnant diabetic women in us managed care. ( Delaney, JA; Knox, CA; Winterstein, AG, 2014) |
| "To compare the incidence of gestational diabetes mellitus (GDM) in Iranian infertile women with polycystic ovary syndrome (PCOS) and women without PCOS after pregnancies resulting from either assisted reproductive technology (ART) or spontaneous as well as to determine the risk factors of GDM in PCOS women." | 1.40 | Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). ( Arabipoor, A; Ashrafi, M; Hosseini, R; Nourbakhsh, F; Sheikhan, F; Zolfaghari, Z, 2014) |
| "Metformin was administered during gestation from E0." | 1.40 | Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. ( Ailanen, L; Eerola, K; Heinäniemi, M; Koulu, M; Pesonen, U; Ruohonen, ST; Salomäki, H; Vähätalo, LH, 2014) |
| "Women with a history of gestational diabetes mellitus (GDM) are at increased risk of future development of type 2 diabetes." | 1.39 | Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. ( Cho, NH; Cho, YM; Choi, SH; Jang, HC; Jung, HS; Kim, K; Kim, SY; Kwak, SH; Lim, S; Park, KS, 2013) |
| "The Metformin in Gestational Diabetes (MiG) trial reported similar pregnancy outcomes for metformin versus insulin; however, supplemental insulin was required in 46% of women on metformin." | 1.39 | Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus. ( Campbell, J; Corbould, A; Dennis, A; McBeath, S; Radford, A; Swinton, F, 2013) |
| "Metformin is a drug used in the treatment of diabetes and of some disorders related to insulin resistance, such as polycystic ovary syndrome." | 1.38 | Metformin exposure affects human and mouse fetal testicular cells. ( Dupont, J; Froment, P; Frydman, N; Frydman, R; Guibert, E; Habert, R; Lecureuil, C; Moison, D; Pozzi, S; Rouiller-Fabre, V; Tartarin, P, 2012) |
| "Metformin treatment of PNA mice restored firing activity and LH to control levels." | 1.37 | Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. ( Moenter, SM; Roland, AV, 2011) |
| "Glyburide and metformin have been shown to be as effective as insulin for the treatment of gestational diabetes." | 1.37 | Oral hypoglycemic agents in pregnancy. ( Refuerzo, JS, 2011) |
| "There were 1269 women with gestational diabetes; treatment was diet in 371, insulin in 399 and metformin in 465 (249 metformin alone, 216 metformin and insulin)." | 1.37 | Metformin for gestational diabetes in routine clinical practice. ( Goh, JE; Rowan, J; Sadler, L, 2011) |
| "Cimetidine was used as an inhibitor for OCT-dependent active transfer." | 1.36 | The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. ( Ekblad, U; Heikkinen, T; Laine, K; Rahi, M; Rönnemaa, T; Tertti, K, 2010) |
| "Glyburide was transported by multidrug resistance protein (43 +/- 4%); breast cancer resistance protein (25 +/- 5%); and P-glycoprotein (9 +/- 5%)." | 1.36 | Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. ( Ahmed, MS; Hankins, GD; Hemauer, SJ; Nanovskaya, TN; Patrikeeva, SL, 2010) |
| "Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant." | 1.36 | Metformin treatment for Type 2 diabetes in pregnancy? ( Simmons, D, 2010) |
| "Metformin is a polar positively charged compound." | 1.35 | Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. ( Golan, A; Hoffman, A; Kogman, N; Kovo, M; Nakash, I; Ovadia, O, 2008) |
| "24 and 48h post-implantation) induces embryo resorption of early pregnant BALB/c mice while simultaneous treatment with metformin (240mg/kg, oral 24 and 48h post-implantation) prevents it." | 1.35 | Dehydroepiandrosterone and metformin modulate progesterone-induced blocking factor (PIBF), cyclooxygenase 2 (COX2) and cytokines in early pregnant mice. ( Luchetti, CG; Mikó, E; Motta, AB; Paz, DA; Szekeres-Bartho, J, 2008) |
| "GVHD had little effect." | 1.35 | O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. ( Bernard, GR; Ely, EW; Harvey, SB; Homoncik, M; Jilma, B; Kasthuri, RS; Kellogg, TA; Lund, TC; Monkkonen, T; Nelsestuen, GL; Swan, T; Verneris, MR; Wilson-Grady, J; Zeisler, H; Zhang, Y, 2009) |
| "Treatment of gestational diabetes mellitus is a hotly debated topic." | 1.35 | [Oral blood glucose-lowering medication as a monotherapy in gestational diabetes: a hotly debated topic]. ( de Valk, HW, 2009) |
| "Sixty women with gestational and type 2 diabetes were enrolled, 30 each for metformin and insulin." | 1.35 | Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy. ( Kamath, A; Meenakshi, D; Rai, L, 2009) |
| "For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction." | 1.34 | Ovulation induction management of PCOS. ( Guzick, DS, 2007) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 1.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "Metformin treatment did not modify the percentage of CD4(+) and CD8(+) T cells from both axillar and retroperitoneal lymph nodes but prevented the increase of serum tumour necrosis factor +/- produced in DHEA-treated mice." | 1.33 | Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "Impaired glucose tolerance is defined as two-hour glucose levels of 140 to 199 mg per dL (7." | 1.32 | Impaired glucose tolerance and impaired fasting glucose. ( Disraeli, P; McGregor, T; Rao, SS, 2004) |
| "Metformin was then administered." | 1.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "Polycystic ovary syndrome is the most common form of female infertility in the United States." | 1.31 | Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. ( Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE; Roberts, KA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (1.12) | 18.7374 |
| 1990's | 7 (0.79) | 18.2507 |
| 2000's | 232 (26.04) | 29.6817 |
| 2010's | 407 (45.68) | 24.3611 |
| 2020's | 235 (26.37) | 2.80 |
| Authors | Studies |
|---|---|
| Estrella, J | 1 |
| Wiley, V | 1 |
| Simmons, D | 6 |
| Hng, TM | 1 |
| McLean, M | 1 |
| Benham, JL | 1 |
| Donovan, LE | 3 |
| Yamamoto, JM | 1 |
| Whelan, AR | 1 |
| Ayala, NK | 1 |
| Werner, EF | 4 |
| Huang, SW | 1 |
| Ou, YC | 1 |
| Tang, KS | 1 |
| Yu, HR | 4 |
| Huang, LT | 4 |
| Tain, YL | 5 |
| Lin, IC | 4 |
| Sheen, JM | 4 |
| Hou, CY | 1 |
| Tsai, CC | 4 |
| Tiao, MM | 4 |
| Hanem, LGE | 4 |
| Salvesen, Ø | 10 |
| Madsen, A | 1 |
| Sagen, JV | 1 |
| Mellgren, G | 1 |
| Juliusson, PB | 3 |
| Carlsen, SM | 26 |
| Vanky, E | 37 |
| Ødegård, R | 5 |
| Hufnagel, A | 1 |
| Fernandez-Twinn, DS | 3 |
| Blackmore, HL | 3 |
| Ashmore, TJ | 3 |
| Heaton, RA | 1 |
| Jenkins, B | 2 |
| Koulman, A | 2 |
| Hargreaves, IP | 1 |
| Aiken, CE | 7 |
| Ozanne, SE | 6 |
| Cwynar-Zając, Ł | 1 |
| Cluver, CA | 2 |
| Hiscock, R | 2 |
| Decloedt, EH | 1 |
| Hall, DR | 2 |
| Schell, S | 1 |
| Mol, BW | 7 |
| Brownfoot, F | 3 |
| Kaitu'u-Lino, TJ | 7 |
| Walker, SP | 5 |
| Tong, S | 9 |
| Newman, C | 5 |
| Dunne, FP | 2 |
| Cao, Q | 1 |
| Hu, Y | 3 |
| Fu, J | 2 |
| Huang, X | 2 |
| Wu, L | 4 |
| Zhang, J | 11 |
| Huang, W | 4 |
| Rajasekaran, K | 1 |
| Malhotra, N | 1 |
| Mahey, R | 4 |
| Khadgawat, R | 3 |
| Kalaivani, M | 1 |
| Venkatesh, KK | 1 |
| Chiang, CW | 1 |
| Castillo, WC | 1 |
| Battarbee, AN | 1 |
| Donneyong, M | 1 |
| Harper, LM | 1 |
| Costantine, M | 2 |
| Saade, G | 1 |
| Boggess, KA | 3 |
| Landon, MB | 2 |
| Yu, DQ | 1 |
| Xu, GX | 1 |
| Teng, XY | 1 |
| Xu, JW | 1 |
| Tang, LF | 1 |
| Feng, C | 2 |
| Rao, JP | 1 |
| Jin, M | 1 |
| Wang, LQ | 1 |
| Díaz González-Colmenero, F | 1 |
| García-Campa, M | 1 |
| Rodríguez-Gutiérrez, R | 1 |
| Cui, J | 3 |
| Song, L | 3 |
| Wang, R | 5 |
| Hu, S | 2 |
| Yang, Z | 1 |
| Zhang, Z | 4 |
| Sun, B | 4 |
| Cui, W | 2 |
| Paavilainen, E | 4 |
| Tertti, K | 14 |
| Nikkinen, H | 4 |
| Veijola, R | 3 |
| Vääräsmäki, M | 8 |
| Loo, BM | 3 |
| Tossavainen, P | 3 |
| Rönnemaa, T | 15 |
| Niinikoski, H | 4 |
| Lin, W | 2 |
| Feng, J | 4 |
| Zhou, H | 1 |
| Chen, X | 7 |
| Diao, W | 1 |
| Ma, P | 1 |
| Qian, H | 1 |
| Xu, W | 1 |
| Cui, L | 1 |
| Wang, J | 12 |
| Tang, M | 1 |
| Wei, M | 1 |
| Wang, L | 5 |
| Faure, MC | 1 |
| Khoueiry, R | 1 |
| Quanico, J | 1 |
| Acloque, H | 1 |
| Guerquin, MJ | 1 |
| Bertoldo, MJ | 1 |
| Chevaleyre, C | 1 |
| Ramé, C | 1 |
| Fournier, I | 1 |
| Salzet, M | 1 |
| Dupont, J | 2 |
| Froment, P | 2 |
| Palatnik, A | 2 |
| Harrison, RK | 2 |
| Thakkar, MY | 1 |
| Walker, RJ | 1 |
| Egede, LE | 1 |
| Simmons, R | 1 |
| Chae-Kim, J | 1 |
| Garg, G | 1 |
| Gavrilova-Jordan, L | 1 |
| Blake, LE | 1 |
| Kim, TT | 1 |
| Wu, Q | 2 |
| Hayslip, CC | 1 |
| Molina-Vega, M | 3 |
| Picón-César, MJ | 3 |
| Gutiérrez-Repiso, C | 1 |
| Fernández-Valero, A | 1 |
| Lima-Rubio, F | 1 |
| González-Romero, S | 3 |
| Moreno-Indias, I | 1 |
| Tinahones, FJ | 2 |
| Molin, J | 2 |
| Løvvik, TS | 4 |
| Dehlin, E | 1 |
| Bixo, M | 3 |
| Wen, Q | 2 |
| Hu, M | 2 |
| Lai, M | 1 |
| Li, J | 19 |
| Hu, Z | 1 |
| Quan, K | 1 |
| Liu, J | 3 |
| Liu, H | 4 |
| Meng, Y | 3 |
| Wang, S | 5 |
| Wen, X | 1 |
| Yu, C | 1 |
| Li, S | 4 |
| Huang, S | 1 |
| Zheng, Y | 2 |
| Lin, H | 1 |
| Liang, X | 1 |
| Lu, L | 2 |
| Mai, Z | 1 |
| Zhang, C | 3 |
| Wu, T | 2 |
| Ng, EHY | 1 |
| Stener-Victorin, E | 2 |
| Ma, H | 2 |
| Li, C | 6 |
| Gao, C | 2 |
| Zhang, X | 11 |
| Zhang, L | 5 |
| Shi, H | 1 |
| Jia, X | 1 |
| Wood, ME | 1 |
| Patorno, E | 2 |
| Huybrechts, KF | 2 |
| Bateman, BT | 2 |
| Gray, KJ | 1 |
| Seely, EW | 2 |
| Vine, S | 2 |
| Hernández-Díaz, S | 3 |
| Espnes, KA | 1 |
| Hønnås, A | 1 |
| Gundersen, POM | 1 |
| Naavik, A | 1 |
| Skogvoll, E | 1 |
| Westin, AA | 1 |
| Spigset, O | 2 |
| Brand, KMG | 1 |
| Saarelainen, L | 4 |
| Sonajalg, J | 4 |
| Boutmy, E | 4 |
| Foch, C | 4 |
| Morin-Papunen, L | 6 |
| Schlachter, J | 4 |
| Hakkarainen, KM | 4 |
| Korhonen, P | 1 |
| Allehdan, S | 1 |
| Basha, A | 1 |
| Hyassat, D | 1 |
| Nabhan, M | 1 |
| Qasrawi, H | 1 |
| Tayyem, R | 1 |
| Acheampong, T | 1 |
| Lee Argov, EJ | 1 |
| Terry, MB | 1 |
| Rodriguez, CB | 1 |
| Agovino, M | 1 |
| Wei, Y | 3 |
| Athilat, S | 1 |
| Tehranifar, P | 1 |
| Tracer, H | 1 |
| Mohnot, S | 1 |
| Walter, K | 1 |
| Abduljalil, K | 1 |
| Pansari, A | 1 |
| Ning, J | 2 |
| Jamei, M | 1 |
| Mercado-Méndez, S | 1 |
| González-Sepúlveda, L | 1 |
| Romaguera, J | 1 |
| González-Rodríguez, LA | 1 |
| Grindheim, S | 1 |
| Ebbing, C | 1 |
| Karlsen, HO | 1 |
| Skulstad, SM | 1 |
| Real, FG | 1 |
| Lønnebotn, M | 2 |
| Løvvik, T | 2 |
| Kessler, J | 1 |
| Huang, J | 2 |
| Ru, G | 1 |
| Sun, J | 2 |
| Sun, L | 1 |
| Li, Z | 7 |
| Fornes, R | 1 |
| Simin, J | 1 |
| Nguyen, MH | 1 |
| Cruz, G | 2 |
| Crisosto, N | 3 |
| van der Schaaf, M | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| Elnahas, EM | 1 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Magzoub, R | 1 |
| Kheirelseid, EAH | 1 |
| Perks, C | 1 |
| Lewis, S | 1 |
| Notaro, ALG | 1 |
| Neto, FTL | 1 |
| Oliveira, MM | 1 |
| Andrade, KFO | 1 |
| Lima, GHS | 1 |
| Rocha, TC | 1 |
| Jiao, Y | 1 |
| Qiao, Z | 1 |
| Han, R | 1 |
| Du, J | 1 |
| Zhang, S | 7 |
| Tseng, E | 1 |
| Durkin, N | 1 |
| Clark, JM | 1 |
| Maruthur, NM | 1 |
| Marsteller, JA | 1 |
| Segal, JB | 1 |
| Tomlinson, G | 4 |
| Feig, DS | 7 |
| Trouva, A | 3 |
| Alvarsson, M | 1 |
| Calissendorff, J | 1 |
| Åsvold, BO | 1 |
| Hirschberg, AL | 3 |
| Adams, JH | 2 |
| Poehlmann, J | 1 |
| Racine, JL | 2 |
| Iruretagoyena, JI | 2 |
| Eddy, A | 2 |
| Hoppe, KK | 2 |
| Stewart, K | 1 |
| Rhoades, J | 1 |
| Antony, KM | 2 |
| Huhtala, M | 1 |
| Ilias, I | 1 |
| Rizzo, M | 1 |
| Zabuliene, L | 1 |
| van Hoorn, EGM | 1 |
| van Dijk, PR | 1 |
| Prins, JR | 1 |
| Lutgers, HL | 1 |
| Hoogenberg, K | 1 |
| Erwich, JJHM | 1 |
| Kooy, A | 1 |
| Lin, J | 3 |
| Tu, RZ | 1 |
| Hong, XY | 1 |
| Bastian, B | 1 |
| Smithers, LG | 1 |
| Davis, W | 1 |
| Pape, A | 1 |
| Francois, ME | 1 |
| Sabzali, M | 1 |
| Eidi, A | 1 |
| Khaksari, M | 1 |
| Khastar, H | 1 |
| Hu, L | 1 |
| Ma, L | 1 |
| Xia, X | 2 |
| Ying, T | 1 |
| Zhou, M | 1 |
| Zou, S | 1 |
| Yu, H | 3 |
| Yin, J | 1 |
| Pan, ML | 2 |
| Chen, LR | 2 |
| Chen, KH | 2 |
| Zhao, Q | 2 |
| He, J | 2 |
| Linder, T | 1 |
| Eder, A | 1 |
| Monod, C | 1 |
| Rosicky, I | 1 |
| Eppel, D | 1 |
| Redling, K | 1 |
| Geissler, F | 1 |
| Huhn, EA | 1 |
| Hösli, I | 1 |
| Göbl, CS | 1 |
| Zinman, B | 3 |
| Asztalos, E | 3 |
| Shah, PS | 1 |
| Sanchez, JJ | 2 |
| Murphy, KE | 2 |
| Schmitz, K | 1 |
| Turnwald, EM | 1 |
| Kretschmer, T | 1 |
| Janoschek, R | 1 |
| Bae-Gartz, I | 1 |
| Voßbrecher, K | 1 |
| Kammerer, MD | 1 |
| Köninger, A | 1 |
| Gellhaus, A | 1 |
| Handwerk, M | 1 |
| Wohlfarth, M | 1 |
| Gründemann, D | 1 |
| Hucklenbruch-Rother, E | 1 |
| Dötsch, J | 1 |
| Appel, S | 1 |
| Wegler, C | 1 |
| Saleh, A | 1 |
| Lindqvist, A | 1 |
| Nordeng, H | 1 |
| Smeraglia, J | 1 |
| Baranczewski, P | 1 |
| de Oliveira, JS | 1 |
| Silva, AADN | 1 |
| Dias, FCR | 1 |
| de Oliveira, EL | 1 |
| de Oliveira Filho, EF | 1 |
| Soares, PC | 1 |
| Ferreira, CMO | 1 |
| da Silva Junior, VA | 1 |
| Li, R | 1 |
| Mai, T | 1 |
| Zheng, S | 1 |
| Zhang, Y | 12 |
| Li, F | 3 |
| Liu, L | 3 |
| Marx, CM | 1 |
| Liu, W | 3 |
| Kong, WY | 1 |
| Liu, ZA | 2 |
| Zhang, N | 1 |
| Wu, X | 7 |
| Zhao, XB | 1 |
| Yan, L | 1 |
| Lovell, H | 1 |
| Mitchell, A | 1 |
| Ovadia, C | 1 |
| Pitrelli, N | 1 |
| Briley, A | 1 |
| Singh, C | 1 |
| Marschall, HU | 1 |
| Cruickshank, K | 1 |
| Murphy, H | 1 |
| Seed, P | 2 |
| Williamson, C | 1 |
| Ramalho, D | 1 |
| Correia, S | 1 |
| Realista, R | 1 |
| Rocha, G | 1 |
| Alves, H | 1 |
| Almeida, L | 1 |
| Ferreira, E | 1 |
| Monteiro, S | 1 |
| Oliveira, MJ | 1 |
| Almeida, MC | 2 |
| McEwen, LN | 1 |
| Hurst, TE | 1 |
| Joiner, KL | 1 |
| Herman, WH | 4 |
| Selen, DJ | 1 |
| Powe, CE | 2 |
| Matorras, R | 1 |
| Pijoan, JI | 1 |
| Laínz, L | 1 |
| Díaz-Nuñez, M | 1 |
| Sainz, H | 1 |
| Pérez-Fernandez, S | 1 |
| Moreira, D | 1 |
| Bramante, CT | 2 |
| Huling, JD | 2 |
| Tignanelli, CJ | 2 |
| Buse, JB | 2 |
| Liebovitz, DM | 2 |
| Nicklas, JM | 2 |
| Cohen, K | 2 |
| Puskarich, MA | 2 |
| Belani, HK | 2 |
| Proper, JL | 2 |
| Siegel, LK | 2 |
| Klatt, NR | 2 |
| Odde, DJ | 2 |
| Luke, DG | 1 |
| Anderson, B | 1 |
| Karger, AB | 2 |
| Ingraham, NE | 1 |
| Hartman, KM | 2 |
| Rao, V | 1 |
| Hagen, AA | 1 |
| Patel, B | 2 |
| Fenno, SL | 2 |
| Avula, N | 1 |
| Reddy, NV | 1 |
| Erickson, SM | 2 |
| Lindberg, S | 1 |
| Fricton, R | 1 |
| Lee, S | 1 |
| Zaman, A | 1 |
| Saveraid, HG | 1 |
| Tordsen, WJ | 1 |
| Pullen, MF | 1 |
| Biros, M | 1 |
| Sherwood, NE | 2 |
| Thompson, JL | 2 |
| Boulware, DR | 2 |
| Murray, TA | 2 |
| Pilszyk, A | 1 |
| Niebrzydowska, M | 1 |
| Pilszyk, Z | 1 |
| Wierzchowska-Opoka, M | 1 |
| Kimber-Trojnar, Ż | 1 |
| Li, H | 7 |
| Shang, L | 1 |
| Deussen, AR | 3 |
| Louise, J | 3 |
| Dodd, JM | 4 |
| Lan, Y | 2 |
| Yang, L | 3 |
| Liu, Y | 8 |
| Zhu, X | 1 |
| Zhao, Y | 8 |
| Long, C | 1 |
| Wang, M | 3 |
| Xie, Q | 3 |
| Wu, J | 3 |
| Schoonejans, JM | 2 |
| Pantaleão, LC | 2 |
| Pellegrini Pisani, L | 1 |
| Dearden, L | 1 |
| Tadross, JA | 1 |
| Dunne, F | 3 |
| Devane, D | 3 |
| Smyth, A | 3 |
| Alvarez-Iglesias, A | 2 |
| Gillespie, P | 2 |
| Browne, M | 2 |
| O'Donnell, M | 2 |
| Uccella, S | 1 |
| Zorzato, PC | 1 |
| Dababou, S | 1 |
| Bosco, M | 1 |
| Torella, M | 1 |
| Braga, A | 1 |
| Frigerio, M | 1 |
| Gardella, B | 1 |
| Cianci, S | 1 |
| Laganà, AS | 1 |
| Franchi, MP | 1 |
| Garzon, S | 1 |
| Pagotto, V | 1 |
| Posadas Martínez, ML | 1 |
| Salzberg, S | 1 |
| Pochettino, PA | 1 |
| Wang, Y | 11 |
| Chen, J | 2 |
| Dong, H | 1 |
| Ma, R | 1 |
| Zou, Y | 1 |
| Wang, W | 2 |
| Zheng, Q | 1 |
| Feng, Y | 2 |
| Tan, Z | 1 |
| Zeng, X | 1 |
| Deng, Y | 1 |
| Gu, B | 1 |
| Sun, A | 1 |
| Alfayez, OM | 1 |
| Alsallum, AA | 1 |
| Aljabri, AF | 1 |
| Almutairi, FS | 1 |
| Al-Azzeh, O | 1 |
| Almalki, OS | 1 |
| Al Yami, MS | 1 |
| Almohammed, OA | 1 |
| Mansukhani, T | 1 |
| Arechvo, A | 1 |
| Cecchini, F | 1 |
| Breim, M | 1 |
| Wright, A | 1 |
| Nicolaides, KH | 2 |
| Charakida, M | 2 |
| Unanyan, A | 1 |
| Pivazyan, L | 1 |
| Krylova, E | 1 |
| Eskin, A | 1 |
| Zakaryan, A | 1 |
| Sarkisova, A | 1 |
| Ishchenko, A | 1 |
| Sarayani, A | 1 |
| Hampp, C | 2 |
| Brown, JD | 1 |
| Donahoo, WT | 1 |
| Winterstein, AG | 2 |
| McDougall, ARA | 1 |
| Hastie, R | 5 |
| Goldstein, M | 1 |
| Tuttle, A | 1 |
| Ammerdorffer, A | 1 |
| Gülmezoglu, AM | 1 |
| Vogel, JP | 1 |
| Zhao, X | 4 |
| Niu, J | 1 |
| Shi, C | 1 |
| Liu, Z | 4 |
| Madievsky, R | 3 |
| Vu, A | 3 |
| Cheng, F | 3 |
| Chon, J | 3 |
| Turk, N | 3 |
| Krueger, A | 3 |
| Krong, J | 3 |
| Maranon, R | 3 |
| Liu, S | 3 |
| Han, CS | 5 |
| Norris, KC | 3 |
| Mangione, C | 3 |
| Page, J | 3 |
| Thomas, S | 4 |
| Duru, OK | 3 |
| Moin, T | 4 |
| Huang, CF | 3 |
| Hsu, CN | 3 |
| Lin, YJ | 3 |
| Brand, KM | 3 |
| Thoren, R | 3 |
| Jiang, XL | 3 |
| Tai, H | 3 |
| Xiao, XS | 3 |
| Zhang, SY | 3 |
| Cui, SC | 3 |
| Qi, SB | 3 |
| Hu, DD | 3 |
| Zhang, LN | 3 |
| Kuang, JS | 3 |
| Meng, XS | 3 |
| Li, SM | 3 |
| Wang, T | 2 |
| Jing, Y | 1 |
| Guo, H | 1 |
| Xu, J | 2 |
| Huang, L | 2 |
| Chen, H | 5 |
| Liu, X | 3 |
| Wang, N | 2 |
| Sorice, GP | 1 |
| Caporusso, M | 1 |
| Cignarelli, A | 1 |
| Perrini, S | 1 |
| Natalicchio, A | 1 |
| Giorgino, F | 1 |
| Hancke, K | 1 |
| Sheng, B | 1 |
| Ni, J | 1 |
| Lv, B | 2 |
| Jiang, G | 1 |
| Lin, X | 1 |
| Ushijima, K | 1 |
| Tsuda, N | 1 |
| Yamagami, W | 1 |
| Mitsuhashi, A | 1 |
| Mikami, M | 1 |
| Yaegashi, N | 1 |
| Enomoto, T | 1 |
| Abolhassani, N | 1 |
| Winterfeld, U | 3 |
| Kaplan, YC | 2 |
| Jaques, C | 1 |
| Minder Wyssmann, B | 1 |
| Del Giovane, C | 1 |
| Panchaud, A | 3 |
| Haqq, AM | 1 |
| Fantus, IG | 3 |
| Lipscombe, L | 2 |
| Armson, A | 1 |
| Barrett, J | 1 |
| Donovan, L | 2 |
| Karanicolas, P | 1 |
| Tobin, S | 1 |
| Mangoff, K | 1 |
| Klein, G | 1 |
| Jiang, Y | 4 |
| Hamilton, J | 1 |
| Kusinski, LC | 1 |
| Meek, CL | 2 |
| Dingena, CF | 1 |
| Holmes, MJ | 1 |
| Campbell, MD | 1 |
| Cade, JE | 1 |
| Scott, EM | 1 |
| Zulyniak, MA | 1 |
| Brzozowska, MM | 1 |
| Puvanendran, A | 1 |
| Bliuc, D | 1 |
| Zuschmann, A | 1 |
| Piotrowicz, AK | 1 |
| O'Sullivan, A | 1 |
| Rickert, M | 1 |
| Caughey, AB | 1 |
| Valent, AM | 2 |
| Gao, R | 2 |
| Qin, L | 1 |
| Min, W | 1 |
| Cunningham, A | 1 |
| Li, E | 1 |
| Silverio, A | 1 |
| Mills, G | 1 |
| Han, J | 1 |
| Waters, A | 1 |
| Peng, G | 1 |
| Yan, Z | 3 |
| Ma, J | 2 |
| Tong, N | 1 |
| Ryssdal, M | 1 |
| Stokkeland, LMT | 1 |
| Jarmund, AH | 1 |
| Steinkjer, B | 1 |
| Madssen, TS | 1 |
| Iversen, AC | 1 |
| Giskeødegård, GF | 1 |
| Ye, ZR | 1 |
| Yan, CQ | 1 |
| Liao, N | 1 |
| Wen, SH | 1 |
| Yu, YH | 1 |
| Platt, RW | 1 |
| Reynier, P | 1 |
| Yu, OHY | 1 |
| Filion, KB | 1 |
| Semertzidou, A | 1 |
| Grout-Smith, H | 1 |
| Kalliala, I | 1 |
| Garg, A | 1 |
| Terzidou, V | 1 |
| Marchesi, J | 1 |
| MacIntyre, D | 1 |
| Bennett, P | 1 |
| Tsilidis, K | 1 |
| Kyrgiou, M | 1 |
| Anness, AR | 2 |
| Nath, M | 2 |
| Osman, MW | 2 |
| Webb, D | 1 |
| Robinson, T | 1 |
| Khalil, A | 4 |
| Mousa, HA | 3 |
| Gerbier, E | 1 |
| Favre, G | 1 |
| Maisonneuve, E | 1 |
| Ceulemans, M | 1 |
| Dao, K | 1 |
| Schmid, CPR | 1 |
| Jenkinson, SP | 1 |
| Niznik, B | 1 |
| Baud, D | 2 |
| Spoendlin, J | 1 |
| Lofthouse, EM | 1 |
| Cleal, J | 1 |
| Lewis, RM | 1 |
| Sengers, BG | 1 |
| Nazirudeen, R | 1 |
| Sridhar, S | 1 |
| Priyanka, R | 1 |
| Sumathi, B | 1 |
| Natarajan, V | 1 |
| Subbiah, E | 1 |
| Raghavan, KS | 1 |
| Sangumani, J | 1 |
| Bergman, L | 1 |
| Bergkvist, J | 1 |
| Imberg, H | 1 |
| Geerts, L | 1 |
| Anderson, BJ | 1 |
| Pullen, M | 1 |
| Wirtz, EL | 1 |
| Lindberg, SM | 1 |
| Beckman, KB | 1 |
| Rose, MR | 1 |
| Mehta, T | 1 |
| Griffiths, G | 1 |
| Bhat, NS | 1 |
| Parkkola, R | 1 |
| Koskensalo, K | 1 |
| Kjerpeseth, LJ | 1 |
| Cesta, CE | 3 |
| Furu, K | 1 |
| Engeland, A | 1 |
| Gissler, M | 1 |
| Gulseth, HL | 1 |
| Karlstad, Ø | 1 |
| Leinonen, MK | 2 |
| Pazzagli, L | 2 |
| Zoega, H | 1 |
| Cohen, JM | 1 |
| Swenson, KS | 1 |
| Wang, D | 1 |
| Jones, AK | 1 |
| Nash, MJ | 1 |
| O'Rourke, R | 1 |
| Takahashi, DL | 1 |
| Kievit, P | 1 |
| Hennebold, JD | 1 |
| Aagaard, KM | 1 |
| Friedman, JE | 3 |
| Jones, KL | 1 |
| Rozance, PJ | 1 |
| Brown, LD | 1 |
| Wesolowski, SR | 1 |
| Rabbitt, L | 1 |
| Ero, A | 1 |
| Velazquez, C | 1 |
| Herrero, Y | 1 |
| Bianchi, MS | 1 |
| Cohen, DJ | 1 |
| Cuasnicu, P | 1 |
| Prost, K | 1 |
| Marinoni, R | 1 |
| Pascuali, N | 1 |
| Parborell, F | 1 |
| Abramovich, D | 1 |
| Sciacca, L | 1 |
| Bianchi, C | 1 |
| Burlina, S | 1 |
| Formoso, G | 1 |
| Manicardi, E | 1 |
| Sculli, MA | 1 |
| Resi, V | 1 |
| Tosti, G | 1 |
| Barberio, A | 1 |
| Tartaglione, L | 1 |
| Rizzi, A | 1 |
| Di Leo, M | 1 |
| Viti, L | 1 |
| Sirico, A | 1 |
| De Carolis, S | 1 |
| Pontecorvi, A | 1 |
| Lanzone, A | 3 |
| Pitocco, D | 1 |
| Shao, F | 1 |
| Li, Y | 12 |
| Martine-Edith, G | 1 |
| Johnson, W | 1 |
| Petherick, ES | 1 |
| Tarry-Adkins, JL | 3 |
| Robinson, IG | 1 |
| Armstrong, JL | 1 |
| Thackray, BD | 1 |
| Holzner, LMW | 1 |
| Knapton, AE | 1 |
| Virtue, S | 1 |
| Murray, AJ | 1 |
| Minis, E | 1 |
| Stanford, FC | 2 |
| Mahalingaiah, S | 1 |
| Ferguson, J | 1 |
| O'Shea, P | 1 |
| Bogdanet, D | 2 |
| Kgosidialwa, O | 2 |
| Egan, A | 2 |
| Finn, Y | 1 |
| Gaffney, G | 1 |
| Khattak, A | 1 |
| O'Keeffe, D | 1 |
| Liew, A | 2 |
| He, L | 1 |
| Zhan, F | 1 |
| Li, X | 15 |
| Zhou, L | 3 |
| Qu, H | 1 |
| Shou, L | 1 |
| Song, X | 1 |
| Hamiti, S | 1 |
| Ma, Y | 3 |
| Yusufu, M | 1 |
| Wang, X | 10 |
| Zhang, K | 1 |
| Guo, Y | 1 |
| Ujvari, D | 1 |
| Bolou, A | 2 |
| Drymoussi, Z | 2 |
| Lanz, D | 2 |
| Amaefule, CE | 2 |
| Gonzalez Carreras, FJ | 2 |
| Pardo Llorente, MDC | 2 |
| Dodds, J | 2 |
| Pizzo, E | 2 |
| Thomas, A | 2 |
| Heighway, J | 2 |
| Harden, A | 2 |
| Sanghi, A | 2 |
| Hitman, G | 2 |
| Zamora, J | 2 |
| Pérez, T | 2 |
| Huda, MSB | 1 |
| Thangaratinam, S | 3 |
| Nyman, A | 1 |
| Bettencourt-Silva, R | 1 |
| Neves, JS | 1 |
| Ferreira, MJ | 1 |
| Souteiro, P | 1 |
| Belo, S | 1 |
| Oliveira, AI | 1 |
| Carvalho, D | 1 |
| Namora, G | 1 |
| Montenegro, N | 1 |
| Queirós, J | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Yan, K | 1 |
| Li, L | 5 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 4 |
| Yan, D | 2 |
| Lou, H | 1 |
| Wang, Z | 3 |
| Hu, X | 2 |
| Shen, Y | 2 |
| Hu, D | 3 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 2 |
| Yang, X | 4 |
| Wang, H | 4 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 4 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 2 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Bian, L | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 2 |
| Fan, W | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Geng, Y | 1 |
| Basit, A | 1 |
| Miao, T | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Cao, G | 2 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 3 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 3 |
| Guo, Q | 2 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Wang, C | 5 |
| Zhao, W | 2 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Mo, J | 1 |
| Huang, T | 2 |
| Zhu, Q | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 2 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 3 |
| Frew, R | 1 |
| Guo, X | 2 |
| Gong, Q | 2 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 7 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 2 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 2 |
| Xiao, J | 2 |
| Song, M | 1 |
| Chen, C | 3 |
| Huang, Q | 1 |
| Cao, Y | 2 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 3 |
| Zhang, W | 4 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 2 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 2 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 5 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 2 |
| Deng, W | 2 |
| Wu, D | 4 |
| Zhang, Q | 3 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 7 |
| Xu, C | 4 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 2 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| de Wit, L | 1 |
| Rademaker, D | 1 |
| Voormolen, DN | 1 |
| Akerboom, BMC | 1 |
| Kiewiet-Kemper, RM | 1 |
| Soeters, MR | 1 |
| Verwij-Didden, MAL | 1 |
| Assouiki, F | 1 |
| Schippers, DH | 1 |
| Vermeulen, MAR | 1 |
| Kuppens, SMI | 1 |
| Oosterwerff, MM | 1 |
| Zwart, JJ | 1 |
| Diekman, MJM | 1 |
| Vogelvang, TE | 1 |
| Gallas, PRJ | 1 |
| Galjaard, S | 1 |
| Visser, W | 1 |
| Horree, N | 1 |
| Klooker, TK | 1 |
| Laan, R | 1 |
| Heijligenberg, R | 1 |
| Huisjes, AJM | 1 |
| van Bemmel, T | 1 |
| van Meir, CA | 1 |
| van den Beld, AW | 1 |
| Hermes, W | 1 |
| Vidarsdottir, S | 1 |
| Veldhuis-Vlug, AG | 1 |
| Dullemond, RC | 1 |
| Jansen, HJ | 1 |
| Sueters, M | 1 |
| de Koning, EJP | 1 |
| van Laar, JOEH | 1 |
| Wouters-van Poppel, P | 1 |
| Sanson-van Praag, ME | 1 |
| van den Akker, ES | 1 |
| Brouwer, CB | 1 |
| Hermsen, BB | 1 |
| Potter van Loon, BJ | 1 |
| van der Heijden, OWH | 1 |
| de Galan, BE | 1 |
| van Leeuwen, M | 1 |
| Wijbenga, JAM | 1 |
| de Boer, K | 1 |
| van Bon, AC | 1 |
| van der Made, FW | 1 |
| Eskes, SA | 1 |
| Zandstra, M | 1 |
| van Houtum, WH | 1 |
| Braams-Lisman, BAM | 1 |
| Daemen-Gubbels, CRGM | 1 |
| Wouters, MGAJ | 1 |
| IJzerman, RG | 1 |
| Mensing van Charante, NA | 1 |
| Zwertbroek, R | 1 |
| Bosmans, JE | 1 |
| Evers, IM | 1 |
| de Valk, HW | 2 |
| Groenendaal, F | 1 |
| Naaktgeboren, CA | 1 |
| Painter, RC | 1 |
| deVries, JH | 1 |
| Franx, A | 1 |
| van Rijn, BB | 1 |
| Kim, JK | 1 |
| Cho, J | 3 |
| Kim, SH | 1 |
| Kang, HC | 1 |
| Kim, DS | 1 |
| Kim, VN | 1 |
| Lee, JH | 1 |
| Bao, LX | 1 |
| Shi, WT | 1 |
| Han, YX | 1 |
| Kumar, R | 1 |
| Lowe, J | 1 |
| Thompson-Hutchison, F | 1 |
| Steinberg, D | 1 |
| Shah, B | 1 |
| Halperin, I | 1 |
| Ding, Y | 1 |
| Yuan, X | 1 |
| Gu, W | 2 |
| Underdal, MO | 3 |
| Henriksen, AH | 1 |
| Andersen, M | 1 |
| Kelty, E | 1 |
| Tran, DD | 1 |
| Atkinson, A | 1 |
| Preen, DB | 1 |
| Havard, A | 1 |
| Li, W | 3 |
| Bordewijk, EM | 2 |
| Legro, RS | 17 |
| Gao, J | 1 |
| Homburg, R | 3 |
| König, TE | 1 |
| Moll, E | 2 |
| Kar, S | 1 |
| Johnson, NP | 5 |
| Amer, SA | 1 |
| Vegetti, W | 1 |
| Palomba, S | 19 |
| Falbo, A | 18 |
| Özmen, Ü | 1 |
| Nazik, H | 1 |
| Williams, CD | 1 |
| Federica, G | 1 |
| Lord, J | 1 |
| Sahin, Y | 2 |
| Bhattacharya, S | 2 |
| Norman, RJ | 10 |
| van Wely, M | 5 |
| Seppälä, LK | 1 |
| Vettenranta, K | 1 |
| Pitkäniemi, J | 1 |
| Hirvonen, E | 1 |
| Madanat-Harjuoja, LM | 1 |
| Doi, SAR | 1 |
| Furuya-Kanamori, L | 2 |
| Toft, E | 2 |
| Musa, OAH | 2 |
| Islam, N | 1 |
| Clark, J | 2 |
| Thalib, L | 2 |
| Sainio, A | 1 |
| Takabe, P | 1 |
| Oikari, S | 1 |
| Salomäki-Myftari, H | 1 |
| Koulu, M | 3 |
| Söderström, M | 1 |
| Pasonen-Seppänen, S | 1 |
| Järveläinen, H | 1 |
| Landi, SN | 2 |
| Radke, S | 2 |
| Boggess, K | 4 |
| Engel, SM | 2 |
| Stürmer, T | 2 |
| Howe, AS | 2 |
| Jonsson Funk, M | 1 |
| Carris, NW | 1 |
| Nwabuobi, CK | 1 |
| He, W | 1 |
| Bullers, K | 1 |
| Wilson, RE | 1 |
| Louis, JM | 1 |
| Magness, RR | 1 |
| Shuster, DL | 2 |
| Shireman, LM | 2 |
| Ma, X | 2 |
| Shen, DD | 3 |
| Flood Nichols, SK | 2 |
| Ahmed, MS | 5 |
| Clark, S | 2 |
| Caritis, S | 2 |
| Venkataramanan, R | 2 |
| Haas, DM | 2 |
| Quinney, SK | 2 |
| Haneline, LS | 2 |
| Tita, AT | 2 |
| Manuck, TA | 2 |
| Thummel, KE | 2 |
| Morris Brown, L | 1 |
| Ren, Z | 2 |
| Brown, Z | 3 |
| Easterling, TR | 4 |
| Hebert, MF | 5 |
| Song, Y | 2 |
| Huang, H | 3 |
| Zhu, Z | 1 |
| Guo, L | 2 |
| Tang, J | 1 |
| Blair, RA | 1 |
| Rosenberg, EA | 1 |
| Palermo, NE | 1 |
| Sharpe, A | 1 |
| Morley, LC | 3 |
| Tang, T | 9 |
| Balen, AH | 8 |
| Souza, MLR | 2 |
| Silva, RRE | 1 |
| Silva, TRE | 1 |
| Oliveira, LC | 1 |
| Dienstmann, G | 3 |
| Nascimento, IBD | 3 |
| Silva, JC | 6 |
| Chávez-García, L | 1 |
| Valle-Leal, JG | 1 |
| Jiménez-Mapula, C | 1 |
| Quintero-Medrano, SM | 1 |
| López-Villegas, MN | 1 |
| Brown, LM | 1 |
| Wang, F | 4 |
| Yi, W | 1 |
| Cao, X | 2 |
| Pancer, J | 1 |
| Wu, N | 2 |
| Mahmoud, I | 1 |
| Dasgupta, K | 2 |
| Kim, C | 2 |
| Younes, N | 1 |
| Temprosa, M | 1 |
| Edelstein, S | 1 |
| Goldberg, RB | 1 |
| Araneta, MG | 1 |
| Wallia, A | 1 |
| Brown, A | 2 |
| Darwin, C | 1 |
| Ibebuogu, U | 1 |
| Pi-Sunyer, X | 2 |
| Knowler, WC | 4 |
| Panagiotopoulou, O | 1 |
| Syngelaki, A | 3 |
| Georgiopoulos, G | 1 |
| Simpson, J | 1 |
| Akolekar, R | 2 |
| Shehata, H | 7 |
| Nicolaides, K | 2 |
| Greger, HK | 1 |
| Østgård, HF | 1 |
| Elkind-Hirsch, KE | 3 |
| Shaler, D | 2 |
| Harris, R | 2 |
| Rana, U | 1 |
| Callan, E | 1 |
| Entringer, B | 1 |
| Michalkiewicz, T | 1 |
| Joshi, A | 1 |
| Parchur, AK | 1 |
| Teng, RJ | 1 |
| Konduri, GG | 1 |
| Udler, MS | 1 |
| Austin-Tse, CA | 1 |
| Acosta-Torres, S | 1 |
| Murdock, T | 1 |
| Matsuno, R | 1 |
| Beavis, AL | 1 |
| Stone, RL | 1 |
| Wethington, SL | 1 |
| Levinson, K | 1 |
| Grumbine, F | 1 |
| Ferriss, JS | 1 |
| Tanner, EJ | 1 |
| Fader, AN | 1 |
| Zhang, XQ | 2 |
| Ma, YD | 2 |
| Wang, YC | 2 |
| Zhang, LX | 2 |
| Guo, WJ | 2 |
| Zhang, JH | 2 |
| Nie, L | 2 |
| Yue, LM | 2 |
| Lawal, SK | 1 |
| Adeniji, AA | 1 |
| Sulaiman, SO | 1 |
| Akajewole, MM | 1 |
| Buhari, MO | 1 |
| Osinubi, AA | 1 |
| Carlson, Z | 1 |
| Hafner, H | 2 |
| Mulcahy, M | 1 |
| Bullock, K | 1 |
| Zhu, A | 1 |
| Bridges, D | 1 |
| Bernal-Mizrachi, E | 3 |
| Gregg, B | 2 |
| White, SL | 2 |
| Begum, S | 1 |
| Vieira, MC | 1 |
| Lawlor, DL | 1 |
| Sattar, N | 1 |
| Nelson, SM | 1 |
| Welsh, P | 1 |
| Pasupathy, D | 1 |
| Poston, L | 1 |
| Xi, H | 1 |
| Liu, C | 4 |
| Qu, F | 1 |
| Feng, X | 2 |
| Nayak, G | 1 |
| Salian, SR | 1 |
| Agarwal, P | 1 |
| Suresh Poojary, P | 1 |
| Rao, A | 1 |
| Kumari, S | 1 |
| Kalthur, SG | 1 |
| Shreya, AB | 1 |
| Mutalik, S | 1 |
| Adiga, SK | 1 |
| Kalthur, G | 1 |
| Kim, CH | 1 |
| Chon, SJ | 1 |
| Lee, SH | 1 |
| Krupej-Kędzierska, J | 1 |
| Cichocka, E | 1 |
| Kędzierski, L | 1 |
| Okopień, B | 1 |
| Gumprecht, J | 1 |
| Ishola, IO | 1 |
| Balogun, AO | 1 |
| Adeyemi, OO | 1 |
| Sweeney, L | 1 |
| D'Amico, M | 1 |
| Daru, J | 1 |
| Sobhy, S | 1 |
| Robson, J | 1 |
| Khan, K | 1 |
| Huda, MS | 1 |
| Jiang, S | 1 |
| Teague, AM | 1 |
| Tryggestad, JB | 1 |
| Jensen, ME | 1 |
| Chernausek, SD | 1 |
| Mousa, A | 1 |
| Hilkka, I | 1 |
| Burden, C | 1 |
| Norman, JE | 5 |
| Rowan, J | 6 |
| Hague, W | 7 |
| Teede, HJ | 2 |
| Brownfoot, FC | 4 |
| Hannan, NJ | 4 |
| Cannon, P | 4 |
| Nguyen, TV | 4 |
| Tuohey, L | 2 |
| Cluver, C | 3 |
| Griffith, RJ | 1 |
| Alsweiler, J | 1 |
| Moore, AE | 1 |
| Brown, S | 1 |
| Middleton, P | 2 |
| Shepherd, E | 2 |
| Crowther, CA | 2 |
| Oskovi-Kaplan, ZA | 1 |
| Ozgu-Erdinc, AS | 1 |
| Sun, GY | 1 |
| Gong, S | 1 |
| Kong, QQ | 1 |
| Li, ZB | 1 |
| Xu, MT | 1 |
| Luo, MJ | 1 |
| Tan, JH | 1 |
| Huhtala, MS | 4 |
| Juhila, J | 1 |
| Sorsa, T | 1 |
| Virtanen, A | 1 |
| Huttala, O | 1 |
| Tihtonen, K | 1 |
| Toimela, T | 1 |
| Heinonen, T | 1 |
| Laivuori, H | 1 |
| Uotila, J | 1 |
| Zhou, X | 3 |
| Yu, X | 2 |
| Wang, A | 2 |
| Qi, H | 2 |
| Han, TL | 1 |
| Baker, PN | 1 |
| Wu, Y | 3 |
| Tu, M | 1 |
| Huang, Y | 3 |
| Zhang, D | 4 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 2 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 2 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xiang, Y | 1 |
| Xu, X | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 2 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Deng, L | 1 |
| Meng, J | 1 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 4 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Hu, W | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 2 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 2 |
| Kong, X | 1 |
| Yang, T | 3 |
| Dong, Y | 1 |
| Xu, Y | 3 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Yang, H | 3 |
| Zhu, C | 1 |
| Huang, Z | 3 |
| Qian, J | 1 |
| Ge, J | 3 |
| Hu, J | 3 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 2 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 3 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 2 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 2 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Chen, W | 2 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 2 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Gao, W | 3 |
| Ma, S | 1 |
| Zhou, T | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 2 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 2 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 4 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 2 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Feng, H | 1 |
| Chang, Y | 2 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Wei, L | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Li, Q | 2 |
| Cao, T | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Song, W | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 3 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 1 |
| Xie, H | 1 |
| Sun, Z | 2 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 2 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 2 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 2 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Andræ, F | 2 |
| Abbott, D | 1 |
| Stridsklev, S | 7 |
| Schmedes, AV | 1 |
| Odsæter, IH | 1 |
| Krispin, E | 1 |
| Ashkenazi Katz, A | 1 |
| Shmuel, E | 1 |
| Toledano, Y | 2 |
| Hadar, E | 2 |
| Lin, SF | 1 |
| Chang, SH | 1 |
| Kuo, CF | 1 |
| Lin, WT | 1 |
| Chiou, MJ | 1 |
| Huang, YT | 1 |
| Alenzi, EO | 1 |
| Gupta, M | 3 |
| Bansiwal, R | 1 |
| Sethi, A | 1 |
| Poprzeczny, AJ | 1 |
| Ayas, B | 1 |
| Kırmızıkan, S | 1 |
| Kocaman, A | 1 |
| Avcı, B | 1 |
| Davidson, MB | 1 |
| Prabhakar, P | 1 |
| Kachhawa, G | 3 |
| Sharma, JB | 2 |
| Vanamail, P | 4 |
| Kumari, R | 2 |
| Bhatla, N | 2 |
| Bailey, CJ | 1 |
| Hannan, N | 1 |
| Abdi, L | 1 |
| Kieler, H | 1 |
| Kurosawa, K | 1 |
| Chiba, K | 1 |
| Nishimura, T | 1 |
| Tomi, M | 1 |
| Riar, SS | 1 |
| Toppings, NB | 1 |
| Cui, ZH | 1 |
| Yuan, DZ | 1 |
| Aye, ILMH | 1 |
| Charnock-Jones, DS | 1 |
| Smith, GCS | 1 |
| Piltonen, TT | 1 |
| Giudice, LC | 4 |
| Rindone, GM | 1 |
| Gorga, A | 1 |
| Pellizzari, EH | 1 |
| Camberos, MDC | 1 |
| Galardo, MN | 1 |
| Da Ros, VG | 1 |
| Buffone, MG | 1 |
| Meroni, SB | 1 |
| Riera, MF | 1 |
| Seidemann, E | 1 |
| Mao, W | 1 |
| Shen, S | 1 |
| Chaves, C | 1 |
| Cunha, F | 1 |
| Martinho, M | 1 |
| Garrido, S | 1 |
| Silva-Vieira, M | 1 |
| Estevinho, C | 1 |
| Melo, A | 1 |
| Figueiredo, O | 1 |
| Morgado, A | 1 |
| Almeida, M | 1 |
| Bjekić-Macut, J | 1 |
| Vukašin, T | 1 |
| Velija-Ašimi, Z | 1 |
| Bureković, A | 1 |
| Zdravković, M | 1 |
| Andrić, Z | 1 |
| Branković, M | 1 |
| Crevar-Marinović, S | 1 |
| Madić, T | 1 |
| Stanojlović, O | 1 |
| Milutinović, DV | 1 |
| Livadas, S | 1 |
| Mastorakos, G | 1 |
| Chang, C | 1 |
| Chang, S | 2 |
| Poles, J | 1 |
| Popov, V | 1 |
| Chatzakis, C | 1 |
| Cavoretto, P | 1 |
| Sotiriadis, A | 1 |
| Skibinska, M | 1 |
| Zurawska-Klis, M | 1 |
| Krekora, M | 1 |
| Cypryk, K | 1 |
| Jahanshahi, M | 1 |
| Shahmirzadi, AR | 1 |
| Kashani, E | 1 |
| Alipoor, R | 1 |
| Vosough, S | 1 |
| Hong, JGS | 2 |
| Tan, PC | 2 |
| Kamarudin, M | 1 |
| Omar, SZ | 2 |
| Noh, Y | 1 |
| Choe, SA | 1 |
| Shin, JY | 1 |
| Raperport, C | 1 |
| Chronopoulou, E | 1 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 1 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Mohamed, AM | 1 |
| Chivese, T | 1 |
| Bashir, M | 2 |
| Abou-Samra, AB | 2 |
| Doi, SA | 1 |
| Kulshrestha, V | 1 |
| Balani, S | 1 |
| Taghavi, SA | 2 |
| Jahanfar, S | 2 |
| Bazarganipour, F | 2 |
| Mecacci, F | 1 |
| Lisi, F | 1 |
| Vannuccini, S | 1 |
| Ottanelli, S | 1 |
| Rambaldi, MP | 1 |
| Serena, C | 1 |
| Simeone, S | 1 |
| Petraglia, F | 2 |
| Baldo, A | 1 |
| Webb, DR | 2 |
| Robinson, TG | 2 |
| Ouyang, H | 1 |
| Al-Mureish, A | 1 |
| Versace, VL | 1 |
| Beks, H | 1 |
| Wesley, H | 1 |
| McNamara, K | 1 |
| Anjana, RM | 1 |
| Mohan, V | 1 |
| Khunti, K | 1 |
| Dunbar, JA | 1 |
| Suárez-Arana, M | 1 |
| González-Mesa, E | 1 |
| Sola-Moyano, AP | 1 |
| Roldan-López, R | 1 |
| Romero-Narbona, F | 1 |
| Olveira, G | 1 |
| Tew, MP | 1 |
| Saaid, R | 1 |
| Stewart, KS | 1 |
| Rhoades, JS | 1 |
| Lee, E | 1 |
| Davitt, C | 1 |
| Flynn, KE | 1 |
| Pan, A | 1 |
| Hurrell, A | 1 |
| Webster, LM | 1 |
| Bidhendi Yarandi, R | 1 |
| Amiri, M | 1 |
| Ramezani Tehrani, F | 1 |
| Behboudi-Gandevani, S | 1 |
| Tauqir, S | 1 |
| Israr, M | 1 |
| Rauf, B | 1 |
| Malik, MO | 1 |
| Habib, SH | 1 |
| Shah, FA | 1 |
| Usman, M | 1 |
| Raza, MA | 1 |
| Shah, I | 1 |
| Badshah, H | 1 |
| Ehtesham, E | 1 |
| Shah, M | 1 |
| Brož, J | 1 |
| Brožová, K | 1 |
| Pellonperä, O | 3 |
| Herrera, KM | 1 |
| Ou, JP | 1 |
| Persad, MD | 1 |
| Bernasko, J | 1 |
| Garretto, D | 1 |
| Garry, D | 1 |
| Yuan, L | 1 |
| Wu, H | 2 |
| Bi, Y | 1 |
| Qin, A | 1 |
| Lacey, L | 1 |
| Whyte, S | 3 |
| Quenby, S | 3 |
| Denison, FC | 3 |
| Dhaun, N | 1 |
| Drake, AJ | 3 |
| Reynolds, RM | 4 |
| Man, B | 1 |
| Schwartz, A | 1 |
| Pugach, O | 1 |
| Gerber, B | 1 |
| O'Shea, PM | 1 |
| Biesty, L | 1 |
| McDonagh, C | 1 |
| O'Shea, C | 1 |
| Mirabelli, M | 1 |
| Chiefari, E | 1 |
| Tocci, V | 1 |
| Greco, E | 1 |
| Foti, D | 1 |
| Brunetti, A | 1 |
| He, K | 1 |
| Jing, Z | 1 |
| Garcha, D | 1 |
| MacDonald, TM | 1 |
| Hyett, J | 1 |
| Jellins, J | 1 |
| Myers, J | 1 |
| Illanes, SE | 2 |
| Nien, JK | 1 |
| Schepeler, M | 1 |
| Keenan, E | 1 |
| Whigham, CA | 1 |
| Murray, E | 1 |
| Kandel, M | 1 |
| Masci, J | 1 |
| Murphy, C | 2 |
| Cruickshank, T | 1 |
| Pritchard, N | 1 |
| Roddy Mitchell, A | 1 |
| Middleton, A | 1 |
| Pell, G | 1 |
| Wong, GP | 1 |
| Jogiraju, VK | 1 |
| Avvari, S | 1 |
| Gollen, R | 1 |
| Taft, DR | 1 |
| Nouhjah, S | 1 |
| Shahbazian, H | 1 |
| Shahbazian, N | 1 |
| Jahanshahi, A | 1 |
| Cheraghian, B | 1 |
| Kalra, S | 2 |
| Khandelwal, D | 1 |
| Singla, R | 2 |
| Aggarwal, S | 1 |
| Dutta, D | 1 |
| Kasher-Meron, M | 1 |
| Grajower, MM | 1 |
| Bowker, SL | 1 |
| Savu, A | 1 |
| Yeung, RO | 1 |
| Johnson, JA | 1 |
| Ryan, EA | 2 |
| Kaul, P | 1 |
| Romero, R | 1 |
| Erez, O | 1 |
| Hüttemann, M | 2 |
| Maymon, E | 1 |
| Panaitescu, B | 1 |
| Conde-Agudelo, A | 1 |
| Pacora, P | 1 |
| Yoon, BH | 1 |
| Grossman, LI | 1 |
| Farrar, D | 1 |
| Simmonds, M | 1 |
| Bryant, M | 1 |
| Sheldon, TA | 1 |
| Tuffnell, D | 1 |
| Golder, S | 1 |
| Lawlor, DA | 1 |
| Nemati, M | 1 |
| Nemati, S | 1 |
| Taheri, AM | 1 |
| Heidari, B | 1 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Tunc-Ozcan, E | 1 |
| Wert, SL | 1 |
| Lim, PH | 1 |
| Ferreira, A | 1 |
| Redei, EE | 1 |
| Novi, DRBS | 2 |
| Forcato, S | 3 |
| Vidigal, CB | 2 |
| Loiola, GH | 1 |
| Gerardin, DCC | 3 |
| Ceravolo, GS | 4 |
| Barbour, LA | 4 |
| Davies, JK | 1 |
| Nachum, Z | 2 |
| Yefet, E | 2 |
| Lindsay, RS | 2 |
| Loeken, MR | 3 |
| Medina, G | 1 |
| Maliqueo, M | 3 |
| Echiburú, B | 2 |
| Sir-Petermann, T | 3 |
| Lara, HE | 1 |
| Hedrington, MS | 1 |
| Davis, SN | 1 |
| Mukerji, G | 1 |
| Novi, DRBDS | 1 |
| Costa, NO | 1 |
| Borges, LI | 1 |
| Góes, MLM | 1 |
| do Valle, JB | 1 |
| Oliveira, DS | 1 |
| Martins, L | 1 |
| Lewandowski, A | 1 |
| Horst, W | 1 |
| Liang, HL | 1 |
| Ma, SJ | 1 |
| Xiao, YN | 1 |
| Tan, HZ | 1 |
| Juszczak, E | 1 |
| Bell, JL | 1 |
| Penneycard, J | 1 |
| Strachan, MWJ | 1 |
| Alexander, CI | 1 |
| Love, CDB | 1 |
| Mackenzie, F | 1 |
| Stenson, B | 1 |
| Tripathi, R | 1 |
| Tyagi, S | 1 |
| Goel, V | 1 |
| Singh, N | 1 |
| Madhu, M | 1 |
| Malik, N | 1 |
| Kumar, S | 2 |
| Alqudah, A | 1 |
| McKinley, MC | 1 |
| McNally, R | 1 |
| Graham, U | 1 |
| Watson, CJ | 1 |
| Lyons, TJ | 1 |
| McClements, L | 1 |
| Tieu, J | 1 |
| Coat, S | 5 |
| Gante, I | 1 |
| Melo, L | 1 |
| Dores, J | 1 |
| Ruas, L | 1 |
| Almeida, MDC | 1 |
| Rezk, M | 1 |
| Shaheen, AE | 1 |
| Saif El-Nasr, I | 1 |
| Yan, Y | 1 |
| Bao, S | 1 |
| Sheng, S | 1 |
| Tu, W | 1 |
| Valdés, E | 1 |
| Candia, P | 1 |
| Abusada, N | 1 |
| Orellana, R | 1 |
| Manukian, B | 1 |
| Cuellar, E | 1 |
| Brzozowska, M | 1 |
| Bieniek, E | 1 |
| Szosland, K | 1 |
| Lewinski, A | 1 |
| Hjorth-Hansen, A | 1 |
| Engen Hanem, LG | 1 |
| Eggebø, T | 1 |
| Salvesen, KÅ | 5 |
| Ali, A | 3 |
| Shastry, S | 1 |
| Nithiyananthan, R | 1 |
| Ganapathy, R | 1 |
| Yasmin, E | 4 |
| Rousson, V | 1 |
| Vial, T | 1 |
| Bernard, N | 1 |
| Amar, E | 1 |
| De Santis, M | 1 |
| Pistelli, A | 1 |
| Dautriche, A | 1 |
| Beau-Salinas, F | 1 |
| Cassina, M | 1 |
| Dunstan, H | 1 |
| Passier, A | 1 |
| Duman, MK | 1 |
| Maňáková, E | 1 |
| Eleftheriou, G | 1 |
| Klinger, G | 1 |
| Rothuizen, LE | 1 |
| Buclin, T | 1 |
| Csajka, C | 1 |
| Deng, J | 1 |
| Mueller, M | 1 |
| Geng, T | 1 |
| Hou, P | 1 |
| Mamillapalli, R | 1 |
| Taylor, HS | 1 |
| Paidas, M | 1 |
| Tavenier, A | 1 |
| Leishman, E | 1 |
| Bradshaw, HB | 1 |
| Dey, SK | 1 |
| Dasgupta, R | 1 |
| Ramachandran, R | 1 |
| Mathews, JE | 2 |
| Regi, A | 1 |
| Thomas, N | 3 |
| Gupta, V | 1 |
| Visalakshi, P | 1 |
| Asha, HS | 1 |
| Paul, T | 1 |
| Qvigstad, E | 1 |
| Dukhovny, S | 1 |
| Van Bennekom, CM | 1 |
| Gagnon, DR | 1 |
| Hernandez Diaz, S | 1 |
| Parker, SE | 1 |
| Anderka, M | 1 |
| Werler, MM | 1 |
| Mitchell, AA | 1 |
| Brink, HS | 1 |
| Alkemade, M | 1 |
| van der Lely, AJ | 1 |
| van der Linden, J | 1 |
| Beard, S | 1 |
| Binder, NK | 1 |
| Roelants, M | 1 |
| Langer, O | 1 |
| Vestin, E | 1 |
| Cui, P | 1 |
| Wu, XK | 1 |
| Brännström, M | 1 |
| Shao, LR | 1 |
| Billig, H | 1 |
| Jewel, R | 1 |
| Jacob, JJ | 1 |
| Greenhill, C | 1 |
| Paterson, MS | 1 |
| Gutowski, HC | 1 |
| Gray, SG | 2 |
| Sweeting, AN | 1 |
| Mcguire, TM | 2 |
| Cohen, N | 2 |
| Ross, GP | 1 |
| Little, PJ | 2 |
| Khin, MO | 1 |
| Gates, S | 1 |
| Saravanan, P | 1 |
| Wu, KLH | 1 |
| Lee, WC | 1 |
| Leu, S | 1 |
| Chan, JYH | 1 |
| Gregg, BE | 1 |
| Botezatu, N | 1 |
| Brill, JD | 1 |
| Vadrevu, S | 1 |
| Satin, LS | 1 |
| Alejandro, EU | 2 |
| Oppen, IH | 1 |
| Høgetveit, K | 1 |
| Andersen, MS | 2 |
| Yue, P | 1 |
| Yu, T | 1 |
| Zhou, J | 1 |
| Kong, D | 1 |
| Nicodemus, NA | 1 |
| Sales, WB | 1 |
| Silva, GDD | 1 |
| Salamun, V | 1 |
| Jensterle, M | 1 |
| Janez, A | 1 |
| Vrtacnik Bokal, E | 1 |
| Soobryan, N | 1 |
| Murugesan, S | 1 |
| Pandiyan, A | 1 |
| Moodley, J | 1 |
| Mackraj, I | 1 |
| Kalafat, E | 1 |
| Sukur, YE | 1 |
| Abdi, A | 1 |
| Thilaganathan, B | 1 |
| Correia-Branco, A | 1 |
| Keating, E | 1 |
| Martel, F | 1 |
| Moura, KF | 1 |
| Picinin, R | 1 |
| Montagnini, BG | 2 |
| Silva, RNOD | 1 |
| da Silva, MDV | 1 |
| de Andrade, FG | 1 |
| Akamine, EH | 1 |
| Puscheck, EE | 1 |
| Bolnick, A | 1 |
| Awonuga, A | 1 |
| Abdulhasan, M | 1 |
| Secor, E | 1 |
| Louden, E | 1 |
| Rappolee, DA | 1 |
| Ghandi, Y | 1 |
| Habibi, D | 1 |
| Nasri, K | 1 |
| Alinejad, S | 1 |
| Taherahmad, H | 1 |
| Arjmand Shabestari, A | 1 |
| Nematinejad, A | 1 |
| Aiken, CEM | 1 |
| Hone, L | 1 |
| Murphy, HR | 1 |
| Given, JE | 1 |
| Loane, M | 1 |
| Garne, E | 1 |
| Addor, MC | 1 |
| Bakker, M | 1 |
| Bertaut-Nativel, B | 1 |
| Gatt, M | 1 |
| Klungsoyr, K | 1 |
| Lelong, N | 1 |
| Morgan, M | 1 |
| Neville, AJ | 1 |
| Pierini, A | 1 |
| Rissmann, A | 1 |
| Dolk, H | 1 |
| Scifres, C | 1 |
| Buchanan, TA | 1 |
| Coustan, D | 1 |
| Aagaard, K | 1 |
| Thornburg, KL | 1 |
| Catalano, PM | 3 |
| Galan, HL | 1 |
| Hay, WW | 1 |
| Frias, AE | 1 |
| Shankar, K | 1 |
| Simmons, RA | 1 |
| Moses, RG | 2 |
| Sacks, DA | 3 |
| Christian, SJ | 1 |
| Boama, V | 1 |
| Satti, H | 1 |
| Ramawat, J | 1 |
| Elhadd, TA | 2 |
| Ashawesh, K | 1 |
| Dukhan, K | 1 |
| Beer, S | 1 |
| Hyer, S | 3 |
| Balani, J | 4 |
| Vora, NL | 1 |
| Grace, MR | 1 |
| Smeester, L | 1 |
| Dotters-Katz, SK | 1 |
| Fry, RC | 1 |
| Bae-Jump, V | 1 |
| Paschou, SA | 1 |
| Wolffenbuttel, BHR | 1 |
| Lee, N | 1 |
| Wagner, DJ | 1 |
| Liang, CJ | 1 |
| Rice, K | 1 |
| Scherneck, S | 1 |
| Schlinke, N | 1 |
| Beck, E | 1 |
| Grupe, K | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Zhen, XM | 1 |
| Finley, J | 1 |
| Marciniak, A | 1 |
| Lejman-Larysz, K | 1 |
| Nawrocka-Rutkowska, J | 1 |
| Brodowska, A | 1 |
| Songin, D | 1 |
| Farahvar, S | 1 |
| Walfisch, A | 1 |
| Sheiner, E | 1 |
| Szukiewicz, D | 1 |
| Szewczyk, G | 1 |
| Pyzlak, M | 1 |
| Stangret, A | 1 |
| Bachanek, M | 1 |
| Trojanowski, S | 1 |
| Alkhalayla, H | 1 |
| Wejman, J | 1 |
| Feig, D | 1 |
| Nankervis, A | 1 |
| Price, S | 1 |
| Conn, J | 1 |
| Okely, J | 1 |
| Mason, C | 1 |
| Collier, A | 1 |
| Dunnachie, N | 1 |
| Swanson, V | 1 |
| Schmittdiel, JA | 1 |
| Flory, JH | 1 |
| Yeh, J | 1 |
| Karter, AJ | 1 |
| Kruge, LE | 1 |
| Schillinger, D | 1 |
| Mangione, CM | 1 |
| Walker, EA | 1 |
| Nguyen, L | 1 |
| Chan, SY | 1 |
| Teo, AKK | 1 |
| Ghomian, N | 1 |
| Vahed, SHM | 1 |
| Firouz, S | 1 |
| Yaghoubi, MA | 1 |
| Mohebbi, M | 1 |
| D'Amato, G | 1 |
| Caringella, AM | 1 |
| Stanziano, A | 1 |
| Cantatore, C | 1 |
| Palini, S | 1 |
| Caroppo, E | 1 |
| Finneran, MM | 1 |
| Álvarez, D | 1 |
| Ceballo, K | 1 |
| Olguín, S | 1 |
| Martinez-Pinto, J | 1 |
| Fernandois, D | 1 |
| Sotomayor-Zárate, R | 1 |
| Snehalatha, C | 2 |
| Priscilla, S | 1 |
| Nanditha, A | 1 |
| Arun, R | 1 |
| Satheesh, K | 1 |
| Ramachandran, A | 1 |
| Alecsandru, D | 1 |
| Barrio, A | 1 |
| Andia, V | 1 |
| Cruz, E | 1 |
| Aparicio, P | 1 |
| Serna, J | 1 |
| Cruz, M | 1 |
| Pellicer, A | 1 |
| Garcia-Velasco, JA | 1 |
| de Souza, MLR | 1 |
| Fleig, R | 1 |
| Hoffmann, CBPC | 1 |
| Kocan, M | 1 |
| Duran, I | 1 |
| Entler, S | 1 |
| Vayakis, G | 1 |
| Agostinetti, P | 1 |
| Brombin, M | 1 |
| Carmona, JM | 1 |
| Gambetta, G | 1 |
| Jirman, T | 1 |
| Marconato, N | 1 |
| Moreau, P | 1 |
| Peruzzo, S | 1 |
| Spuig, P | 1 |
| Walsh, M | 1 |
| Garbarino, VR | 1 |
| Santos, TA | 1 |
| Nelson, AR | 1 |
| Zhang, WQ | 1 |
| Smolik, CM | 1 |
| Javors, MA | 1 |
| Daws, LC | 1 |
| Gould, GG | 1 |
| Funk, MJ | 1 |
| Grivell, RM | 1 |
| Dekker, G | 1 |
| McPhee, AJ | 1 |
| Garcia-Martin, I | 1 |
| Penketh, RJA | 1 |
| Janssen, AB | 1 |
| Jones, RE | 1 |
| Grimstead, J | 1 |
| Baird, DM | 1 |
| John, RM | 1 |
| Berry, DC | 1 |
| Thomas, SD | 1 |
| Dorman, KF | 1 |
| Ivins, AR | 1 |
| de Los Angeles Abreu, M | 1 |
| Young, L | 1 |
| Showell, MG | 1 |
| Mackenzie-Proctor, R | 1 |
| Jordan, V | 1 |
| Hodgson, R | 1 |
| Farquhar, C | 2 |
| Scheen, AJ | 1 |
| Philips, JC | 1 |
| Kridelka, F | 1 |
| Dabbous, Z | 1 |
| Baagar, K | 1 |
| Elkhatib, F | 1 |
| Ibrahim, A | 2 |
| Brich, SA | 1 |
| Abdel-Rahman, ME | 1 |
| Konje, JC | 2 |
| Gonzalez, CD | 1 |
| Alvariñas, J | 1 |
| Bagnes, MFG | 1 |
| Di Girolamo, G | 2 |
| Agrawal, A | 1 |
| Kriplani, A | 1 |
| Huang, YL | 1 |
| Maple-Brown, LJ | 1 |
| Lindenmayer, G | 1 |
| Barzi, F | 1 |
| Whitbread, C | 1 |
| Connors, C | 1 |
| Moore, E | 1 |
| Boyle, J | 2 |
| Kirkwood, M | 1 |
| Lee, IL | 1 |
| Longmore, D | 1 |
| van Dokkum, P | 1 |
| Wicks, M | 1 |
| Dowden, M | 1 |
| Inglis, C | 1 |
| Cotter, M | 1 |
| Kirkham, R | 1 |
| Corpus, S | 1 |
| Chitturi, S | 1 |
| O'Dea, K | 1 |
| Zimmet, P | 1 |
| Oats, J | 1 |
| McIntyre, HD | 6 |
| Shaw, JE | 1 |
| Nossum, MCF | 1 |
| Vaage, MØ | 1 |
| Abbott, DH | 1 |
| Vega, M | 1 |
| Mauro, M | 1 |
| Williams, Z | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| McGurk, C | 1 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Todd, M | 1 |
| Tuthill, A | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Kuhlmann-Capek, M | 1 |
| Chiossi, G | 1 |
| Monsivais, L | 1 |
| Lozovyy, V | 1 |
| Gallagher, L | 1 |
| Kirsch, N | 1 |
| Florence, E | 1 |
| Petruzzi, V | 1 |
| Chang, J | 1 |
| Buenaventura, S | 1 |
| Walden, P | 1 |
| Gardner, B | 1 |
| Munn, M | 1 |
| Ibáñez, L | 2 |
| de Zegher, F | 2 |
| Steffensen, B | 1 |
| Gómez-Real, F | 1 |
| Hestvold, KV | 1 |
| Zabielska, R | 1 |
| Thorarinsdottir, S | 1 |
| Hjelle, S | 2 |
| Berg, AH | 2 |
| Poromaa, IS | 1 |
| Mohlin, J | 1 |
| Underdal, M | 1 |
| El Sharkwy, I | 1 |
| Sharaf El-Din, M | 1 |
| Jainchill, AL | 1 |
| Gawrys, BL | 1 |
| Arnold, JJ | 1 |
| Pourghasem, S | 1 |
| Kutenaee, MA | 1 |
| Abruzzese, GA | 1 |
| Heber, MF | 1 |
| Ferrer, MJ | 1 |
| Ferreira, SR | 1 |
| Silva, AF | 1 |
| Motta, AB | 7 |
| Tong, C | 1 |
| D'Ambrosio, V | 1 |
| Brunelli, R | 1 |
| Vena, F | 1 |
| Di Mascio, D | 1 |
| Marchetti, C | 1 |
| Boccherini, C | 1 |
| Piccioni, MG | 1 |
| Benedetti Panici, P | 1 |
| Giancotti, A | 1 |
| Xu, Q | 1 |
| Schmedes, A | 1 |
| Feghali, MN | 1 |
| Umans, JG | 3 |
| Hall, D | 1 |
| Garcia-Contreras, C | 1 |
| Vazquez-Gomez, M | 1 |
| Pesantez-Pacheco, JL | 1 |
| Torres-Rovira, L | 1 |
| Heras-Molina, A | 1 |
| Encinas, T | 1 |
| Astiz, S | 1 |
| Gonzalez-Bulnes, A | 1 |
| de Góes, MLM | 1 |
| da Silva Novi, DRB | 1 |
| Inhasz Kiss, AC | 1 |
| Ceccatto Gerardin, DC | 1 |
| Bishop, KC | 1 |
| Harris, BS | 1 |
| Boyd, BK | 1 |
| Reiff, ES | 1 |
| Brown, L | 1 |
| Kuller, JA | 1 |
| Overgaard, MD | 1 |
| Duvald, CS | 1 |
| Vendelbo, MH | 1 |
| Pedersen, SB | 1 |
| Jakobsen, S | 1 |
| Alstrup, AKO | 1 |
| Mikkelsen, E | 1 |
| Ovesen, PG | 1 |
| Pedersen, M | 1 |
| Chiakpo, E | 1 |
| Shu, C | 1 |
| Mo, Y | 1 |
| Gu, J | 1 |
| Shah, NK | 1 |
| Dong, S | 1 |
| Pascual-Morena, C | 1 |
| Martínez-Vizcaíno, V | 1 |
| Álvarez-Bueno, C | 1 |
| Pozuelo-Carrascosa, DP | 1 |
| Notario-Pacheco, B | 1 |
| Saz-Lara, A | 1 |
| Fernández-Rodriguez, R | 1 |
| Cavero-Redondo, I | 1 |
| Catalano, P | 1 |
| Desoye, G | 1 |
| Mathiesen, ER | 5 |
| Damm, P | 4 |
| Zhu, B | 3 |
| Gatford, KL | 3 |
| Houda, CM | 2 |
| Lu, ZX | 1 |
| Baghurst, PA | 1 |
| Owens, JA | 3 |
| Sikaris, K | 1 |
| Rowan, JA | 11 |
| Hague, WM | 8 |
| Salomäki, H | 2 |
| Vähätalo, LH | 2 |
| Laurila, K | 1 |
| Jäppinen, NT | 1 |
| Penttinen, AM | 1 |
| Ailanen, L | 2 |
| Ilyasizadeh, J | 1 |
| Pesonen, U | 2 |
| Thirumalai, A | 1 |
| Holing, E | 1 |
| Gilliam, LK | 1 |
| Spaulonci, CP | 1 |
| Bernardes, LS | 1 |
| Trindade, TC | 1 |
| Zugaib, M | 1 |
| Francisco, RP | 1 |
| Ahmadimoghaddam, D | 1 |
| Staud, F | 1 |
| Shan, PF | 1 |
| Hosseini, MA | 1 |
| Alleyassin, A | 1 |
| Sarvi, F | 1 |
| Safdarian, L | 1 |
| Kokab, A | 1 |
| Fanisalek, M | 1 |
| Helseth, R | 2 |
| Salvesen, O | 1 |
| Desai, N | 2 |
| Roman, A | 1 |
| Rochelson, B | 1 |
| Xue, X | 1 |
| Chatterjee, PK | 2 |
| Tam Tam, H | 1 |
| Metz, CN | 2 |
| Sullivan, SD | 4 |
| Gui, J | 1 |
| Feng, L | 2 |
| Banerjee, P | 1 |
| Bhonde, RR | 1 |
| Pal, R | 1 |
| An, Y | 1 |
| Liu, B | 1 |
| Guan, Y | 1 |
| Lautatzis, ME | 1 |
| Goulis, DG | 1 |
| Vrontakis, M | 1 |
| Lee, HY | 2 |
| Wei, D | 1 |
| Panidis, D | 1 |
| Tziomalos, K | 1 |
| Papadakis, E | 1 |
| Katsikis, I | 1 |
| Berggren, EK | 1 |
| Kwak, SH | 1 |
| Choi, SH | 1 |
| Kim, K | 1 |
| Jung, HS | 1 |
| Cho, YM | 1 |
| Lim, S | 1 |
| Cho, NH | 1 |
| Kim, SY | 1 |
| Park, KS | 1 |
| Jang, HC | 1 |
| Karatas, A | 1 |
| Özlü, T | 1 |
| Erdem, A | 1 |
| Ibrahim, MI | 1 |
| Hamdy, A | 1 |
| Shafik, A | 1 |
| Taha, S | 1 |
| Anwar, M | 1 |
| Faris, M | 1 |
| Jablonski, KA | 1 |
| Florez, JC | 1 |
| Dabelea, D | 2 |
| Franks, PW | 1 |
| Dagogo-Jack, S | 1 |
| Christophi, CA | 4 |
| Ratner, R | 2 |
| Basu, A | 1 |
| Corbould, A | 2 |
| Manno, M | 2 |
| Tomei, F | 2 |
| Waheed, S | 1 |
| Malik, FP | 1 |
| Mazhar, SB | 1 |
| La Sala, GB | 3 |
| Clemens, I | 1 |
| Knox, CA | 1 |
| Delaney, JA | 1 |
| Ke, RW | 1 |
| Holt, RI | 1 |
| Lambert, KD | 1 |
| Vogt, C | 1 |
| Laine, K | 2 |
| Ekblad, U | 4 |
| Rinne, V | 1 |
| Cefalu, WT | 1 |
| Nathan, N | 1 |
| Su, DF | 1 |
| Wang, XY | 1 |
| Pasquali, R | 1 |
| Gupta, Y | 1 |
| Heilmaier, C | 1 |
| Thielscher, C | 1 |
| Ziller, M | 1 |
| Altmann, V | 1 |
| Kostev, K | 1 |
| Refuerzo, JS | 3 |
| Gowen, R | 1 |
| Pedroza, C | 2 |
| Hutchinson, M | 2 |
| Blackwell, SC | 2 |
| Ramin, S | 1 |
| Lemos, AJ | 1 |
| Peixoto, CA | 1 |
| Teixeira, AA | 1 |
| Luna, RL | 1 |
| Rocha, SW | 1 |
| Santos, HM | 1 |
| Silva, AK | 1 |
| Nunes, AK | 1 |
| Wanderley-Teixeira, V | 1 |
| Zhuo, Z | 1 |
| Leanza, V | 1 |
| Coco, L | 1 |
| Grasso, F | 1 |
| Leanza, G | 1 |
| Zarbo, G | 1 |
| Palumbo, M | 1 |
| Ijäs, H | 2 |
| Saarela, T | 2 |
| Keravuo, R | 2 |
| Raudaskoski, T | 2 |
| Bijok, J | 1 |
| Bińkowska, M | 1 |
| Jakiel, G | 1 |
| Stokes, VJ | 1 |
| Anderson, RA | 1 |
| George, JT | 1 |
| Ashrafi, M | 1 |
| Sheikhan, F | 1 |
| Arabipoor, A | 1 |
| Hosseini, R | 1 |
| Nourbakhsh, F | 1 |
| Zolfaghari, Z | 1 |
| Vernikovskaya, DI | 1 |
| Fokina, VM | 1 |
| Nanovskaya, TN | 3 |
| Hankins, GD | 4 |
| Elghazi, L | 1 |
| Smith, MR | 1 |
| Blandino-Rosano, M | 1 |
| El-Gabri, D | 1 |
| Cras-Méneur, C | 1 |
| Christiansen, SC | 1 |
| Klungland, H | 1 |
| Stafne, SN | 1 |
| Mørkved, S | 1 |
| Sæther, M | 1 |
| Poolsup, N | 2 |
| Suksomboon, N | 2 |
| Amin, M | 2 |
| Wang, XH | 1 |
| Wang, JQ | 2 |
| Huang, LP | 1 |
| Ryu, RJ | 1 |
| Hays, KE | 1 |
| Morton, S | 1 |
| Kirkwood, S | 1 |
| Herrin, MA | 1 |
| Pitruzzello, MC | 1 |
| Mulla, MJ | 1 |
| Pettker, CM | 2 |
| Flannery, CA | 1 |
| Abrahams, VM | 1 |
| Tso, LO | 4 |
| Costello, MF | 8 |
| Albuquerque, LE | 3 |
| Andriolo, RB | 3 |
| Macedo, CR | 2 |
| Jeve, YB | 1 |
| Doshani, A | 1 |
| Benhalima, K | 1 |
| Devlieger, R | 1 |
| Van Assche, A | 1 |
| Ainuddin, J | 1 |
| Karim, N | 2 |
| Hasan, AA | 2 |
| Naqvi, SA | 1 |
| Louden, ED | 1 |
| Luzzo, KM | 1 |
| Jimenez, PT | 1 |
| Chi, T | 1 |
| Chi, M | 1 |
| Moley, KH | 3 |
| Enkhtuvshin, B | 1 |
| Nagashima, S | 1 |
| Saito, N | 1 |
| Wakabayashi, T | 1 |
| Ando, A | 1 |
| Takahashi, M | 1 |
| Sakai, K | 1 |
| Yamamuro, D | 1 |
| Nagasaka, S | 1 |
| Tamemoto, H | 1 |
| Ishibashi, S | 1 |
| Anisimov, VN | 1 |
| Popovich, IG | 1 |
| Zabezhinski, MA | 1 |
| Egormin, PA | 1 |
| Yurova, MN | 1 |
| Semenchenko, AV | 1 |
| Tyndyk, ML | 1 |
| Panchenko, AV | 1 |
| Trashkov, AP | 1 |
| Vasiliev, AG | 1 |
| Khaitsev, NV | 1 |
| Viteri, OA | 1 |
| Tyson, JE | 1 |
| Ramin, SM | 1 |
| Heinäniemi, M | 1 |
| Eerola, K | 1 |
| Ruohonen, ST | 1 |
| Cui, S | 1 |
| Chiswick, CA | 1 |
| Whyte, SA | 1 |
| Newby, DE | 2 |
| Walker, BR | 3 |
| Forbes, S | 2 |
| Murray, GD | 1 |
| Wray, S | 2 |
| Balsells, M | 1 |
| García-Patterson, A | 1 |
| Solà, I | 1 |
| Roqué, M | 1 |
| Gich, I | 1 |
| Corcoy, R | 1 |
| Buschur, E | 1 |
| Brown, F | 1 |
| Wyckoff, J | 2 |
| Cheng, X | 1 |
| Xie, J | 1 |
| Christianson, MS | 1 |
| Yemini, M | 1 |
| Leong, M | 1 |
| Shoham, Z | 1 |
| Sharma, A | 1 |
| Bahadursingh, S | 1 |
| Ramsewak, S | 1 |
| Teelucksingh, S | 1 |
| George, A | 1 |
| Sam, D | 1 |
| Beck, M | 1 |
| Benjamin, SJ | 1 |
| Abraham, A | 1 |
| Antonisamy, B | 1 |
| Jana, AK | 1 |
| Aroda, VR | 1 |
| Edelstein, SL | 1 |
| Barrett-Connor, E | 1 |
| Delahanty, LM | 1 |
| Montez, MG | 1 |
| Ackermann, RT | 1 |
| Zhuo, X | 1 |
| Ratner, RE | 2 |
| Mayor, S | 1 |
| Quon, MJ | 1 |
| Yang, P | 1 |
| Spritzer, PM | 1 |
| Diamanti-Kandarakis, E | 4 |
| Jiang, YF | 1 |
| Chen, XY | 1 |
| Ding, T | 1 |
| Wang, XF | 1 |
| Zhu, ZN | 1 |
| Su, SW | 1 |
| Liong, S | 1 |
| Lappas, M | 1 |
| Ainuddin, JA | 2 |
| Zaheer, S | 1 |
| Ali, SS | 1 |
| Kazi, S | 1 |
| Aftab, S | 1 |
| Kamran, A | 1 |
| Aung, YY | 1 |
| Sowter, M | 1 |
| Kenealy, T | 1 |
| Herman, J | 1 |
| Ekeroma, A | 1 |
| Rahimpanah, F | 1 |
| Barclay, M | 1 |
| Carroll, D | 1 |
| Kelley, KW | 1 |
| Padmanabhan, V | 1 |
| Veiga-Lopez, A | 1 |
| Herkimer, C | 1 |
| Abi Salloum, B | 1 |
| Moeller, J | 1 |
| Beckett, E | 1 |
| Sreedharan, R | 1 |
| Zhao, LP | 1 |
| Sheng, XY | 1 |
| Zhou, S | 1 |
| Ma, LY | 1 |
| Zhou, Y | 1 |
| Cui, YM | 1 |
| Battin, MR | 2 |
| Obolonkin, V | 2 |
| Rush, E | 1 |
| Beyuo, T | 1 |
| Obed, SA | 1 |
| Adjepong-Yamoah, KK | 1 |
| Bugyei, KA | 1 |
| Oppong, SA | 1 |
| Marfoh, K | 1 |
| Abu Hashim, H | 6 |
| Foda, O | 1 |
| Ghayaty, E | 1 |
| Moreno, LE | 1 |
| Bonnell, A | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Malik, O | 1 |
| Marjoribanks, J | 1 |
| Kitwitee, P | 1 |
| Limwattananon, S | 1 |
| Limwattananon, C | 1 |
| Waleekachonlert, O | 1 |
| Ratanachotpanich, T | 1 |
| Phimphilai, M | 1 |
| Pongchaiyakul, C | 1 |
| Refuerzo, J | 1 |
| Chiswick, C | 1 |
| Denison, F | 1 |
| Weeks, A | 1 |
| Lashen, H | 1 |
| Rodriguez, A | 1 |
| Murray, G | 1 |
| Al-Biate, MA | 1 |
| Maged, AM | 1 |
| Elsawah, H | 1 |
| Abdelhafez, A | 1 |
| Bakry, A | 1 |
| Mostafa, WA | 1 |
| Wang, P | 19 |
| Tal, R | 1 |
| Lv, F | 1 |
| Zhou, R | 1 |
| Lu, Q | 1 |
| Miao, Y | 1 |
| Zhao, C | 1 |
| Vahlberg, T | 2 |
| Lin, XF | 1 |
| Wan, ZH | 1 |
| Du, YK | 1 |
| Tsao, HM | 1 |
| Pedersen, KD | 1 |
| Bülow, NS | 1 |
| Aaboe, K | 1 |
| Galsgaard, J | 1 |
| Odgaard, HS | 1 |
| Lauenborg, J | 1 |
| Parry, LJ | 1 |
| Senadheera, S | 1 |
| Shigiyama, F | 1 |
| Kumashiro, N | 1 |
| Rikitake, T | 1 |
| Usui, S | 1 |
| Saegusa, M | 1 |
| Kitamura, M | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Shetelig Løvvik, T | 1 |
| Kotecha, R | 1 |
| Pastides, A | 1 |
| Toppari, J | 1 |
| Virtanen, HE | 1 |
| Sadov, S | 1 |
| Fan, YY | 1 |
| Li, XG | 1 |
| Liu, T | 1 |
| Cao, YS | 1 |
| Zhao, ZG | 1 |
| Ashoush, S | 1 |
| El-Said, M | 1 |
| Fathi, H | 1 |
| Abdelnaby, M | 1 |
| Andrade, C | 1 |
| Butalia, S | 1 |
| Gutierrez, L | 1 |
| Lodha, A | 1 |
| Aitken, E | 1 |
| Zakariasen, A | 1 |
| Sinai Talaulikar, V | 1 |
| Steurer, J | 1 |
| Zawiejska, A | 1 |
| Wender-Ozegowska, E | 1 |
| Grewling-Szmit, K | 1 |
| Brazert, M | 1 |
| Brazert, J | 1 |
| Kennelly, MA | 1 |
| McAuliffe, FM | 1 |
| McGrath, RT | 1 |
| Glastras, SJ | 1 |
| Hocking, S | 1 |
| Fulcher, GR | 1 |
| Sahin, M | 1 |
| Corapcioglu, D | 1 |
| Alfaris, N | 1 |
| Misra, M | 1 |
| Agha-Jaffar, R | 1 |
| Oliver, N | 1 |
| Johnston, D | 1 |
| Robinson, S | 1 |
| Teng, Y | 1 |
| Lv, X | 1 |
| Yin, Y | 1 |
| Gandica, R | 1 |
| Zeitler, P | 1 |
| Dravecká, I | 1 |
| Figurová, J | 1 |
| Javorský, M | 1 |
| Petríková, J | 1 |
| Vaľková, M | 1 |
| Lazúrová, I | 1 |
| Murphy, K | 1 |
| Sanchez, J | 1 |
| Ohlsson, A | 1 |
| Armson, AB | 1 |
| Lipscombe, LL | 1 |
| Barrett, JF | 1 |
| Misso, M | 1 |
| Franks, S | 2 |
| Wijeyaratne, CN | 1 |
| Fauser, BC | 2 |
| Teede, H | 1 |
| Farrant, MT | 1 |
| Williamson, K | 1 |
| Battin, M | 2 |
| Bajaj, S | 1 |
| Zeng, XL | 1 |
| Zhang, YF | 1 |
| Tian, Q | 1 |
| Xue, Y | 2 |
| An, RF | 1 |
| Tan, X | 1 |
| Fang, C | 1 |
| Bergel, R | 1 |
| Hod, M | 1 |
| Jacob, SL | 1 |
| Brewer, C | 2 |
| Picton, HM | 1 |
| Barth, JH | 3 |
| Tan, MH | 1 |
| Alquraini, H | 1 |
| Mizokami-Stout, K | 1 |
| MacEachern, M | 1 |
| Elfituri, A | 1 |
| Gu, Q | 1 |
| Gu, Y | 1 |
| Shi, Q | 1 |
| Perng, P | 1 |
| Zampella, JG | 1 |
| Okoye, GA | 1 |
| Zafran, N | 1 |
| Salim, R | 1 |
| Hissin, N | 1 |
| Hasanein, J | 1 |
| Gam Ze Letova, Y | 1 |
| Suleiman, A | 1 |
| Mourad, S | 1 |
| Brown, J | 2 |
| Nahuis, M | 1 |
| Van der Veen, F | 3 |
| Martis, R | 1 |
| Hughes, B | 1 |
| Kim, BV | 1 |
| Ng, EH | 2 |
| Albaghdadi, AJ | 1 |
| Hewitt, MA | 1 |
| Putos, SM | 1 |
| Wells, M | 1 |
| Ozolinš, TR | 1 |
| Kan, FW | 1 |
| Haas, J | 1 |
| Bentov, Y | 1 |
| Kalem, MN | 1 |
| Kalem, Z | 1 |
| Gurgan, T | 1 |
| Kovo, M | 3 |
| Kogman, N | 1 |
| Ovadia, O | 1 |
| Nakash, I | 1 |
| Golan, A | 1 |
| Hoffman, A | 2 |
| Elizur, SE | 1 |
| Tulandi, T | 3 |
| Nestler, JE | 13 |
| Glueck, CJ | 19 |
| Goldenberg, N | 12 |
| Sieve, L | 6 |
| Luchetti, CG | 2 |
| Mikó, E | 1 |
| Szekeres-Bartho, J | 1 |
| Paz, DA | 1 |
| Cocksedge, KA | 1 |
| Li, TC | 1 |
| Saravelos, SH | 1 |
| Metwally, M | 2 |
| Fougner, KJ | 2 |
| Orio, F | 14 |
| Zullo, F | 15 |
| Gardiner, SJ | 3 |
| Kirkpatrick, CM | 2 |
| Begg, EJ | 3 |
| Lundberg, GD | 1 |
| Metzger, BE | 1 |
| Bennett, PH | 1 |
| Fowler, S | 1 |
| Kahn, SE | 1 |
| Nawaz, FH | 2 |
| Khalid, R | 1 |
| Naru, T | 1 |
| Rizvi, J | 2 |
| Harvey, SB | 1 |
| Wilson-Grady, J | 1 |
| Monkkonen, T | 1 |
| Nelsestuen, GL | 1 |
| Kasthuri, RS | 1 |
| Verneris, MR | 1 |
| Lund, TC | 1 |
| Ely, EW | 1 |
| Bernard, GR | 1 |
| Zeisler, H | 1 |
| Homoncik, M | 1 |
| Jilma, B | 1 |
| Swan, T | 1 |
| Kellogg, TA | 1 |
| Ecker, JL | 2 |
| Hart, R | 3 |
| Mathur, R | 1 |
| Alexander, CJ | 1 |
| Yano, J | 1 |
| Trivax, B | 1 |
| Azziz, R | 1 |
| Ramidi, G | 1 |
| Khan, N | 1 |
| Nicholson, W | 2 |
| Bolen, S | 1 |
| Witkop, CT | 2 |
| Neale, D | 1 |
| Wilson, L | 1 |
| Bass, E | 1 |
| Kumbak, B | 1 |
| Kahraman, S | 1 |
| Freitas, V | 1 |
| Fraser, R | 2 |
| Wensel, TM | 1 |
| Luen, S | 1 |
| Hughes, RC | 3 |
| Sadler, LC | 1 |
| McCowan, LM | 1 |
| Cheung, NW | 1 |
| Karimzadeh, MA | 1 |
| Javedani, M | 1 |
| González, CR | 1 |
| Caminos, JE | 1 |
| Vázquez, MJ | 1 |
| Garcés, MF | 1 |
| Cepeda, LA | 1 |
| Angel, A | 1 |
| González, AC | 1 |
| García-Rendueles, ME | 1 |
| Sangiao-Alvarellos, S | 1 |
| López, M | 1 |
| Bravo, SB | 1 |
| Nogueiras, R | 1 |
| Diéguez, C | 1 |
| Sander, VA | 1 |
| Facorro, GB | 1 |
| Piehl, L | 1 |
| Rubín de Celis, E | 1 |
| Pagidas, K | 1 |
| Carson, SA | 4 |
| McGovern, PG | 4 |
| Barnhart, HX | 3 |
| Myers, ER | 4 |
| Diamond, MP | 5 |
| Carr, BR | 4 |
| Schlaff, WD | 4 |
| Coutifaris, C | 5 |
| Steinkampf, MP | 4 |
| Cataldo, NA | 4 |
| Gosman, G | 2 |
| Kazerooni, T | 2 |
| Ghaffarpasand, F | 1 |
| Kazerooni, Y | 1 |
| Kazerooni, M | 1 |
| Setoodeh, S | 1 |
| Bloomgarden, ZT | 1 |
| Rashidi, B | 1 |
| Haghollahi, F | 2 |
| Shariat, M | 2 |
| Zayerii, F | 1 |
| Paglia, MJ | 1 |
| Coustan, DR | 3 |
| Begum, MR | 1 |
| Khanam, NN | 1 |
| Quadir, E | 1 |
| Ferdous, J | 1 |
| Begum, MS | 1 |
| Khan, F | 1 |
| Begum, A | 1 |
| Hyer, SL | 1 |
| Rodin, DA | 1 |
| Wagner, J | 1 |
| Allen, NA | 1 |
| Swalley, LM | 1 |
| Melkus, GD | 1 |
| Whittemore, R | 1 |
| Shokeir, T | 1 |
| Badawy, A | 1 |
| Qublan, HS | 5 |
| Al-Khaderei, S | 1 |
| Abu-Salem, AN | 1 |
| Al-Zpoon, A | 1 |
| Al-Khateeb, M | 1 |
| Al-Ibrahim, N | 1 |
| Megdadi, M | 1 |
| Al-Ahmad, N | 1 |
| Lanker, A | 1 |
| Müller, B | 1 |
| Diem, P | 1 |
| Moran, LJ | 1 |
| Hutchison, SK | 1 |
| Zoungas, S | 1 |
| Christakou, CD | 1 |
| Kandaraki, E | 1 |
| Economou, FN | 1 |
| Guercio, G | 1 |
| Di Palma, MI | 1 |
| Pepe, C | 1 |
| Saraco, NI | 1 |
| Prieto, M | 1 |
| Saure, C | 1 |
| Mazza, C | 1 |
| Rivarola, MA | 1 |
| Belgorosky, A | 1 |
| Fowler, SE | 1 |
| Hamman, RF | 1 |
| Hoffman, HJ | 1 |
| Brenneman, AT | 1 |
| Brown-Friday, JO | 1 |
| Goldberg, R | 1 |
| Venditti, E | 1 |
| Nathan, DM | 1 |
| Hamed, HO | 1 |
| Hasan, AF | 1 |
| Ahmed, OG | 1 |
| Ahmed, MA | 1 |
| Heikkinen, T | 1 |
| Rahi, M | 1 |
| Moore, LE | 2 |
| Clokey, D | 2 |
| Rappaport, VJ | 1 |
| Curet, LB | 1 |
| Rai, L | 1 |
| Meenakshi, D | 1 |
| Kamath, A | 1 |
| Duranteau, L | 1 |
| Lefevre, P | 1 |
| Jeandidier, N | 1 |
| Simon, T | 1 |
| Christin-Maitre, S | 1 |
| Lord, JM | 3 |
| Battista, L | 1 |
| Russo, T | 11 |
| Venturella, R | 1 |
| Tolino, A | 11 |
| Nader, S | 2 |
| Eyal, S | 1 |
| Carr, D | 1 |
| Miodovnik, M | 1 |
| Clark, SM | 1 |
| Risler, L | 1 |
| Kelly, EJ | 1 |
| Fajans, SS | 1 |
| Raffone, E | 2 |
| Rizzo, P | 2 |
| Benedetto, V | 1 |
| Hemauer, SJ | 1 |
| Patrikeeva, SL | 2 |
| Stewart, AW | 2 |
| Falkiner, J | 1 |
| Farquhar, CM | 1 |
| Milsom, S | 1 |
| Singh, VP | 1 |
| Okonkwo, QL | 1 |
| Buckingham, KL | 1 |
| Sohrabvand, F | 2 |
| Bagheri, B | 1 |
| Jungheim, ES | 2 |
| Odibo, AO | 1 |
| Ott, J | 1 |
| Kurz, C | 1 |
| Nouri, K | 1 |
| Wirth, S | 1 |
| Vytiska-Binstorfer, E | 1 |
| Huber, JC | 1 |
| Mayerhofer, K | 1 |
| Baran, S | 1 |
| Api, M | 1 |
| Goksedef, BP | 1 |
| Cetin, A | 1 |
| Marsh, KA | 1 |
| Steinbeck, KS | 1 |
| Atkinson, FS | 1 |
| Petocz, P | 1 |
| Brand-Miller, JC | 1 |
| Boudhrâa, K | 1 |
| Jellouli, MA | 1 |
| Amri, M | 1 |
| Farhat, M | 1 |
| Torkhani, F | 1 |
| Gara, MF | 1 |
| Pacheco, C | 1 |
| Bizato, J | 1 |
| de Souza, BV | 1 |
| Ribeiro, TE | 1 |
| Bertini, AM | 2 |
| Wafa, A | 1 |
| El Rakhawy, M | 1 |
| Genazzani, AD | 1 |
| Ricchieri, F | 1 |
| Lanzoni, C | 1 |
| Casson, PR | 1 |
| Krawetz, SA | 1 |
| Brzyski, RG | 1 |
| Christman, GM | 1 |
| Santoro, N | 2 |
| Eisenberg, E | 2 |
| Dhulkotia, JS | 1 |
| Ola, B | 1 |
| Farrell, T | 2 |
| Economou, F | 1 |
| Palimeri, S | 1 |
| Christakou, C | 1 |
| Vause, TD | 1 |
| Cheung, AP | 1 |
| Sierra, S | 1 |
| Claman, P | 1 |
| Graham, J | 1 |
| Guillemin, JA | 1 |
| Lapensée, L | 1 |
| Steward, S | 1 |
| Wong, BC | 1 |
| Acharya, S | 1 |
| Thake, F | 1 |
| Balen, A | 1 |
| Heimstad, R | 2 |
| Romundstad, P | 4 |
| Skogøy, K | 1 |
| Kleggetveit, O | 1 |
| von Brandis, P | 1 |
| Eikeland, T | 1 |
| Flo, K | 1 |
| Berg, KF | 1 |
| Bunford, G | 1 |
| Lund, A | 1 |
| Bjerke, C | 1 |
| Almås, I | 1 |
| Danielson, A | 1 |
| Lahmami, G | 1 |
| Anwar, K | 1 |
| El-Fatah, RA | 1 |
| Ebeling, T | 1 |
| El Lakany, N | 1 |
| Sherief, L | 1 |
| Roland, AV | 1 |
| Moenter, SM | 1 |
| Maymone, AC | 1 |
| Baillargeon, JP | 1 |
| Ménard, J | 1 |
| Ardilouze, JL | 1 |
| Khattab, S | 3 |
| Mohsen, IA | 2 |
| Aboul Foutouh, I | 1 |
| Ashmawi, HS | 1 |
| Mohsen, MN | 1 |
| Youssef, MA | 1 |
| Baptiste-Roberts, K | 1 |
| Bals-Pratsch, M | 1 |
| Grosser, B | 1 |
| Seifert, B | 1 |
| Ortmann, O | 2 |
| Seifarth, C | 1 |
| Johnson, N | 1 |
| Fernandez, H | 1 |
| Morin-Surruca, M | 1 |
| Torre, A | 1 |
| Faivre, E | 1 |
| Deffieux, X | 1 |
| Gervaise, A | 1 |
| Weerakiet, S | 2 |
| Sophonsritsuk, A | 2 |
| Lertvikool, S | 1 |
| Satirapot, C | 1 |
| Leelaphiwat, S | 1 |
| Jultanmas, R | 1 |
| De Leo, V | 3 |
| Musacchio, MC | 1 |
| Piomboni, P | 1 |
| Di Sabatino, A | 1 |
| Morgante, G | 2 |
| de Oliveira Baraldi, C | 2 |
| Lanchote, VL | 2 |
| de Jesus Antunes, N | 2 |
| de Jesus Ponte Carvalho, TM | 2 |
| Dantas Moisés, EC | 1 |
| Dantes Moisés, EC | 1 |
| Duarte, G | 2 |
| Cavalli, RC | 2 |
| Swanton, A | 1 |
| Lighten, A | 1 |
| Granne, I | 1 |
| McVeigh, E | 1 |
| Lavery, S | 1 |
| Trew, G | 1 |
| Talmor, A | 1 |
| Raine-Fenning, N | 1 |
| Jayaprakasan, K | 1 |
| Child, T | 1 |
| Kjøtrød, SB | 3 |
| Rasmussen, PE | 1 |
| Holst-Larsen, T | 1 |
| Mellembakken, J | 1 |
| Thurin-Kjellberg, A | 1 |
| Haapaniemikouru, K | 1 |
| Humaidan, P | 1 |
| Sunde, A | 2 |
| von Düring, V | 3 |
| Lv, J | 1 |
| Bontekoe, S | 1 |
| Goh, JE | 1 |
| Sadler, L | 1 |
| Di Cello, A | 2 |
| Cappiello, F | 2 |
| Rush, EC | 1 |
| Wouldes, T | 1 |
| Pauli, JM | 1 |
| Raja-Khan, N | 1 |
| Carrillo, L | 1 |
| Villani, MT | 1 |
| Capasso, S | 1 |
| Colao, A | 4 |
| Mastrantonio, P | 1 |
| Cittadini, E | 1 |
| Pérez, V | 1 |
| Ladrón de Guevara, A | 1 |
| Preisler, J | 1 |
| Sánchez, F | 1 |
| Ringholm, L | 1 |
| D'Anna, R | 1 |
| Di Benedetto, V | 1 |
| Interdonato, ML | 1 |
| Corrado, F | 1 |
| Di Benedetto, A | 1 |
| Gandhi, P | 1 |
| Bustani, R | 1 |
| Madhuvrata, P | 1 |
| Ballas, J | 1 |
| Moore, TR | 1 |
| Ramos, GA | 1 |
| Ullah, I | 1 |
| Ullah, N | 1 |
| Naseer, MI | 1 |
| Kim, MO | 1 |
| Van Pelt, RE | 1 |
| Brumbaugh, DE | 1 |
| Hernandez, TL | 1 |
| Lau, SM | 1 |
| Ghazeeri, GS | 1 |
| Nassar, AH | 1 |
| Younes, Z | 1 |
| Awwad, JT | 1 |
| Weickert, MO | 1 |
| Hodges, P | 1 |
| Tan, BK | 1 |
| Randeva, HS | 1 |
| Rantala, AS | 1 |
| Unkila-Kallio, L | 1 |
| Tiitinen, A | 1 |
| Hippeläinen, M | 1 |
| Perheentupa, A | 1 |
| Tinkanen, H | 1 |
| Bloigu, R | 1 |
| Puukka, K | 1 |
| Ruokonen, A | 1 |
| Tapanainen, JS | 1 |
| Fachin, DR | 1 |
| Coral, ML | 1 |
| Siebert, TI | 2 |
| Viola, MI | 1 |
| Steyn, DW | 2 |
| Kruger, TF | 2 |
| Kruger, M | 1 |
| Casson, P | 1 |
| Schlaff, W | 1 |
| Brzyski, R | 1 |
| Christman, G | 1 |
| Gosman, GG | 2 |
| Carson, S | 1 |
| Myers, EE | 1 |
| Hehir, MP | 1 |
| Morrison, JJ | 1 |
| Zhelyazkova-Savova, M | 1 |
| Tartarin, P | 1 |
| Moison, D | 1 |
| Guibert, E | 1 |
| Habert, R | 1 |
| Rouiller-Fabre, V | 1 |
| Frydman, N | 2 |
| Pozzi, S | 1 |
| Frydman, R | 2 |
| Lecureuil, C | 1 |
| Zuckerwise, LC | 1 |
| McMahon-Brown, EK | 1 |
| Thung, SF | 1 |
| Nordskar, JJ | 1 |
| Leithe, H | 1 |
| Hjorth-Hansen, AK | 1 |
| Martinussen, M | 1 |
| Hawkins, JZ | 1 |
| Wing, D | 1 |
| Rø, TB | 1 |
| Ludvigsen, HV | 1 |
| Díaz, M | 1 |
| Moisés, EC | 1 |
| Koskinen, P | 1 |
| Barrett, HL | 2 |
| De Blasio, MJ | 2 |
| Callaway, LK | 1 |
| Dekker Nitert, M | 2 |
| Gagnon, J | 1 |
| Sheppard, E | 1 |
| Anini, Y | 1 |
| Niromanesh, S | 1 |
| Alavi, A | 1 |
| Sharbaf, FR | 1 |
| Amjadi, N | 1 |
| Moosavi, S | 1 |
| Akbari, S | 1 |
| Martinussen, MP | 1 |
| Hickman, MA | 1 |
| McBride, R | 1 |
| Strauss, R | 1 |
| Usadi, RS | 1 |
| Wang, LL | 1 |
| Ren, W | 1 |
| Cheng, QF | 1 |
| Fan, XD | 1 |
| Propst, AM | 1 |
| Bates, GW | 1 |
| Pranikoff, J | 4 |
| Khan, Z | 1 |
| Padda, J | 1 |
| Swinton, F | 1 |
| Radford, A | 1 |
| Campbell, J | 1 |
| McBeath, S | 1 |
| Dennis, A | 1 |
| Lawrence, JM | 1 |
| Andrade, SE | 1 |
| Avalos, LA | 1 |
| Beaton, SJ | 1 |
| Chiu, VY | 1 |
| Davis, RL | 1 |
| Dublin, S | 1 |
| Pawloski, PA | 1 |
| Raebel, MA | 1 |
| Smith, DH | 1 |
| Toh, S | 1 |
| Kaplan, S | 1 |
| Amini, T | 1 |
| Hammad, TA | 1 |
| Scott, PE | 1 |
| Cheetham, TC | 1 |
| Romualdi, D | 2 |
| De Cicco, S | 1 |
| Gagliano, D | 1 |
| Busacca, M | 1 |
| Campagna, G | 1 |
| Guido, M | 2 |
| Abd Elgafor, I | 1 |
| Jones, L | 1 |
| O'Rourke, P | 1 |
| Lust, K | 1 |
| Callaway, L | 1 |
| Sieve-Smith, L | 3 |
| Streicher, P | 2 |
| Solignac, M | 1 |
| Eden, JA | 1 |
| Cleasby, ME | 1 |
| Livingstone, DE | 1 |
| Nyirenda, MJ | 1 |
| Seckl, JR | 1 |
| George, SS | 1 |
| George, K | 1 |
| Irwin, C | 1 |
| Job, V | 1 |
| Selvakumar, R | 1 |
| Jeyaseelan, V | 1 |
| Seshadri, MS | 1 |
| Davoren, PM | 1 |
| Oliver, J | 1 |
| Barbieri, RL | 2 |
| Tasdemir, S | 1 |
| Ficicioglu, C | 1 |
| Yalti, S | 1 |
| Gurbuz, B | 1 |
| Basaran, T | 1 |
| Yildirim, G | 1 |
| Massin, N | 1 |
| Galey, J | 1 |
| Basille, C | 1 |
| Théron-Gérard, L | 1 |
| Bry-Gauillard, H | 1 |
| Cédrin-Durnerin, I | 1 |
| Hugues, JN | 1 |
| Cardone, VS | 1 |
| Malkawi, HY | 3 |
| Hamaideh, AH | 1 |
| Visnová, H | 1 |
| Ventruba, P | 1 |
| Crha, I | 1 |
| Záková, J | 1 |
| Pirwany, I | 1 |
| POULSEN, JE | 1 |
| CAGLI, V | 1 |
| Frank-Raue, K | 1 |
| Schulze, E | 1 |
| Clemens, A | 1 |
| Riemann, JF | 1 |
| Siegel, EG | 1 |
| la Marca, A | 3 |
| Flight, IH | 1 |
| Zhao, JZ | 1 |
| Ye, BL | 1 |
| Lin, JJ | 1 |
| Lin, WQ | 1 |
| Chi, HH | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| McCarthy, EA | 1 |
| McLachlan, K | 1 |
| Permezel, M | 1 |
| Gargiulo, AR | 1 |
| Petersen, KU | 1 |
| Loftspring, M | 2 |
| Sherman, A | 1 |
| Belosi, C | 1 |
| Selvaggi, L | 1 |
| Yirmibeş, U | 1 |
| Keleştimur, F | 1 |
| Aygen, E | 1 |
| Walters, BN | 1 |
| Rao, SS | 1 |
| Disraeli, P | 1 |
| McGregor, T | 1 |
| Wang, JX | 1 |
| Cheang, KI | 2 |
| Saleh, AM | 1 |
| Khalil, HS | 1 |
| Al-Fadhli, R | 1 |
| Gomel, V | 1 |
| Yarali, H | 2 |
| Ben-Haroush, A | 1 |
| Yogev, Y | 1 |
| Fisch, B | 1 |
| Bornovali, S | 1 |
| Dharashivkar, S | 1 |
| Buckham, RB | 1 |
| Kashyap, S | 1 |
| Wells, GA | 1 |
| Rosenwaks, Z | 1 |
| Nardo, LG | 2 |
| Corea, D | 1 |
| Doldo, P | 1 |
| Lombardi, G | 1 |
| Xue, YM | 1 |
| Chen, LX | 1 |
| Cui, QH | 1 |
| Yuan, T | 1 |
| Aruna, J | 1 |
| Mittal, S | 1 |
| Misra, R | 1 |
| Dadhwal, V | 1 |
| Vimala, N | 1 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Lam, PM | 1 |
| Cheung, LP | 1 |
| Haines, C | 1 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Tingthanatikul, Y | 1 |
| Choktanasiri, W | 1 |
| Wansumrith, S | 1 |
| Rojanasakul, A | 1 |
| Manguso, F | 4 |
| Cascella, T | 1 |
| Carmina, E | 1 |
| Vijay, V | 2 |
| Vijayalaskhmi, S | 1 |
| Zahlsen, K | 1 |
| Brock, B | 1 |
| Smidt, K | 1 |
| Ovesen, P | 1 |
| Schmitz, O | 1 |
| Rungby, J | 1 |
| Silva, SG | 1 |
| Hafley, G | 1 |
| Kunselman, AR | 1 |
| Hwu, YM | 1 |
| Lin, SY | 1 |
| Huang, WY | 1 |
| Lin, MH | 1 |
| Lee, RK | 1 |
| Onalan, G | 2 |
| Selam, B | 1 |
| Baran, Y | 1 |
| Cincik, M | 2 |
| Onalan, R | 1 |
| Gündüz, U | 1 |
| Ural, AU | 1 |
| Pabuccu, R | 2 |
| Artensio, AC | 1 |
| Stabile, G | 1 |
| Volpe, A | 1 |
| Annamaria, C | 1 |
| Dale, B | 1 |
| Petrányi, G | 1 |
| Lee, MS | 1 |
| Kang, SK | 1 |
| Lee, BC | 1 |
| Hwang, WS | 1 |
| Gilbert, CJ | 1 |
| Koren, G | 4 |
| Vaughan, TB | 1 |
| Bell, DS | 1 |
| van Santbrink, EJ | 1 |
| Eijkemans, MJ | 1 |
| Laven, JS | 1 |
| Goktolga, U | 1 |
| Ceyhan, T | 1 |
| Bagis, T | 1 |
| Glanville, J | 2 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Caterina, G | 1 |
| Boothroyd, C | 1 |
| Yazdani, A | 1 |
| Charles, B | 1 |
| Norris, R | 1 |
| Xiao, X | 1 |
| Brown, FM | 1 |
| Jovanovic, L | 1 |
| Briggs, GG | 2 |
| Chapman, M | 1 |
| Conway, U | 1 |
| Ansari, Sh | 1 |
| Bagheri, M | 1 |
| Hawthorne, G | 1 |
| Hjorth-Hansen, H | 2 |
| Bjerve, K | 1 |
| Orsi, N | 1 |
| Gilbert, C | 2 |
| Valois, M | 2 |
| Thatcher, SS | 1 |
| Jackson, EM | 1 |
| Rouzi, AA | 1 |
| Ardawi, MS | 1 |
| Golnik, KC | 1 |
| Aregawi, D | 2 |
| Turner, MJ | 2 |
| Walsh, J | 2 |
| Byrne, KM | 1 |
| Langan, H | 1 |
| Farah, N | 1 |
| Liu, JH | 1 |
| Bill, AH | 1 |
| Salehi, M | 1 |
| Kocak, I | 1 |
| Ustün, C | 1 |
| Norman, R | 1 |
| Lilja, AE | 1 |
| Nekhayeva, IA | 1 |
| Solano, ME | 1 |
| Elia, E | 1 |
| Sander, V | 1 |
| Gonzalez, C | 1 |
| Fotouh, IA | 1 |
| Mohesn, IA | 1 |
| Moaz, M | 2 |
| Liu, KE | 1 |
| Tataryn, IV | 1 |
| Sagle, M | 1 |
| Weissman, A | 1 |
| Gur, D | 1 |
| Levran, D | 1 |
| Rotmensch, S | 1 |
| Glezerman, M | 2 |
| Fiad, T | 1 |
| Meer, L | 1 |
| Nosarka, S | 1 |
| Marchesan, E | 1 |
| Neveu, N | 1 |
| Granger, L | 1 |
| St-Michel, P | 1 |
| Lavoie, HB | 1 |
| Ashokkumar, N | 1 |
| Pari, L | 1 |
| Rao, ChA | 1 |
| Sharma, ST | 1 |
| Foutouh, IA | 1 |
| Ramadan, A | 1 |
| Al-Inany, H | 1 |
| Boomsma, CM | 1 |
| Macklon, NS | 1 |
| Gorry, A | 1 |
| White, DM | 1 |
| Kestilä, KK | 1 |
| Ekblad, UU | 1 |
| Shibahara, H | 1 |
| Kikuchi, K | 1 |
| Hirano, Y | 1 |
| Suzuki, T | 1 |
| Takamizawa, S | 1 |
| Suzuki, M | 1 |
| Wessler, I | 1 |
| Herschel, S | 1 |
| Bittinger, F | 1 |
| Kirkpatrick, CJ | 1 |
| Leppert, PC | 2 |
| Guzick, DS | 2 |
| Haroutiunian, S | 1 |
| Feldman, N | 1 |
| Kjøtrød, S | 1 |
| Shahine, L | 1 |
| Lathi, RB | 1 |
| Dahan, MH | 1 |
| Kadoch, IJ | 1 |
| Fanchin, R | 1 |
| Le Du, A | 1 |
| De Feo, P | 1 |
| Eng, GS | 1 |
| Sheridan, RA | 1 |
| Wyman, A | 1 |
| Chi, MM | 2 |
| Bibee, KP | 1 |
| Clapauch, R | 1 |
| Mattos, TM | 1 |
| Thaler, CJ | 1 |
| Nagai, T | 1 |
| Imamura, M | 1 |
| Mori, M | 1 |
| Ratchford, AM | 1 |
| Chang, AS | 1 |
| Sheridan, R | 1 |
| Alvarez, S | 1 |
| Martínez-Bermejo, E | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Yannakoula, EK | 1 |
| Al-Qudah, MA | 1 |
| El-Uri, FI | 1 |
| Ratts, VS | 2 |
| Pauls, RN | 1 |
| Pinto, AB | 1 |
| Kraja, A | 1 |
| Williams, DB | 1 |
| Odem, RR | 1 |
| Zolghadri, J | 1 |
| Tavana, Z | 1 |
| Soveid, M | 1 |
| Taghieh, M | 1 |
| Wei, Z | 1 |
| Cong, L | 1 |
| Zhou, P | 1 |
| Tien, JC | 1 |
| Tan, TY | 1 |
| Briery, CM | 1 |
| Martin, RW | 1 |
| Williford, NJ | 1 |
| Bofill, JA | 1 |
| Morrison, JC | 1 |
| Schaefer-Graf, UM | 1 |
| Kleinwechter, H | 1 |
| Glueck, C | 1 |
| Tollino, A | 1 |
| Zain, MM | 1 |
| Jamaluddin, R | 1 |
| Creanga, AA | 1 |
| Bradley, HM | 1 |
| McCormick, C | 1 |
| Kumar, HK | 1 |
| Bromer, JG | 1 |
| Cetinkaya, MB | 1 |
| Arici, A | 1 |
| Bolton, S | 1 |
| Cleary, B | 1 |
| Dempsey, E | 1 |
| Moore, MP | 1 |
| Greene, MF | 1 |
| Hong, YC | 1 |
| O'Boyle, CP | 1 |
| Chen, IC | 1 |
| Hsiao, CT | 1 |
| Kuan, JT | 1 |
| Korevaar, JC | 1 |
| Bossuyt, PM | 1 |
| Coetzee, EJ | 4 |
| Jackson, WP | 4 |
| Denno, KM | 1 |
| Sadler, TW | 1 |
| Velazquez, EM | 1 |
| Mendoza, S | 1 |
| Hamer, T | 1 |
| Sosa, F | 1 |
| Sulkin, TV | 1 |
| Bosman, D | 1 |
| Krentz, AJ | 1 |
| Sarlis, NJ | 1 |
| Weil, SJ | 1 |
| Nelson, LM | 1 |
| Ditto, A | 1 |
| Cianci, A | 1 |
| Holstein, A | 1 |
| Nahrwold, D | 1 |
| Hinze, S | 1 |
| Egberts, EH | 1 |
| Zapanti, E | 1 |
| Sills, ES | 1 |
| Perloe, M | 1 |
| Palermo, GD | 1 |
| Seale, FG | 1 |
| Robinson, RD | 1 |
| Neal, GS | 1 |
| Awadalla, SG | 1 |
| Phillips, H | 3 |
| Cameron, D | 2 |
| Fontaine, RN | 1 |
| Hellmuth, E | 1 |
| Mølsted-Pedersen, L | 1 |
| Vandermolen, DT | 1 |
| Evans, WS | 1 |
| Stovall, DW | 1 |
| Kauma, SW | 1 |
| Jakubowicz, DJ | 3 |
| Seppälä, M | 1 |
| Jakubowicz, S | 2 |
| Rodriguez-Armas, O | 1 |
| Rivas-Santiago, A | 1 |
| Koistinen, H | 1 |
| Koistinen, R | 1 |
| Stadtmauer, LA | 1 |
| Toma, SK | 1 |
| Riehl, RM | 1 |
| Talbert, LM | 1 |
| Phipps, WR | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Wat, NM | 1 |
| Ho, PC | 1 |
| Dornan, T | 1 |
| Hollis, S | 1 |
| Dornhorst, A | 1 |
| Batukan, C | 1 |
| Baysal, B | 1 |
| Rai, R | 1 |
| Kocak, M | 1 |
| Caliskan, E | 1 |
| Simsir, C | 1 |
| Haberal, A | 1 |
| Stovall, D | 1 |
| Akhter, N | 1 |
| Iuorno, MJ | 2 |
| Yildiz, BO | 1 |
| Demirol, A | 1 |
| Zeyneloğlu, HB | 1 |
| Yiğit, N | 1 |
| Bükülmez, O | 1 |
| Koray, Z | 1 |
| Roberts, KA | 1 |
| Kobayashi, S | 1 |
| Heard, MJ | 1 |
| Pierce, A | 1 |
| Buster, JE | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Shen, H | 1 |
| Sturrock, ND | 1 |
| Lannon, B | 1 |
| Fay, TN | 1 |
| Seli, E | 1 |
| Duleba, AJ | 1 |
| Brearley, BF | 1 |
| Gill, G | 1 |
| Tattersall, RB | 1 |
| Harris, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Implementation of a Pragmatic Approach to Lower Diabetes Mellitus Risk After a Diagnosis of Gestational Diabetes Mellitus[NCT05280496] | Phase 3 | 36 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Preeclampsia Intervention 4 - A Triple Blind Phase III Randomised Controlled Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia[NCT06033131] | Phase 3 | 294 participants (Anticipated) | Interventional | 2024-01-22 | Not yet recruiting | ||
| Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age[NCT02417090] | 173 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Studying the Effectiveness of Carbohydrate Counting and Dietary Approach to Stop Hypertension Dietary Intervention on Glycemic Control and Maternal and Newborn Health Outcomes Among Jordanian Pregnant Women With Gestational Diabetes[NCT03244579] | 180 participants (Anticipated) | Interventional | 2017-08-20 | Recruiting | |||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Pregnancy Outcomes: Effects of Metformin Study (POEM Study), a Long Term Randomized Controlled Study in Gestational Diabetes[NCT02947503] | Phase 3 | 500 participants (Anticipated) | Interventional | 2019-11-26 | Recruiting | ||
| Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study[NCT05702905] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| Randomised Controlled Trial of Gestational Treatment With Ursodeoxycholic Acid Compared to Metformin to Reduce Effects of Diabetes Mellitus[NCT04407650] | Phase 4 | 158 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| A Randomised Placebo Controlled Trial of the Effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE)[NCT02980276] | Phase 3 | 535 participants (Actual) | Interventional | 2017-06-06 | Completed | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Pilot Study of Pharmacist-Coordinated Implementation of the Diabetes Prevention Program (DPP) for Women With a History of Gestational Diabetes Mellitus (GDM)[NCT03766256] | 33 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| Abnormalities of the Endometrium Persist Despite Adequate Progesterone Supplementation in the Polycystic Ovary Syndrome[NCT05062135] | 36 participants (Actual) | Interventional | 2014-02-10 | Completed | |||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)[NCT01234649] | Phase 3 | 153 participants (Actual) | Interventional | 2011-08-11 | Completed | ||
| The Effect Birth Outcome and Diabetes Management of Planned Behavior Theory Based Education Model in Women With Gestational Diabetes[NCT04874922] | 66 participants (Actual) | Interventional | 2021-05-15 | Completed | |||
| Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.[NCT01240785] | Phase 4 | 221 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities[NCT02338193] | Phase 3 | 69 participants (Actual) | Interventional | 2015-09-22 | Completed | ||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Comparative Studies of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta[NCT04907708] | 156 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS[NCT02080377] | Phase 3 | 23 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women a Randomized Control Trial.[NCT05554679] | Phase 4 | 178 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy[NCT02932475] | Phase 3 | 831 participants (Actual) | Interventional | 2017-05-25 | Terminated (stopped due to Recommendation by the DSMB that the study be stopped for futility) | ||
| A Prospective, Randomized, Double-blind, Multi-centre Study, Where the Possible Effect of Metformin to Prevent Late Miscarriage and Preterm Delivery is Studied in Women With Polycystic Ovary Syndrome (PCOS)[NCT01587378] | 489 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Management of Intrapartum Glycemia in Gestational Diabetic Mothers: A Randomized Controlled Trial[NCT05647798] | 120 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | |||
| Long-term Effects of Flash Glucose Monitoring System in Patients With Gestational Diabetes[NCT06031987] | 100 participants (Anticipated) | Interventional | 2022-01-26 | Recruiting | |||
| Diagnostic Efficiency Analysis of Oral Glucose Tolerance Test and Prediction Model Establishment in the First Trimester for Gestational Diabetes Mellitus: a Prospective Cohort Study[NCT05487352] | 781 participants (Actual) | Observational | 2021-05-30 | Active, not recruiting | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.[NCT01998113] | 2,509 participants (Actual) | Observational | 2013-03-31 | Completed | |||
| Uterine Artery Blood Flow in Pregnant Women With Polycystic Ovary Syndrome(PCOS)Treated With Metformin - a Substudy to The PregMet Study[NCT00466622] | Phase 3 | 48 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. ACARB-GDM Study.[NCT03380546] | Phase 3 | 341 participants (Actual) | Interventional | 2018-07-04 | Active, not recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country[NCT01855763] | Phase 2/Phase 3 | 300 participants (Actual) | Interventional | 2008-12-31 | Active, not recruiting | ||
| Effect of Adding Metformin to Insulin in Uncontrolled Diabetic Patients During the 3rd Trimester of Pregnancy on Glycemic Control, Fetal and Neonatal Outcomes ,Randomized Controlled Trial[NCT05479214] | Phase 4 | 150 participants (Actual) | Interventional | 2022-07-29 | Completed | ||
| Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome[NCT00068861] | Phase 3 | 678 participants | Interventional | 2002-11-30 | Completed | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.[NCT04385667] | Phase 2/Phase 3 | 143 participants (Actual) | Interventional | 2020-05-20 | Completed | ||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Lower Vitamin D Levels During Second Trimester Are Associated With Developing Gestational Diabetes Mellitus: an Observational Cross-sectional Study[NCT03665974] | 80 participants (Actual) | Observational | 2013-01-05 | Completed | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Metformin in Women With Type 2 Diabetes in Pregnancy Trial[NCT01353391] | Phase 3 | 500 participants (Actual) | Interventional | 2011-05-25 | Completed | ||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study[NCT03056274] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| [NCT01563120] | Phase 4 | 108 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection With Letrozole /Antagonist Protocol: A Randomized Controlled Trial[NCT04069117] | Phase 4 | 200 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| Face-it: A Health Promotion Intervention for Women With Prior Gestational Diabetes and Their Families - A Randomised Controlled Trial[NCT03997773] | 277 participants (Actual) | Interventional | 2019-05-21 | Active, not recruiting | |||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| Study of Awareness of Gestational Diabetes Problem Among Sohag Governorate Women[NCT05148897] | 500 participants (Anticipated) | Observational [Patient Registry] | 2021-10-01 | Recruiting | |||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort[NCT02910154] | 62 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429] | 35 participants (Actual) | Interventional | 2020-06-09 | Completed | |||
| WellStart Type 2 Diabetes Study[NCT03731533] | 0 participants (Actual) | Interventional | 2018-12-01 | Withdrawn (stopped due to Grantor withdrew from study) | |||
| Metabolic Syndrome and Severe Obesity: Randomized Nutritional Trial to Study Long Term Effect of Very-low-calories Ketogenic Diet (VLCKD) on Weight Control and Cardiovascular Risk Factors[NCT05781269] | 100 participants (Anticipated) | Interventional | 2022-02-20 | Recruiting | |||
| Benefits of Adding Continuous Glucose Monitoring to Glycemic Load, Exercise, and Monitoring of Blood Glucose (GEM) for Adults With Type 2 Diabetes - Phase 2[NCT03207893] | 24 participants (Actual) | Interventional | 2018-07-19 | Completed | |||
| Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification[NCT03196895] | 192 participants (Actual) | Interventional | 2017-06-28 | Completed | |||
| Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes[NCT03398902] | 150 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | |||
| Assessment of Designer Functional Foods on Parameters of Metabolic and Vascular Status in Individuals With Prediabetes.[NCT02400450] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn | |||
| A Randomized Prospective Trial of Metformin Compared to Glyburide in Gestational Diabetes[NCT00965991] | 149 participants (Actual) | Interventional | 2003-07-31 | Completed | |||
| Glyburide vs Glucovance in the Treatment of Gestational Diabetes[NCT02726490] | Early Phase 1 | 7 participants (Actual) | Interventional | 2016-07-31 | Terminated (stopped due to Lack of Recruitment) | ||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome[NCT00795808] | Phase 4 | 171 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus: a Randomized Controlled Study[NCT01087866] | Phase 2/Phase 3 | 97 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Preventing Recurrent Gestational Diabetes Mellitus With Early Metformin Intervention[NCT02394158] | Phase 4 | 112 participants (Anticipated) | Interventional | 2015-01-27 | Recruiting | ||
| Metformin Treatment Before IVF in Women With Ultrasound Evidence of Polycystic Ovaries; a Prospective, Randomised, Double Blind, Placebo Study[NCT01046032] | 134 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome[NCT00159575] | Phase 4 | 150 participants (Actual) | Interventional | 2005-03-31 | Terminated (stopped due to Slow patient recruitment and expiry of study medication(aug2009)) | ||
| Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response[NCT01208740] | Phase 4 | 88 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Concerns about safety at the first interim analysis) | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization[NCT01233206] | Phase 4 | 120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [NCT01511822] | Phase 4 | 0 participants | Interventional | Completed | |||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Role Of Dydrogesterone Towards Oocyte and Embryo Quality in Polycystic Ovarian Syndrome (PCOS)[NCT04175990] | Phase 1 | 155 participants (Actual) | Interventional | 2018-05-10 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)[NCT00835861] | Phase 2 | 31 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [NCT01594697] | 60 participants (Actual) | Interventional | Completed | ||||
| PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1[NCT00883766] | 172 participants (Anticipated) | Interventional | 2009-04-30 | Terminated | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812] | Phase 3 | 326 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial[NCT00558077] | Phase 4 | 50 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome[NCT00471523] | Phase 4 | 80 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients[NCT00501904] | Phase 4 | 20 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial[NCT00461643] | Phase 4 | 552 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study.[NCT00501839] | Phase 4 | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn | ||
| What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.[NCT00502229] | Phase 4 | 0 participants (Actual) | Interventional | 2010-01-31 | Withdrawn | ||
| Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome[NCT03316469] | 40 participants (Anticipated) | Interventional | 2018-07-31 | Not yet recruiting | |||
| Letrozole Versus Combined Metformin and Clomiphene Citrate for Ovulation Induction in Clomiphene-Resistant Women With Polycystic Ovary Syndrome[NCT00911313] | 250 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome[NCT00969631] | 282 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome[NCT01008046] | 192 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial[NCT01212263] | 174 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Real-time Continuous Glucose Monitoring for the Treatment of Gestational Diabetes: a Randomized Trial[NCT03326232] | 40 participants (Anticipated) | Interventional | 2017-11-13 | Recruiting | |||
| [NCT01784380] | 1,159 participants (Actual) | Observational | 2006-10-31 | Completed | |||
| The Experience of Living With Polycystic Ovary Syndrome in the Military[NCT03876665] | 24 participants (Actual) | Observational | 2019-08-15 | Completed | |||
| Pulsatile GnRH in Anovulatory Infertility[NCT00383656] | Phase 2 | 270 participants (Anticipated) | Interventional | 1989-01-31 | Recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Body weight in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | kilograms (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.2 |
| Metformin XR Plus Placebo | 91.3 |
Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 32.3 |
| Metformin XR Plus Placebo | 31 |
ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of ALT (U/L)/ AST (U/L) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 1.2 |
| Metformin XR Plus Placebo | 1.18 |
The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 27 |
| Metformin XR Plus Placebo | 28 |
BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | weight (kg) /height (m) squared (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 33.8 |
| Metformin XR Plus Placebo | 32.8 |
Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent. (NCT01234649)
Timeframe: Change from baseline (time 0) to study end (84 weeks)
| Intervention | percent change in weight from baseline (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | -7.2 |
| Metformin XR Plus Placebo | -3.1 |
DBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 77.6 |
| Metformin XR Plus Placebo | 77 |
Fasting glucose levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 90 |
| Metformin XR Plus Placebo | 91.7 |
HDL-C levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 51 |
| Metformin XR Plus Placebo | 48.7 |
HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.2 |
| Metformin XR Plus Placebo | 2.45 |
IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET) (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 418.4 |
| Metformin XR Plus Placebo | 333 |
IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 0.8 |
| Metformin XR Plus Placebo | 0.62 |
LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 110 |
| Metformin XR Plus Placebo | 107 |
OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 5.9 |
| Metformin XR Plus Placebo | 5.4 |
MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 121.6 |
| Metformin XR Plus Placebo | 118.8 |
SBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 122 |
| Metformin XR Plus Placebo | 123 |
CHOL levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 183.7 |
| Metformin XR Plus Placebo | 183.8 |
TRG concentrations in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 120 |
| Metformin XR Plus Placebo | 125 |
TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of TRG (mg/dL)/HDL-C (mg/dl) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.56 |
| Metformin XR Plus Placebo | 2.95 |
Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.3 |
| Metformin XR Plus Placebo | 95.3 |
Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist /height (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .56 |
| Metformin XR Plus Placebo | .57 |
Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist/hip circumference (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .81 |
| Metformin XR Plus Placebo | .81 |
Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome (NCT01240785)
Timeframe: 5 minutes after delivery
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 8.7 |
| Insulin | 8.9 |
birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies (NCT01240785)
Timeframe: delivery
| Intervention | g (Mean) |
|---|---|
| Metformin | 3604 |
| Insulin | 3589 |
(NCT01240785)
Timeframe: delivery
| Intervention | weeks (Mean) |
|---|---|
| Metformin | 39.2 |
| Insulin | 39.3 |
(NCT01240785)
Timeframe: delivery
| Intervention | participants (Number) |
|---|---|
| Metformin | 42 |
| Insulin | 58 |
(NCT01240785)
Timeframe: up to on the average 40 weeks of gestation
| Intervention | kg (Mean) |
|---|---|
| Metformin | 8.0 |
| Insulin | 7.9 |
(NCT01240785)
Timeframe: delivery
| Intervention | no of cesarean section (Number) |
|---|---|
| Metformin | 15 |
| Insulin | 18 |
(NCT01240785)
Timeframe: 0-3 days after delivery
| Intervention | participants (Number) |
|---|---|
| Metformin | 9 |
| Insulin | 10 |
(NCT01240785)
Timeframe: 0-24 h after delivery
| Intervention | participants (Number) |
|---|---|
| Metformin | 18 |
| Insulin | 18 |
(NCT01240785)
Timeframe: 0-5 days after delivery
| Intervention | participants (Number) |
|---|---|
| Metformin | 34 |
| Insulin | 39 |
(NCT01240785)
Timeframe: up to on the average 40 weeks of gestation
| Intervention | participants (Number) |
|---|---|
| Metformin | 5 |
| Insulin | 10 |
Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure > 30 mmHg or diastolic blood pressure > 15 mmHg (NCT01240785)
Timeframe: up to on the average 40 weeks of gestation
| Intervention | participants (Number) |
|---|---|
| Metformin | 2 |
| Insulin | 4 |
(NCT01240785)
Timeframe: delivery
| Intervention | participants (Number) |
|---|---|
| Metformin | 1 |
| Insulin | 2 |
BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | kg/m2 (Mean) |
|---|---|
| DAPA/MET XR | 33 |
| Dapaglifloxin | 33.7 |
| Metformin XR | 31 |
Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24 (NCT02338193)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | kilograms (Mean) |
|---|---|
| DAPA/MET XR | -21.5 |
| Dapaglifloxin | -12.5 |
| Metformin XR | -4.4 |
Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24 (NCT02338193)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percent weight loss from baseline (Mean) |
|---|---|
| DAPA/MET XR | -4.9 |
| Dapaglifloxin | -3.2 |
| Metformin XR | -1.1 |
Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment)
| Intervention | mmHG (Mean) |
|---|---|
| DAPA/MET XR | 79 |
| Dapaglifloxin | 77.8 |
| Metformin XR | 79 |
Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 89 |
| Dapaglifloxin | 91 |
| Metformin XR | 87 |
HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 2.6 |
| Dapaglifloxin | 2.4 |
| Metformin XR | 1.8 |
Corrected early insulin response to glucose challenge [(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)] with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 1.7 |
| Dapaglifloxin | 1.1 |
| Metformin XR | 0.77 |
ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| DAPA/MET XR | 1.13 |
| Dapaglifloxin | 1.12 |
| Metformin XR | 1.18 |
Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Index (Mean) |
|---|---|
| DAPA/MET XR | 6.0 |
| Dapaglifloxin | 6.3 |
| Metformin XR | 5.42 |
Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 109.5 |
| Dapaglifloxin | 110.1 |
| Metformin XR | 112.5 |
Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| DAPA/MET XR | 125 |
| Dapaglifloxin | 124 |
| Metformin XR | 119.6 |
Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 196 |
| Dapaglifloxin | 168 |
| Metformin XR | 178 |
Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| DAPA/MET XR | 119 |
| Dapaglifloxin | 89.8 |
| Metformin XR | 212 |
Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| DAPA/MET XR | 95.6 |
| Dapaglifloxin | 95 |
| Metformin XR | 91.7 |
Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| DAPA/MET XR | 0.81 |
| Dapaglifloxin | 0.80 |
| Metformin XR | 0.83 |
Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy (NCT02338193)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| DAPA/MET XR | 0.58 |
| Dapaglifloxin | 0.57 |
| Metformin XR | 0.56 |
Neonatal fat mass measured by skin-fold thickness (anthropometrics).The circumference of the upper limb is the circumference of the upper arm, and the circumference of the lower limb equals the mean of the circumferences measured at the midthigh and calf. The volume of the subcutaneous layer of fat covering each cylinder is estimated by multiplying the length times the circumference times the layer of fat estimated by the skinfold measures. The triceps skinfold measure is used as an estimate of the fat thickness of the limbs, and the subscapular skinfold measure approximates the fat thickness of the trunk. Total body fat is estimated by summing the volumes of fat covering each of the cylinders and multiplying by 0.9 (the density of fat). (NCT02932475)
Timeframe: Within 72 hrs of birth
| Intervention | kg (Mean) |
|---|---|
| Maternal Metformin | 0.46 |
| Maternal Placebo | 0.5 |
"Participants with one or more of the following:~capillary blood glucose level of < 30 mg/dL or capillary blood glucose requiring medical treatment, or~Birth trauma (umbilical cord artery pH < 7.0 or shoulder dystocia with brachial plexus injury), or~Hyperbilirubinemia requiring phototherapy, or~Deliver < 37 weeks' gestation, or~Miscarry, are stillborn, experience a neonatal demise, or~Large for gestational age infant (birth weight > 90th percentile for gestational age), or~Small for gestational age infant (birth weight < 10th percentile for gestational age) or low birth weight (< 2500 gm)" (NCT02932475)
Timeframe: An average of 48 hours for term infants and 30 days for preterm infants
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 269 |
| Placebo | 277 |
Adverse maternal outcomes. (NCT02932475)
Timeframe: An average of 48 hours following delivery
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Any adverse event leading to early study agent discontinuation | Any adverse event associated with maternal death | Any adverse event associated with fetal death | Any maternal serious adverse event | Any maternal non-serious adverse event | |
| Metformin | 13 | 2 | 10 | 113 | 149 |
| Placebo | 20 | 1 | 10 | 111 | 157 |
Adverse neonatal outcomes (NCT02932475)
Timeframe: up to 28 days of life
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any neonatal serious adverse event | Any neonatal non-serious adverse event | |
| Maternal Metformin | 81 | 157 |
| Maternal Placebo | 105 | 162 |
"Secondary outcome of maternal side effects were defined as:~clinically relevant hypoglycemia defined as capillary blood glucose < 60 or < 80 with symptoms~GI side effects defined as nausea, vomiting, diarrhea" (NCT02932475)
Timeframe: Throughout study until delivery at 40 weeks gestation
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Clinically relevant hypoglycemia | Gastrointestinal side effects | |
| Metformin | 87 | 182 |
| Placebo | 85 | 171 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
The importance of exercise in the management of blood glucose was emphasized, and 30 minutes of walking per day was recommended. Patients received instruction from a nurse educator or a certified diabetes educator regarding diet and the use of the glucometer. Number of participants with a glucose level <100 mg/dL. (NCT00965991)
Timeframe: fasting and 2 hour postprandial blood glucose
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 50 |
| Glyburide | 50 |
(NCT00835861)
Timeframe: Baseline throughout pregnancy until last prenatal visit.
| Intervention | kg/week (Median) |
|---|---|
| Metformin | 0.28 |
| Insulin | 0.30 |
Resuscitation in the delivery room, preterm birth < 37 weeks, neonatal intensive care unit care, birth injury or diagnosis of neonatal complication, glucose infusion, antibiotics, or phototherapy. (NCT00835861)
Timeframe: Delivery until hospital discharge
| Intervention | number of babies (Number) |
|---|---|
| Metformin | 4 |
| Insulin | 7 |
Initial neonatal glucose < 40 mg/dL (NCT00835861)
Timeframe: Time of delivery through hospital discharge
| Intervention | Number of babies (Number) |
|---|---|
| Metformin | 2 |
| Insulin | 0 |
Maternal glucose < 60 mg/dL (NCT00835861)
Timeframe: Baseline throughout pregnancy until time of delivery
| Intervention | Number of episodes (Number) |
|---|---|
| Metformin | 1 |
| Insulin | 7 |
Maternal complications were stillbirths, major malformations, shoulder dystocia, or postpartum hemorrhage requiring transfusion. (NCT00835861)
Timeframe: Throughout pregnancy until hospital discharge following delivery.
| Intervention | participants (Number) |
|---|---|
| Metformin | 0 |
| Insulin | 0 |
Patients self monitored glucose measures throughout pregnancy to aid glycemic control. Fasting morning measures and postprandial measures were taken at 1 hour after breakfast, lunch, and dinner. (NCT00835861)
Timeframe: Daily fasting and 1-hr post prandial measures were taken from time of enrollment until delivery
| Intervention | mg/dL (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Fasting throughout enrollment | Fasting 18-20 weeks | Fasting 28-30 weeks | Fasting 36-38 weeks | Postprandial throughout enrollment | Postprandial 18-20 weeks | Postprandial 28-30 weeks | Postprandial 36-38 weeks | |
| Insulin | 95.04 | 92.38 | 90.64 | 85.18 | 128.62 | 120.46 | 126.45 | 125.25 |
| Metformin | 97.38 | 97.00 | 92.43 | 89.49 | 120.40 | 118.40 | 119.00 | 122.59 |
(NCT00835861)
Timeframe: 1st, 2nd, and 3rd trimester
| Intervention | percentage of glycosolated hemoglobin (Median) | ||
|---|---|---|---|
| 1st trimester | 2nd trimester | 3rd trimester | |
| Insulin | 6.2 | 5.5 | 5.6 |
| Metformin | 5.8 | 5.6 | 5.9 |
NUMBER OF ASSESSMENTS OF FASTING GLUCOSE VALUES <95 (NCT00835861)
Timeframe: Baseline throughout pregnancy until time of delivery
| Intervention | percent of glucose values (Number) | |||
|---|---|---|---|---|
| Throughout enrollment; n=1634, 1432 | 18-20 weeks; n=148, 259 | 28-30 weeks; n=253, 201 | 36-38 weeks; n=115, 83 | |
| Insulin | 58 | 64 | 62 | 96 |
| Metformin | 48 | 42 | 64 | 76 |
NUMBER OF ASSESSMENTS OF POSTPRANDIAL GLUCOSE VALUES <130 (NCT00835861)
Timeframe: Baseline throughout pregnancy until time of delivery
| Intervention | percent of glucose values (Number) | |||
|---|---|---|---|---|
| Throughout enrollment; n=4195, 3796 | 18-20 weeks; n=368, 428 | 28-30 weeks; n=652, 559 | 36-38 weeks; n=272,228 | |
| Insulin | 61 | 67 | 58 | 65 |
| Metformin | 69 | 72 | 71 | 66 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
271 reviews available for metformin and Pregnancy
| Article | Year |
|---|---|
Metformin in Pregnancy for Women with Type 2 Diabetes: a Review.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents | 2021 |
Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin; Postpartum Period; Preg | 2021 |
Metformin - a new approach.
Topics: COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; SARS | 2021 |
Metformin for pregnancy and beyond: the pros and cons.
Topics: Administration, Oral; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational W | 2022 |
Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformi | 2021 |
Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Glycemic Control; Humans; Hypoglycem | 2021 |
Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; Ovulation Indu | 2022 |
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasm | 2021 |
Comparison of the effectiveness and safety of insulin and oral hypoglycemic drugs in the treatment of gestational diabetes mellitus: a meta-analysis of 26 randomized controlled trials.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Met | 2022 |
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Live Birth; Metformin; Ov | 2022 |
The use of metformin in women with polycystic ovary syndrome: an updated review.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Insu | 2022 |
Metformin versus glyburide in treatment and control of gestational diabetes mellitus: a systematic review with meta-analysis.
Topics: Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newbor | 2022 |
Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.
Topics: COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfo | 2022 |
Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials.
Topics: Abortion, Spontaneous; Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Infant, Newbor | 2022 |
Histomorphometric and oxidative evaluation of the offspring's testis from type 2 diabetic female rats treated with metformin and pentoxifylline.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Lipid Peroxidation; Male; Metformin; Oxidative Stress; P | 2022 |
Update on metformin safety in pregnancy.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Government Agencies; Humans; Metformin; Pre | 2022 |
Efficacy and safety of metformin compared to insulin in gestational diabetes: a systemic review and meta-analysis of Chinese randomized controlled trials.
Topics: Blood Glucose; Diabetes, Gestational; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infa | 2022 |
Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome.
Topics: Diabetes, Gestational; Female; Humans; Infertility; Metformin; Polycystic Ovary Syndrome; Pregnancy; | 2022 |
Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis.
Topics: Abortion, Spontaneous; Female; Fertilization in Vitro; Humans; Metformin; Polycystic Ovary Syndrome; | 2023 |
Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dipeptidyl-Peptidase IV Inhibitors; | 2022 |
Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Acupuncture Therapy; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pregn | 2022 |
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.
Topics: Conservative Treatment; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservati | 2022 |
Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Live Birth; Metformin; Polycystic Ovary Syndrome; Pre | 2022 |
Short-term neonatal outcomes in women with gestational diabetes treated using metformin versus insulin: a systematic review and meta-analysis of randomized controlled trials.
Topics: Birth Weight; Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Infant, Newb | 2023 |
Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2023 |
Medications for Managing Preexisting and Gestational Diabetes in Pregnancy.
Topics: Child; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pr | 2023 |
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Netwo | 2023 |
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pre | 2023 |
Diabetes and anti-diabetic interventions and the risk of gynaecological and obstetric morbidity: an umbrella review of the literature.
Topics: Cesarean Section; Diabetes, Gestational; Female; Humans; Incidence; Infant; Metformin; Pregnancy; Sy | 2023 |
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant; Insul | 2023 |
Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy.
Topics: Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant | 2023 |
Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond.
Topics: Abortion, Spontaneous; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hum | 2023 |
Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Metformin; N | 2023 |
Glucagon-like peptide-1 receptor agonists and safety in the preconception period.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Recepto | 2023 |
Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.
Topics: Female; Humans; Insulin Resistance; Metformin; Periodicity; Polycystic Ovary Syndrome; Pregnancy; Pr | 2023 |
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pre | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Infant, Newborn; Insulin; | 2021 |
First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.
Topics: Birth Rate; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female | 2019 |
Metformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Randomized | 2020 |
Review of Prediabetes and Hypertensive Disorders of Pregnancy.
Topics: Blood Glucose Self-Monitoring; Diet Therapy; Exercise; Female; Glycated Hemoglobin; Humans; Hyperten | 2021 |
Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis.
Topics: Acetylcysteine; Body Mass Index; Female; Follicle Stimulating Hormone; Free Radical Scavengers; Huma | 2020 |
Comparative Efficacy and Safety of Metformin, Glyburide, and Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Age | 2019 |
The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy.
Topics: Acarbose; Diabetes, Gestational; Female; Glyburide; Healthy Lifestyle; Humans; Hypoglycemic Agents; | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Pharmacological intervention for diabetes after pregnancy prevention in women with prior gestational diabetes: A scoping review.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Prospective | 2020 |
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me | 2020 |
Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis.
Topics: Biomarkers; Body Weights and Measures; Female; Humans; Hypoglycemic Agents; Infertility, Female; Lif | 2020 |
Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2020 |
Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews.
Topics: Diabetes, Gestational; Diet, Diabetic; Dietary Supplements; Exercise; Fatty Acids, Omega-3; Female; | 2020 |
Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis.
Topics: Adult; Body Mass Index; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Metformin; Midd | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
Topics: Antibodies, Monoclonal; Antioxidants; Antithrombin III; Biological Products; Blood Component Removal | 2022 |
Placental energy metabolism in health and disease-significance of development and implications for preeclampsia.
Topics: Antioxidants; Energy Metabolism; Epigenesis, Genetic; Female; Gene Expression; Homeostasis; Humans; | 2022 |
Endometrial function in women with polycystic ovary syndrome: a comprehensive review.
Topics: Endometrium; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Polycystic Ovary Sy | 2021 |
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metabolic Syndrome; Metformin; Polycystic Ovar | 2021 |
The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis.
Topics: Bariatric Surgery; Female; Humans; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcom | 2021 |
Gestational Diabetes Mellitus Pharmacological Prevention and Treatment.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2021 |
Metformin administration during pregnancy - current insight.
Topics: Child; Diabetes Mellitus; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2021 |
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Live Birth; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pr | 2021 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
Metformin is comparable to insulin for pharmacotherapy in gestational diabetes mellitus: A network meta-analysis evaluating 6046 women.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2021 |
Pharmacological and non-pharmacological strategies for obese women with subfertility.
Topics: Abortion, Spontaneous; Appetite Depressants; Bias; Carnitine; Clomiphene; Dexfenfluramine; Drug Ther | 2021 |
Effect of metformin on biomarkers of placental- mediated disease: A systematic review and meta-analysis.
Topics: Adult; Biomarkers; C-Reactive Protein; Female; Humans; Metformin; Placenta; Pregnancy; Vascular Endo | 2021 |
Research progress of metformin in gestational diabetes mellitus: a narrative review.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2021 |
Metformin for Preventing Type 2 Diabetes Mellitus in Women with a Previous Diagnosis of Gestational Diabetes: A Narrative Review.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Life Style; Metformin; Postpartum | 2020 |
Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis.
Topics: Birth Weight; Databases, Factual; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Matern | 2021 |
Comparison of Insulin, Metformin, and Glyburide on Perinatal Complications of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Topics: Cesarean Section; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, New | 2021 |
Prescribing for pregnancy: managing diabetes.
Topics: Blood Glucose Self-Monitoring; Female; Gestational Age; Humans; Hypoglycemic Agents; Insulin; Insuli | 2021 |
Effectiveness of antidiabetic agents for treatment of gestational diabetes: A methodological quality assessment of meta-analyses and network meta-analysis.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, | 2021 |
The function of metformin in endometrial receptivity (ER) of patients with polycyclic ovary syndrome (PCOS): a systematic review and meta-analysis.
Topics: Endometrium; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; R | 2021 |
A systematic review on outcome reporting in randomised controlled trials assessing treatment interventions in pregnant women with pregestational diabetes.
Topics: Blood Glucose Self-Monitoring; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy | 2021 |
Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options.
Topics: Diabetes, Gestational; Female; Fetal Development; Glyburide; Humans; Hypoglycemic Agents; Infant, Ne | 2021 |
The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials.
Topics: Birth Weight; Diabetes Mellitus, Type 2; Diabetes, Gestational; Drug Therapy, Combination; Female; G | 2022 |
Malaria and diabetes.
Topics: Animals; Antimalarials; Diabetes Mellitus, Type 2; Female; Glucosephosphate Dehydrogenase Deficiency | 2017 |
Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Humans; Hypogl | 2017 |
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Longevity; Maternal N | 2017 |
Treatments for gestational diabetes: a systematic review and meta-analysis.
Topics: Bayes Theorem; Cesarean Section; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agen | 2017 |
Metformin use in pregnancy: promises and uncertainties.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Teratogenesis | 2017 |
The care of pregestational and gestational diabetes and drug metabolism considerations.
Topics: Animals; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic | 2017 |
Pharmacological Management of Gestational Diabetes Mellitus.
Topics: Acarbose; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemi | 2017 |
Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.
Topics: Comorbidity; Evidence-Based Medicine; Female; Humans; Infertility, Female; Metformin; Ovulation Indu | 2017 |
Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis.
Topics: Administration, Oral; Adult; Blood Glucose; Comparative Effectiveness Research; Diabetes, Gestationa | 2017 |
Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.
Topics: Administration, Oral; Diabetes Mellitus; Diabetes, Gestational; Female; Glucose Intolerance; Humans; | 2017 |
Gestational diabetes - is diet and insulin the only solution?
Topics: Blood Glucose; Diabetes, Gestational; Diet, Carbohydrate-Restricted; Female; Glucose Tolerance Test; | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Intra-partum management of women with diabetes.
Topics: Adrenal Cortex Hormones; Blood Glucose; Delivery, Obstetric; Diabetes, Gestational; Disease Manageme | 2018 |
Changing environment of hyperglycemia in pregnancy: Gestational diabetes and diabetes mellitus in pregnancy.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Infant, Newborn; M | 2018 |
Prevention of Excessive Gestational Weight Gain and Postpartum Weight Retention.
Topics: Adult; Anti-Obesity Agents; Diet, Healthy; Diet, Reducing; Evidence-Based Medicine; Exercise; Female | 2018 |
Angiogenic Dysregulation in Pregnancy-Related Hypertension-A Role for Metformin.
Topics: Angiogenesis Inducing Agents; Animals; Endothelial Cells; Female; Humans; Hypertension, Pregnancy-In | 2018 |
Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Glyburide; Humans; Hypertension, Pregnancy-Induced; In | 2018 |
Why AMPK agonists not known to be stressors may surprisingly contribute to miscarriage or hinder IVF/ART.
Topics: Abortion, Spontaneous; Adenosine Triphosphate; AMP-Activated Protein Kinase Kinases; Blastocyst; Die | 2018 |
The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Outcome Assessment, He | 2020 |
Metformin in Pregnancy: Mechanisms and Clinical Applications.
Topics: Adult; Animals; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Insulin; Me | 2018 |
[Polycystic ovary syndrome - current state of knowledge].
Topics: Adult; Clomiphene; Diabetes Mellitus, Type 2; Female; Fertility Agents, Female; Humans; Infertility, | 2018 |
Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review.
Topics: Bariatric Surgery; Body Mass Index; Diabetes, Gestational; Disease Management; Evidence-Based Medici | 2019 |
Meta-analysis suggests that metformin may reduce pre-eclampsia compared with insulin use during pregnancy.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulins; Metformin; Pre-Eclampsia; Preg | 2019 |
Review of Metformin Use for Type 2 Diabetes Prevention.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Metformin from mother to unborn child - Are there unwarranted effects?
Topics: Embryonic Development; Female; Humans; Maternal Exposure; Maternal-Fetal Exchange; Metformin; Models | 2018 |
Oral Agents for the Treatment of Gestational Diabetes.
Topics: Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin | 2018 |
Metformin in Prevention of Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pr | 2018 |
Topics: Clinical Trials as Topic; Female; Humans; Metformin; Pre-Eclampsia; Pregnancy; Treatment Outcome | 2018 |
Inositol for subfertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Birth Rate; Clomiphene; Combined Modality Therapy; Fema | 2018 |
[Role of metformin in gynaecology and obstetrics].
Topics: Breast Neoplasms; Diabetes, Gestational; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; | 2018 |
Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions.
Topics: Adult; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; Hypoglycemic Agents; Metformi | 2019 |
Metformin for Improving Maternal and Infant Outcomes in Pregnant Women Who are Obese.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Obesity; Pregnancy; Pregnancy Compl | 2019 |
Metformin reduces maternal weight gain in obese pregnant women: A systematic review and meta-analysis of two randomized controlled trials.
Topics: Female; Gestational Weight Gain; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; Pregnan | 2019 |
Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis.
Topics: Child; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Long Term Adve | 2019 |
Drugs to Control Diabetes During Pregnancy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glycated Hemogl | 2019 |
Pharmacologic Treatment of Diabetes in Pregnancy.
Topics: Diabetes, Gestational; Exercise; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Gestational diabetes mellitus.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperglycemia; | 2019 |
Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis.
Topics: Child Development; Child, Preschool; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inf | 2019 |
Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Topics: Clomiphene; Confidence Intervals; Female; Fertility Agents, Female; Humans; Infertility, Female; Liv | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
Metformin vs insulin in the management of gestational diabetes: a meta-analysis.
Topics: Birth Weight; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; | 2013 |
Diverse roles of metformin during peri-implantation development: revisiting novel molecular mechanisms underlying clinical implications.
Topics: Abortion, Spontaneous; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Embryo I | 2013 |
Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.
Topics: Adult; Clinical Trials as Topic; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin | 2013 |
Oral agents for the management of gestational diabetes.
Topics: Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2013 |
Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials.
Topics: Birth Rate; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Metformin; | 2014 |
Endocrine basis for recurrent pregnancy loss.
Topics: Abortion, Habitual; Female; Humans; Hyperinsulinism; Hyperprolactinemia; Hypoglycemic Agents; Lutein | 2014 |
The use of oral hypoglycaemic agents in pregnancy.
Topics: Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Glycoside Hydrolase Inhibitors; Humans; | 2014 |
The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS).
Topics: Animals; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Letrozole; Metfo | 2014 |
Metformin vs insulin in the management of gestational diabetes: a systematic review and meta-analysis.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy; Prognosis | 2014 |
Unresolved controversies in gestational diabetes: implications on maternal and infant health.
Topics: Caloric Restriction; Diabetes, Gestational; Diet, Carbohydrate-Restricted; Diet, Diabetic; Female; F | 2014 |
Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; | 2014 |
[Metformin in pregnancy].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycysti | 2014 |
Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2014 |
Gestational diabetes mellitus management with oral hypoglycemic agents.
Topics: Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin | 2014 |
Interventions to modify the progression to type 2 diabetes mellitus in women with gestational diabetes: a systematic review of literature.
Topics: Breast Feeding; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, D | 2014 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2014 |
Placental dysfunction in obese women and antenatal surveillance strategies.
Topics: Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglycemic Agents; Inflammation; Metform | 2015 |
Screening and management of gestational diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet | 2015 |
Safety considerations with pharmacological treatment of gestational diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic | 2015 |
Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Humans; Insulin; Metformin; Pre-Eclamp | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Humans; Hypoglycemi | 2015 |
Using oral agents to manage gestational diabetes: what have we learned?
Topics: Acarbose; Administration, Oral; Birth Weight; Diabetes, Gestational; Female; Glyburide; Humans; Hypo | 2015 |
Medical and surgical interventions to improve outcomes in obese women planning for pregnancy.
Topics: Bariatric Surgery; Exercise; Feeding Behavior; Female; Humans; Hypoglycemic Agents; Infertility, Fem | 2015 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic | 2015 |
Metformin for the management of gestational diabetes mellitus.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy; Pregnancy | 2015 |
Metformin versus insulin for gestational diabetes mellitus: a meta-analysis.
Topics: Diabetes, Gestational; Female; Humans; Hypertension, Pregnancy-Induced; Insulin; Metformin; Pregnanc | 2015 |
Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents | 2015 |
Clinical Inquiry: What therapies alleviate symptoms of polycystic ovary syndrome?
Topics: Body Mass Index; Contraceptives, Oral; Diuretics; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2015 |
Prevention of gestational diabetes mellitus: Where are we now?
Topics: Diabetes, Gestational; Diet; Dietary Supplements; Exercise Therapy; Female; Humans; Hypoglycemic Age | 2015 |
Comparison of glyburide with metformin in treating gestational diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Birth Weight; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, | 2015 |
Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review.
Topics: Chi-Square Distribution; Female; Fertility; Fertilization in Vitro; Humans; Hypoglycemic Agents; Inf | 2015 |
Metformin for the treatment of gestational diabetes: An updated meta-analysis.
Topics: Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agent | 2015 |
A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Live Birth; Metformin; Ovarian Hy | 2015 |
Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis.
Topics: Abortion, Spontaneous; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Age | 2015 |
[Metformin and the obstetric patient].
Topics: Breast Feeding; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ov | 2015 |
Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?
Topics: Evidence-Based Practice; Female; Humans; Infertility, Female; Metformin; Ovulation Induction; Polycy | 2016 |
Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials.
Topics: Birth Weight; Cesarean Section; Diabetes, Gestational; Female; Gestational Age; Humans; Infant, Newb | 2016 |
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglyc | 2017 |
Is it worth treating gestational diabetes: if so, when and how?
Topics: Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Metformin; Pregnancy; Pregnancy Com | 2016 |
Role of Metformin in Women's Health: Review of Its Current Place in Clinical Practice and Emerging Indications for Future.
Topics: Anticarcinogenic Agents; Clomiphene; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Ferti | 2016 |
Prediction and prevention of Gestational Diabetes: an update of recent literature.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pr | 2016 |
Gestational diabetes mellitus: does an effective prevention strategy exist?
Topics: Diabetes, Gestational; Dietary Supplements; Exercise; Female; Fetal Development; Humans; Insulin Res | 2016 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; | 2016 |
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Consensus; Female; Fertility Agents, Female; Fertiliz | 2016 |
Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Glycated Hemoglobin; Humans; Hypoglyce | 2017 |
Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outc | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Pharmacological Management of Gestational Diabetes Mellitus.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2016 |
Metformin: From Research to Clinical Practice.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Management of hidradenitis suppurativa in pregnancy.
Topics: Anti-Bacterial Agents; Biological Products; Contraindications; Cryotherapy; Female; Hidradenitis Sup | 2017 |
Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
Topics: Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovarian Hyperstim | 2017 |
Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome.
Topics: Coitus; Combined Modality Therapy; Drug Therapy, Combination; Female; Fertility Agents, Female; Fert | 2017 |
Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes.
Topics: Acarbose; Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypo | 2017 |
The emerging role of metformin in gestational diabetes mellitus.
Topics: Australia; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2017 |
Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis
Topics: Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Letrozole; | 2017 |
Drugs in infertility and fetal safety.
Topics: Clomiphene; Estrogens; Female; Fertility Agents, Female; Fetus; Gonadotropins; Humans; Infertility, | 2008 |
Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Abortion, Spontaneous; Adult; Algorithms; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
PCOS and infertility.
Topics: Clomiphene; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic A | 2008 |
Use of metformin in polycystic ovary syndrome.
Topics: Adolescent; Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 2008 |
Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review.
Topics: Acarbose; Administration, Oral; Birth Weight; Diabetes, Gestational; Female; Glyburide; Humans; Hypo | 2009 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2009 |
Gestational diabetes mellitus: developments in diagnosis and treatment.
Topics: Amniotic Fluid; Diabetes, Gestational; Female; Fetal Diseases; Humans; Hyperinsulinism; Hypoglycemic | 2009 |
Role of metformin in the treatment of gestational diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; | 2009 |
The management of gestational diabetes.
Topics: Administration, Oral; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes, Gestational; Drug Admi | 2009 |
The use of oral antidiabetic medications in gestational diabetes mellitus.
Topics: Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2009 |
Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome.
Topics: Animals; Female; Glucose; Humans; Hypoglycemic Agents; Metformin; Ovulation Induction; Polycystic Ov | 2009 |
[Insulin and type 2 diabetes mellitus].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combina | 2009 |
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2010 |
Should physicians prescribe metformin to women with polycystic ovary syndrome PCOS?
Topics: Adult; Body Mass Index; Clomiphene; Diabetes Mellitus; Diabetes, Gestational; Female; Fertility Agen | 2010 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Live Bir | 2010 |
Hemoglobin A1c for the diagnosis of diabetes: practical considerations.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes, Gestational; False Negative R | 2010 |
Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome.
Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Embryo Loss; Female; Humans; Hyp | 2010 |
Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents.
Topics: Administration, Oral; Adult; Algorithms; Clomiphene; Decision Support Techniques; Drug Combinations; | 2010 |
Use of metformin in the treatment of polycystic ovary syndrome.
Topics: Adaptation, Psychological; Body Mass Index; Endocrine System; Female; Humans; Hyperandrogenism; Hypo | 2010 |
Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis.
Topics: Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metfo | 2010 |
Metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metabolic Disease | 2010 |
Oral hypoglycemic agents for gestational diabetes mellitus?
Topics: Administration, Oral; Animals; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents | 2011 |
Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety.
Topics: Acarbose; Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agent | 2011 |
Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials.
Topics: Anovulation; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Fe | 2011 |
Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review.
Topics: Clomiphene; Female; Humans; Infertility, Female; Laparoscopy; Metformin; Ovary; Ovulation Induction; | 2011 |
Current perspectives of insulin resistance and polycystic ovary syndrome.
Topics: Adipose Tissue; Cardiovascular Diseases; Female; Fertility; Humans; Hypoglycemic Agents; Insulin Res | 2011 |
Gestational diabetes: implications for cardiovascular health.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetes, Ge | 2012 |
Management of diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Huma | 2012 |
Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hyp | 2012 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis.
Topics: Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Humans; Infertility, Female; Live Bi | 2012 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin | 2012 |
[Drug therapy for diabetes mellitus during pregnancy and breastfeeding in the beginning of 21 century: status quo and new challenges].
Topics: Breast Feeding; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulins; Met | 2012 |
The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Evidence-Based M | 2012 |
Abnormal glucose metabolism: diagnosis and management in the ambulatory setting.
Topics: Ambulatory Care; Blood Glucose Self-Monitoring; Diabetes, Gestational; Diet Therapy; Exercise Therap | 2012 |
On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Polycystic Ovary Syn | 2012 |
Reproductive impact of polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Clomiphene; Female; Fertilization in Vitro; Humans; Infant, Newborn; Infertil | 2012 |
[Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis].
Topics: Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; In | 2012 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials.
Topics: Abortion, Spontaneous; Dinoprostone; Embryo Implantation; Female; Fertility Agents, Female; Fertiliz | 2013 |
The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Human | 2002 |
A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertilization in Vitro; Follicle Stimulating Hormone; | 2003 |
Metformin for the treatment of polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Clomiphene; Drug Therapy, Combination; Education, Medical, Continuing; Fem | 2003 |
[Should infertile women with polycystic ovarian syndrome be treated with metformine?].
Topics: Clomiphene; Drug Synergism; Estrogen Antagonists; Female; Fertility Agents, Female; Humans; Hyperand | 2003 |
GnRH antagonists for treatment of polycystic ovarian syndrome.
Topics: Female; Gonadotropin-Releasing Hormone; Humans; Menstrual Cycle; Metformin; Polycystic Ovary Syndrom | 2003 |
Metformin and gestational diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Humans; | 2003 |
Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure?
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Gynecologic Surgical Procedures; Humans; Hypogl | 2003 |
[Optimized diabetes therapy in type 2 diabetics].
Topics: Adolescent; Adult; Benzamides; Blood Glucose; Body Mass Index; Child; Cholesterol, LDL; Diabetes Mel | 2003 |
Insulin-lowering agents in the management of polycystic ovary syndrome.
Topics: Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnanc | 2003 |
Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
Topics: Blood Pressure; Body Weight; Double-Blind Method; Female; Fertility Agents, Female; Humans; Insulin; | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Metformin in obstetric and gynecologic practice: a review.
Topics: Abortion, Spontaneous; Anovulation; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Human | 2004 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
Metformin therapy and diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2004 |
Should we continue or stop insulin sensitizing drugs during pregnancy?
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycy | 2004 |
Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Hypoglyce | 2004 |
Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Female; Fertility Agents, Femal | 2004 |
Laparoscopic treatment of polycystic ovaries: is its place diminishing?
Topics: Female; Humans; Hypoglycemic Agents; Laparoscopy; Metformin; Ovary; Polycystic Ovary Syndrome; Pregn | 2004 |
Insulin resistance and metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2004 |
Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome.
Topics: Clomiphene; Cohort Studies; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertili | 2004 |
Revisit of metformin treatment in polycystic ovarian syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |
Polycystic ovary syndrome--a management update.
Topics: Contraceptives, Oral; Family Practice; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inf | 2005 |
Is metformin therapy for polycystic ovary syndrome safe during pregnancy?
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Anencephaly; Animals; Anophthalmos; Blastocyst; | 2005 |
Metformin treatment of PCOS during adolescence and the reproductive period.
Topics: Adolescent; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studie | 2005 |
Patient-tailored conventional ovulation induction algorithms in anovulatory infertility.
Topics: Algorithms; Anovulation; Clomiphene; Electrocoagulation; Female; Fertilization in Vitro; Follicle St | 2005 |
Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature.
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2006 |
A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Gonadotropins; Humans; Metformin; Odds Ratio; Ovulation Induc | 2006 |
Polycystic ovarian syndrome--prognosis and outcomes.
Topics: Adolescent; Anovulation; Cardiovascular Diseases; Clomiphene; Contraceptives, Oral; Diabetes Mellitu | 2006 |
Pregnancy complications in PCOS.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperinsulinism; Hypertension, Pregnan | 2006 |
Polycystic ovary syndrome and metformin in pregnancy.
Topics: Drug Administration Schedule; Female; Humans; Metformin; Ovulation Induction; Polycystic Ovary Syndr | 2006 |
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Canada; Comorbidity; Female; Humans; Hypoglycemic Agents; Incidence; Me | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
Topics: Anovulation; Clinical Trials as Topic; Female; Fertility Agents, Female; Humans; Infertility, Female | 2006 |
What can the clinician do to improve implantation?
Topics: Aromatase Inhibitors; Ascorbic Acid; Aspirin; Embryo Implantation; Embryo Transfer; Enzyme Inhibitor | 2006 |
Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.
Topics: Adult; Anovulation; Clomiphene; Female; Gonadotropins; Humans; Infertility, Female; Metformin; Ovula | 2006 |
Metformin before and during pregnancy and lactation in polycystic ovary syndrome.
Topics: Female; Humans; Infant; Lactation; Metformin; Polycystic Ovary Syndrome; Pregnancy; Time Factors | 2007 |
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
Topics: Administration, Oral; Animals; Breast Feeding; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2007 |
Pharmacological management of gestational diabetes: an overview.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metformin; Pregnancy | 2007 |
Triplet pregnancy after metformin in a woman with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Polycystic Ovary Syndrom | 2008 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Polycystic ovarian syndrome--prognosis and treatment outcomes.
Topics: Anovulation; Cardiovascular Diseases; Combined Modality Therapy; Contraceptives, Oral; Diabetes Mell | 2007 |
Non-surgical interventions for threatened and recurrent miscarriages.
Topics: Abortion, Habitual; Abortion, Threatened; Antiphospholipid Syndrome; Aspirin; Bed Rest; Chorionic Go | 2007 |
Diagnosis and new approaches in the therapy of gestational diabetes mellitus.
Topics: Blood Glucose; Diabetes, Gestational; Female; Fetal Development; Fetus; Glyburide; Humans; Hypoglyce | 2006 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Role of metformin in patients with polycystic ovary syndrome: the state of the art.
Topics: Clomiphene; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fertility Age | 2008 |
Use of metformin in polycystic ovary syndrome: a meta-analysis.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents | 2008 |
Pretreatments before the induction of ovulation in assisted reproduction technologies: evidence-based medicine in 2007.
Topics: Adrenal Cortex Hormones; Aspirin; Contraceptives, Oral; Evidence-Based Medicine; Female; Fertilizati | 2008 |
Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes.
Topics: Clomiphene; Drug Resistance; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Ovulat | 2000 |
Polycystic ovary syndrome and ovulation induction.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Ovulation Indu | 2001 |
Critical appraisal of published research evidence: treatment of gestational diabetes.
Topics: Attitude of Health Personnel; Clinical Trials as Topic; Diabetes, Gestational; Evidence-Based Medici | 2001 |
Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Topics: Endocrine System; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Menstrual | 2001 |
Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.
Topics: Algorithms; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, | 2002 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
Optimizing ovulation induction in women with polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Clomiphene; Female; Fertility Agents, Female; Humans; Metformin; Ovulation | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
Practical management of diabetes in the tropics.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucose | 1990 |
224 trials available for metformin and Pregnancy
| Article | Year |
|---|---|
Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study.
Topics: Child; Female; Glucose; Homeostasis; Humans; Male; Metformin; Polycystic Ovary Syndrome; Pregnancy; | 2021 |
Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Endoglin; Female; Gestational Age; Humans; | 2021 |
Myoinositol
Topics: Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Inositol; Metformin; Ovarian | 2022 |
Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow-up study of two open-label, randomized controlled trials.
Topics: Anthropometry; Blood Glucose; Child; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypog | 2022 |
Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial.
Topics: Female; Humans; Insulin; Insulin Resistance; Kidney; Metabolic Syndrome; Metformin; Polycystic Ovary | 2021 |
Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Gastrointestinal Microbiome; Glycemic Control | 2022 |
Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial.
Topics: Acupuncture Therapy; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin Resistance; Male; M | 2022 |
Effectiveness of carbohydrate counting and Dietary Approach to Stop Hypertension dietary intervention on managing Gestational Diabetes Mellitus among pregnant women who used metformin: A randomized controlled clinical trial.
Topics: Adult; Blood Glucose; Combined Modality Therapy; Diabetes, Gestational; Diet, Carbohydrate-Restricte | 2022 |
Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Fetus; Humans; Liver Circulation; Metformin; Polycystic Ovary Sy | 2022 |
Gestational weight gain in women with type 2 diabetes and perinatal outcomes: A secondary analysis of the metformin in women with type 2 diabetes in pregnancy (MiTy) trial.
Topics: Birth Weight; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Pregnancy Outcomes: Effects of Metformin (POEM) study: a protocol for a long-term, multicentre, open-label, randomised controlled trial in gestational diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newbo | 2022 |
Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Bariatric Surgery; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2022 |
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Hyp | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; O | 2022 |
A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes.
Topics: Endometrial Hyperplasia; Female; Humans; Hyperplasia; Infertility, Female; Metformin; Polycystic Ova | 2022 |
A multi-centered trial investigating gestational treatment with ursodeoxycholic acid compared to metformin to reduce effects of diabetes mellitus (GUARD): a randomized controlled trial protocol.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Humans; Infant, Ne | 2022 |
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind M | 2022 |
Childhood follow-up of the GRoW randomized trial: Metformin in addition to dietary and lifestyle advice for pregnant women with overweight or obesity.
Topics: Child; Diet; Female; Follow-Up Studies; Humans; Life Style; Metformin; Overweight; Pediatric Obesity | 2023 |
A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes, Gestational; Female; Galactose; Gestat | 2022 |
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Fema | 2022 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
A randomized controlled trial of a shared decision making intervention for diabetes prevention for women with a history of gestational diabetes mellitus: The Gestational diabetes Risk Attenuation for New Diabetes (GRAND study).
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin | 2023 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.
Topics: Canada; Child; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; In | 2023 |
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ov | 2023 |
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Fluvoxamine; Humans; Incidenc | 2023 |
Metformin versus insulin for gestational diabetes: Adiposity variables and adipocytokines in offspring at age of 9 years.
Topics: Adipokines; Adiponectin; Adiposity; Child; Diabetes, Gestational; Female; Humans; Inflammation; Insu | 2023 |
Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.
Topics: Adult; Birth Weight; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemic Agents | 2023 |
Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials.
Topics: Female; Gastrointestinal Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Infant, Newborn; M | 2023 |
Metformin in the prevention of type 2 diabetes after gestational diabetes in postnatal women (OMAhA): a UK multicentre randomised, placebo-controlled, double-blind feasibility trial with nested qualitative study.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Feasibility Studies; Female; | 2023 |
Metformin Versus Insulin for Gestational Diabetes: Cognitive and Neuropsychological Profiles of Children Aged 9 years.
Topics: Child; Cognition; Diabetes, Gestational; Female; Humans; Insulin; Metformin; Mothers; Pregnancy | 2023 |
SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial.
Topics: Administration, Oral; Blood Glucose; Cost-Benefit Analysis; Diabetes, Gestational; Drug Therapy, Com | 2019 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Healthy | 2020 |
Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.
Topics: Adolescent; Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Glyburid | 2020 |
Infertility, Gravidity, and Risk Of Diabetes among High-Risk Women in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gravidity; Humans; Incidence; Infertility, Female; L | 2020 |
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring.
Topics: Adiponectin; Adult; Arterial Pressure; Blood Pressure; Body Composition; Child, Preschool; Cholester | 2020 |
Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT.
Topics: Adult; Child; Child, Preschool; Cognition; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; I | 2020 |
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Energy Met | 2020 |
Effectiveness and acceptability of metformin in preventing the onset of type 2 diabetes after gestational diabetes in postnatal women: a protocol for a randomised, placebo-controlled, double-blind feasibility trial—Optimising health outcomes with Metformi
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Feasibility Studies; Female; Humans; London; Metfo | 2020 |
Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insuli | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus.
Topics: Adult; Androgens; Body Mass Index; Female; Fetal Blood; Fetus; Humans; Hyperandrogenism; Male; Metfo | 2020 |
Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial.
Topics: Adiposity; Adult; Body Mass Index; Diet; Exercise; Female; Fetal Development; Fetus; Gestational Age | 2020 |
Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol | 2021 |
Serum lipids and their association with birth weight in metformin and insulin treated patients with gestational diabetes.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Birth Weight; Cholesterol; Diabetes, Gestational; F | 2020 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; | 2020 |
Effects of metformin and insulin therapy regimens on postpartum oral glucose tolerance test results in pregnant women with gestational diabetes mellitus: a comparative study.
Topics: Blood Glucose; Body Mass Index; Diabetes, Gestational; Female; Glucose Tolerance Test; Humans; Insul | 2020 |
Prophylactic metformin after antenatal corticosteroids (PROMAC): a double blind randomized controlled trial.
Topics: Adult; Dexamethasone; Diabetes, Gestational; Double-Blind Method; Female; Fetal Distress; Glucocorti | 2021 |
Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; India; Inositol; Insulin; Metformin; Pil | 2021 |
Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial.
Topics: Adult; Cesarean Section; Diabetes, Gestational; Female; Gestational Weight Gain; Humans; Hypoglycemi | 2021 |
Metformin in gestational diabetes mellitus: A double-blind placebo-controlled randomized trial.
Topics: Blood Glucose; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Female; Fetal | 2022 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Metformin in obese pregnancy has no adverse effects on cardiovascular risk in early childhood.
Topics: Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-Up Studies; Heart Disease Risk Fact | 2022 |
A clinical diabetes risk prediction model for prediabetic women with prior gestational diabetes.
Topics: Diabetes, Gestational; Female; Glycated Hemoglobin; Humans; Metformin; Prediabetic State; Pregnancy | 2021 |
Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adjuvants, Pharmaceutic; Adult; Clomiphene; Drug Administration Schedule; Drug Resis | 2017 |
Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Feasibility Studies; Female; | 2017 |
Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Letrozole; Metformin; Nitriles; Ovulati | 2018 |
Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study.
Topics: Adult; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resi | 2018 |
Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS.
Topics: Adult; Birth Weight; Double-Blind Method; Female; Fetal Development; Humans; Infant, Newborn; Metfor | 2018 |
Metformin in women at high risk of gestational diabetes mellitus.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; Pregnancy; | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
Topics: Adolescent; Adult; Body Mass Index; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Metf | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Effectiveness of Metformin in the Prevention of Gestational Diabetes Mellitus in Obese Pregnant Women.
Topics: Adolescent; Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
The efficacy of metformin compared with insulin in regulating blood glucose levels during gestational diabetes mellitus: A randomized clinical trial.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Female; Glycated Hemoglobin; Hu | 2019 |
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
Topics: Adult; Diet Therapy; Double-Blind Method; Exercise; Female; Fetal Macrosomia; Gestational Weight Gai | 2019 |
Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study.
Topics: Adolescent; Adult; Birth Injuries; Diabetes Mellitus, Type 2; Disease Management; Double-Blind Metho | 2018 |
Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial.
Topics: Adult; Birth Rate; Drug Synergism; Drug Therapy, Combination; Female; Fertility Agents, Female; Fert | 2019 |
[Effect of Qilin Pill Combined Metformin on Polycystic Ovaries Induced Infertility Patients].
Topics: Drugs, Chinese Herbal; Female; Humans; Hypoglycemic Agents; Infertility, Female; Luteinizing Hormone | 2016 |
Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial.
Topics: Adult; Body Mass Index; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hypoglycemic Age | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
Topics: Adult; Blood Glucose; Carnitine; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Horm | 2019 |
The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole.
Topics: Adult; Female; Folic Acid; Humans; Infertility, Female; Inositol; Letrozole; Metformin; Ovulation In | 2019 |
Vitamin B12 and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment.
Topics: Adult; Biomarkers; Cohort Studies; Diabetes, Gestational; Female; Homocysteine; Humans; Hyperhomocys | 2013 |
Randomized trial of metformin vs insulin in the management of gestational diabetes.
Topics: Blood Glucose; Brazil; Diabetes, Gestational; Female; Gestational Age; Humans; Hypoglycemic Agents; | 2013 |
Metformin treatment in different phenotypes of polycystic ovary syndrome.
Topics: Adult; Female; Folic Acid; Humans; Hypoglycemic Agents; Insemination, Artificial; Metformin; Ovulati | 2013 |
Gestational diabetes mellitus among Norwegian women with polycystic ovary syndrome: prevalence and risk factors according to the WHO and the modified IADPSG criteria.
Topics: Adult; Analysis of Variance; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemi | 2013 |
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment.
Topics: Adult; Berberine; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; | 2014 |
The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial.
Topics: Administration, Oral; Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Egypt; Fasting; Fem | 2014 |
Efficacy of metformin versus insulin in the management of pregnancy with diabetes.
Topics: Adult; Blood Glucose; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fasting; Female; Huma | 2013 |
Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Placebos; Polycystic | 2014 |
Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin.
Topics: Adult; Double-Blind Method; Female; Fetal Blood; Humans; Hyperinsulinism; Hypoglycemic Agents; Insul | 2014 |
The degree of fetal metformin exposure does not influence fetal outcome in gestational diabetes mellitus.
Topics: Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, New | 2014 |
A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes Mellitus, Type 2; Dystocia; Female; Fetal Macrosomia; G | 2015 |
Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2014 |
The effect of exercise and metformin treatment on circulating free DNA in pregnancy.
Topics: Adolescent; Adult; DNA; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary S | 2014 |
Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Laparoscopy; Me | 2015 |
Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial.
Topics: Adult; Blood Glucose; Developing Countries; Diabetes, Gestational; Drug Therapy, Combination; Female | 2015 |
The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Diabetes, Gestational; Drug Administration Schedule; Female; Follow-Up Studies; H | 2015 |
Efficacy of metformin in pregnant obese women: a randomised controlled trial.
Topics: Adolescent; Adult; Birth Weight; Blood Glucose; Clinical Protocols; Diabetes, Gestational; Double-Bl | 2015 |
Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide--a randomised controlled trial.
Topics: Adult; Birth Injuries; Birth Weight; Diabetes, Gestational; Female; Fetal Macrosomia; Glyburide; Hum | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglyc | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu | 2015 |
Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial.
Topics: Blood Pressure; Body Fat Distribution; Child, Preschool; Diabetes, Gestational; Female; Follow-Up St | 2015 |
Metformin versus Insulin in the Management of Pre-Gestational Diabetes Mellitus in Pregnancy and Gestational Diabetes Mellitus at the Korle Bu Teaching Hospital: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetes, Gestat | 2015 |
Pregnancy in polycystic ovary syndrome I: lessons from a pragmatic explanatory with repository clinical trial.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Fertility Agents, Female; Humans; Hypog | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome.
Topics: Acetylcysteine; Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Huma | 2015 |
The effects of metformin treatment of gestational diabetes on maternal weight and glucose tolerance postpartum--a prospective follow-up study.
Topics: Adult; Blood Glucose; Body Weight; Diabetes, Gestational; Female; Follow-Up Studies; Glucose Toleran | 2016 |
Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect?
Topics: Adolescent; Adult; Androgens; Androstenedione; Cervical Length Measurement; Dehydroepiandrosterone S | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
Topics: Adult; Birth Weight; Body Mass Index; Double-Blind Method; Female; Fetal Macrosomia; Humans; Hypogly | 2016 |
Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus.
Topics: Adult; Apgar Score; Blood Glucose; Body Mass Index; Diabetes, Gestational; Drug Therapy, Combination | 2016 |
[Metformin has no effect on median birth weight score in pregnant non-diabetic women with BMI >35].
Topics: Adult; Birth Weight; Body Mass Index; Diabetes, Gestational; Double-Blind Method; Female; Humans; In | 2016 |
Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: results of a prospective, randomised study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglyce | 2016 |
The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study.
Topics: Adult; Female; Humans; Hydroxycholecalciferols; Hyperandrogenism; Hypoglycemic Agents; Insulin Resis | 2016 |
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method | 2016 |
A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.
Topics: Adult; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Infertility, Female; Met | 2016 |
Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study.
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combina | 2017 |
An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Topics: Adult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabete | 2008 |
Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study.
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Female; Glucose; Homeostasis; Humans; | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus; Diabetes, Gestational; Double-Blind Method; Femal | 2008 |
Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Blood Coagulation Disorders; Dose- | 2009 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial.
Topics: Adult; Clomiphene; Coitus; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; | 2010 |
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; | 2009 |
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study.
Topics: Administration, Oral; Adult; Calcium; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 2009 |
RETRACTED: Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Algorithms; Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; | 2010 |
Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Humans; Hypoglycemic Ag | 2009 |
Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.
Topics: Adiponectin; Adiposity; Aldosterone; Biomarkers; Body Mass Index; Cross-Sectional Studies; Female; H | 2010 |
Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial.
Topics: Birth Weight; Diabetes Complications; Diabetes, Gestational; Female; Gestational Age; Glucose Tolera | 2010 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Hormones; Humans; Hypoglycemic Agents; Insulin | 2010 |
Metformin influence on hormone levels at birth, in PCOS mothers and their newborns.
Topics: Adult; Androgens; Androstane-3,17-diol; Estradiol; Estrone; Female; Fetal Blood; Humans; Hypoglycemi | 2010 |
Metformin compared with glyburide in gestational diabetes: a randomized controlled trial.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2010 |
Metformin compared with glyburide in gestational diabetes: a randomized controlled trial.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2010 |
Metformin compared with glyburide in gestational diabetes: a randomized controlled trial.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2010 |
Metformin compared with glyburide in gestational diabetes: a randomized controlled trial.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Metform | 2010 |
Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome.
Topics: Abortion, Habitual; Adult; Body Mass Index; Case-Control Studies; Diabetes, Gestational; Female; Fet | 2010 |
Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial.
Topics: Abortion, Spontaneous; Anovulation; Body Mass Index; Clomiphene; Diathermy; Drug Therapy, Combinatio | 2010 |
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women.
Topics: Adult; Anovulation; Dietary Supplements; Drug Therapy, Combination; Female; Fertility Agents, Female | 2010 |
PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Ovulat | 2010 |
Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Met | 2009 |
Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infer | 2010 |
[Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases].
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Femal | 2010 |
Metformin compared with glyburide for the management of gestational diabetes.
Topics: Birth Weight; Blood Glucose; Diabetes, Gestational; Fasting; Female; Glyburide; Glycated Hemoglobin; | 2010 |
Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial.
Topics: Adult; Chi-Square Distribution; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Folli | 2011 |
Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.
Topics: Adult; Blood Pressure; Delivery, Obstetric; Diabetes, Gestational; Double-Blind Method; Female; Hear | 2010 |
N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial.
Topics: Abortion, Spontaneous; Acetylcysteine; Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination | 2010 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents | 2011 |
Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Endometrium; Female; Humans; Laparosco | 2011 |
Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Female; Fertility Agents, Female; Humans; Hyper | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial.
Topics: Double-Blind Method; Female; Fertilization in Vitro; Humans; Live Birth; Metformin; Ovarian Hypersti | 2011 |
Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study.
Topics: Adult; Double-Blind Method; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrom | 2011 |
Prognostic value of total testosterone for pregnancy during treatment in patients with clomiphene-citrate-resistant polycystic ovary syndrome: a pilot study.
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Resistance; Drug Therapy, Combination; Estradiol; Fe | 2011 |
Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
Topics: Adult; Chi-Square Distribution; Double-Blind Method; Early Termination of Clinical Trials; Female; F | 2011 |
Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Fem | 2011 |
Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial.
Topics: Abortion, Spontaneous; Adult; Birth Rate; Double-Blind Method; Female; Humans; Infertility, Female; | 2012 |
Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Glyburide | 2012 |
Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fer | 2012 |
Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo.
Topics: Body Composition; Body Mass Index; Breast; Breast Feeding; Female; Follow-Up Studies; Humans; Hypogl | 2012 |
Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero.
Topics: Absorptiometry, Photon; Body Composition; Child; Female; Growth; Humans; Hypoglycemic Agents; Male; | 2012 |
Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycysti | 2012 |
Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Drug Administration Schedule; Female; Hum | 2013 |
Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment.
Topics: Adult; Blood Glucose; C-Peptide; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Diab | 2013 |
Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
Topics: Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Fetal | 2012 |
Metformin's effect on first-year weight gain: a follow-up study.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infant; Infant, | 2012 |
Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetal Blood; Humans; Hyp | 2013 |
Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic | 2013 |
Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome.
Topics: Adult; Aromatase Inhibitors; Blood Glucose; Clomiphene; Drug Therapy, Combination; Female; Fertility | 2013 |
Determinants of maternal triglycerides in women with gestational diabetes mellitus in the Metformin in Gestational Diabetes (MiG) study.
Topics: Adult; Diabetes, Gestational; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Preg | 2013 |
Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial.
Topics: Adult; Clomiphene; Cost-Benefit Analysis; Drug Resistance; Drug Therapy, Combination; Fasting; Femal | 2003 |
Contraindications to use of metformin. Metformin may be useful in gestational diabetes.
Topics: Adult; Contraindications; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetus; Humans; H | 2003 |
The effect of metformin treatment to ovarian response in cases with PCOS.
Topics: Adult; Female; Fertility Agents; Gonadotropins; Humans; Metformin; Ovulation; Polycystic Ovary Syndr | 2004 |
Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Humans; Laparoscopy; Menstrual | 2003 |
[Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome].
Topics: Adult; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Ovarian Hyperstimulation | 2003 |
Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Topics: Adult; Aged; Area Under Curve; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Rel | 2004 |
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg
Topics: Adult; Body Weight; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insu | 2004 |
The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Endometrium; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Inferti | 2004 |
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy.
Topics: Adult; Body Height; Body Weight; Child Development; Diabetes, Gestational; Female; Humans; Hypoglyce | 2004 |
Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Fertilization; Fertilization in Vi | 2004 |
Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.
Topics: Adult; Androgens; Birth Weight; Diabetes, Gestational; Female; Gestational Age; Glucose Tolerance Te | 2004 |
Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial.
Topics: Adult; Ambulatory Surgical Procedures; Clomiphene; Double-Blind Method; Drug Resistance; Electrocoag | 2004 |
Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Blood Coagulation Disorders; Case-Control Studies; | 2004 |
[Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Topics: Adult; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Insulin Resistance; M | 2004 |
Metformin therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cholesterol; Female; Follicle Stimulating Hormone; Glucose Toler | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial.
Topics: Adolescent; Adult; Anovulation; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Humans; M | 2005 |
Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; | 2005 |
Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Topics: Adult; Apoptosis; Biomarkers; Fas Ligand Protein; fas Receptor; Female; Fertilization in Vitro; Foll | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial.
Topics: Adult; Female; Fertilization in Vitro; Humans; Live Birth; Metformin; Polycystic Ovary Syndrome; Pre | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Combined Modality Therapy; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2005 |
Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease.
Topics: Adult; Aromatase Inhibitors; Clomiphene; Drug Resistance; Drug Therapy, Combination; Endometrium; Fe | 2006 |
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Topics: Activated Protein C Resistance; Adult; Antithrombin III; Blood Coagulation; C-Reactive Protein; Fema | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Hor | 2006 |
No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedu | 2006 |
Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling.
Topics: Adult; Androgens; Blood Glucose; Combined Modality Therapy; Electrocoagulation; Female; Humans; Hypo | 2006 |
Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach.
Topics: Adult; Drug Therapy, Combination; Embryo Transfer; Estrogens; Female; Follicle Stimulating Hormone; | 2006 |
Is metformin or clomiphene citrate more effective for ovulation induction in polycystic ovary syndrome?
Topics: Adult; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; Polycystic O | 2006 |
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome.
Topics: Adult; Canada; Clomiphene; Comorbidity; Drug Combinations; Female; Fertility Agents, Female; Humans; | 2007 |
Metformin reduces abortion in pregnant women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndr | 2006 |
Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes, Gestational; Drug Therapy, Combinatio | 2007 |
Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome.
Topics: Adult; Drug Therapy, Combination; Female; Gonadotropins; Humans; Infertility, Female; Metformin; Pol | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation?
Topics: Adult; Chi-Square Distribution; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; | 2007 |
Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome.
Topics: Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Metformin; Methylenetetrahydrofolate | 2007 |
Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Body Weight; Female; Glucose Clamp Technique; Hormones; Hu | 2007 |
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
Topics: Administration, Oral; Animals; Breast Feeding; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2007 |
C-reactive protein levels are unaffected by metformin during pretreatment and an IVF cycle in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Biomarkers; Body Mass Index; C-Peptide; C-Reactive Protein; Double-Blind Method; F | 2008 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial).
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Morbidity; Pr | 2007 |
Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insul | 2008 |
Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study.
Topics: Adult; Chi-Square Distribution; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Menstruation; M | 2007 |
Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study.
Topics: Abortion, Habitual; Adolescent; Adult; Comorbidity; Female; Glucose Tolerance Test; Humans; Hyperins | 2008 |
Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study.
Topics: Abortion, Habitual; Adolescent; Adult; Comorbidity; Female; Glucose Tolerance Test; Humans; Hyperins | 2008 |
Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study.
Topics: Abortion, Habitual; Adolescent; Adult; Comorbidity; Female; Glucose Tolerance Test; Humans; Hyperins | 2008 |
Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study.
Topics: Abortion, Habitual; Adolescent; Adult; Comorbidity; Female; Glucose Tolerance Test; Humans; Hyperins | 2008 |
Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; | 2008 |
Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial.
Topics: Clomiphene; Community Networks; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2008 |
Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison.
Topics: Adult; Area Under Curve; Birth Weight; Blood Glucose; Diabetes, Gestational; Fasting; Female; Glucos | 2007 |
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Anovulation; Asian People; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, F | 2009 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Metformin versus insulin for the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Topics: Adult; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Metf | 2008 |
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.
Topics: Adult; Androstenedione; Clomiphene; Drug Therapy, Combination; Estradiol; Female; Fertility Agents, | 1999 |
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Birth Weight; Female; Health Status Indic | 2001 |
Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone.
Topics: Adolescent; Adult; Androstenedione; Body Mass Index; Clomiphene; Dehydroepiandrosterone Sulfate; Dou | 2001 |
Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.
Topics: Adult; Blood Flow Velocity; Clomiphene; Female; Follicular Phase; Glycodelin; Glycoproteins; Humans; | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial.
Topics: Adult; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; Female; Fertility Agents, | 2001 |
Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Female; Fertility Agents, Female; Gonadal S | 2002 |
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Fem | 2002 |
Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice.
Topics: Adult; Clomiphene; Cross-Over Studies; Double-Blind Method; Drug Resistance; Female; Fertility Agent | 2002 |
The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Hum | 2002 |
398 other studies available for metformin and Pregnancy
| Article | Year |
|---|---|
Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening.
Topics: Case-Control Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant; Infant, Ne | 2021 |
Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis.
Topics: Administration, Oral; Animals; Apoptosis; Diet, High-Fat; Disease Models, Animal; Drinking Water; Dy | 2021 |
Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance.
Topics: Animals; Diet, High-Fat; Female; Fetal Growth Retardation; Glucose Intolerance; Humans; Infectious D | 2022 |
Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study.
Topics: Adolescent; Adult; Cross-Sectional Studies; Diabetes, Gestational; Drug Prescriptions; Female; Glybu | 2022 |
Doubts about the true effectiveness of metformin for gestational diabetes.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2022 |
Maternal Metformin Treatment during Gestation and Lactation Improves Skeletal Muscle Development in Offspring of Rat Dams Fed High-Fat Diet.
Topics: Animals; Biomarkers; Body Weight; Diet, High-Fat; Female; Gene Expression Regulation; Gestational Ag | 2021 |
Topics: Animals; DNA Damage; DNA Methylation; DNA-Binding Proteins; Female; Hypoglycemic Agents; Infertility | 2021 |
Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes.
Topics: Administration, Oral; Adult; Analysis of Variance; Blood Glucose; Diabetes, Gestational; Female; Gly | 2022 |
Metformin in pregnancy: a re-examination of its safety.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy | 2022 |
Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study.
Topics: Appetite; Body Mass Index; Cohort Studies; Female; Gestational Weight Gain; Ghrelin; Humans; Leptin; | 2022 |
The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States.
Topics: Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin, Regular, | 2022 |
Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycystic O | 2022 |
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study.
Topics: Child; Cohort Studies; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Metformin; Pre | 2022 |
Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use.
Topics: Adult; Aspirin; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Hydroxyme | 2022 |
Screening for Prediabetes and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetes, Gestational; Exercise; Female; Humans; Hypoglycemi | 2022 |
What Is Polycystic Ovary Syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Symptom Assess | 2022 |
Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.
Topics: Acyclovir; Emtricitabine; Female; Fetus; Humans; Lamivudine; Maternal-Fetal Exchange; Metformin; Mod | 2022 |
The Use of Oral Hypoglycemic Agents during Pregnancy: An Alternative to Insulin?
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant | 2021 |
Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Disease Susceptibility; Embryonic Development; Epig | 2022 |
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newbo | 2022 |
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Effects of metformin and insulin on gestational diabetes mellitus: A dual drugs therapy approach.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2022 |
Clinical Care Among Individuals with Prediabetes in Primary Care: a Retrospective Cohort Study.
Topics: Adult; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Pred | 2022 |
Weight gain in pregnancy: can metformin steady the scales?
Topics: Birth Weight; Diabetes Mellitus, Type 2; Female; Humans; Infant, Newborn; Metformin; Pregnancy; Preg | 2022 |
Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials.
Topics: Anthropometry; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; | 2022 |
Comparative efficacy and safety of glyburide, metformin, and insulin in treatment of gestational diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Meta-Analysis as Top | 2022 |
Metformin: A promising option for the management of gestational diabetes mellitus - Exploring the benefits, challenges and clinical needs in the current management of gestational diabetes mellitus.
Topics: Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregn | 2022 |
Anti-inflammatory, Antioxidant, and Antiapoptotic Action of Metformin Attenuates Ethanol Neurotoxicity in the Animal Model of Fetal Alcohol Spectrum Disorders.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease Models, Animal; Ethanol; Female; | 2022 |
Prepregnancy Polycystic Ovary Syndrome as a Risk Factor of Subsequent Preterm Labor: A National Population-Based Cohort Study.
Topics: Cohort Studies; Female; Humans; Infant, Newborn; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pr | 2022 |
Impact Of Prepregnancy Overweight And Obesity On Treatment Modality And Pregnancy Outcome In Women With Gestational Diabetes Mellitus.
Topics: Cesarean Section; Diabetes, Gestational; Female; Glucose; Humans; Insulin, Short-Acting; Metformin; | 2022 |
Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Female; Humans; Intra-Abdominal Fat; | 2022 |
Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS.
Topics: Cetirizine; Chromatography, High Pressure Liquid; Desvenlafaxine Succinate; Female; Humans; Infant; | 2022 |
Impact of pharmacological treatment of gestational diabetes on the mode of delivery and birth weight: a nationwide population-based study on a subset of singleton pregnant Portuguese women.
Topics: Birth Weight; Cesarean Section; Diabetes, Gestational; Female; Humans; Infant, Newborn; Insulin; Met | 2022 |
Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Male; | 2022 |
Maternal Treatment with Metformin Persistently Ameliorates High-Fat Diet-Induced Metabolic Symptoms and Modulates Gut Microbiota in Rat Offspring.
Topics: Animals; Diet, High-Fat; Female; Gastrointestinal Microbiome; Humans; Inflammation; Male; Maternal N | 2022 |
Tert-butylhydroquinone Mitigates Renal Dysfunction in Pregnant Diabetic Rats
Topics: Animals; Antioxidants; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes, Gestat | 2023 |
Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
Topics: Adult; Animals; Body Composition; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Hig | 2022 |
[Gestational diabetes mellitus in a hospital in the city of Buenos Aires, Argentina: incidence, treatment, and frequency of screening for reclassification after childbirth]
Topics: Argentina; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose Intolera | 2022 |
The Disparity in the Management of Polycystic Ovary Syndrome between Obstetrician-Gynecologists in Different-Level Hospitals under the Hierarchical Medical System.
Topics: Androgens; Blood Glucose; Female; Hospitals; Humans; Insulin Resistance; Letrozole; Lipids; Metformi | 2022 |
The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.
Topics: Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glycated Hemogl | 2022 |
Vascular phenotype at 35-37 weeks' gestation in women with gestational diabetes mellitus.
Topics: Diabetes, Gestational; Female; Humans; Insulins; Metformin; Pregnancy; Ultrasonography, Doppler; Vas | 2023 |
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male | 2022 |
Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles.
Topics: Biological Products; Dietary Supplements; Female; Humans; Metformin; Pre-Eclampsia; Pregnancy; Vitam | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Maternal Metformin Treatment Reprograms Maternal High-Fat Diet-Induced Hepatic Steatosis in Offspring Associated with Placental Glucose Transporter Modifications.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Dietary Fats; Female; Glucose Transport Prot | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study.
Topics: Child; Cohort Studies; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2022 |
Efficacy and safety of hypoglycemic agents on gestational diabetes mellitus in women: A Bayesian network analysis of randomized controlled trials.
Topics: Birth Weight; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; I | 2022 |
Metformin use in pregnancy: efficacy, safety, and potential benefits.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy; Pregnancy | 2023 |
[PCOS - desire for children and pregnancy].
Topics: Anovulation; Child; Female; Humans; Hyperandrogenism; Life Style; Metformin; Polycystic Ovary Syndro | 2023 |
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2023 |
Big babies, small babies: metformin exposure in pregnancy.
Topics: Birth Weight; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy Outcome | 2023 |
Observational assessments of the relationship of dietary and pharmacological treatment on continuous measures of dysglycemia over 24 hours in women with gestational diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes, Gestational; Diet; Female; Humans; Metformin | 2023 |
Predictors for pharmacological therapy and perinatal outcomes with metformin treatment in women with gestational diabetes.
Topics: Australia; Cesarean Section; Diabetes, Gestational; Female; Glucose; Humans; Hypoglycemic Agents; In | 2023 |
The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome.
Topics: Embryo Transfer; Female; Fertilization in Vitro; Homeostasis; Humans; Insulin Resistance; Judgment; | 2023 |
Patient and provider prediabetes knowledge, attitudes, and behavior in a large urban family medicine practice.
Topics: Adult; Cross-Sectional Studies; Family Practice; Female; Health Knowledge, Attitudes, Practice; Huma | 2022 |
Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS.
Topics: Abortion, Spontaneous; Cytokines; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; P | 2023 |
Use of metformin and insulin among pregnant women with gestation diabetes in the United Kingdom: A population-based cohort study.
Topics: Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Preg | 2023 |
Free leptin index, excessive weight gain, and metformin treatment during pregnancy in polycystic ovary syndrome: What about inflammation?
Topics: Female; Humans; Hypoglycemic Agents; Leptin; Metformin; Polycystic Ovary Syndrome; Pregnancy; Weight | 2023 |
Does treatment modality affect measures of arterial stiffness in women with gestational diabetes?
Topics: Diabetes, Gestational; Female; Humans; Infant; Insulin; Longitudinal Studies; Metformin; Pregnancy; | 2023 |
Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort.
Topics: Blood Glucose; Diabetes, Gestational; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Metform | 2023 |
Computational Modelling of Paracellular Diffusion and OCT3 Mediated Transport of Metformin in the Perfused Human Placenta.
Topics: Computer Simulation; Female; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Membrane Transpor | 2023 |
Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia.
Topics: Cesarean Section; Female; Fetal Growth Retardation; Humans; Infant; Infant, Newborn; Metformin; Pre- | 2023 |
Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study.
Topics: Abnormalities, Drug-Induced; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Ins | 2023 |
Metformin Disrupts Signaling and Metabolism in Fetal Hepatocytes.
Topics: AMP-Activated Protein Kinases; Animals; Female; Fetus; Glucose; Hepatocytes; Mammals; Metformin; Pre | 2023 |
Beneficial effects of metformin on mice female fertility after a high-fat diet intake.
Topics: Animals; Diet, High-Fat; Female; Fertility; Infertility; Metformin; Mice; Mice, Inbred C57BL; Overwe | 2023 |
Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hypoglycemic Agents; Ins | 2023 |
Associations between maternal gestational diabetes metformin or insulin treatment and offspring growth trajectories from birth to 60 months of age: Findings from the Born in Bradford (BiB) study.
Topics: Birth Weight; Body Mass Index; Cohort Studies; Diabetes, Gestational; Female; Humans; Insulin; Metfo | 2023 |
The metabolic response of human trophoblasts derived from term placentas to metformin.
Topics: Cesarean Section; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Metformin; Placenta; Pregna | 2023 |
Protective role of metformin in preeclampsia via the regulation of NF-κB/sFlt-1 and Nrf2/HO-1 signaling pathways by activating AMPK.
Topics: AMP-Activated Protein Kinases; Female; Humans; Inflammation; Lipopolysaccharides; Metformin; NF-E2-R | 2023 |
Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Gestational Weight Gain; Humans; Hypoglycemic A | 2019 |
Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy.
Topics: Animals; Brain; Disease Models, Animal; Drug Resistant Epilepsy; Epilepsies, Partial; Female; Gene E | 2019 |
Implementation and Evaluation of the "Metformin First" Protocol for Management of Gestational Diabetes.
Topics: Adult; Clinical Protocols; Diabetes, Gestational; Female; Health Plan Implementation; Humans; Hypogl | 2019 |
Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9.
Topics: Cell Movement; Computer Simulation; Female; Human Umbilical Vein Endothelial Cells; Humans; Matrix M | 2019 |
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study.
Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma | 2020 |
Maternal diabetes and risk of childhood cancer in the offspring.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus; Diabetes, Gestational; | 2020 |
Metformin decreases hyaluronan synthesis by vascular smooth muscle cells.
Topics: Animals; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Hyaluroni | 2020 |
Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand.
Topics: Adolescent; Adult; Birth Weight; Cesarean Section; Diabetes, Gestational; Female; Humans; Hypoglycem | 2019 |
Factors Associated with the Need for Insulin as a Complementary Treatment to Metformin in Gestational Diabetes Mellitus.
Topics: Adult; Blood Glucose; Case-Control Studies; Diabetes, Gestational; Drug Therapy, Combination; Exerci | 2019 |
[Gestational diabetes adherence to treatment and metabolic control].
Topics: Adult; Cross-Sectional Studies; Diabetes, Gestational; Educational Status; Female; Gestational Age; | 2019 |
Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet.
Topics: Animals; Blood Pressure; Body Weight; Diet, High-Fat; Disease Models, Animal; Female; Matrix Metallo | 2019 |
AMP-Kinase Dysfunction Alters Notch Ligands to Impair Angiogenesis in Neonatal Pulmonary Hypertension.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Animals, Newborn; Biphenyl Compounds; Ductus Arterios | 2020 |
Case 6-2020: A 34-Year-Old Woman with Hyperglycemia.
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diagnosis, Differential; | 2020 |
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cohort Studies; Endometria | 2020 |
Impact of Disturbed Glucose Homeostasis Regulated by AMPK in Endometrium on Embryo Implantation in Diabetes Mice.
Topics: Adenylate Kinase; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes, Gestational; Em | 2020 |
Comparative effects of glibenclamide, metformin and insulin on fetal pancreatic histology and maternal blood glucose in pregnant streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes, Gestational; Female; | 2019 |
Lactational metformin exposure programs offspring white adipose tissue glucose homeostasis and resilience to metabolic stress in a sex-dependent manner.
Topics: Adipose Tissue, White; Animals; Cell Proliferation; Female; Glucose; Homeostasis; Hypoglycemic Agent | 2020 |
Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Diet; Female; Humans; Hypoglycemic Agents; | 2020 |
Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos.
Topics: Adult; Animals; Blastocyst; Blood Glucose; Diabetes, Gestational; Disease Models, Animal; Embryonic | 2020 |
Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system.
Topics: Animals; Anticonvulsants; Antioxidants; Autism Spectrum Disorder; Disease Models, Animal; Female; Hy | 2020 |
Role of metformin in epigenetic regulation of placental mitochondrial biogenesis in maternal diabetes.
Topics: Acetylation; Adult; AMP-Activated Protein Kinases; Animals; Cohort Studies; Diabetes, Gestational; D | 2020 |
Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis.
Topics: Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemia; Infant, Newborn; Meta-Analysis a | 2020 |
Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Topics: Drug Therapy, Combination; Endoglin; Endothelin-1; Female; Humans; Metformin; Placenta; Placenta Gro | 2020 |
Management of Gestational Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents | 2021 |
Role of AMP-activated protein kinase during postovulatory aging of mouse oocytes†.
Topics: AMP-Activated Protein Kinases; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kina | 2020 |
Therapeutic doses of metformin do not have impact on angiogenesis in presence of sera from pre-eclamptic, IUGR and healthy pregnancies.
Topics: Adult; Angiogenesis Inhibitors; Case-Control Studies; Dose-Response Relationship, Drug; Female; Feta | 2020 |
Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes.
Topics: Animals; Cognitive Dysfunction; Diabetes, Gestational; Diet, Fat-Restricted; Diet, High-Fat; Female; | 2020 |
Characterization of women with gestational diabetes who failed to achieve glycemic control by lifestyle modifications.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes, Gestational; Female; Glucose Tolerance Test; Glybur | 2021 |
Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Met | 2020 |
Cost-effectiveness analysis of polycystic ovary syndrome management and the risk of gestational diabetes in pregnant women: a decision-tree model.
Topics: Adult; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Diabetes, Gestational; Disease Progres | 2021 |
Successful IVF outcome after repeat laparoscopic ovarian drilling in a case of resistant PCOS.
Topics: Abortion, Habitual; Adult; Female; Fertilization in Vitro; Glucose Metabolism Disorders; Humans; Hyp | 2020 |
The effects of metformin treatment on the ovaries and uterus of offspring.
Topics: Animals; Endometrium; Estradiol; Female; Hypoglycemic Agents; Metformin; Oocytes; Organ Size; Ovaria | 2021 |
Metformin Should Not Be Used to Treat Prediabetes.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dia | 2020 |
Metformin in women with type 2 diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pr | 2020 |
Metformin versus insulin use for treatment of gestational diabetes and delivery by caesarean section: A nationwide Swedish cohort study.
Topics: Cesarean Section; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newborn; Insulin; M | 2020 |
Development of a Pharmacokinetic Model of Transplacental Transfer of Metformin to Predict In Vivo Fetal Exposure.
Topics: Cell Membrane; Computer Simulation; Female; Fetus; Humans; Maternal-Fetal Exchange; Metformin; Model | 2020 |
Glycemic Impact of Metformin in Diabetes Caused by Heterozygous Insulin Gene Mutation R46Q.
Topics: Adult; Diabetes Mellitus; Female; Glycated Hemoglobin; Glycemic Control; Heterozygote; Humans; Hypog | 2021 |
The Effects of Altered Endometrial Glucose Homeostasis on Embryo Implantation in Type 2 Diabetic Mice.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; | 2021 |
Postnatal metformin treatment alters rat Sertoli cell proliferation and daily sperm production.
Topics: Animals; Animals, Newborn; Cell Proliferation; Drug Evaluation, Preclinical; Female; Hypoglycemic Ag | 2021 |
Efficacy and safety of metformin in the treatment of gestational diabetes: A protocol for systematic review and meta-analysis.
Topics: Adult; Clinical Protocols; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Meta-Analysis | 2021 |
Metformin combined with insulin in women with gestational diabetes mellitus: a propensity score-matched study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2021 |
Trends and associated maternal characteristics of antidiabetic medication use among pregnant women in South Korea.
Topics: Adolescent; Adult; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Midd | 2021 |
Different Gestational Diabetes Phenotypes: Which Insulin Regimen Fits Better?
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes, Gestational; Fasting; Female; Glucose Tolerance Tes | 2021 |
Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes.
Topics: Adult; Birth Weight; Diabetes Mellitus, Type 2; Female; Fetal Growth Retardation; Humans; Hypertensi | 2021 |
Diabetes: Screening, Diagnosis, and Prevention of Type 2 Diabetes.
Topics: Adult; Aged; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Mass Screening | 2021 |
Current practices in gestational diabetes mellitus diagnosis and management in the United States: survey of maternal-fetal medicine specialists.
Topics: Blood Glucose; Decision Making, Shared; Diabetes, Gestational; Exercise; Female; Humans; Hypoglycemi | 2021 |
Gestational diabetes, metformin, and the risk of hypoglycemia.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pregnancy | 2021 |
Gestational diabetes, metformin, and risk of hypoglycemia.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pregnancy | 2021 |
Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone.
Topics: Birth Weight; Diabetes, Gestational; Diet; Female; Humans; Infant, Newborn; Insulin; Metabolome; Met | 2021 |
Risk of metformin failure in the treatment of women with gestational diabetes.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Substitution; Female; Glucose Tolerance Test; Glyc | 2021 |
Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner.
Topics: Adiposity; Animals; Animals, Newborn; Diabetes, Gestational; Female; Male; Metformin; Mice; Mice, In | 2021 |
Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Topics: Adult; Area Under Curve; Birth Weight; Cell Hypoxia; Delivery, Obstetric; Diabetes, Gestational; Ele | 2021 |
Gestational diabetes mellitus: Berlin and beyond.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Diabetic; Early Diagnosis; Female; Glycemic | 2017 |
Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations.
Topics: Adult; Computer Simulation; Female; Humans; Metformin; Middle Aged; Models, Biological; Oseltamivir; | 2017 |
Incidence and Contributing Factors of Persistent Hyperglycemia at 6-12 Weeks Postpartum in Iranian Women with Gestational Diabetes: Results from LAGA Cohort Study.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fasting; Fem | 2017 |
Patterns of glucose-lowering therapies and neonatal outcomes in the treatment of gestational diabetes in Canada, 2009-2014.
Topics: Adult; Birth Weight; Blood Glucose; Canada; Diabetes, Gestational; Drug Therapy, Combination; Female | 2017 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Hippocampus-dependent memory and allele-specific gene expression in adult offspring of alcohol-consuming dams after neonatal treatment with thyroxin or metformin.
Topics: Alcohol Drinking; Alleles; Animals; Ethanol; Fear; Female; Fetal Alcohol Spectrum Disorders; Hippoca | 2018 |
Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings.
Topics: Age Factors; Animals; Animals, Newborn; Aorta, Thoracic; Dose-Response Relationship, Drug; Female; H | 2017 |
Comment on Nachum et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care 2017;40:332-337.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; In | 2017 |
Response to Comment on Nachum et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care 2017;40:332-337.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; In | 2017 |
Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome.
Topics: Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Norepinephrine Plasma M | 2017 |
In utero and lactational exposure to metformin induces reproductive alterations in male rat offspring.
Topics: Animals; Body Weight; Female; Fertility; Genitalia, Male; Hypoglycemic Agents; Lactation; Male; Mate | 2017 |
Use of a clinical-laboratory score to guide treatment of gestational diabetes.
Topics: Adult; Apgar Score; Clinical Decision-Making; Decision Support Systems, Clinical; Diabetes, Gestatio | 2018 |
Metformin in gestational diabetes mellitus.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2017 |
Efficacy of metformin in improving glycaemic control & perinatal outcome in gestational diabetes mellitus: A non-randomized study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; I | 2017 |
Metformin in gestational diabetes mellitus: predictors of poor response.
Topics: Adult; Age Factors; Blood Glucose; Body Mass Index; Cohort Studies; Diabetes, Gestational; Female; H | 2018 |
Insulin resistance in patients with recurrent pregnancy loss is associated with lymphocyte population aberration.
Topics: Abortion, Habitual; Adult; Body Mass Index; CD3 Complex; CD4 Lymphocyte Count; CD56 Antigen; Fasting | 2017 |
Gestational diabetes-Predictors of response to treatment and obstetric outcome.
Topics: Adult; Body Mass Index; Diabetes, Gestational; Diet, Carbohydrate-Restricted; Female; Humans; Hypogl | 2018 |
Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
Topics: Abortion, Spontaneous; Adult; Cohort Studies; Female; Humans; Hypoglycemic Agents; Metformin; Pregna | 2018 |
H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses.
Topics: Adenosylhomocysteinase; Animals; Base Sequence; Cell Line, Tumor; Female; Fetus; Gene Expression Pro | 2017 |
Metformin attenuates susceptibility to inflammation-induced preterm birth in mice with higher endocannabinoid levels.
Topics: Amidohydrolases; Animals; Decidua; Endocannabinoids; Female; Hypoglycemic Agents; Inflammation; Lipo | 2018 |
How safe is metformin when initiated in early pregnancy? A retrospective 5-year study of pregnant women with gestational diabetes mellitus from India.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; India; Infant, Newborn; Metformin | 2018 |
The diversity of gestational diabetes: a therapeutic challenge.
Topics: Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pract | 2018 |
Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Hypoglycemic Agents; Logistic Models; Metformin; | 2018 |
Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
Topics: Endothelium, Vascular; Esomeprazole; Female; Human Umbilical Vein Endothelial Cells; Humans; Metform | 2018 |
Pharmacological treatment of gestational diabetes mellitus: point/counterpoint.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2018 |
The effects of metformin on maternal haemodynamics in gestational diabetes mellitus: A pilot study.
Topics: Adult; Diabetes, Gestational; Female; Hemodynamics; Humans; Hypoglycemic Agents; Incidence; Metformi | 2018 |
Uterine progesterone signaling is a target for metformin therapy in PCOS-like rats.
Topics: Animals; Chorionic Gonadotropin; Disease Models, Animal; Embryo Implantation; Female; Gene Expressio | 2018 |
PCOS: Metformin risk for offspring.
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Predictors of metformin failure in gestational diabetes mellitus (GDM).
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Fasting; Female; | 2018 |
Prenatal Metformin Therapy Attenuates Hypertension of Developmental Origin in Male Adult Offspring Exposed to Maternal High-Fructose and Post-Weaning High-Fat Diets.
Topics: Animals; Diet, High-Fat; Female; High Fructose Corn Syrup; Hypertension; Hypoglycemic Agents; Male; | 2018 |
Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring.
Topics: Age Factors; Animals; Disease Models, Animal; Female; Glucose; Glucose Tolerance Test; Insulin; Insu | 2018 |
Combined intervention of swimming plus metformin ameliorates the insulin resistance and impaired lipid metabolism in murine gestational diabetes mellitus.
Topics: Animals; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetes, Gestat | 2018 |
Involvement of mTOR, JNK and PI3K in the negative effect of ethanol and metformin on the human first-trimester extravillous trophoblast HTR-8/SVneo cell line.
Topics: Acetaldehyde; Apoptosis; Cell Line; Cell Movement; Cell Survival; Ethanol; Female; Humans; Hypoglyce | 2018 |
Intrauterine exposure to metformin: Evaluation of endothelial and perivascular adipose tissue function in abdominal aorta of adult offspring.
Topics: Adipose Tissue; Animals; Aorta, Abdominal; Body Weight; Dose-Response Relationship, Drug; Endothelia | 2018 |
Effect of well-controlled gestational diabetes on left ventricular diastolic dysfunction in neonates.
Topics: Adult; Cardiomegaly; Case-Control Studies; Cross-Sectional Studies; Diabetes, Gestational; Echocardi | 2019 |
Improving outcomes in gestational diabetes: does gestational weight gain matter?
Topics: Adult; Body Mass Index; Delivery, Obstetric; Diabetes, Gestational; Female; Fetal Macrosomia; Gestat | 2019 |
Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.
Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Mater | 2018 |
A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Obstetrics; Practice Guidelin | 2018 |
Metformin or insulin: logical treatment in women with gestational diabetes in the Middle East, our experience.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle East; | 2018 |
Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Fetal Development; Gene Expression; Gene Ex | 2019 |
Metformin use during pregnancy: Is it really safe?
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy Complica | 2018 |
Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy.
Topics: Animals; Biological Transport; Cell Line; Female; Fetus; HEK293 Cells; Humans; Hypoglycemic Agents; | 2018 |
Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Diabetes Mellitus, Type 2; Fe | 2018 |
Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin.
Topics: Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Follow-Up Studies; Humans; Hypoglycemic Agen | 2018 |
Transposable elements, placental development, and oocyte activation: Cellular stress and AMPK links jumping genes with the creation of human life.
Topics: AMP-Activated Protein Kinases; Animals; Calcium; Cell Differentiation; Cytoplasm; DNA Transposable E | 2018 |
Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments.
Topics: Adult; Animals; Anti-Inflammatory Agents; Blood Glucose; Chemokine CX3CL1; CX3C Chemokine Receptor 1 | 2018 |
Gestational diabetes mellitus: A pragmatic approach to diagnosis and management.
Topics: Blood Glucose; Diabetes, Gestational; Disease Management; Female; Humans; Hypoglycemic Agents; Insul | 2018 |
Diagnosis of gestational diabetes: a 'teachable moment'.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes, Gestational; Diet; Emotions; Female; | 2019 |
Metformin in pregnancy - safe or sorry?
Topics: Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy Trimester | 2018 |
Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study.
Topics: Adult; Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Metformin; Nitriles; Oocyte Re | 2018 |
Amino acid profile in women with gestational diabetes mellitus treated with metformin or insulin.
Topics: Adult; Amino Acids; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; | 2018 |
Prenatal metformin treatment improves ovarian function in offspring of obese rats.
Topics: Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Lactation; Metfo | 2018 |
Pancreatic autoimmunity: An unknown etiology on patients with assisted reproductive techniques (ART)-recurrent reproductive failure.
Topics: Abortion, Habitual; Adult; Autoimmunity; Birth Rate; Diabetes Mellitus; Female; Glucose Tolerance Te | 2018 |
Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice.
Topics: Animals; Behavior, Animal; Brain; Female; Hypoglycemic Agents; Male; Maternal-Fetal Exchange; Metfor | 2019 |
Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
Topics: Adult; Child Behavior; Child Development; Child, Preschool; Diabetes, Gestational; Female; Follow-Up | 2019 |
Reassessing strategies to improve pregnancy outcomes in overweight and obese women.
Topics: Double-Blind Method; Female; Humans; Life Style; Metformin; Obesity; Overweight; Pregnancy; Pregnanc | 2019 |
Metformin and insulin treatment prevent placental telomere attrition in boys exposed to maternal diabetes.
Topics: Adult; Analysis of Variance; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hypoglycem | 2018 |
Type 2 diabetes mellitus in pregnancy: The impact of maternal weight and early glycaemic control on outcomes.
Topics: Adult; Case-Control Studies; Cesarean Section; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; | 2019 |
Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register.
Topics: Adult; Australia; Biomarkers; Birth Weight; Blood Glucose; Case-Control Studies; Diabetes Mellitus, | 2019 |
Metformin use in polycystic ovary syndrome pregnancy impacts on offspring obesity.
Topics: Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Metformin; Obesity; Polycystic Ovary Syn | 2019 |
Direct toxicity of insulin on the human placenta and protection by metformin.
Topics: Apoptosis; Biomarkers; Caspase 3; Cell Proliferation; Cells, Cultured; Cytoprotection; DNA Damage; F | 2019 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
Effects of medication intake in early pregnancy on the fetal fraction of cell-free DNA testing.
Topics: Adult; Cell-Free Nucleic Acids; Female; Humans; Hypoglycemic Agents; Metformin; Noninvasive Prenatal | 2019 |
Exploring the use of metformin in pregnant women with polycystic ovary syndrome: new evidence, new wisdom.
Topics: Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Preg | 2019 |
Effects of in utero androgen excess and metformin treatment on hepatic functions.
Topics: Animals; Female; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Dis | 2019 |
Renal dysfunction in a mouse model of GDM is prevented by metformin through MAPKs.
Topics: Animals; Blood Glucose; Diabetes, Gestational; Diet, High-Fat; Disease Models, Animal; Female; Gluco | 2019 |
Prolactin and breast increase during pregnancy in PCOS: linked to long-term metabolic health?
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Breast; Female; Follow-Up Studies; Gestational A | 2019 |
A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol.
Topics: Double-Blind Method; Female; Humans; Metformin; Placebos; Pre-Eclampsia; Pregnancy; Randomized Contr | 2019 |
Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses.
Topics: Animals; Body Size; Body Weight; Female; Fetal Growth Retardation; Fetus; Metformin; Organ Size; Pre | 2019 |
Reproductive evaluations in female rat offspring exposed to metformin during intrauterine and intrauterine/lactational periods.
Topics: Animals; Behavior, Animal; Estradiol; Estrous Cycle; Female; Fertility; Hypoglycemic Agents; Lactati | 2019 |
Biodistribution of [
Topics: Animals; Carbon Radioisotopes; Chinchilla; Female; Humans; Liver; Membrane Transport Proteins; Metfo | 2019 |
"I'm Sticking With You, Doc".
Topics: Delivery, Obstetric; Family Practice; Female; Fertility; Humans; Hypoglycemic Agents; Hypoplastic Le | 2019 |
Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways.
Topics: Animals; Cells, Cultured; DNA Methylation; Female; Gene Expression Regulation; Interleukin-6; Interl | 2019 |
Exercise vs metformin for gestational diabetes mellitus: Protocol for a network meta-analysis.
Topics: Diabetes, Gestational; Exercise; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Meta-Analysi | 2019 |
Protective effect of metformin on a rat model of lipopolysaccharide-induced preeclampsia.
Topics: Animals; Disease Models, Animal; Female; Lipopolysaccharides; Metformin; NF-kappa B; Oxidative Stres | 2019 |
Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood.
Topics: Animals; Body Weight; Diet, High-Fat; Eating; Female; Fetus; Gene Expression Regulation; Glucose Tol | 2013 |
A case of hepatocyte nuclear factor-1β (TCF2) maturity onset diabetes of the young misdiagnosed as type 1 diabetes and treated unnecessarily with insulin.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnostic Errors; Female; Hepatocyte Nuclear | 2013 |
Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) protein.
Topics: Animals; Antiporters; Female; Hypoglycemic Agents; In Vitro Techniques; Maternal-Fetal Exchange; Met | 2013 |
Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome.
Topics: Animals; Diet, High-Fat; Dietary Carbohydrates; Female; Fetus; Inflammation; Interleukin-6; Male; Me | 2013 |
Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)?
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2013 |
Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes, | 2014 |
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.
Topics: Clomiphene; Exercise; Female; Fertilization in Vitro; Humans; Infertility, Female; Life Style; Metfo | 2013 |
Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Foll | 2013 |
Reply: To PMID 23659985.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Maternal metformin, obesity, and metabolic syndrome: the contribution of autonomic nervous system function.
Topics: Animals; Female; Fetus; Inflammation; Male; Metabolic Syndrome; Metformin; Obesity; Pregnancy | 2014 |
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; | 2014 |
Re: Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus by Corbould A, Swinton F, Radford A, Campbell, McBeath S, Dennis A. Aust N Z J Obstet Gynaecol 2013; 53: 125-129.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy | 2013 |
Re: Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus by Corbould A, Swinton F, Radford A, Campbell, McBeath S, Dennis A. Aust N Z J Obstet Gynaecol 2013; 53: 125-129.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy | 2013 |
Can we prevent premature luteinization in IVF cycles?
Topics: Female; Fertilization in Vitro; Humans; Luteinization; Metformin; Models, Biological; Ovulation Indu | 2014 |
Anti-diabetic drug utilization of pregnant diabetic women in us managed care.
Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; | 2014 |
A "spoonful of sugar" and the realities of diabetes prevention!
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Life Style; M | 2014 |
Reproductive endocrinology: Maternal and fetal insulin levels at birth in women with PCOS.
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Metformin; Polycystic Ovary Syndrome; | 2014 |
Metformin use in gestational diabetes mellitus.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2014 |
Use of antidiabetic agents in the treatment of gestational diabetes mellitus in Germany, 2008-2012.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Practice Patt | 2014 |
Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome.
Topics: Animals; Antioxidants; Drug Therapy, Combination; Female; Liver; Melatonin; Metformin; Oxidative Str | 2014 |
A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months.
Topics: Adult; Body Height; Body Weight; Child Development; Diabetes, Gestational; Female; Follow-Up Studies | 2015 |
Is metformin ready for prime time in pregnancy? Probably not yet.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2015 |
How does obesity affect fertility in men - and what are the treatment options?
Topics: Adiposity; Androgens; Aromatase Inhibitors; Body Mass Index; Clomiphene; Erectile Dysfunction; Estro | 2015 |
Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS).
Topics: Adult; Cross-Sectional Studies; Diabetes, Gestational; Female; Fertilization; Humans; Hypoglycemic A | 2014 |
Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes, Gestational; Female; Glyburide; Humans; Hypog | 2015 |
Exposure of mouse embryonic pancreas to metformin enhances the number of pancreatic progenitors.
Topics: Animals; Cell Differentiation; Female; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Mice | 2014 |
Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency.
Topics: Angiogenesis Inducing Agents; Antigens, CD; Carrier Proteins; Cell Line; Cell Movement; Chemokine CC | 2015 |
TallyHO obese female mice experience poor reproductive outcomes and abnormal blastocyst metabolism that is reversed by metformin.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; AMP-Activated Protein Kinases; Animals; Apoptosis; Blastocyst; Blo | 2014 |
Successful pregnancy outcomes in a patient with type A insulin resistance syndrome.
Topics: Adult; Antigens, CD; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metform | 2015 |
Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.
Topics: Aging; Animals; Animals, Newborn; Body Temperature; Body Weight; Cell Transformation, Neoplastic; Es | 2015 |
Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring.
Topics: Adipocytes; Adipokines; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Cell Size; Diet, | 2014 |
Which oral hypoglycaemic for gestational diabetes?
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2015 |
[Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Metformin | 2014 |
Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.
Topics: Abortion, Spontaneous; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Insulin Resistan | 2015 |
Lifestyle changes or metformin reduce type 2 diabetes risk in women with gestational diabetes, US study shows.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Life Style; M | 2015 |
Cellular Stress, Excessive Apoptosis, and the Effect of Metformin in a Mouse Model of Type 2 Diabetic Embryopathy.
Topics: Animals; Apoptosis; Caspases; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; End | 2015 |
Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes.
Topics: Adipose Tissue; Adult; Biomarkers; Caspase 1; Connexins; Diabetes, Gestational; Endoplasmic Reticulu | 2015 |
Diabetes: Therapy for gestational diabetes mellitus--time for a change?
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2015 |
Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Me | 2015 |
Gestational diabetes mellitus screening, management and outcomes in the Cook Islands.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Diet, Reducing; Female; Glucose Tolerance Test; Gravidi | 2015 |
In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2015 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypog | 2015 |
Metformin and pregnancy outcomes in obese women.
Topics: Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity, Ab | 2015 |
Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndr | 2015 |
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; China; Endometrial Hyperplasia; Endome | 2015 |
Relationship between Polycystic Ovarian Syndrome and Subsequent Gestational Diabetes Mellitus: A Nationwide Population-Based Study.
Topics: Adolescent; Adult; Comorbidity; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformi | 2015 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Topics: Antigens, CD; Biomarkers; Cardiovascular Agents; Electron Transport Chain Complex Proteins; Endoglin | 2016 |
A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
Topics: Adult; Diabetes Mellitus, Type 1; Disease Progression; Female; Humans; Hypoglycemic Agents; Metformi | 2016 |
Metformin Treatment Does Not Affect Testicular Size in Offspring Born to Mothers with Gestational Diabetes.
Topics: Adult; Child; Child, Preschool; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; | 2016 |
Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Gly | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin versus Placebo in Obese Pregnant Women without Diabetes.
Topics: Birth Weight; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity; Pregnancy; | 2016 |
Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Diabetes Complications; Diabetes Melli | 2016 |
The use of dextrose/insulin infusions during labour and delivery in women with gestational diabetes mellitus: Is there any point?
Topics: Blood Glucose; Diabetes, Gestational; Female; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; In | 2017 |
Non-insulin pharmacological therapy in pregnancy.
Topics: Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2016 |
Managing Recurring Obstetric Cholestasis With Metformin.
Topics: Adult; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Diabetes, Gesta | 2016 |
Metformin Enhances Osteogenesis and Suppresses Adipogenesis of Human Chorionic Villous Mesenchymal Stem Cells.
Topics: Adipocytes; Adipogenesis; Cell Proliferation; Chorionic Villi; Female; Humans; Mesenchymal Stem Cell | 2017 |
Tacrolimus in the prevention of adverse pregnancy outcomes and diabetes-associated embryopathies in obese and diabetic mice.
Topics: Animals; Bone and Bones; Diabetes Mellitus, Experimental; Diet, High-Fat; Female; Fetal Diseases; Gl | 2017 |
Should metformin be included in fertility treatment of PCOS patients?
Topics: Adenosine Triphosphate; Diabetes Mellitus, Type 2; Diabetes, Gestational; Electron Transport; Female | 2017 |
Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.
Topics: Adult; Contraceptives, Oral; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypo | 2017 |
Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Biological Transport; Carrier Proteins; Chromat | 2008 |
Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective.
Topics: Clomiphene; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Dehydroepiandrosterone and metformin modulate progesterone-induced blocking factor (PIBF), cyclooxygenase 2 (COX2) and cytokines in early pregnant mice.
Topics: Animals; Cyclooxygenase 2; Cytokines; Dehydroepiandrosterone; Embryo Implantation; Embryo Loss; Embr | 2008 |
A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage.
Topics: Abortion, Habitual; Androgens; Anovulation; Female; Gonadotropins; Humans; Infertility, Female; Insu | 2008 |
Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Ovulation Induction; Polycystic Ovary Syndrome; Preg | 2008 |
Cimetidine does not appear to influence the distribution of metformin into human milk.
Topics: Adult; Biological Transport, Active; Breast Feeding; Cimetidine; Drug Administration Schedule; Femal | 2008 |
Metformin Trumps insulin in the treatment of gestational diabetes.
Topics: Adult; Diabetes, Gestational; Drug Therapy, Combination; Female; Gestational Age; Humans; Hypoglycem | 2008 |
Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?
Topics: Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycy | 2008 |
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.
Topics: Adult; Aged; Apolipoprotein C-III; Bariatric Surgery; Biomarkers; Diabetes Mellitus; Female; Glycosi | 2009 |
Gestational diabetes: an opportunity for improvement.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Disease Progression; Female; Glucose Intolerance; Human | 2008 |
Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
Topics: Adult; Blood Glucose; Body Mass Index; Case-Control Studies; Chorionic Gonadotropin; Dinoprostone; E | 2009 |
Customised birthweight centiles are useful for identifying small-for-gestational-age babies in women with type 2 diabetes.
Topics: Adult; Birth Weight; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2009 |
Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue.
Topics: Aging; Animals; Female; Gene Expression Regulation; Intra-Abdominal Fat; Metformin; Nutritional Stat | 2009 |
Effect of DHEA and metformin on corpus luteum in mice.
Topics: Animals; Corpus Luteum; Dehydroepiandrosterone; Dinoprost; Female; Hyperandrogenism; Hypoglycemic Ag | 2009 |
Bone disease, gestational diabetes mellitus, and health care.
Topics: Bone Density; Bone Diseases; Collagen; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fra | 2009 |
Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome.
Topics: Adult; Apgar Score; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Met | 2009 |
Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study.
Topics: Birth Weight; Blood Glucose; Body Weight; Case-Control Studies; Diabetes, Gestational; Female; Human | 2009 |
Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Connecticut; Depression; Diabetes Mellitus, Type | 2009 |
[Oral blood glucose-lowering medication as a monotherapy in gestational diabetes: a hotly debated topic].
Topics: Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin | 2009 |
Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency.
Topics: Androgen Antagonists; Androgens; Aromatase; Child; Diabetes Mellitus, Type 2; Estrogen Replacement T | 2009 |
The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta.
Topics: Antipyrine; Biological Transport, Active; Cimetidine; Female; Humans; Maternal-Fetal Exchange; Metfo | 2010 |
Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy.
Topics: Analysis of Variance; Blood Glucose; Body Mass Index; Confidence Intervals; Diabetes Mellitus, Type | 2009 |
Reproductive endocrinology: live birth prediction in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Live Birth; Metformin; | 2010 |
Pharmacokinetics of metformin during pregnancy.
Topics: Adult; Area Under Curve; Creatinine; Female; Fetal Blood; Genotype; Humans; Infant, Newborn; Kidney; | 2010 |
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.
Topics: Adenosine Triphosphate; Biological Transport; Carbon Radioisotopes; Carrier Proteins; Cell Polarity; | 2010 |
Pregnancy outcome in women with polycystic ovary syndrome comparing the effects of laparoscopic ovarian drilling and clomiphene citrate stimulation in women pre-treated with metformin: a retrospective study.
Topics: Adult; Clomiphene; Drug Administration Schedule; Female; Fertility Agents, Female; Gynecologic Surgi | 2010 |
Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular Diseases; Diet; | 2010 |
Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome.
Topics: Age Factors; Androgens; Anovulation; Body Mass Index; Clomiphene; Decision Trees; Drug Therapy, Comb | 2010 |
Metformin treatment for Type 2 diabetes in pregnancy?
Topics: Adult; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2010 |
Ovulation induction in polycystic ovary syndrome: No. 242, May 2010.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2010 |
Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome.
Topics: Adult; Birth Rate; Cryopreservation; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hyperi | 2010 |
Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2010 |
Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood.
Topics: Animals; Dihydrotestosterone; Electrophysiology; Estrous Cycle; Female; Glucose Tolerance Test; Gona | 2011 |
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
Topics: Abdominal Pain; Adult; Cohort Studies; Diabetes, Gestational; Egypt; Female; Fertilization in Vitro; | 2011 |
Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction.
Topics: Adult; Age of Onset; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inf | 2011 |
Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Fetal Blood; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Metfor | 2011 |
Oral hypoglycemic agents in pregnancy.
Topics: Administration, Oral; Breast Feeding; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic | 2011 |
Metformin as adjuvant therapy to IVF in women with PCOS: when is intention-to-treat unintentional?
Topics: Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2011 |
Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial.
Topics: Anovulation; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Fem | 2011 |
Metformin for gestational diabetes in routine clinical practice.
Topics: Adult; Birth Weight; Body Mass Index; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypogly | 2011 |
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age.
Topics: Absorptiometry, Photon; Anthropometry; Body Composition; Child, Preschool; Diabetes, Gestational; Fe | 2011 |
Metformin therapy during pregnancy: good for the goose and good for the gosling too?
Topics: Body Composition; Diabetes, Gestational; Female; Humans; Male; Metformin; Pregnancy | 2011 |
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters.
Topics: Adult; Anti-Mullerian Hormone; Birth Weight; Diabetes, Gestational; Female; Fertility Agents, Female | 2012 |
Pregnancy management of women with pregestational diabetes.
Topics: Congenital Abnormalities; Counseling; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Me | 2011 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Introduction of metformin for gestational diabetes mellitus in clinical practice: Has it had an impact?
Topics: Adult; Birth Weight; Cohort Studies; Combined Modality Therapy; Diabetes, Gestational; Drug Therapy, | 2012 |
Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Benzoquinones; Calcium; Carbocyanine | 2012 |
Comment on: Rowan et al. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284.
Topics: Body Composition; Diabetes, Gestational; Female; Humans; Male; Metformin; Pregnancy | 2012 |
Comment on: Rowan et al. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284.
Topics: Body Composition; Diabetes, Gestational; Female; Humans; Male; Metformin; Pregnancy | 2012 |
Metformin and human uterine contractility.
Topics: Adult; Biopsy; Female; Humans; Hypoglycemic Agents; In Vitro Techniques; Isometric Contraction; Metf | 2012 |
Metformin exposure affects human and mouse fetal testicular cells.
Topics: Animals; Animals, Newborn; Cell Proliferation; Embryo, Mammalian; Female; Gene Expression Regulation | 2012 |
Pregestational diabetes with extreme insulin resistance: use of U-500 insulin in pregnancy.
Topics: Blood Glucose; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2012 |
Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells.
Topics: AMP-Activated Protein Kinases; Animals; Animals, Newborn; Chief Cells, Gastric; Female; Gastric Muco | 2013 |
Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus.
Topics: Adult; Blood Glucose; Delayed-Action Preparations; Diabetes, Gestational; Female; Glucose Tolerance | 2013 |
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007.
Topics: Adolescent; Adult; Child; Diabetes, Gestational; Female; Humans; Hyperglycemia; Hypoglycemic Agents; | 2013 |
How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Polyc | 2013 |
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
Topics: Abortion, Spontaneous; Birth Weight; Body Height; Child Development; Female; Follow-Up Studies; Huma | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocortico | 2003 |
Insulin-sensitizing drugs for polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnan | 2003 |
[ORAL DIABETIC DRUGS].
Topics: Carbutamide; Chlorpropamide; Diabetes Mellitus; Female; Humans; Metformin; Phenformin; Pregnancy; Pr | 1964 |
[THE THERAPY OF DIABETES MELLITUS].
Topics: Carbutamide; Chlorpropamide; Diabetes Mellitus; Diabetic Coma; Diet, Diabetic; Female; Globins; Hypo | 1964 |
[Hirsutism].
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Anti-Inflammatory Agents; | 2003 |
[Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome].
Topics: Adult; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Insulin; Leptin; Metformin; Ovul | 2003 |
Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: a case report.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Humans; Hyperinsulinism | 2004 |
Impaired glucose tolerance and impaired fasting glucose.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes, Gestational; Disease Progression; Female; Glucose Intole | 2004 |
Surgical treatment of polycystic ovary syndrome associated with infertility.
Topics: Clomiphene; Female; Gonadotropins; Gynecologic Surgical Procedures; Humans; Hyperandrogenism; Infert | 2004 |
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome.
Topics: Adult; Birth Weight; Body Weight; Diabetes, Gestational; Female; Gestational Age; HELLP Syndrome; Hu | 2004 |
Metformin therapy and diabetes in pregnancy.
Topics: Breast Feeding; Female; Humans; Hypoglycemic Agents; Metformin; Milk, Human; Practice Guidelines as | 2004 |
Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome.
Topics: Adult; Androstenedione; Body Mass Index; Clomiphene; Coitus; Female; Humans; Hypoglycemic Agents; In | 2004 |
Use of metformin in pregnancies with diabetes: a case series from India.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pilot Projects; Precon | 2005 |
Placental passage of metformin in women with polycystic ovary syndrome.
Topics: Female; Humans; Maternal-Fetal Exchange; Metformin; Placenta; Polycystic Ovary Syndrome; Pregnancy | 2005 |
[Treatment experience with metformin in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
The beneficial effects of insulin and metformin on in vitro developmental potential of porcine oocytes and embryos.
Topics: Animals; Cells, Cultured; Embryo Culture Techniques; Embryonic Development; Female; Fertilization in | 2005 |
Safety of metformin use during the first trimester.
Topics: Abnormalities, Drug-Induced; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; Pregnancy Tr | 2005 |
Stockpiling of ovarian follicles and the response to rosiglitazone.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Middle Aged; Ovarian Follicle; Poly | 2005 |
Metformin in the treatment of clomiphene citrate-resistant women with high BMI and primary infertility: clinical results and reproductive outcome.
Topics: Adult; Body Mass Index; Clomiphene; Drug Resistance; Female; Humans; Hypoglycemic Agents; Infertilit | 2005 |
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Female; Humans; Laparoscopy; Metformin; Ovary; Plasminogen Activator Inhibito | 2005 |
Population pharmacokinetics of metformin in late pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Drug Monitoring; Female; Fetal Blood; Half- | 2006 |
Metformin in pregnancy: its time has not yet come.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2006 |
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Body Mass Index; Case-Control Studies; Female; Genotype; Humans; Insulin Resi | 2006 |
Metformin use and diabetic pregnancy-has its time come?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetus; Humans; Hypoglycemic Agents; Insuli | 2006 |
Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?
Topics: Adult; Body Mass Index; Chronic Disease; Delivery, Obstetric; Diabetes Mellitus, Type 2; Female; Fet | 2006 |
Effect of pregnancy on the pharmacokinetics of metformin.
Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hy | 2006 |
Metformin use during the first trimester of pregnancy. Is it safe?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Comp | 2006 |
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin.
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Infertility, Female; Male; Metformin; Polycystic | 2006 |
Response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.
Topics: Diet Therapy; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ovary Synd | 2005 |
Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome.
Topics: Abortion, Habitual; Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2006 |
Outcome of clinical pregnancies after ovulation induction using metformin.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Female; Fo | 2006 |
Expanding applications for metformin in polycystic ovarian syndrome.
Topics: Child Development; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycystic Ovary | 2006 |
Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome.
Topics: Adult; Bottle Feeding; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hypogly | 2006 |
Transfer of metformin across the dually perfused human placental lobule.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Metformin; Perf | 2006 |
Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice.
Topics: Animals; Blood Glucose; CD4-CD8 Ratio; Dehydroepiandrosterone; Estradiol; Female; Fetal Resorption; | 2006 |
Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance.
Topics: Adult; Blood Glucose; Cohort Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insuli | 2006 |
Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy.
Topics: Adult; Birth Weight; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hyperbilirubinemia | 2006 |
Metformin and early pregnancy?
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Infertility, Female; Male; Metformin; Polycystic | 2006 |
Ovarian stockpiling in polycystic ovary syndrome, infertility, and the combined use of rosiglitazone and metformin.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary S | 2006 |
Polycystic ovary-related miscarriage: should metformin be proposed to such frustrated women?
Topics: Abortion, Habitual; Adult; Female; Humans; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2007 |
Effect of N-benzoyl-D-phenylalanine and metformin on insulin receptors in neonatal streptozotocin-induced diabetic rats: studies on insulin binding to erythrocytes.
Topics: Animals; Animals, Newborn; Binding, Competitive; Blood Glucose; Diabetes Mellitus, Experimental; Ery | 2006 |
Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants.
Topics: Acetylcholine; Amitriptyline; Antidepressive Agents; Dose-Response Relationship, Drug; Doxepin; Fema | 2007 |
Treating the polycystic ovary syndrome the old-fashioned way.
Topics: Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypogly | 2007 |
Ovulation induction management of PCOS.
Topics: Aromatase Inhibitors; Clomiphene; Endometrial Neoplasms; Female; Fertility Agents, Female; Glucocort | 2007 |
Pregnancy considerations in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2007 |
Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Female; Humans; Hypoglycemic Agents; Maternal-F | 2008 |
Metformin and fetal malformations.
Topics: Female; Fetal Diseases; Fetus; Humans; Metformin; Pregnancy | 2007 |
Controlled natural cycle IVF: a novel approach for a dominant follicle during an in-vitro maturation cycle.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Ovarian Follicle; Polycy | 2007 |
AMP kinase activation increases glucose uptake, decreases apoptosis, and improves pregnancy outcome in embryos exposed to high IGF-I concentrations.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Apoptosis; Enzyme Activation; Female; Glucose | 2007 |
[Polycystic ovary syndrome (PCOS)].
Topics: Drug Therapy, Combination; Family Practice; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2007 |
Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Insulin Res | 2003 |
Maternal diabetes adversely affects AMP-activated protein kinase activity and cellular metabolism in murine oocytes.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetyl-CoA Carboxylase; Adenosine Monophosphate; Adenosine Triphos | 2007 |
[Alternative approaches to ovarian stimulation].
Topics: Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovulation Inducti | 2007 |
Risk of multiple gestation after ovulation induction in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Met | 2007 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovarian syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Comp | 2008 |
A 40-year-old woman with diabetes contemplating pregnancy after gastric bypass surgery.
Topics: Adult; Antihypertensive Agents; Breast Feeding; Diabetes Mellitus, Type 2; Female; Gastric Bypass; G | 2008 |
Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.
Topics: Adult; Birth Weight; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin Resistance; Metfo | 2009 |
Gestational diabetes--setting limits, exploring treatments.
Topics: Blood Glucose; Diabetes, Gestational; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Me | 2008 |
Metformin-associated lactic acidosis in a pregnant patient.
Topics: Acidosis, Lactic; Adult; Birth Weight; Charcoal; Female; Humans; Hypoglycemic Agents; Infant, Newbor | 2008 |
Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital.
Topics: Diabetes Mellitus; Female; Glyburide; Humans; Infant Mortality; Insulin; Labor, Induced; Metformin; | 1980 |
Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis.
Topics: Animals; Culture Techniques; Embryonic and Fetal Development; Female; Hypoglycemic Agents; Metformin | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Contraindications to metformin therapy in patients with NIDDM.
Topics: Acidosis, Lactic; Alcoholism; Contraindications; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; D | 1997 |
Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.
Topics: Adult; Diabetes Mellitus, Type 1; Disorders of Sex Development; Female; Humans; Hyperandrogenism; Hy | 1999 |
Contra-indications to metformin therapy are largely disregarded.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coronary Disease; Cross-Sectional Studies; Diabet | 1999 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Poly | 2000 |
Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.
Topics: Abortion, Habitual; Adult; Amenorrhea; Androstenedione; Embryo Transfer; Female; Fertilization in Vi | 2000 |
Oral hypoglycaemic agents in 118 diabetic pregnancies.
Topics: Abruptio Placentae; Adult; Birth Weight; Cesarean Section; Cohort Studies; Diabetes Mellitus, Type 2 | 2000 |
Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors.
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Resistance; Embryo Transfer; Embryo, Mammalian; Estr | 2001 |
A comparison of glyburide and insulin in women with gestational diabetes mellitus.
Topics: Adult; Diabetes, Gestational; Female; Glucose Intolerance; Glyburide; Humans; Hypoglycemic Agents; I | 2001 |
Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; Ovulati | 2001 |
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Androgens; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin | 2002 |
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Diabet | 2002 |
Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metfo | 2002 |
[Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Topics: Adult; Androstenedione; Blood Glucose; Cholesterol; Cholesterol, LDL; Clomiphene; Drug Resistance; E | 2002 |
Diabetes newly diagnosed during pregnancy: A 4-year study at Groote Schuur Hospital.
Topics: Adolescent; Adult; Birth Weight; Black or African American; Black People; Delivery, Obstetric; Diabe | 1979 |
Metformin in management of pregnant insulin-independent diabetics.
Topics: Apgar Score; Drug Evaluation; Female; Humans; Infant Mortality; Infant, Newborn; Metformin; Pregnanc | 1979 |
Side-effects of metformin.
Topics: Female; Humans; Metformin; Pregnancy | 1979 |
The management of pregnancy in diabetes mellitus.
Topics: Birth Weight; Blood Glucose; Chlorpropamide; Delivery, Obstetric; Diet, Diabetic; Female; Fetal Deat | 1975 |
Mild familial diabetes with dominant inheritance.
Topics: Acetohexamide; Adolescent; Adult; Aged; Blood Glucose; Carbohydrates; Child; Chlorpropamide; Diabete | 1974 |
Diabetes mellitus--refractory obesity.
Topics: Biguanides; Diabetes Mellitus; Diet Therapy; Female; Fetal Death; Glucose Tolerance Test; Glycosuria | 1972 |
Adverse reactions to oral antidiabetic agents.
Topics: Acetohexamide; Acidosis; Administration, Oral; Anemia; Chlorpropamide; Drug Antagonism; Drug Synergi | 1971 |